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Abstract 
 
Over the past 20 years, the incorporation of eHealth within health services in England has 
expanded organically in diverse ways, usually in response to local perceived need, interest or 
funding.  UK government policy and strategies have taken an optimistic view of how eHealth 
can revolutionise publically funded health care provision and implementation lags far behind 
expectations. Although there are some excellent examples of how eHealth has been 
incorporated into NHS practice in a beneficial manner, there is also a concerning lack of 
evidence to support many of the interventions and new models of service delivery. This largely 
reflects a disparate and fragmented evidence base within current eHealth literature, 
particularly in relation to methods for developing online care pathways.   
This doctoral research is focused on developing and implementing an online automated clinical 
care pathway for people with genital chlamydia infection, and developing a robust framework 
for its evaluation.  The care pathway is a core component of an eSexual Health Clinic, also 
developed as part of this work, which is fully integrated within an NHS specialist sexual health 
service.  An online clinical pathway taking a person from diagnosis of a new condition, through 
an automated clinical consultation, partner notification and collection of antibiotics from a 
community pharmacy via an electronic prescription has never been done before in the UK.   
The novelty of the work and paucity of literature in this field at times necessitated a different 
approach from conventional research practice. I started by conducting a scoping review to 
identify the legal, regulatory, ethical and perceptual barriers to introducing such a pathway 
into the NHS. Electronic prescribing across the secondary and primary care interface stood out 
as a barrier to implementation. There was also a clear lack of evidence in terms of the content 
and accuracy of sexual health mobile medical applications. I went on to conduct detailed 
reviews of both of these areas. 
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In the absence of any relevant guidance on developing online clinical care pathways, I then 
developed my own methods, underpinned by evidence adapted from guidance aimed at 
traditional clinical care, existing protocols and practice, eHealth and sexual health literature 
and questionnaires, and created a new eClinical Care Pathway Framework. I then applied this 
framework to guide my development of the online clinical care pathway for people with 
genital chlamydia.  
We then needed to demonstrate that the Chlamydia online clinical care pathway was feasible, 
acceptable and safe to take forward into a large scale trial, and potentially implement into 
clinical practice. There are no accepted methods for evaluation of this type of online clinical 
care pathway and my final piece of work focussed on developing a set of evaluation 
techniques and activities, which would assess all these elements to determine whether the 
online pathway was fit for purpose.  
Outputs of this doctoral work include: a comprehensive review of contemporary sexually 
transmitted infection and sexual health mobile applications (apps); a comprehensive review of 
electronic prescribing in the UK; a method for developing complex online clinical care 
pathways based on a novel framework;   UK’s first automated online clinical care pathway for 
people with genital chlamydia, and finally a method for evaluation of online clinical care 
pathways.  
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Introduction  
 
Sexually transmitted infections (STIs) continue to be an important public health issue in 
England although the increasingly austere financial environment and National Health Service 
structural reforms appear to be threatening existing service provision. Currently people are 
able to access STI and sexual health care in state-provided healthcare settings via a number of 
different routes including specialist Genitourinary Medicine clinics and sexual health clinics 
(the two names are used synonymously), family planning clinics, general practice, pharmacies, 
and people age 15-24 can use the National Chlamydia Screening Programme. Developments in 
diagnostics mean that it is now possible for people to self-sample for many of the commonly 
diagnosed infections including chlamydia, gonorrhoea, HIV, syphilis and hepatitis B, within a 
healthcare setting, in non-clinical venues, or in their own homes. Rapid advances in digital 
technology has led to a transformation in the way that services are provided and in the way 
that information is collected, stored, transmitted and communicated. The combination of 
these factors means that it is now possible for people to self-sample or even self-test (for some 
infections), receive a diagnosis and receive care remotely without contact with a health care 
professional.  
This doctoral research is rooted in online sexual health and was undertaken as part of the eSTI2 
[Electronic Self-Testing Instruments for Sexually Transmitted Infections] Consortium(4). The 
Consortium is a collaboration of academic, NHS and industry partners which includes Queen 
Mary, University of London. It aims to ‘reduce the high impact of sexual transmitted infections 
(STIs), a national priority for UK health, by building translation capacity to develop, improve, 
evaluate and implement simple to use, rapid, accurate, polymicrobial and affordable point of 
care and non- point of care micro-diagnostics that can be mobile-phone networked’(4). I will 
discuss this in more detail in Chapters 1 and 3.  
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THE KEY AIMS OF THIS DOCTORAL RESEARCH ARE: 
To develop, and evaluate a novel internet-based clinical care pathway for the management of 
genital Chlamydia trachomatis to enable patients to be managed remotely in a safe and timely 
manner, within the legal and regulatory constraints of the NHS in England. 
RESEARCH QUESTIONS 
 
My principal research questions were: 
1. What is the accuracy and content of mobile medical apps for sexually transmitted and 
genital infections 
2. What is possible and what are the constraints with electronic prescribing across the 
secondary and primary care interface within the NHS? 
3. How can we design a clinical care pathway for the remote management of patients 
testing for Chlamydia trachomatis which includes a results service, automated online 
clinical consultation, partner notification and electronic prescribing 
4. How can we best evaluate online clinical care pathways for genital chlamydia 
 
SPECIFIC OBJECTIVES 
1. To conduct a comprehensive review of currently available mobile medical applications 
for sexually transmitted and other genital infections 
2. To undertake a comprehensive review of ePrescribing in the UK 
3. To develop the methodology to design an online clinical care pathway for 
management of sexually transmitted genital Chlamydia trachomatis 
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4. To develop an online clinical care pathway for management of sexually transmitted 
genital Chlamydia trachomatis 
5. To evaluate the eSTI2 chlamydia online clinical care pathway 
RESEARCH STUDIES UNDERTAKEN TO ADDRESS RESEARCH 
QUESTIONS AND MEET SPECIFIC OBJECTIVES 
1. A systematic review of STI and genital infection mobile medical apps 
2. A comprehensive review of ePrescribing in the UK 
3. Development of the eClinical Care Pathway Framework as a method for designing an 
online care pathway 
4. Application of the eClinical Care Pathway Framework to design the Chlamydia Online 
Clinical Care Pathway 
5. Development of methods to evaluate the feasibility, acceptability and safety of the 
Chlamydia Online Clinical Care Pathway 
OVERALL APPROACH  
eHealth is a very broad field with a large body of literature which is rapidly evolving, disparate, 
poorly collated, and of variable quality(5). In order to provide workable boundaries for my 
studies, I have concentrated on online eHealth, whilst expanding to other elements of eHealth 
where relevant, and focussing on specialist Sexual Health Services in a National Health Service 
(NHS) context.  
I initially conducted a literature review of the legal, ethical, regulatory and perceptual barriers 
to introducing a novel clinical care pathway into the NHS, with a focus on the issues related to 
the introduction of an online clinical consultation for Chlamydia trachomatis. This topic was 
not conducive to a systematic review due to its breadth and complexity and lack of 
14 
 
randomised controlled trials or other empirical studies. I developed my own framework for 
analysing and applying the different barriers found in different elements of the care pathway. I 
identified gaps and issues with the current knowledge base and legislation and regulations. 
The outputs from this were used directly to inform feasibility of our intended approach within 
the research consortium. After much consideration, I have chosen not to include this as a 
separate body of work in my thesis as it did not fit with the flow of this work, however its 
outputs have clearly informed development of the pathway.  
My doctoral work has been coupled to tight research consortium deliverables. This meant that, 
with the agreement of my supervisors, I have had to focus on specific outputs, such as the 
development of the online clinical consultation, ahead of developing the publications which 
will stem from them. I have therefore listed conference presentations and proposed first 
author publications on page 9.  Due to close collaboration with other members of the eSTI2 
consortium and the multi-disciplinary nature of the this research, I have clearly stated at 
relevant points in the text where the work described has been conducted by myself, where it 
has been conducted in conjunction with other members of the team, and where another 
researcher has undertaken the work.    
I provide an overview of the content of my chapters below. Two studies (the medical mobile 
app review and ePrescribing review) lend themselves to a traditional research write up 
framework. However, the iterative and interdependent nature of my work on methodology, 
development and evaluation of the online clinical pathway did not lend itself to “best practice” 
write up structures and attempts to shoehorn the work into a classical style resulted in a lack 
of clarity and duplication across chapters. I have therefore chosen a different approach as I 
believe this is the clearest method of describing the research. However, due to the iterative 
and continuous evaluative nature of the evolution of the online clinical care pathway, there is 
some unavoidable cross-referencing between these three chapters. Due to the 
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interdependency of these chapters, I have combined the discussion for all three chapters at 
the end of Chapter 6.  
CHAPTER 1: BACKGROUND 
 
I start by providing a background to eHealth before focussing on sexual health and then 
eSexual Health. I provide a background to the eSTI2 consortium (within which my PhD is 
funded) and the Chlamydia Online Clinical Care Pathway exploratory study.   
CHAPTER 2: CONTENT AND ACCURACY OF CURRENTLY 
AVAILABLE MOBILE MEDICAL APPLICATIONS FOR SEXUALLY 
TRANSMITTED AND OTHER GENITAL INFECTIONS: A 
COMPREHENSIVE REVIEW 
 
In this chapter I review the content and accuracy of mobile medical apps for sexually 
transmitted and other genital infections. The main findings were that the content and accuracy 
of currently available mobile medical apps for sexually transmitted and other genital infections 
are highly variable, with no way for a member of the public to determine the reliability of the 
information provided. A process for accreditation could be useful but may be unfeasible within 
short timeframes.   
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CHAPTER 3: REVIEW OF ELECTRONIC PRESCRIBING IN THE 
UK TO INFORM THE DESIGN OF THE CHLAMYDIA ONLINE 
CLINICAL CARE PATHWAY 
Here I review electronic prescribing in primary and secondary care in the UK from a legal, 
regulatory and structural perspective. I also formulate and discuss the options for electronic 
prescribing within the Chlamydia Online Clinical Care Pathway. Although I developed a 
workable process for the exploratory study within the eSTI2 consortium, significant barriers 
exist for wider implementation.  
CHAPTER 4: METHODOLOGY FOR THE DEVELOPMENT OF A 
REMOTE ONLINE CLINICAL CARE PATHWAY FOR THE 
MANAGEMENT OF GENITAL CHLAMYDIA  
In this chapter I describe the limited existing evidence base for informing online clinical care 
pathway development for the management of genital chlamydia before describing the process 
of developing a robust methodology for developing the eClinical Care Pathway Framework. As 
previously discussed, I discuss the findings from Chapters 4, 5 and 6 together at the end of 
Chapter 6.  
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CHAPTER 5: DEVELOPMENT OF THE CHLAMYDIA ONLINE 
CLINICAL CARE PATHWAY USING THE eCLINICAL CARE 
PATHWAY FRAMEWORK 
Here I describe how I used the eClinical Care Pathway Framework, described in chapter 4, to 
develop the chlamydia online clinical care pathway.  
CHAPTER 6: DEVELOPMENT OF METHODS TO DETERMINE 
WHETHER THE ESTI2 CHLAMYDIA ONLINE CLINICAL CARE 
PATHWAY IS FEASIBLE, ACCEPTABLE AND SAFE, 
THROUGHOUT AN EXPLORATORY CLINICAL STUDY 
 
In this chapter I discuss evaluation of eHealth interventions and describe how I used available 
evidence to guide my methods to determine the feasibility, acceptability and safety of the 
eSTI2 Chlamydia Online Clinical Care Pathway. I conclude with a discussion covering Chapters 4, 
5 and 6. 
 
CHAPTER 7: CONCLUSIONS 
Finally I draw together my findings from this body of work in a section on conclusions and 
recommendations.   
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Chapter 1: Background 
 
Here I set the scene for my doctoral research. As eHealth and eSexual Health encompass a very 
diverse body of work and literature, by necessity I focus on the literature background relevant 
to the original work presented within this thesis.   
Mobile and electronic information and communication technology (ICT) play an important role 
in most people’s everyday life in the UK. Between 2004 and 2014, the proportion of 
households with broadband access rose from 16% to 77% (6). It is possible to search for and 
find information or advice on anything that comes to mind within a matter of seconds using 
internet-enabled devices. For many people communicating via short message service (SMS), 
email and social media has become the norm.  Mobile phones are ubiquitous within the UK 
with 61% of adults owning a smartphone (6). Boulos et al estimate that within 10 years 80-90% 
of the UK population will have a smartphone(7). Likewise, there is a digital divide in terms of 
smartphone ownership depending on age and socio-economic group with highest rates of 
ownership in 16-24 year olds (88%) and those living in socio-economic group ABC1 (69% 
ownership compared to 51% in group C2DE)(6).  
 Fifty seven percent of people access the internet via their mobile phone(6). The most popular 
internet-enabled devices are laptops, with 63% of households possessing one(6). Young people 
are particularly adept at using digital technology, with a higher proportion of men having a 
high level of confidence using  ICT compared to women (6). People in ABC1 socio-economic 
group (traditionally defined as lower middle class to upper middle class (8)) have a higher level 
of confidence with digital technology, than those in C2DE(6).  
It is natural, therefore, that this ease and convenience of communication should be applied to 
publically funded health care (National Health Service (NHS)) in the form of eHealth.   eHealth 
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has the potential to increase patient choice and control of one’s own health, which is very 
much in keeping with the current political climate(9;10). In addition, it is thought that it will 
lead to increased efficiency and efficacy, although this has yet to be sufficiently demonstrated 
in practice. 
I will start by giving an overview of eHealth and Sexual Health before focussing in on eSexual 
Health.  
1.1 eHEALTH 
1.1 WHAT IS eHEALTH?  
eHealth is the utilisation of evolving information and communication technology to develop 
and improve the organisation and delivery of health services and healthcare(11;12). Eysenbach 
expands this definition to include ‘a new way of working, an attitude, and a commitment for 
networked, global thinking, to improve health care locally, regionally and worldwide by using 
information and communication technology’(12).  
1.2 THE CURRENT STATE OF eHEALTH IN THE NHS 
eHealth has developed organically in the UK over the past 20 years and is increasingly 
incorporated into everyday practice both from the clinician and patient perspective. Driven by 
advances in technology, perceived increased efficiency and cost-effectiveness, and latterly 
policy (discussed below) notable examples of its adoption include telephone consultations, 
telemedicine for e.g. dermatology consultations(13), computer-based access to laboratory 
results and medical imaging, adoption of email between physicians and other healthcare 
professionals as an acceptable form of communication and latterly physician and patient, 
introduction of electronic health records (EHR), electronic prescribing, short message service 
(SMS) reminders for appointments and test results, and the use of personal digital assistants 
predominately for physician-assisted clinical care.   
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Particularly relevant to my work is the use of eHealth tools for history taking in primary care, 
outpatient clinics and acute settings. Over time this has moved away from being guided by a 
clinician’s own technique towards the use of standardised data collection tools. Medical 
history proformas have gained popularity as a means of improving the quality and relevance of 
data collected in these settings (14-17). These were initially in a paper format and formed part 
of a patient’s paper record. In the last 10 years there has been an increasing move towards the 
use of EHRs, with the history being inputted by a clinician or, in some cases, by the patient. 
There is great variation in how the term ‘Electronic Health Records’ has been interpreted and 
applied (5;18). In the context of this paper, EHR is being used to describe the collated data that 
is being collected from the registration of an individual prior to, or when, conducting a POC 
test, the result of that test, and if that test is positive, the information gathered during the 
online clinical consultation.    
 A key question is whether an electronic questionnaire can replace a clinician and be used to 
inform a decision tool to decide patient outcome (i.e. to treat or to refer to HCP input).  
Whilst taking a history from a patient a clinician digests the information and uses it to decide: 
1. what, if any, examination is required; 2. which investigations are required; 3. what is the 
differential diagnosis; 4. the best way to manage the patient A wide array of clinical decision 
support tools or systems (Clinical Decision Support Systems) have been introduced, initially in a 
research setting, into clinical practice in recent years to aid or in part replace physicians in this 
decision making process(19-38). 
Most of the literature relating to decision support is in the context of practitioners using the 
software, as opposed to the case of patients using the tool outside a medical setting, without 
clinician input. In addition, there is only weak evidence that Clinical Decision Support Systems 
improve clinician performance, or that even where behaviour change occurred, that there was 
an improvement in quality of care (20;39). 
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Richens et al demonstrated that the utilisation of a computer interview, irrespective of 
whether it was a HCP or patient inputting the data, led to greater disclosure of sensitive 
information. They concluded that it was the rigid structure of the computer interview, with the 
mandatory answering of what may be perceived as embarrassing questions, which led to this 
as opposed to a reduction in social desirability bias which had been postulated from earlier 
studies (40).  Munger et al have shown non-inferiority when comparing an electronic medical 
interview tool and a traditional medical consultation for prescribing erectile dysfunction drugs.  
They found that the electronic tool was superior to traditional methods for medication 
counselling, and that standard diagnostic questions that were asked by the electronic medical 
interview were rarely asked in the traditional consultation (41).   
The way results of investigations are communicated is an important aspect of medical care. 
With growing pressure on healthcare resources and advances in technology the use of 
electronic means of communicating with patients is increasingly being used.  
In terms of literature, a Cochrane review on mobile phone messaging for communicating 
results of medical investigations published in 2012 found only one low quality study that fitted 
their selection criteria(42). A Cochrane review on email for communicating results of medical 
investigations published in 2012 failed to find any studies that met its selection criteria(43). 
It is clear that good quality studies need to be conducted which evaluate the use of both 
mobile phone and email use in clinical practice. 
 
Concerns with the use of mobile phones as communication tools in healthcare include possible 
breaches of privacy and confidentiality if the phone is borrowed, lost or stolen(44). In addition, 
if the only contact details for an individual is a mobile phone number, and the phone is lost, 
then it is then no longer possible to contact that patient. There is also the issue of the 
exclusion of populations who are unable to afford or access information and communication 
technology.Clinicians are encouraged to use the NHS.net email service if communicating to or 
about patients, because of its higher security standards compared to other email services. 
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Clinicians are also advised to print any email communication sent or received from patients 
and file it in their health records(45).  Car et al have made clear suggestions for minimising the 
legal risks of using email in practice(5). When implementing an email service within NHS 
hospitals it is necessary to get permission from the Trust NHS Information Governance board. 
This can be where the largest barrier to implementation lies, with, for example, at least one 
NHS London Teaching Hospital being prohibitively averse to the use of email communication 
with patients in clinical practice (46).  
In recent years the internet has also been the focus of eHealth initiatives, harnessing more 
sophisticated forms of eHealth such as internet-based information and interventions, 
smartphone apps and healthcare professional use of social networking, for example for 
partner notification (PN).  My doctoral work is rooted within internet forms of eHealth, 
incorporating other elements of eHealth as they interdigitate with online care.  
To date the majority of user / patient targeted eHealth innovations have centred on 
monitoring of a diagnosed chronic condition and promoting self-care e.g. asthma, diabetes, 
medication adherence e.g. HIV, behavioural interventions e.g. smoking cessation. 
(23;33;47;47-63).  They are largely internet-based web applications, smartphone apps, or SMS-
based, and the majority are intended to be used in partnership with the health care provider 
e.g. hospital service as an adjunct to routine “traditional” care. There have been several 
reviews of mobile phone apps available for patients living with HIV (64;65), asthma (66;67), 
diabetes (68;69), and people trying to give up smoking (70;71). Concerns have been raised 
over the lack of regulation of the content and accuracy of existing medical mobile phone apps 
(72-77) I discuss this in further detail in Chapter two. Only a small portion of eHealth has been 
directed to both diagnosis of a new condition and remote management. Clinician-targeted 
mobile apps generally aim to aid health care professionals in their management of patients 
(78-82). 
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Policy for eHealth first appeared in 1998(83). The Department of Health’s aspiration was for a 
patient-centred, patient-accessible, integrated provision of care, with flow of information and 
interoperability, whilst maintaining adequate confidentiality. Great emphasis was being put on 
the introduction and utilisation of eHealth technologies (84-88). This ethos has been continued 
by NHS England(9;89;90). However, there is a disparity between the Department of Health’s 
ideals, NHS England’s policy and current practice. This is discussed in further detail in Chapter 
3.  
In the current NHS environment of efficiency, stream-lining and financial austerity, a major 
driver for the introduction of eHealth has been its perceived cost-effectiveness compared to 
traditional services. Costs and economic evaluation are included in the outcomes considered in 
the assessment of new healthcare technology(91). However, economic evaluation of eHealth 
initiatives has been largely untested with implementation occurring with minimal 
evaluation(92). Health economists are performing a cost-consequence analysis of the 
Chlamydia-OCCP as part of eSTI2 work stream 4. 
 
2 SEXUALLY TRANSMITTED INFECTIONS 
2.1 WHAT ARE SEXUALLY TRANSMITTED INFECTIONS? 
 
Sexually transmitted infections (STIs) are bacteria, viruses and protozoa that are transmitted 
between individuals during sexual intercourse. This usually involves contact with one 
individual’s genitalia and another individual’s genitalia, anus/rectum or oropharynx. However 
some STIs, for example HIV and syphilis, can be transmitted via contact with blood or skin 
lesions respectively. 
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2.2 OVERVIEW OF EPIDEMIOLOGY OF STIS  
 
Rate of transmission of STIs is dependent on three factors: 1. Duration of infectivity; 2. 
Infectiousness of the organism; 3. Number of people who are susceptible to the infection that 
the index patient comes into contact with(93). This is represented by the following equation: 
Basic reproductive rate (Ro) = C x P x D 
Where C is the number of people the index patient makes contact with per unit time, P is the 
probability of transmission when contact takes place, and D is the time that the index patient 
remains infectious to others. When Ro is greater than 1 then transmission of an infection is 
sustainable within a population(93). In terms of public health interventions, only C and D can 
be manipulated to reduce Ro.  
STIs are common, with more than one million new infections every day worldwide(94).  The 
most prevalent treatable STIs are chlamydia, gonorrhoea, trichomonas and syphilis; the most 
prevalent incurable STIs are genital herpes, human papillomavirus, hepatitis B and HIV(94). The 
majority of sexually transmitted infections are asymptomatic and therefore go undiagnosed 
and untreated. They are a major cause of morbidity with approximately 500 million people per 
year suffering adverse effects secondary to infection with chlamydia, gonorrhoea, syphilis and 
trichomonas. As well as causing clinical symptoms and complications to the infected person, 
some STIs can cause adverse outcomes in pregnancy, disease in neonates and increase the risk 
of HIV transmission by three-fold or more(94).  
England:  
 
England has a robust public health surveillance programme led by Public Health England. Data 
from genitourinary clinics on new diagnoses of STIs, along with service provision, is collected 
on a quarterly basis from all Level 3 (specialist) and commissioned Level 2 (intermediate) 
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sexual health services(95). The Genitourinary Medicine Clinic Activity Dataset (GUMCADv2) is 
pseudo-anonymised and consists of basic demographics, attendance information, clinical 
details and coding of service provided, diagnoses made and management(95). Since 2012, 
primary care and community services have been required to complete the Chlamydia Testing 
Activity Dataset(96) `. 
In 2013 there was a small decline in the overall incidence of STIs when compared to 2012, with 
446,253 new diagnoses made in England. For the preceding 10 years there had been a steady 
increase in overall new diagnoses of STIs. The advent of new tests using polymerase chain 
reaction to detect certain infections, with increased accuracy of tests and introduction of self-
sampling, is likely to have contributed to this increase(97). In addition, in 2012 there was a 
change in Public Health England surveillance methods and, for the first time, community 
genital chlamydia diagnoses for adults aged over 24 were incorporated in the 2012 figures(98). 
Despite this, the consensus is that current methods are not adequately controlling STIs in the 
UK and that there is a need for greater access for all age groups (97;99).  
Although there has been an overall decrease in incidence of STIs, there continues to be a 
significant increase in the incidence of certain STIs, for example gonorrhoea, particularly in 
men who have sex with men and some ethnicities (e.g. black ethnicity)(97). Young people aged 
16-24 have disproportionately higher incidences of STIs compared to other age groups. The 
commonest bacterial STI in England is Chlamydia trachomatis and there was a small increase in 
diagnoses of this infection between 2012 (207,795) and 2013 (208,755). 58% of chlamydia 
diagnoses in 2013 were made in women.  In 2013, 101,179 people were diagnosed with 
chlamydia in GUM clinics whilst 107,576 were diagnosed in the community. A higher 
proportion of women were diagnosed in the community (60.1%), whereas a greater 
proportion of men were diagnosed in GUM clinics (61.4%)(100). 
For the purposes of my doctoral work (and the eSTI2 exploratory trials, Chapters 3 to 5) we 
focus on Chlamydia trachomatis as it is common, easy to diagnose, and the first-line treatment 
26 
 
is with a single dose of oral azithromycin 1g.  This, along with advances in diagnostic tests, self-
sampling, and information communication technology, means that Chlamydia trachomatis is 
amenable to various internet based eHealth interventions including remote (outside 
traditional healthcare services with no direct contact with a healthcare professional) 
management. 
2.3 CHLAMYDIA TRACHOMATIS 
 
Chlamydia trachomatis is an obligate intracellular bacteria belonging to the genus Chlamydia. 
It cannot be cultured on artificial media, and is diagnosed using nucleic acid amplification tests 
(93).  The major outer membrane protein gene is used to type Chlamydia trachomatis strains 
(93). I have summarised the different strains of Chlamydia trachomatis, and the diseases they 
cause, in Table 1 below: 
I will focus on serovars B to K and use the term genital chlamydia to describe this.  
Genital chlamydia infects squamocolumnar-columnar epithelium, with sites of infection 
including the urethra, cervix, fallopian tubes, epididymis, rectum, pharynx, conjunctiva and 
liver capsule. Clinical sequelae of infection include urethritis, cervicitis, salpingitis, epididymitis, 
proctitis, conjunctivitis, sexually acquired reactive arthritis and Fitz-Hugh-Curtis Syndrome(93).   
Genital chlamydia is the commonest bacterial sexually transmitted infection diagnosed and 
managed in the United Kingdom(98), North America and Europe(93). The main burden of 
infection is seen in young adults (15-24 years of age), with 63% of diagnoses of genital 
chlamydia in heterosexuals being in this age group in 2013(97) . One of the major challenges in 
detecting and diagnosing Chlamydia trachomatis is that a substantial proportion of infections 
are asymptomatic(93).   
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Table 1: The different strains of Chlamydia trachomatis, adapted from Holmes et al(93) p559 
Species Biovar Serovar Disease 
C.trachomatis Lymphogranuloma 
venereum 
L1, L2 
and L3 
Lymphogranuloma venereum 
C.trachomatis Trachoma A, B, Ba, 
C 
Trachoma 
C.trachomatis Trachoma B, D, E, F, 
G, H, I, J, 
K 
Neonates: inclusion conjunctivitis and 
pneumonia 
Adults: asymptomatic infection, urethritis, 
cervicitis, epididymitis, salpingitis, 
proctitis, sexually acquired reactive 
arthritis, Fitz-Hugh-Curtis Syndrome 
 
The high rates of infection, asymptomatic nature of the infection, and the complications and 
morbidity associated with infection led to the introduction of the National Chlamydia 
Screening Programme (NCSP) for women in the UK in 2003(101). The NCSP is described in 
further detail on page 32. 
2.4 SEXUAL HEALTH? 
Worldwide 
Sexual health is defined by the World Health Organization as: “…a state of physical, emotional, 
mental and social well-being in relation to sexuality; it is not merely the absence of disease, 
dysfunction or infirmity. Sexual health requires a positive and respectful approach to sexuality 
and sexual relationships, as well as the possibility of having pleasurable and safe sexual 
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experiences, free of coercion, discrimination and violence. For sexual health to be attained and 
maintained, the sexual rights of all persons must be respected, protected and fulfilled.”(102). It 
is recognised that human sexual behaviour is complex and that “these factors affect whether 
the expression of sexuality leads to sexual health and well-being or to sexual behaviours that 
put people at risk or make vulnerable to sexual and reproductive ill-health.”(102) 
Britain 
The importance of including sexual behaviour, experiences and relationships, as well sexual 
health outcomes, in the scope of sexual health was reiterated by Wellings and Johnson in their 
Comment published in the Lancet accompanying the publication of the results of the third 
British National Survey of Sexual Attitudes and Lifestyles (Natsal-3)(103). Major findings from 
the recent Natsal-3 publications included the persistence of high rates of STIs despite an 
increase in the proportion of the population testing for STIs and accessing Sexual Health 
services, with 3.1% of women, and 2.3% of men aged 16 to 24 years of age testing positive for 
Chlamydia trachomatis (104). Nine point eight percent of women and 1.4% of men reported 
non-consensual sex, with a median age at the most recent incident of 18 years for women and 
16 years for men. A variety of adverse health outcomes were found to be associated with non-
consensual sex (105).In addition, poor health was found to have an adverse effect on sexual 
activity and sexual satisfaction, irrespective of age(106).  Other findings included multiple 
factors being associated with low sexual function including a strong association with current 
depression, poor self-assessed general health, non-consensual  sex and having had a STI 
diagnosed within the past five years. 41.6% of men and 51.2% of women reported at least one 
sexual function problem lasting three months or more in the past year (107). Compared to 
Natsal-2, women reported having more male sexual partners over their lifetime, the 
proportion of women reporting genital contact with a female and at least one female sexual 
partner increased, and there was a decrease in the number of occasions heterosexual 
participants reported having sexual intercourse in the preceding four weeks. There was an 
increase in the proportion of heterosexual participants reporting oral and anal sex. Although 
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there is a reduction in frequency and repertoire, people continue to have sexual intercourse 
into later life (108).  
2.5 SEXUAL HEALTH SERVICES IN ENGLAND 
Development of contemporary sexual health provision in England  
 
The National Strategy for sexual health and HIV, “a comprehensive framework for England for 
preventing the sexual causes of premature death and ill health”, was published in July 
2001(109). This was produced in response to concerns about the state and capacity of Genito-
Urinary Medicine (GUM) services within England. Over the preceding decade there had been a 
marked increase in number of new attendees at GUM clinics and new diagnoses of chlamydia 
and gonorrhoea. Outbreaks of syphilis were reported in London, Brighton and Manchester 
(110;110-112).  GUM clinics lacked the resources to adapt to this increase in demand 
(113;114). In 2000 only 54% of clinics were able to provide access within 24 hours for acute 
cases. There was a median waiting time of 5 and 6 days (range 1-28 days), for men and women 
respectively (115).  Kinghorn described “unacceptable geographical inequities in the levels of 
sexual ill health and service provision”(116). The National Strategy was followed by an 
Implementation Action Plan that was published in 2002(117). The specific aims of the strategy 
were: “1.Reducing the transmission of HIV and STIs; 2. Reducing the prevalence of undiagnosed 
HIV and STIs; 3. Reducing unintended pregnancy rates; 4. Improving health and social care for 
people living with HIV; 5. Reducing the stigma associated with HIV and STIs”(109) 
The main recommendations of the strategy were divided in to four sections: prevention; 
standards and targets; services; research and training(109;116). Some of the major changes 
and implementations that came about following the introduction of this strategy were: 
1. National standards for sexual health services 
2. National standards for the management of STIs 
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3. Development of care pathways and clinical networks 
4. Increased role of primary care  with the introduction of three levels of service (Level 1 
(basic), Level 2 (intermediate) and Level 3 (specialist)) 
5. Improved access to GUM services  
6. National Chlamydia Screening Programme 
In 2003 the House of Commons Health Select Committee called for action in resolving what 
they described as a crisis in sexual health in England. The committee found that primary care 
trusts (PCTs) were failing to engage with the aims and objectives set out in the National 
Strategy for sexual health and HIV (118). Following this report, the Department of Health 
announced that they were investing more money in sexual health (119). 
In 2006 the Chief Medical Officer, Sir Liam Donaldson, sent out a letter, flagged urgent, to all 
chief executives of primary care trusts and strategic health authorities in England, entitled 
‘Improving the Prevention and Treatment of Sexually Transmitted Infections (STIs), including 
HIV’(120). Within this letter Sir Donaldson draws chief executives attention to the National 
Standards for sexual health (in 2005)(121) and HIV (in 2003)(122) that had been published by 
MedFASH, as well as discussing ‘The NHS in England: the operating framework for 
2006/7’(120;123). Sexual health and access to GUM services were prioritised in this 
framework, and targets for access were introduced; by 2008 all patients were to be offered an 
appointment within 48 hours. Despite this, sexual health services in England remain in a state 
of flux. There have been marked improvements, with patients having shorter waiting times, 
and a more direct route, to access GUM care in 2009 compared to 2004/5(124). 
Recent changes in sexual health commissioning 
 
Following on from a wide ranging reform of the delivery of the NHS across UK (health and 
social care act) , in March 2013 ‘A Framework for Sexual Health Improvement in England’(125) 
was published, superseding the National Strategy for Sexual Health and HIV. Key objectives of 
31 
 
this document include: “Improve the sexual health of the whole population; Reduce inequalities 
and improve sexual health outcomes; Build knowledge and resilience among young people; 
Rapid access to high quality services; People remain healthy as they age; Prioritise prevention; 
Reduce rates of STIs among people of all ages; Reduce onward transmission of HIV and 
avoidable deaths from it; Reduce unintended pregnancies among all women of fertile age; 
Continue to reduce the rate of under 16 and under 18 conceptions” (125).  
The framework calls for “collaboration and integration between a broad range of 
organisations, including commissioning organisations, in order to achieve desired 
outcomes”(125). 
These reforms have brought unprecedented change to commissioning arrangements. Since 
April 2013, comprehensive sexual health services have been within the remit of Public Health 
England and therefore Local Authorities are responsible for commissioning these services. 
Certain aspects of sexual health, including HIV care, are commissioned by NHS England(125). 
The ‘shop-front’ provision of sexual health is provided by a number of different healthcare 
providers including tertiary genitourinary clinics, sexual and reproductive health clinics, 
general practice, family planning clinics, and the NCSP. This increase in provision of screening, 
particularly for Chlamydia trachomatis, out with traditional specialist GUM services was 
advocated over 20 years ago (126), and has been increasingly promoted as a solution to 
problems with sexual health service provision by the Department of Health(109;125).  
A greater proportion of the diagnoses of Chlamydia trachomatis in female patients are now 
made in the community, whilst men continue to be more commonly diagnosed within GUM 
clinics. However, access to testing, quality and cost of care, both to the patient and Local 
Authorities, continues to differ depending on the geographical location where the patient 
abides (127-129). In addition, collaborative integrated services, combining contraception and 
sexual health, are in vogue, although there is a lack of guidance on what constitutes an 
integrated service, which services should be integrated and evidence supporting this approach 
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(130). There has been a move towards shifting tertiary services into the community, with some 
areas being put out to tender.  It is my opinion that there continues to be unacceptable 
inequality in care depending on where one accesses a service, duplication or replication occurs 
with people still needing to be seen, or needing to access, two or three different services in 
order to be managed in full, and there remains a lack of communication between individual 
services provided in one area.   
England’s National Chlamydia Screening Programme (NCSP) 
In 1998 the Chief Medical Officer published the findings of an Expert Advisory Group on 
Chlamydia trachomatis. The main conclusions of this report included the need to reduce the 
prevalence, and thereby the morbidity, of infection with Chlamydia trachomatis, and the need 
for innovative methods of testing, which should be coordinate with existing methods in a 
national screening programme(131). In 1999, two pilot chlamydia screening programmes were 
conducted in 16-24 year olds living in the Wirral and Portsmouth. Services that participated in 
recruiting young people for the trials included general practices, family planning clinics, GUM 
clinics, gynaecology services, antenatal clinics and colposcopy clinics.  Women were primarily 
targeted, along with men who were offered testing in specific settings(132). The pilot 
screening programmes were found to be both feasible and acceptable methods of 
implementing screening programmes in the population tested. The pilot studies proved a good 
illustration of where targeted standard screening involving all services that provide sexual 
health screening can be effective. 
The English NCSP was rolled out by the Department of Health in 2003. It aimed ‘to ensure that 
all sexually active young people under 25 are aware of chlamydia, its effects, and have access 
to free and confidential testing services’(101). General practices, GUM clinics, and 
gynaecological services were excluded from this programme. 
 The scientific rationale for the implementation of the NCSP has since been criticised. Adams et 
al, in their evaluation of the cost effectiveness of opportunistic chlamydia screening published 
33 
 
in 2007, conclude that a less inclusive screening programme is likely to be more cost-effective 
than the current NCSP (133). Another concern with an opportunistic national screening 
programme is that we will not reach a high enough proportion of the population to influence 
transmission, and prevent complications(134).   
In 2008, Dr Ruth Hussey, the North West Regional Director of Public Health, was requested to 
review the effect and achievements of the NCSP. Welcome findings of this review included an 
improvement the proportion of 16-24 years old accessing chlamydia screening and improved 
insight into the actions required to continue successful opportunistic screening in this 
population. Concerns included the multiple points of access for requesting postal testing via 
the internet, with a national standard internet access felt to be preferable, and the array of 
messages being projected from different chlamydia screening offices. Furthermore, variable 
costs for sexual health services, ‘even within the same region’, were raised (135;136).  
Although in 2011 91.6% of patients diagnosed positive for chlamydia via the NCSP had 
treatment outcomes recorded, there was great variability in terms of both Strategic Health 
Authority and individual Primary Care Trusts. For example, London had a treatment outcome 
of 83.9% whilst Yorkshire and Humber achieved 91.6%.  The Primary Care Trust  with the 
lowest treatment outcome was Shropshire County with an index treatment rate of 56.2%(137).   
In recent years, the NCSP has recommended that 16-24 year olds test annually for chlamydia 
and certain providers offer dual screening for Neisseria gonorrhoea, despite low national levels 
of gonorrhoea and the low positive predictive value of NAAT testing for this organism in most 
community settings. 
Our interactions with the NCSP within London have indicated that each former Primary Care 
Trust, and current local authority, have their own NCSP office. Each office is allowed to 
implement the programme in a manner that they feel best. Some offices have collaborated 
and use a shared website to promote screening, and the same laboratory for testing and 
delivery of results, whilst other chlamydia screening offices have chosen to work 
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independently. At present there does not seem to be a clear method for highlighting those 
chlamydia screening offices that are most successful, and could therefore be held as an 
example of best practice, and those that are failing, and therefore need input, as the data 
collected for the Chlamydia Testing Activity Dataset is regional. The Chlamydia Testing Activity 
Dataset was introduced in 2012, replacing the NCSP core data return, as a way of collating 
NCSP and community (non-GUM, non-NCSP) data by Public Health England(96).   
2.6 DIFFERENCES BETWEEN SEXUAL HEALTH AND OTHER OUTPATIENT SERVICES 
WITHIN THE NHS  
Open access 
GUM clinics have traditionally worked on an open access basis, with patients being able to self-
refer to the clinic without going through their GP. This process dates back to the Venereal 
Disease Act in 1916 (see below), when the government was attempting to deal with increasing 
numbers of new diagnoses of sexually transmitted infections in the Armed Forces during the 
First World War. The 1916 Public Health Venereal Disease Regulations stated that services 
needed to be available and accessible for confidential  STI testing and treatment should be free 
at the point of access (138).  
The majority of patients accessing GUM services today continue to access the clinic via self-
referral or via other routes that bypass GPs. Patients are asked which method for 
communication of results or other necessary contact is acceptable, and in some cases 
preferable, to them and whether the clinic has permission to contact their GP. Currently 
patients are able to access any GUM clinic they wish to visit and are not restricted to the local 
authority within which they live. With the new commissioning changes implemented in April 
2014, clinicians may be scrutinised by commissioners as to the resident versus non-resident 
population they are serving.  
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Confidentiality 
The sensitive nature of the information collected within a sexual health consultation, led to the 
introduction of the 1916 Venereal Disease Regulations(138). This regulation ensured that 
people accessing GUM services could remain anonymous and would be able to access 
treatment free of charge. The importance of confidentiality in this setting was reiterated in the 
NHS Trusts and Primary Care Trusts (Sexually Transmitted Diseases) Directions 2000 (139).  It 
remains standard practice for hospital-based GUM clinics to have a separate set of clinic notes 
(electronic or paper) for patients from their other hospital notes. However, the NHS Trusts and 
Primary Care Trusts (Sexually Transmitted Diseases) Directions 2000 does not apply to 
Foundation Trusts nor private STI health providers. It is unclear what the implications of this 
will be in terms of how confidentiality is handled and the use of national NHS identification 
numbers in the future.   
Stigma 
Sexual Health differs from other areas of medicine because of the stigma attached to many of 
the conditions it deals with and, because of this, the requirement of heightened confidentiality 
as I will discuss in later sections of my thesis. 
Population 
GUM is one of the few specialities where the majority of its users are young, healthy and 
mobile, and whose expectations and needs are likely to differ from an older, more stable 
population with existing comorbidities.  
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3 eSEXUAL HEALTH 
3.1 ADOPTION OF eHEALTH BY SEXUAL HEALTH 
 
“eSexual Health” does not currently exist as a MESH terms and there is no official definition of 
the term. Therefore, I will broadly define it as the use of digital technology within sexual 
health.    
GUM and Sexual and Reproductive Health clinics have reflected and, in some cases, led the 
emerging field of eHealth. Paper-based history proformas were rapidly adopted, partly 
because the standard set of questions required in any sexual health consultation lending itself 
naturally to this format, but also because of the role of multiple health care professionals in 
the speciality. For example, specialist and qualified staff nurses, and in some cases, 
technicians, see asymptomatic or minimally symptomatic patients, and junior doctors rotating 
into Sexual Health often have a limited knowledge of the speciality. The adaption of paper 
proformas into electronic format has been driven by the need for a computerised database 
containing patient information for audit requirements, with the speciality having a well-
organised national and regional audit network (140), and for vital Public Health England 
surveillance purposes(141). In certain clinics, asymptomatic patients are able to input their 
own details and history using computer assisted self-interviews, then take their own swabs, 
and finally have their bloods taken by a nurse or health care assistant (142-144). 
The maintenance of clinical notes separate from other departments within a hospital has 
meant that GUM clinics have been able to implement EHRs without being dependent on the 
rest of the hospital. This clearly has advantages including the ability to adapt the EHR to the 
individual clinic’s needs and introduce it in a timely manner. However, disadvantages include 
limited funding, the need to rely on separate general hospital based systems to get laboratory 
and medical imaging results and, in some cases, separate systems for HIV and sexual health 
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patients. Health Level 7 compatibility, whereby systems are able to communicate with each 
other using standardised processes(145), is a relatively new concept and at present is unusual 
within sexual health. Instead it is not uncommon for a clinician to need several different pieces 
of software open to manage an individual patient(46).  
In order to facilitate and improve partner notification, web-based interventions, for example 
inSPOT (146), have been introduced. Index patients are able to send e-cards to their sexual 
partners, with the option to send them anonymously if preferred.  inSPOT was originally 
developed for MSM, with an initial evaluation showing promising results with just under 
50,000 e-cards being sent(146). Kerani conducting a randomised controlled trial to establish 
the efficacy of this method and patient-delivered partner therapy for MSM diagnosed with 
chlamydia and gonorrhoea. The study was terminated early because of low recruitment with 
the authors concluding that inSPOT was unpopular with this population(147). A website 
(www.letthemknow.org.au), offering email and SMS as methods for partner notification, and 
targeting heterosexual men and women, was launched in 2008. Bilardi et al conducted an 
evaluation of this service, finding that the website was visited 6481 times over a 10 month 
period. 108 email and 2727 SMS messages were delivered, with the site becoming increasingly 
popular during the 10 month period(148).   
Currently there is a wide variation in what questions people are asked, and how they are 
managed, in the NHS in the UK depending on whether they present to, a sexual health clinic, 
obstetrics & gynaecology clinic or ward, GP, NSCP chlamydia screening office or a pharmacy. 
Standardisation of the questions asked will encourage greater equity of care, and it has been 
shown that there are fewer missed questions, and greater internal consistency, when using 
computer-assisted self-interviews compared to pen-and-paper interviews (40;149;150). 
Studies have shown that computer-assisted self-interviews are a good way of collecting 
reliable sensitive data (40;151-154). However, they have found that complex patients are 
better being assessed in a face-to-face interview (40;152).  Concerns have been raised that 
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patients may lie when completing a questionnaire without a clinician present. Studies do not 
corroborate this, with high risk behaviour being identified more commonly, or at least 
similarly, by computer-assisted self-interviews than by face-to-face interviews 
(40;151;152;155-157). In addition patients reported that they felt it allowed more candid 
responses (156), and this is confirmed with Langhaug et al finding that there is less reporting 
bias of self-reported sexual behaviour when patients used audio computer-assisted self-
interviews compared to other questionnaire methods(158).  
In 2002 Tideman et al, when surveying patients views on the use of computers in a sexual 
health setting, found that 80% of patients expected computer technology to be used in clinic 
and that patients were less willing to use a computer to give details of their sexual history 
(21%), than to give details of their general health (7%) and registration details (9%)(159). In 
Shoveller et al’s qualitative work one youth explained how a physician ‘probing’ and reacting 
to facial expressions meant that he was far more forth coming in a face-to-face interview , and 
that it is not possible to replicate this using a questionnaire(160). 
 
 Private providers of online eSexual Health services 
An increasing number of pharmacy-based and other private sexual health services offer people 
the opportunity to access both STI self-sampling and self-testing kits and treatment online for 
a fee. These services differ from NHS sexual health services in several fundamentally important 
ways. Users of these services can choose which array of organisms they want to be tested for. 
For example, Superdrug Online Doctor offers a range of services from testing for genital 
chlamydia to what they describe as an ‘extended STI test kit’. The latter includes testing for 
chlamydia, gonorrhoea, genital herpes, trichomonas, Gardenella vaginalis, mycoplasma and 
ureaplasma (161) the latter three organisms are not routinely tested for within in NHS settings 
. They do not provide information on which species of mycoplasma and ureaplasma are being 
tested for, the sensitivity and specificity of the tests, nor inform people that Gardenella 
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vaginalis is currently not classified as an STI. Treatment provided by private online providers 
has recently been brought into question when it was discovered that seven online providers 
were offering sub-optimal therapy for people diagnosed with Neisseria gonorrhoeae with 
Cefixime instead of Ceftriaxone (162;163).   
  
3.2 eSEXUAL HEALTH – THE POTENTIAL BENEFITS AND DRAW-BACKS 
Access 
As well as eHealth having led to changes in the way that specialist GUM clinics are organised 
and run, there has been a rise in the number of chlamydia tests that are being requested 
online via the NCSP, and private providers offering online STI testing(164). Patients are also 
able to pick up self-sampling test kits at some Sexual Health Clinics. However, at present, 
irrespective of method of testing, management of positive results requires users to be seen 
either face-to-face in a GUM Clinic, at their GP, in private consultations having a doctor review 
the information prior to prescription being issued, or patients accessing treatment via a 
patient group direction  (“a legal framework that allows some registered health professionals 
to supply and/administer a specified medicine to a pre-defined group of patients, without 
them seeing a doctor (or dentist) at their local community pharmacy”). In addition, there 
continues to be a wide variation in the care and follow-up a patient receiving positive 
chlamydia results receives, treatment outcomes and partner notification levels, within these 
services (137). 
Of concern is the potential for digital technology and eHealth to produce a digital divide, 
making it harder for vulnerable, most at risk, people to access care(165). Although 88% of 16-
24 year olds have smartphones, this means that more than 1 in 10 young adults do not own 
one, and there is an established digital divide in terms of smartphone ownership and socio-
economic group (see page 18)(6).  This is of particular concern as it is unknown whether those 
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young people who do not have access to a smartphone have access to other modalities which 
they can easily access the internet from, and whether it is those people at highest risk of STIs 
who have poor poorest access to digital technology.  What is known is that there are lower 
rates of chlamydia testing in more deprived areas despite higher rates of diagnosis compared 
to less deprived areas (Ref NATSAL). Further research is required before resources are diverted 
from existing programmes targeting this group of people, to finance new interventions, 
without sufficient evidence for the effectiveness of the latter.  
Stigma 
The stigma and discomfort associated with a person being questioned about and discussing 
their sexual behaviour, both in a clinic setting and in their home (for example with the National 
Survey of Sexual Attitudes and Lifestyles (NATSAL) study), has led to the development of 
(audio) computer assisted self interviews (ACASI/CASI) in a research and clinical context 
(40;150-153;155-157;166-173). 
For some, specialist GUM clinics can be places people are reluctant to access because of the 
stigma and perceptions attached to them. Scoular et al, in their qualitative study of women’s 
perceptions on GUM services, describe three main themes that emerged from their interviews: 
1. ‘other’ people suffered from conditions that required one to access these services; 2.  GUM 
clinics are intimidating and places to be avoided; 3. the humiliation associated with attending 
GUM clinics(174). 
By making testing more sociably acceptable, increasing the range of methods available where 
people are able to access testing, and with one of these options potentially being able to both 
access your test and being managed online, therefore removing all personal interaction, the 
hope is that more people will access testing.  
Confidentiality and Privacy 
Long acknowledged as an important issue within sexual health(138), confidentiality and 
privacy continue to be of prime importance (175-180). Researchers from the eSTI2 consortium 
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undertook a qualitative study using semi-structured qualitative interviews with young people 
at Further Education Colleges at the beginning of the programme to establish acceptability of 
the eSTI2 concept.  Privacy was reported as being more important than confidentiality, the 
latter was felt to be intrinsic with the NHS brand(176). Findings from focus groups conducted 
by a human computer interface researcher, to inform the design of the interface of a mobile 
application, as part of the eSTI2 consortium concurred with this(181). At the moment young 
people inherently believe that the NHS is confidential, and can therefore be trusted, and their 
fear is that friends or family may read SMS messages from the eSexual Health Clinic, leading to 
a breach of their privacy(181).  We have an obligation to maintain this concept and to 
reinforce, and build, their trust in the confidentiality and privacy of the service provided. 
Communication 
eHealth has revolutionised the interaction between patients / users and health care 
professionals, both in terms of appointment reminders and facilitating access to health 
promotion, testing, results and partner notification. This has been driven in part by the reasons 
described above, but also by the GUM clinic clientele, who are mostly young people with low 
levels of comorbidity and who are au fait with using mobile and internet technology.  
Examples of where eHealth has been incorporated into routine GUM clinic practice include 
SMS reminders for appointments, which has shown to reduce non-attendance at clinics(182), 
and SMS reminders to men who have sex to men to remind them to access STI testing. Other 
examples where SMS services are used within sexual health include provision of test results. In 
some cases this is linked to the laboratory where the test is processed so that results are 
provided to patients and to the clinic in real time. 
It is clear that young people accessing online sexual health services want the interface to be 
presented professionally and seriously(183), and have low tolerance of methods that they feel 
are out-dated. 
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Example of existing online sexual health services 
 
In the UK, an increasing proportion of chlamydia screening tests are being requested via the 
internet(164), and in the US Gaydos et al have shown the potential and acceptability of online 
testing with their website (http://www.iwantthekit.org/)(184-187). The latter is the closest 
model to the eSTI2 chlamydia online clinical care pathway. Originally designed as a way for 
women to access internet-based self-sampling test kits, in 2014 Spielberg et al published the 
results of a study, conducted in California, exploring the acceptability and feasibility of an 
online system for the testing, management and integration of STI care (188). This paper was 
published after the methodology described in Chapter 3 had been implemented, and does not 
describe the online treatment in detail. The study involved only small numbers of participants 
with a diagnosis of a STI (n=8) and required a clinician to fax a prescription to a pharmacy 
(188). However, it will provide a useful comparison to the eSTI2 study.  
4 eSTI2 
The eSTI2 Consortium is divided into four main work streams: Work stream 1 – Microbiology; 
Work stream 2 – Micro-engineering; Work stream 3 – Diagnostic evaluation; Work stream 4 – 
Clinical and public health.   
My doctoral research lies within Work stream 4, whose initial objectives were set out as 
follows: ‘Guided by the MRC framework for developing and evaluating complex interventions 
we will assess regulatory, clinical, and economic constraints of eSTI2 community testing and 
develop a wireless-web-based system for clinically managing STI diagnosis. We will conduct a 
community-based proof-of-concept study of eSTI2 deployment. Findings will inform WS [work 
stream] 1 and WS [work stream] 2 and further technological development of mobile-interfacing 
rapid diagnostics, in preparation for future community-based trials’(189).  
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Within the eSTI2 (electronic self-testing instruments for sexually transmitted infections) 
consortium we are developing an eHealth point-of-care test for Chlamydia trachomatis. We 
envisage this being a home test linked via mobile technology to a results service, online clinical 
consultation, antibiotic treatment and partner notification. 
Figure 1 illustrates the initial eSTI2 pathway concept, from testing to accessing results. 
Figure 1: The eSTI2 pathway from testing to results 
 
There is a gap in the literature with regards to whether an online results service, clinical 
consultation and provision of an electronic prescription is acceptable, feasible and whether it 
can adequately, safely and securely replace current methods of results notification and a 
consultation with a health care professional. There is a lack of evidence on the best way to 
phrase the online medical and sexual history questions asked in this context.  In addition, there 
are no guidelines on how to evaluate or accredit an online clinical consultation and currently in 
the UK there is no accrediting body for this type of pathway.  
 
My work within Work stream 4 has developed a novel online clinical care pathway for the 
management of people with genital chlamydia. Clearly this is a multidisciplinary effort, in 
which I worked with other eSTI2 researchers who all contributed different expertise. I describe 
in detail the precise elements I did or I led on and where responsibility was shared. Figure 2 
44 
 
below illustrates the basic eSTI2 online clinical care pathway which underpins all subsequent 
discussion.  
Figure 2: A basic outline of the eSTI2 chlamydia clinical care pathway
Chlamydia-Positive 
Index Patient
Online  automated 
clinical assessment
Electronic 
prescription
Collection at 
pharmacy
Partner 
notification
Health 
Advisor 
Hotline
Not safe to 
prescribe
Fast tracked 
to clinic
eSTI2 Clinical Management Pathway
 
 
The eSTI2 Chlamydia Online Clinical Care Pathway has now been piloted in an exploratory study 
involving patients who have accessed testing via traditional Sexual Health Clinics and via 
National Chlamydia Screening Programme internet postal testing. This is discussed in more 
detail in Chapter 4. At the time of submission this study has completed recruitment and 
analysis is underway.  
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Chapter 2: Content and accuracy of 
currently available mobile medical 
applications for sexually 
transmitted and other genital 
infections: a comprehensive review 
 
 
 
 
 
 
1 BACKGROUND 
The number of people in the UK who own a smartphone continues to rise year on year, with 
61% of adults possessing one in 2014(6). Young adults are more likely to own mobile phones 
(99% of 16-34s) or smart phones (88% of 16-24s) compared to their older counterparts (6).  
The incidence of sexually transmitted infections (STIs) is highest in those under 25 years (97) 
and therefore, with the increasing number of internet websites and mobile phone apps geared 
towards providing information on health-related subjects, it is natural there has also been an 
expansion in the provision of online resources and apps for consumers seeking information on 
sexual health. Evidence-based online resources include NHS websites (e.g. 
http://www.nhs.uk/conditions/sexually-transmitted-infections/pages/introduction.aspx), 
health promotion websites (e.g. Sexunzipped(190)) and sexual health charity websites (e.g. 
This chapter is composed of the following components: 
1. Background 
2. Definitions 
3. Aims of this study 
4. Methods 
5. Results 
6. Discussion 
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http://www.fpa.org.uk/_)(191). There are also a number of private providers who offer online 
information on, and testing for, STIs (e.g. Dr Thom) (192) 
 The 2012 press release from the Department of Health  proposing  that in the near future 
General Practitioners would be prescribing apps to facilitate self-management of long-term 
conditions (193)brought into question whether currently available apps are fit for this 
purpose(66). Although there are understandable concerns surrounding inaccurate medical 
apps per se, apps that purport to be diagnostic or for acute conditions, where people may not 
seek advice elsewhere, pose particular concern.  One example that highlights this issue well is 
the inaccuracy of currently available smart phone apps designed for non-health care 
professionals to use to assess whether pigmented cutaneous lesions are melanomas or not 
(194). There is a growing literature on medical mobile phone apps in the UK and a number of 
reviews have been conducted in different medical fields (66-68;70;73;195-201). 
Currently the UK lacks a robust framework specifically designed to evaluate mobile medical 
apps (66;75;194). Two bodies have evaluated apps to date:  
1. NHS England has introduced a library of NHS-reviewed mobile phone apps (NHS choices 
health apps library)(202). The website (http://apps.nhs.uk/review-process/) describes a five-
step review process which apps accepted into the library must satisfy:  
1. Submission of the app for assessment 
2. Team review (assesses what the app does) 
3. Clinical review (if the team feel this is required) 
4. Approval or rejection 
5. Ongoing review (‘the app listing is reviewed on a regular basis and if a user flag 
concern to us’(203)) 
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However, no further information is provided on who is involved in the review team, what the 
clinical review entails, and how frequently the app listings are reviewed(203). 
2. The Medicines and Healthcare Products Regulatory Agency (MHRA) approved its first app 
(Mersey Burns) in January 2013. However, MHRA approves medical devices, not apps per se. In 
this case, the Mersey burns app calculates percentage of body area burned and fluid 
requirements and so the app was classified as a medical device, although no assessment of its 
clinical content efficacy was made. Clearly many medical apps would not fall into the medical 
device category. The MHRA’s method of defining what is and is not a medical device is an 
opaque process, further complicating matters (75).  
In order to inform development and provide context for the eSTI2 Chlamydia-OCCP study, we 
needed to understand the breadth and quality of available apps for people with sexual health 
concerns. In 2012, Health Computer Interface researchers, working as part of eSTI2 (work 
stream 4), undertook an initial scoping review focussing on the human computer interface of 
available apps(204). The result of this scoping review, along with a review of the grey 
literature, reinforced the need for an assessment of content and accuracy of apps providing 
information on STIs and other genital infections. I undertook this assessment and present this 
work here.  The lack of a robust framework for reviewing the content and accuracy of mobile 
medical apps seemed to me to be a striking omission and led me to consider how a system of 
app accreditation could be developed and implemented.  
2 DEFINITIONS 
Smartphones are defined as portable ‘personal computers’, which allow users to interact with 
other people and modalities via a variety of media (e.g. SMS, social media, email) and provide 
them with access to the internet and applications. 
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 An application, known as an ‘app’, has been defined by Boulos et al as a ‘self-contained piece 
of software coded for a specific purpose and usually optimised to run on a mobile device’ 
(205).  
I have used the term mobile medical app to mean any medical or health-related app.  
The Medicines and Healthcare Product Regulatory Agency (MHRA) describe medical devices as 
including ‘most healthcare products other than medicines used for the diagnosis, prevention, 
monitoring treatment of disease, injury or disability. This means everything from artificial hips 
to wound dressing, incubators to insulin infectors and scanners to scalpels’(206).  
3 AIMS OF THIS STUDY 
 
1. To evaluate the content and accuracy of currently available mobile medical apps for 
sexual health aimed at the general public 
2.  To explore the need for standards to accredit mobile medical apps for sexual health 
and how this might be implemented 
4 METHODS 
The methods I used have been adapted from Huckvale et al(66), Abroms et al(70;207) and  
Muessig et al(64),as discussed below.  I have divided this into three phrases as shown in Figure 
3 and described in detail below. 
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Figure 3: Summary of methods used for mobile medical app review 
 
4.1 PHASE 1: SEARCH 
4I conducted an initial search for apps within Apple iOS, Google Play of Android, Blackberry 
World of Blackberry and Windows Phone Apps and Games Store of Microsoft using the 
following search terms, which included all of the common STIs, genital infections, and genital 
syndromes in the UK along with more general terms to used describe STIs and safe sex, 
between 17/08/14-05/09/14 (see Table 2). 
Inclusion criteria at this stage consisted of all apps that appeared related in any way to STIs or 
sexual health, were in the English Language and were developed for members of the public, 
not healthcare professionals. I considered whether to only include apps that were developed 
within the United Kingdom and were therefore under the legal and regulatory control of the 
UK. However, people living within the UK are able to freely access apps that are developed 
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Table 2: NHS Evidence database thesaurus terms used in initial search 
General terms Specific terms 
Sexually transmitted diseases Condoms Non- specific urethritis 
STD Chlamydia NSU 
STDs Gonorrhoea Non- chlamydial non-gonococcal 
urethritis 
STI Syphilis NCNGU 
STIs HPV Pubic lice 
Sexual infection Genital warts Crabs 
Sexual health HSV Trichomonas 
Safe sex Genital herpes Trichomonas vaginalis 
Safer sex Mycoplasma TV 
 Mycoplasma genitalium  
 
anywhere in the world and I felt that this was an important point to highlight and not to 
exclude. Irrespective of the regulation of apps within the UK, people will still be able to access 
apps from other countries. When a search hit on an app that was more general in nature than 
STIs and HIV but was still relevant (e.g. Virus Encyclopedia), the app was included. 
From the results of this initial search, I amended the search terms and eligibility criteria. I 
chose to exclude ‘TV’ (see table below) as a search term as it captured all apps related to 
television (which also uses the abbreviation TV) and did not add any apps that had not been 
captured within the more specific search terms used. In addition I decided to only include apps 
from iOS and Google Play store. The rationale for this was the paucity of relevant apps in 
Blackberry and Windows world and the small proportion of the market that these platforms 
hold. 
Using my amended search criteria, I searched for mobile phone apps between 10/09/14-
16/09/14. I was assisted by two senior medical students whom were trained to meet the core 
national learning outcomes in sexual and reproductive health and HIV (208) prior to 
commencing the study. This was achieved by passing their Queen Mary University of London 
undergraduate core sexual health and HIV programme, and was supplemented with clinical 
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sessions in Barts Health Sexual Health Services.  The revised search terms are shown in Table 3 
below. 
Table 3: Amended search criteria 
General terms Specific terms 
Sexually transmitted 
diseases 
Condoms Non- specific urethritis 
STD Chlamydia NSU 
STDs Gonorrhoea Non- chlamydial non-gonococcal 
urethritis 
STI Syphilis NCNGU 
STIs HPV Pubic lice 
Sexual infection Genital warts Crabs 
Sexual health HSV Trichomonas 
Safe sex Genital herpes Trichomonas vaginalis 
Safer sex Mycoplasma Pelvic inflammatory disease 
 Mycoplasma 
genitalium 
Epididymitis 
 
One researcher searched using the iTunes store and the other researcher searched using 
Google play; I searched using both platforms. Thus, two researchers were used to search each 
platform. This was important to reduce the possibility of missing relevant apps and in an 
attempt to minimise subjectivity. Data, collected from the developer’s description in the 
relevant apps store, was extracted on the following information, using similar criteria to those 
used in other studies (64;66) (see Table 4) 
Table 4: Basic data extraction table 
Title 
of 
app 
Publisher 
Number of 
downloads 
Rating 
Number 
of ratings 
Age 
restriction 
Theme (e.g. 
health and 
fitness) 
Price 
(£0.00) 
Last 
updated 
Author’s 
description 
          
 
I combined and compared all the results gathered and we discussed any discrepancies, and 
made a final decision as to whether the app in question was to be included or excluded.  I 
made a further refinement of the inclusion and exclusion criteria at this stage, utilising the 
knowledge that we had gained during the search phase. The finalised eligibility criteria are 
52 
 
shown in Table 5 below. The major difference from the search phase was the need to exclude 
apps that: 
a) Were in the form of a game or only contained trivia 
b) Covered information on sex that was unrelated to infections or safe sex 
c) Focussed specifically on contraception and did not contain information on infections 
or safe sex 
d) Contained information specific to a country outside the UK and Ireland.  
It only became apparent that these exclusion criteria were necessary once we had started 
searching the app stores.  
Table 5: Inclusion and exclusion criteria 
Inclusion criteria: 
1. Content or tools addressing one or more aspects of sexual health promotion/safe sex 
advice, STI testing, diagnosis, management or support, partner notification 
2. English Language 
3. Available on UK Apple iOS or Google play  
4. Free and paid apps 
Exclusion criteria 
1. Explicitly disclaimed use for a health-related purpose or that are categorised as 
‘Entertainment’, ‘Games’, ‘Casual’ or ‘Puzzle’ 
2. Apps that are specifically developed for health care professionals 
3. No original content (i.e. only links to secondary source) 
4. Focussed solely on HIV/AIDS  
5. Focussed solely on sexual positions, performance, technique, or sex trivia 
6. Focussed solely on sexual dysfunction 
7. Focussed solely on fertility and ovulation checker 
8. Focussed solely on contraception or condom size 
9. General health or infection apps that are not specifically looking at STIs or sexual 
health 
10. Could not be downloaded because of country restrictions that prevented access in the 
UK 
11. Could not be used because of technical problems with the app, after two attempts 
12. Sexual health clinic/condom locators outside the UK 
13. Paid apps which are a paid version of a free app without adverts 
14. App requires a username and password or creating an account to use it 
 
  
53 
 
4.2 PHASE 2: DATA EXTRACTION 
 
In order to collect, analyse and evaluate the data, I developed a customised data extraction 
form described in detail below. The information that had already been gathered formed the 
first section of the data extraction form (see Table 7 below). At this stage I added country, 
region, researcher’s own description of the app, target audience and include/exclude to this 
section.   
I decided to base the second section of the data extraction form on existing criteria that are 
common to all health apps (see Table 8 below). Having reviewed the literature, I concluded 
that the framework which best met the needs of this review was Huckvale’s and Lewis’s 
adaptation of the Health on The Net (HON) Foundation principles for health information on 
the internet (66;209). It contains 19 criteria and uses existing accepted best practice guidelines 
that are used for information on the internet and can be easily adapted and satisfy the needs 
of medical apps. I added whether the app had been approved by NHS Choices health apps 
library or not as an additional criterion.  
Assessment of content and accuracy of apps 
I started by assessing the apps according to two broad categories: 
1. Comprehensiveness of information 
2. Accuracy of information 
This assessment was designed to measure the apps against the degree to which they provided 
comprehensive and accurate information on STIs and genital infection for non-healthcare 
professionals. 
 As my review aimed to consider whether a lay person seeking STI information would receive 
accurate, comprehensive information on the STIs/infection in question,  I compared the 
content and accuracy against specifically designed patient and public information sources from 
NHS Choices*, the British Association of Sexual Health and HIV (BASHH)** and the Family 
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Planning Association (FPA)*** (see Table 6). I decided that content based on evidenced based 
guidelines was not an appropriate medium to compare these apps against as evidence based 
guidelines are aimed at health care professionals and this study focussed on applications 
aimed at ‘lay people’.  
Initially I divided the criteria into terms concerning management of STIs (e.g. testing, diagnosis, 
treatment, partner notification) and coverage of different types of STIs, common genital 
infections and syndromes (see Tables 9 and 10). 
At this stage Mycoplasma genitalium was removed from the review as there is no information 
on this infection in any of the sources mentioned above.  
 
 
 
 
 
 
 
 
 
 
 
 
 
*NHS Choices is a website provided by NHS England which provides ‘a comprehensive health information service’ for the public. It is 
certified by the Information Standard(1). ** BASHH is ‘the UK’s leading professional organisation dealing with all aspects of Sexual 
Health Care’(2). *** FPA is a sexual health charity which provides ‘straightforward information, advice and support on sexual 
health, sex and relationships to everyone in the UK’(3) 
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Table 6: patient and public information sources  
STI/Genital 
infection/ 
safe sex 
BASHH patient 
information 
 leaflet 
NHS Choices webpage Family 
planning 
association 
leaflet 
Chlamydia  http://www.nhs.uk/conditions/Chlamydia/P
ages/Introduction.aspx 
http://www.fpa.o
rg.uk/sites/defaul
t/files/chlamydia-
information-and-
advice.pdf 
Gonorrhoea  http://www.nhs.uk/conditions/Gonorrhoea/
Pages/Introduction.aspx 
http://www.fpa.o
rg.uk/sites/defaul
t/files/gonorrhoe
a-information-
and-advice.pdf 
Syphilis  http://www.nhs.uk/conditions/Syphilis/Page
s/Introduction.aspx 
http://www.fpa.o
rg.uk/sites/defaul
t/files/syphilis-
information-and-
advice.pdf 
Genital warts  http://www.nhs.uk/conditions/genital_warts
/Pages/Introduction.aspx 
http://www.fpa.o
rg.uk/sites/defaul
t/files/genital-
warts-
information-and-
advice.pdf 
HPV  http://www.nhs.uk/conditions/vaccinations/
pages/hpv-human-papillomavirus-
vaccine.aspx 
http://www.nhs.uk/conditions/genital_warts
/Pages/Introduction.aspx 
 
http://www.fpa.o
rg.uk/sites/defaul
t/files/genital-
warts-
information-and-
advice.pdf 
 
Genital herpes  http://www.nhs.uk/conditions/Genital-
herpes/Pages/Introduction.aspx 
http://www.fpa.o
rg.uk/sites/defaul
t/files/genital-
herpes-
information-and-
advice.pdf 
Pubic lice  http://www.nhs.uk/conditions/pubic-
lice/Pages/Introduction.aspx 
http://www.fpa.o
rg.uk/sites/defaul
t/files/pubic-lice-
scabies-
information-and-
advice.pdf 
Trichomonas 
vaginalis 
http://www.bashh.org/doc
uments/TV%20PIL%20Scre
en%20-%20Edit.pdf 
http://www.nhs.uk/conditions/trichomonas
_vaginalis/Pages/Introduction.aspx 
http://www.fpa.o
rg.uk/sites/defaul
t/files/trichomon
as-vaginalis-
information-and-
advice.pdf 
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These sources generally include information on aetiology, transmission, symptoms, testing, 
diagnosis, treatment, partner notification, complications, safe sex and service provision.  
Having looked at the coverage of the information provided by BASHH, the FPA and NHS 
choices, and having taken into account what we wanted to know from the perspective of the 
eSTI2 consortium, the parameters I chose to include in the assessment of coverage of content 
of the apps were: safe sex; testing, diagnosis, information about STIs/infection, management, 
STI/Genital 
infection/ 
safe sex 
BASHH patient 
information leaflet 
NHS Choices webpage Family planning 
association leaflet 
Vaginal 
candidiasis 
 http://www.nhs.uk/conditions/thrush/pa
ges/introduction.aspx 
http://www.fpa.org.uk
/sites/default/files/thr
ush-bacterial-
vaginosis-information-
and-advice.pdf 
Bacterial 
vaginosis 
http://www.bashh.org/doc
uments/BV%20PIL%20Scre
en%20-%20Edit.pdf 
 http://www.fpa.org.uk
/sites/default/files/thr
ush-bacterial-
vaginosis-information-
and-advice.pdf 
Non-specific 
urethritis 
 http://www.nhs.uk/conditions/non_specif
ic_urethritis/pages/causes.aspx 
http://www.fpa.org.uk
/sites/default/files/no
n-specific-urethritis-
information-and-
advice.pdf 
 
Safe sex  http://www.nhs.uk/conditions/contracept
ion-guide/pages/male-condoms.aspx 
http://www.nhs.uk/conditions/contracept
ion-guide/pages/how-do-i-use-
condom.aspx 
http://www.fpa.org.uk
/sites/default/files/ora
l-sex-and-sexually-
transmitted-
infections.pdf 
http://www.fpa.org.uk
/sites/default/files/you
r-guide-to-
contraception.pdf 
http://www.fpa.org.uk
/sites/default/files/mal
e-and-female-
condoms-your-
guide.pdf 
General 
sexual health  
 http://www.nhs.uk/conditions/sexually-
transmitted-
infections/pages/introduction.aspx 
http://www.fpa.org.uk
/sites/default/files/you
r-sexual-health-where-
to-get-help-and-
advice.pdf 
Pelvic 
inflammatory 
disease 
 http://www.nhs.uk/conditions/chlamydia
/pages/complications.aspx 
http://www.nhs.uk/conditions/pelvic-
inflammatory-
disease/pages/introduction.aspx 
 
Epididymitis  http://www.nhs.uk/conditions/chlamydia
/pages/complications.aspx 
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partner notification, ePrescribing, contraception and service provision. The definitions of these 
different parameters can be found in Table 9.   
I assessed each content criterion, in a similar manner to Huckvale et al (66) and Abroms et al 
(207), as being comprehensively covered, partially covered or not covered. I defined 
completely comprehensive as the app provided information on all or the majority (i.e. more 
than 75% or three or more) of aspects of the parameter. I defined partially comprehensive as 
the app covered information on one or more aspect of the parameter, and absent as no 
information provided on the parameter.  
I assessed accuracy as completely accurate (all information is accurate), majority accurate 
(errors in only one aspect of the information (e.g. testing) and no more than two minor errors), 
partially accurate (errors in more than one aspect of the information or more than two minor 
errors) and not accurate (completely inaccurate). In the absence of any guidelines, this was an 
arbitrary stratification.  
I piloted my final app evaluation framework for sexual health apps which met the eligibility 
criteria, with five iOS apps and five Android apps, which I downloaded at this stage.  
The two researchers piloted the evaluation framework with the same apps with one 
researcher assessing the iOS apps and one researcher assessing the Android apps. I reviewed 
the results and amended the data extraction table as necessary. The finalised data extraction 
table is shown in Tables 7 to 11 below. 
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Table 7: Data extraction table for basic details 
Section Parameter Coding Description 
B
asic d
e
tails 
 
Title of App  Text   
Developer Text Name of software publisher (e.g Gooplay Apps) 
Country Text Country app designed in 
Region Text Region app designed for (e.g. Wirral) 
Version Numerical   
Number of 
downloads 
Numerical This is only available for Android apps 
Rating Numerical   
Number of ratings numerical    
Age restriction text or numerical Numerical for iOS, text for Android 
Theme (e.g. health 
and fitness) 
Text   
Price (£) numerical (£0.00)   
Last date updated Date   
Author's description 
of app 
Text What is stated in iTunes store or google play store.  
Our description of 
app 
Text This is your description of the app 
Target audience 
1= general public 2 
= people with STI 3= 
parents 4= other 
  
Target audience_4 Text (99)=N/A)   
Include/Exclude 
1= include 2= 
exclude 
  
Reason for exclusion text (99=N/A)   
General terms (e.g. 
sexual health) 
text (99=absent) 
This is  a list of the general search terms that the app has 
been found under  
Specific terms (e.g. 
chlamydia) 
text (99=absent) 
This is a list of the specific search terms that the app has 
been found under 
Number of different 
terms apps appeared 
in  
Numerical 
This is the number of general terms and specific terms 
that the apps has been found under summed 
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Table 8: Data extraction of adapted HON criteria* 
Section Parameter Coding Description 
A
d
ap
te
d
 H
O
N
 C
rite
ria
 
Author named 1 = yes 2= no The actual author of the app named (not the publisher) 
Training stated 1 = yes 2= no   
Qualification clearly stated 1 = yes 2 = no   
Clearly stated that info is 
supportive and not a 
replacement 
1 = completely 
2= partially 3 = 
absent 
  
App mission, purpose and 
audience stated 
1 = completely 
2= partially 3 = 
absent 
  
Organisation behind app  
described, incl purpose and 
mission 
1 = completely 
2= partially 3 = 
absent 
  
Privacy policy incl info on 
how emails are managed if 
used 
1 = completely 
2= partially 3 = 
absent 
  
Documented, referenced 
and dated 
1 = completely 2 
= partially 3 = 
absent 
  
Medical content date of 
creation present 
1= yes 2 = no   
Medical content date of 
modification present 
1= yes 2= no   
Grammar and spelling 
correct 
1 = yes 2 = no   
All claims backed up with 
scientific evidence 
1 = completely 
2= partially 3 = 
absent 
  
App operational 1= yes 2= no   
Information accessible and 
clearly stated 
1= yes 2= no   
Method of contacting app 
publisher 
1 = yes 2= no   
Source/s of funding stated 
1 = yes 2 = no 
3= not 
applicable 
  
Conflicts of interest and 
external influences clearly 
stated in disclaimer 
1 = yes 2 = no 3 
= not applicable 
  
Those with paying banners 
have advertising policy 
1= yes 2= no 3= 
not applicable 
  
Any conflict of interest 
explained 
1 = yes 2 = no 3 
= not applicable 
  
Approved by NHS choices 1= yes 2=no   
 
 
 
 
*Health On the NET (HON) Foundation principles for health information on the internet 
Table x: Data extraction of comprehensiveness of clinical content 
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Table 9: Comprehensiveness of content 
Section Parameter Coding Description 
C
o
m
p
re
h
e
n
siven
e
ss o
f clin
ical in
fo
rm
atio
n
 
  
1 = completely 2= 
partially 3 = absent 
Completely = information on all or the majority (i.e. >75% or 3 or 
more) of aspects to do with parameter; Partial = information on 1 or 
more aspect to do with parameter but <75%; Absent = no 
information 
Safe sex 
1 = completely 2= 
partially 3 = absent 
Information on health promotion (e.g. condoms) and how to 
prevent onward transmission of STI/s 
Testing 
1 = completely 2= 
partially 3 = absent 
information on where and how you can get tested (blood 
test/ swabs at clinics etc 
Diagnosis 
1 = completely 2= 
partially 3 = absent 
what exactly the tests were/ how they were processed/ what they 
looked at 
Information about 
STIs/infection 
1 = completely 2= 
partially 3 = absent 
Information about 1 or more STI/infection including on 
aetiology/pathogenesis, symptoms, prevention, transmission, 
natural history 
Management 
1 = completely 2= 
partially 3 = absent 
Information about accessing treatment, what treatment is required, 
follow-up etc 
Partner 
notification 
1 = completely 2= 
partially 3 = absent 
Information about the need to inform partners, abstaining from sex 
until partner treated, look back time for PN 
ePrescribing 
1 = completely 2= 
partially 3 = absent 
Able to get an ePrescription or information on this 
Contraception 
1 = completely 2= 
partially 3 = absent 
Information about different forms of contraception 
Service provision 
1=completely 
2=partially 3=absent 
Information about where to access clinics, condoms, or 
contraceptive services.  
Other Text List any other aspects that are covered 
Chlamydia 
1 = completely 2= 
partially 3 = absent 
Completely = information on all or the majority (i.e. >75% or 3 or 
more) of aspects to do with parameter; Partial = information on 1 or 
more aspect to do with parameter but <75%; Absent = no 
information 
Gonorrhoea 
1 = completely 2= 
partially 3 = absent 
Mycoplasma 
1 = completely 2= 
partially 3 = absent 
Genital warts 
1 = completely 2= 
partially 3 = absent 
HPV 
1 = completely 2= 
partially 3 = absent 
Genital herpes 
1 = completely 2= 
partially 3 = absent 
Pubic lice 
1=completely 
2=partially 3=absent 
Trichomonas 
vaginalis 
1 = completely 2= 
partially 3 = absent 
Vaginal 
candidiasis 
1 = completely 2= 
partially 3 = absent 
Bacterial 
vaginosis 
1 = completely 2= 
partially 3 = absent 
Non-specific 
urethritis 
1 = completely 2= 
partially 3 = absent 
Pelvic 
inflammatory 
disease 
1 = completely 2= 
partially 3 = absent 
Epididymitis 
1=completely 
2=partially 3=absent 
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Table 10: Accuracy of clinical information  
Section Parameter Coding Description 
 
A
ccu
racy o
f clin
ical in
fo
rm
atio
n
 
Safe sex 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
Completely accurate = all information is accurate; Majority 
accurate = errors in only 1 aspect of the information (e.g. 
testing) or no more than 2 minor errors (i.e. will not impact 
on patient safety) throughout; Partially accurate = errors in 
more than 1 aspect of the information or more than 2 
minor errors; Not accurate = completely inaccurate 
Testing 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
Diagnosis 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
Information 
about 
STIs/infection 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
Management 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
Partner 
notification 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
ePrescribing 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
Contraception 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
Service 
provision 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
Assess accuracy by checking at least 2 of clinics/sites listed 
are accurate 
Chlamydia 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
Completely accurate = all information is accurate; Majority 
accurate = errors in only 1 aspect of the information (e.g. 
testing) or no more than 2 minor errors (i.e. will not impact 
on patient safety) throughout; Partially accurate = errors in 
more than 1 aspect of the information or more than 2 
minor errors; Not accurate = completely inaccurate 
Gonorrhoea 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
Syphilis 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
Genital warts 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
HPV 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
Genital 
herpes 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
Pubic lice 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
Trichomonas 
vaginalis 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
Vaginal 
candidiasis 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
Bacterial 
vaginosis 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
Non-specific 
urethritis 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
Pelvic 
inflammatory 
disease 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
Epididymitis 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
Overall 
content 
accuracy 
1= completely 2 = majority accurate 
3 = partially accurate  4 = not 
accurate 
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Table 11: Summary and additional information 
 
Section Parameter Coding Description 
A
d
d
itio
n
a
l in
fo
rm
atio
n
 
App allows interaction 
with a healthcare 
professional  
1 = yes 2 = no   
Type of healthcare 
professional 
1 = doctor 2 = nurse 3 = 
pharmacist 4  = other 
99=N/A 
 Type of HCP app allows contact with 
Contact via email 1= yes 2 = no 99 = N/A  App allows contact via email 
Contact via phone 1= yes 2= no 99= N/A  App allows contact via phone 
Contact via app 1 = yes 2 = no 99= N/A  App allows contact via app 
Able to upload photo 1 = yes 2 = No 99 = N/A   
Able to share info with 
SPs 
1= yes 2= no 
Able to share results/information on app with 
sexual partners 
Any other comments Text 
Any other comments that you think need 
mentioning that have not been covered  
 
All the Android apps were tested on an Android mobile phone touch screen and all the iOS 
apps were tested on an iPhone 4s. The remainder of the eligible apps were downloaded and I 
reviewed all of the apps (n=144) and the two researchers reviewed 26 and 31 apps 
respectively. A Research Health Adviser, fully trained in sexual health/STIs to Foundation Year 
1 (junior doctor) level, was then brought in to review the remaining apps. The study was 
explained to the Research Health Adviser and a pilot period was again conducted to ensure 
that that both the Research Health Adviser and the researcher were interpreting the different 
parameters in the same way. 
Duplicate apps (when the same app was available on both platforms) were reviewed by both 
researchers assigned to the app using different platforms. 
Where there was a discrepancy of more than one point between scores applied to parameters, 
I re-reviewed the app and a discussion was held with the other researchers so that the scores 
were amended to within one point of each other. Where a parameter had been scored as 
‘absent’ by one researcher and had a score applied to it indicating it was present by another 
researcher, I reviewed the app to see whether the parameter was absent or not and adjusted 
the scoring appropriately.  
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4.3 PHASE 3 – ANALYSIS FRAMEWORK 
 
I divided the analysis of the data extracted into the following sections: 
1. Basic details and additional information 
2. Adapted HON criteria (Health On the NET (HON) Foundation principles for health 
information on the internet) 
3. Comprehensiveness of content 
4. Accuracy of content 
I performed all analysis using Microsoft Excel and STATA v13.  
Basic details and additional information 
Descriptive statistics were used to summarise the results in the basic details and additional 
information sections. 
Adapted HON Criteria 
The results of the two researchers who assessed each app were compared for both apps and 
any discrepancies in scoring were discussed and resolved. Descriptive statistics were then used 
to summarise the results. The number of HON criteria met by each individual app was summed 
(maximum of 19). I then stratified these results in to four strata according to the number of 
HON criteria met: 1=16-20; 2=11-15; 3=6-10; 4=0-5.  
Comprehensiveness of content 
Despite the presence of a data extraction table (shown above), it is not possible to remove all 
subjectivity from the process. To try and reduce this as far as possible I took the following 
actions: 
1. Where the two researchers gave a score to the same app and the same parameter that 
differed by more than one point, I reassessed the app and parameter  
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2. The scores from both researchers who assessed an individual app were summed for 
each parameter assessed. I then graded these scores for comprehensiveness as: 2= 
complete; 3-4=partial; 6= absent 
Descriptive statistics were then used to summarise this data by both analysing the data in 
terms of individual content parameters, individual apps, and platforms.  
Accuracy of content 
As with the assessment of comprehensiveness of content, despite the presence of a data 
extraction table (shown above), it is not possible to remove all subjectivity from the process. 
To try and reduce this as far as possible I took the following actions: 
1. Where the two researchers gave a score to the same app and the same parameter that 
differed by more than one point, I reassessed the app and parameter, 
2. The scores from both researchers who assessed an individual app were summed for 
each parameter assessed. I then graded these scores for accuracy as: 2= Completely; 3-
4=majority; 5-6=partially; 7-8= not accurate  
3. Although each researcher made an assessment of each app’s overall content accuracy, 
in order to get a more accurate idea of the content accuracy of individual apps I 
summed the scores for each parameter. I initially summed content type and 
STI/infection type separately and then calculated an overall score. Each of these scores 
for each app was then divided by the number of parameters covered within each 
section (and overall for the overall score) for that app multiplied by 8 (maximum score 
for each parameter), and then multiplied by 100 to produce a percentage. This 
percentage was then subtracted from 100.  As the best score that any app could 
achieve for an individual parameter was 2, this meant that the maximum overall 
percentage any app could achieve was 75%. In order to convert this into a percentage 
out of 100, I then divided the percentage by 75 and multiplied it by 100 to reach a final 
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overall percentage (see table 42 below: content type accuracy %; STI/infection 
accuracy%; overall accuracy).  
For example, iOS app ID i1 (see tables 31 & 42 covered 6 different content parameters. 
The sum of the accuracy score for these content parameters was 13. I therefore 
calculated the content accuracy percentage by using the following steps: 
1.  13/(6*8)*100 = 27.1% 
2.  100-27.1 = 72.9% 
3.  72.9/75*100= 97.2% 
 
5 RESULTS 
Using the search terms cited above, we identified 6,642 eligible apps. After screening the app 
developer’s descriptions on the relevant store (iTunes store for iOS apps and Google play for 
Android apps) against the eligibility criteria, we were left with 144 eligible apps which were 
downloaded for full review (see Figure 4 below). Of the 144 eligible apps, 65% (n=94) were 
Android apps, 20% (n=29) were iOS apps and 15% (n=21) were available in both platforms. 
Once these apps were downloaded, a further 40% (n=57) were found to be ineligible for a 
variety of reasons (see Appendix I). Of the 87 apps that underwent full review and analysis, 
60% (n=52) were Android apps, 23% (n=20) were iOS apps and 17% (n=15) were available in 
both platforms.   
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Total number of eligible apps n= 
6,642 
(itunes n=1828
Googleplay n= 4814)
Apps developer descriptions 
searched against eligibility 
criteria
Apps included 
n= 144
(android n=94
iOS n=29
Both n=21)
Apps excluded (n=6491)
· Not available in English
· No sexual health 
content
· Designed for health care 
professionals
· Categorised as 
‘Entertainment’, 
‘Games’, ‘Casual’ or 
‘Puzzle’
Apps downloaded for 
assessment 
Apps excluded n=57 
(android n=42; iOS n=9; both 
n=6)
· Not available in English
· No sexual health 
content
· Crashed on more than 2 
occasions
· No longer available
· Focussed solely on HIV/
AIDS, sex trivia, sexual 
dysfunction, fertility & 
ovulation, condom size
· Required subscription 
or username & 
password
Apps reviewed 
& analysed
 n= 87
(android n = 52
iOS n=20
Both n = 15)
 
 
 
5.1 GENERAL AND ADDITIONAL INFORMATION 
Tables 12, 13 and 14 below show the general information collected on the iOS, Android and 
both platform apps respectively. The number of times each app had been downloaded was 
unavailable for iOS apps. iOS and Android platforms have different methods of categorising 
age restriction, with iOS apps having a numerical category applied to them and Android apps 
being categorised as ‘everyone’, ‘high maturity’, ‘medium maturity’ and ‘low maturity ’ (see 
Figure 4: consort 
diagram 
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Table 19). There is no explanation as to how these categories are assigned and what the 
Android categories mean. When comparing the age restrictions assigned to apps available in 
both platforms (see Table 20) there is wide variability in terms of the age restriction applied by 
the two app stores.    
Tables 15, 16 and 17 show the additional information that was collected on whether the app 
provides a method of contacting a healthcare professional (HCP) and, if so, what type of 
healthcare professional is contactable and which means of contact are available (e.g. email, 
phone etcetera). In addition, data was collected on whether the app enabled the user to share 
information with sexual partners and any comments noted by the individual reviewers are 
recorded in these tables.  
There was marked variation in terms of whether the country where the app was developed 
was named or not depending on platform, with 55% (11/20) of iOS apps, 13% (45/52) of 
Android apps, and 100% (15/15) of apps available in both platforms having a named country of 
origin (see Table 18 below).Overall, 62% (54/87) of apps had no country of origin stated and 
the UK was the prevalent country of origin at 20% (17/87) of apps.  
iTunes store provided no information on the number of times an app had been downloaded. 
Android apps varied in the number of times they had been downloaded from apps which were 
only downloaded 10 times to apps that were downloaded 50,000 times or more.  
The proportion of apps that were rated by users, by awarding a score of a maximum of five 
stars, varied according to platform (5% (1/20) of iOS apps, 48% (25/52) of Android apps and 
93% (14/15) of apps available in both platforms). There were no ratings for the iOS version of 
the 15 apps that were available in both iOS and Android platforms. 
Overall 18 (21%) apps required users to pay a fee to access them, this included: 40% (8/20) of 
iOS apps; 17% (9/52) of Android apps; 21% (1/15) of apps available in both platforms. The 
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majority of apps (48% (42/87)) were classified as Health and Fitness and this was consistent 
between platforms.  
51% (44/87) of apps had been updated in the 12 months prior to this search being conducted 
(see Table 18). A far higher proportion of Android apps (67% (35/52)) had been updated 
compared to iOS apps (30% (6/20)) or apps available in both platforms (20% (3/15)). With the 
exception of apps available in both platforms, the majority of apps were targeted at the 
general public. 25% (22/87) of all apps were classified as targeting ‘other’ and the majority of 
these were targeted at either young people in general or young people in a specific region. 
67% (10/15) of apps available in both platforms were classified as ‘other’. 
Only a small proportion of apps allowed interaction with a healthcare professional and the 
majority of those apps that did allow interaction did not state what type of healthcare 
professional the user would be in contact with. Only two apps allowed people to share 
information with their sexual partner.  
As well as making general observations, the researchers noted information that they felt was 
particularly concerning in the comments section of the data extraction table (see Tables 15, 16 
and 17). Illustrative ‘concerning content’ quotes included: 
‘Genital warts are bad. If they form in a bunch on your genitals, you will have a very bad time 
getting them treated and your relationships will shatter’ 
‘By sexual behaviour it does not only mean having vaginal intercourse. In fact, homosexuals 
can obtain this dreaded disease too through anal and oral sex’ 
‘Once women have left untreated with Chlamydia, they become highly likely of acquiring HIV or 
the human immunodeficiency virus’ 
‘Both the prescription drug Valtrex and some medicinal herbs have been proven to reduce 
herpes viral shedding in clinical studies…….. Certain medicinal herbs may also be beneficial in 
creating a strong immune response against HSV in non-infected partners’ 
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‘Candida (found in yeast infections) can infect your blood, causing an overload of toxins to 
disrupt your system, wreaking havoc on your mind and body’ 
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Table 12: General information (iOS only) 
 
Platform App ID Title of App Developer Country
Number of 
download
s
Rating
Number of 
ratings
Age 
restriction
Theme 
(e.g. 
health & 
fitness)
Price (£)
Last date 
updated
General 
search 
terms
Specific 
search 
terms
Number of 
different 
terms 
apps 
appeared 
in 
iOS i1
Sexually transmitted disease 
(STD) triage 
iDoc24 AB Sweden 99 No rating 0 12+ Medical 0 05/02/2014 2 2 4
iOS i2 STD Guide ViralMesh USA 99 No rating 0 12+
Health & 
Fitness
0 17/11/2010 1 4 5
iOS i3 STD Glossary
Space 
Monkeys 
LLC
USA 99 No rating 0 9+ Medical 0 02/06/2011 1 - 1
iOS i4 iCondom Coventry Raaza Ltd UK 99 No rating 0 12+
Health & 
Fitness
0 11/07/2012 1 1 2
iOS i5 99 - The Talk
Oneapp 
Applicatio
n Studio 
Inc
USA 99 No rating 0 17+ Books 2.99 23/02/2010 2 - 2
iOS i6 Safer Sex
Jo 
Langford
99 99 No rating 0 12+ Education 0 21/11/2013 4 1 5
iOS i7 STD411 
Frank 
Strona
America 99 No rating 0 17+
Health & 
Fitness
0 08/12/2010 2 - 2
iOS i8 Private Girl Tips KEYsci USA 99 No rating 0 12+
Health & 
Fitness
1.49 26/03/2014 1 - 1
iOS i9 SWISH APP
MyOxygen 
Limited
UK 99 No rating 0 12+ Medical 0 27/02/2013 1 2 3
iOS i10
Sex Health Dictionary & Sexual 
Health Video Lessons
WindyApp 
Studio
99 99 No rating 0 17+
Health & 
Fitness
1.99 29/08/2014 1 - 1
iOS i11 Safesex Guide
Mobile 
Identity 
Danmark 
Aps
Denmark 99 No rating 0 17+
Health & 
Fitness
1.49 16/02/2011 1 1 2
iOS i12 Safe sex ASD Soft 99 99 No rating 0 17+ Medical 0 19/06/2014 1 2 3
iOS i13 SafeSex101
UCLA 
Student 
Media
USA 99 No rating 0 17+ Lifestyle 0 24/02/2013 1 - 1
iOS i14
SAFE - Safety Awareness for 
Everyone
Harish 
Subramma
niam
99 99 No rating 0 17+
Health & 
Fitness
0 15/07/2014 1 - 1
iOS i15
iSex - Sex Education and 
Terminology
Hassan 
Hosam
99 99 4 5 17+ Education 1.49 09/09/2009 - 1 1
iOS i16 Girls's guide for sex myths
Soci 
solution
99 99 No rating 0 17+ Lifestyle 0.69 07/09/2011 - 1 1
iOS i17 CaSH 2 U ICE UK 99 No rating 0 9+
Health & 
Fitness
0 17/07/2013 - 1 1
iOS i18 Pap Test Lite
Elton 
Nallbati
99 99 No rating 0 4+ Medical 0 16/02/2013 - 1 1
iOS i19
Natural Yeast Infection 
Solutions
minervaz 99 99 No rating 0 4+
Health & 
Fitness
2.49 10/02/2010 - 1 1
iOS i20
A woman's guide to yeast 
infections
Aimfire 
LLC
99 99 No rating 0 12+
Health & 
Fitness
0.69 26/01/2010 - 1 1
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Table 13: General information (Android only) 
 
Platform App ID Title of App Developer Country Region
Number of 
downloads
Rating
Number of 
ratings
Age 
restriction
Theme (e.g. 
health & 
fitness)
Price (£)
Last date 
updated
General 
search 
terms
Specific 
search 
terms
Number of 
different 
terms apps 
appeared 
in 
Android a1
Abnormal 
Vaginal 
Discharge
App D 
Store
- - 10 No rating 0
medium 
maturity
lifestyle 1.25 09/10/2011 0 1 1
Android a2
About Herpes 
Simplex 
Infection
Nick 
Montano
- - 50 No rating 0
low 
maturity
Health & 
Fitness
0 02/06/2014 0 3 3
Android a3 After Sex
Sachem 
Software 
LLC
- - 10,000 3.4 42
high 
maturity
Health & 
Fitness
0 19/08/2010 2 0 2
Android a4
Bacterial 
Vaginosis 
Disease
Dmitry 
Grigorinov
- - 10 No rating 0 everyone medical 0 25/08/2014 0 2 2
Android a5
Bacterial 
Vaginosis 
Guide 
KoolAppz - - 50 5 1 everyone
Health & 
Fitness
3.07 05/10/2011 0 1 1
Android a6
Bacterial 
Vaginosis 
Treatments
TokyInc - - 500 4.5 2
medium 
maturity
Health & 
Fitness
0 24/06/2014 0 4 4
Android a7
Chlamydia 
Disease and 
Symptoms
Micheal 
Perterson
- - 1 No rating 0 everyone medical 0 24/08/2014 0 1 1
Android a8
Chlamydia 
Know it 
Prevent it 
Treat it
Kindle 
Trove Apps
- - 10 4 2 everyone
Health & 
Fitness
0 16/06/2014 5 1 6
Android a9
Deadly Herpes 
Virus Acyclovir
WebHoldin
gs
- - 10 No rating 0
low 
maturity
Health & 
Fitness
0 21/06/2014 0 3 3
Android a10 Female Herpes
IMJava 
Mobile
- - 1000 4 3
medium 
maturity
medical 0 18/04/2013 6 3 9
Android a11
Genital herpes 
guide
Ashi 
Company
- - 10 4 1
high 
maturity
books and 
reference
0 28/07/2014 0 3 3
Android a12
Genital Herpes 
Information
Naster 
Solomon
- - 10 No rating 0 everyone medical 0 20/08/2014 0 2 2
Android a13
Genital Herpes 
Treatment
WebHoldin
gs
- - 100 4.7 3
medium 
maturity
Health & 
Fitness
0 13/06/2014 0 3 3
Android a14
Genital Herpes 
Treatment
Ashi 
Company
- - 10 No rating 0
high 
maturity
medical 0 29/07/2014 0 3 3
Android a15
Genital Warts 
Guide
Havana 
Apps
- - 100 No rating 0
low 
maturity
Health & 
Fitness
0 16/05/2014 0 3 3
Android a16
Genital Warts 
Guide
Gooplay 
app
- - 10 No rating 0
low 
maturity
Health & 
Fitness
0 05/06/2014 0 2 2
Android a17
Genital warts 
info
Havana 
Apps
- - 100 3 2
low 
maturity
books and 
reference
0 16/05/2014 0 2 2
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Table 13 continued 
 
Platform App ID Title of App Developer Country Region
Number of 
downloads
Rating
Number of 
ratings
Age 
restriction
Theme (e.g. 
health & 
fitness)
Price (£)
Last date 
updated
General 
search 
terms
Specific 
search 
terms
Number of 
different 
terms apps 
appeared 
in 
Android a18
Genital Warts 
Info
Gooplay 
app
- - 100 No rating 0
low 
maturity
Health & 
Fitness
0 05/06/2014 6 2 8
Android a19
Genital Warts 
Info
Ashi 
Company
- - 10 2 1
medium 
maturity
books and 
reference
0 28/07/2014 6 3 9
Android a20
Genital  Warts 
Information
Naster 
Solomon
- - 10-50 No rating 0 everyone medical 0 20/08/2014 0 2 2
Android a21
Get Rid of 
Bacterial 
Vaginosis
HealthSens
ei
- - 500 5 4
low 
maturity
Health & 
Fitness
0 04/12/2013 0 3 3
Android a22
Get Rid of 
Yeast Infection 
Now !
EclipseBoy - - 100 2 1 everyone
Health & 
Fitness
0 03/11/2013 1 4 5
Android a23
Gonorrhea 
Disease & 
Symptoms
Naster 
Solomon
- - 50 No rating 0 everyone medical 0 20/08/2014 0 1 1
Android a24 Guide to STDs KoolAppz - - 10 1 1 everyone
Health & 
Fitness
3.11 13/07/2011 6 4 9
Android a25
Herpes 
Knowledge
Gooplay 
app
- - 50 No rating 0
low 
maturity
books and 
reference
0 15/05/2014 0 2 2
Android a26
Herpes Lupus 
Psoriasis 
Eczema
Yoav Fael - - 100 4.5 4 everyone
Health & 
Fitness
0 01/06/2014 0 1 1
Android a27
Herpes 
Treatment
KING APPS - - 500 4 4 everyone
Health & 
Fitness
0 30/05/2013 0 2 2
Android a28
HPV Infection 
Information
Naster 
Solomon
- - 10 No rating 0 everyone medical 0 26/08/2014 1 1 2
Android a29 iGirl pip90 Uganda - 100 4.5 2 everyone
Health & 
Fitness
0 16/06/2013 1 0 1
Android a30
Knowledge of 
Herpes
Gooplay 
app
- - 10 No rating 0
low 
maturity
books and 
reference
0 05/06/2014 0 2 2
Android a31 No Worries
Smartphon
e Media
UK Wiltshire 100 4.7 3
medium 
maturity
education 0 14/08/2013 7 0 7
Android a32 NORISKS dkberry UK Suffolk 50 No rating 0 everyone
Health & 
Fitness
0 22/07/2011 2 1 3
Android a33
Painful 
urination in 
men
ConstantaS
oft Inc
- - 1 No rating 0 everyone medical 4.33 05/04/2013 2 4 6
Android a34
Pelvic 
inflammatory 
disease
thaweepon
g 
kongkratin
- - 50 4 3 everyone medical 0 23/08/2014 0 2 2
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Table 13 continued 
 
Platform App ID Title of App Developer Country Region
Number of 
downloads
Rating
Number of 
ratings
Age 
restriction
Theme (e.g. 
health & 
fitness)
Price (£)
Last date 
updated
General 
search 
terms
Specific 
search 
terms
Number of 
different 
terms apps 
appeared 
in 
Android a35
Protection - 
Sex
C-
Dimensions 
Ltd
UK - 5 No rating 0
medium 
maturity
lifestyle 0.59 24/02/2011 2 0 2
Android a36
Pubic Lice 
Crabs 
Information 
Noppawin 
sumongdee
- - 10 4 1 everyone medical 0 21/08/2014 0 2 2
Android a37 SAFE Amphibia Malaysia - 1000 4.3 34
medium 
maturity
Health & 
Fitness
0 20/05/2014 4 0 4
Android a38 Safer sex
C-
Dimensions 
Ltd
- - 10 No rating 0
medium 
maturity
lifestyle 0.59 24/02/2011 4 0 4
Android a39
Samedaydocto
r - STD Testing
Creat 
Solutions 
(UK) Ltd
- - 0 No rating 0
medium 
maturity
medical 0 20/08/2014 2 0 2
Android a40
Sexual 
Education
Deep 
Powder 
Software
- - 5 No rating 0
medium 
maturity
Health & 
Fitness
1.09 31/05/2010 3 0 3
Android a41
Sexually 
transmitted 
Stds
noppawin 
sumongdee
- - 100 2.5 4 everyone medical 0 27/08/2014 7 0 7
Android a42 Sheffield SH
Diva 
Creative
UK Sheffield 100 No rating 0
low 
maturity
Health & 
Fitness
0 09/06/2014 1 0 1
Android a43 STD glossary
Publish 
This, LLC
USA Utah 10 4 1 everyone medical 0.72 16/09/2013 6 0 6
Android a44
Stop Vaginal 
Odor
Gallencraft - - 10000-50000 4 251
medium 
maturity
Health & 
Fitness
0 25/08/2014 2 1 3
Android a45
Syphilis 
Disease and 
Symptoms
Pachara 
Kongsookd
ee
- - 50 3 1 everyone medical 0 22/08/2014 0 1 1
Android a46
The Big Book - 
Symptoms of 
STD
Jak - - 5000 4.1 15 everyone
Health & 
Fitness
0 24/01/2013 6 0 6
Android a47 The Sex Guide
C-
Dimensions 
Ltd
- - 10 No rating 0
high 
maturity
lifestyle 0.59 24/02/2011 4 0 4
Android a48
Treat Genital 
Herpes 
Naturally
Muhhas - - 100 No rating 0
high 
maturity
Health & 
Fitness
0 06/04/2014 0 2 2
Android a49
Trichomoniasis 
information
Pachara 
Kongsookd
ee
- - 10 No rating 0 everyone medical 0 25/08/2014 0 2 2
Android a50 UCT Safe Sex 
Informatio
n Systems 
Dept - 
University 
of Cape 
Town
- - 5000-10000 4.2 53
medium 
maturity
Health & 
Fitness
0 09/05/2014 4 1 5
Android a51 Yeast Infection
Dreamland 
Apps
- - 50 No rating 0 everyone
books and 
reference
0 21/02/2014 1 2 3
Android a52
Yeast Infection 
Home Remedy
Karl Evans - - 500 No rating 0 everyone
Health & 
Fitness
0 05/11/2012 1 2 3
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Table 14: General information (available in both platforms)
  
Platform App ID Title of App Author Country
Number of 
downloads
Android 
rating
iTune 
Rating
Android 
number of 
ratings 
iTune 
Number of 
ratings
Android age 
restriction
iTune Age 
restriction
Android 
Theme
itune 
Theme (e.g. 
health & 
fitness)
Price (£)
iTune last 
date updated
Android Last 
date updated
Target 
audience
Target 
audience_4
Android 
general 
search 
terms 
iTune 
general 
search 
terms
Android 
specific 
search 
terms
iTune 
specific 
search 
terms
Android 
Number of 
different 
terms apps 
appeared in 
iTune 
Number of 
different 
terms apps 
appeared in 
Both b1 C&SH Somerset Scrumpylicious UK 500-1000 4.7 No rating 7 8
Medium 
maturi ty
12+
Health & 
Fi tness
Health& 
Fi tness
0 16/08/2014 20/01/2015 4
Young 
people 
1 1 0 0 1 1
Both b2
Conifer Sex 
Health
Scrumpylicious UK 100 4.2 No rating 4 99
Medium 
maturi ty
12+
health 
and 
fi tness
health 
and 
fi tness
0 14/01/2014 17/01/2014 4
People 
l iving in 
Hul l  & 
East 
Riding
7 1 0 2 7 3
Both b3
FPA - Find a  
Cl inic
FPA UK 100 5 No rating 3 7
Medium 
maturi ty
12+ Medica l Medica l 0 05/02/2014 05/02/2014 4
Young 
people
7 0 3 2 10 2
Both b4 FREE 2 B ME
East Sussex 
County 
Counci l
UK 50 - 100 5 No rating 1 0
Medium 
maturi ty
12+
Health & 
Fi tness
Health & 
fi tness
0 22/02/2013 10/03/2013 4
Young 
people
5 1 2 2 7 3
Both b5
Get Them 
Tested
Codigo Pte Ltd Singapore 500 - 1,000 4 No rating 2 0
High 
maturi ty
12+
Health & 
Fi tness
Health & 
fi tness
0 12/05/2014 12/05/2014 2 99 3 3 0 0 3 3
Both b6 Kent C Card
Kent 
Community 
Health NHS 
Trust
UK 500 - 1,000 3.7 No rating 3 10
Low 
maturi ty
4+
Health & 
fi tness
Health & 
fi tness
0 16/09/2013 16/09/2013 4
Young 
people
1 1 1 1 2 2
Both b7 KIS-SK
Col legeMobi l
e, Inc
Canada 100 - 500 4.7 No rating 3 0
Low 
maturi ty
4+ Medica l Medica l 0 05/05/2014 05/05/2014 4
Students , 
young 
people
1 1 0 0 1 1
Both b8
KYSH - Know 
Your Sexual  
Health
fixers UK 10 to 50 No rating No rating 0 0
High 
maturi ty
12+ Li festyle
Health& 
Fi tness
0 16/12/2013 22/11/2013 4
Young 
people
2 2 1 1 3 3
Both b9 My Sex Doctor MYSD LTD UK 5000 3.7 No rating 73 0
High 
maturi ty
12+ Li festyle l i festyle 0 26/05/2014 26/05/2014 1 99 2 2 0 0 2 2
Both b10 NeedTayKnow 99 UK 100 4.9 No rating 7 0
Medium 
maturi ty
12+ Medica l education 0 03/01/2014 03/01/2014 4
Young 
people 
l iving in 
Tays ide
3 1 0 0 3 1
Both b11 SexPos i tive
Univers i ty of 
Oregon
USA
10,000 - 
50,000
3.6 No rating 46 0
High 
maturi ty
17 Education education 0 05/09/2014 04/09/2014 4
Univers i ty 
s tudents
9 3 0 1 9 4
Both b12
Sexual  Health 
Guide
Global  
Internet 
Radio 
Technologies
Ireland
50,000 - 
100,000
4 No rating 234 0
Medium 
maturi ty
17+ Education education 0 24/07/2012 05/03/2013 1 99 7 2 0 1 7 3
Both b13
Sexual  Health 
Liverpool
Glow New 
Media  Ltd
UK 50 - 100 4 No rating 1 0
Medium 
maturi ty
12+
Health& 
Fi tness
Health& 
Fi tness
0 09/04/2013 16/04/2013 1 99 1 3 0 2 1 5
Both b14
Your rapid 
diagnos is  STD
WWW 
Machealth Pty 
Ltd
Austra l ia 50 - 100 0 0 0 0 Everyone 17 Medica l Medica l £2.99/£3.03 19/10/2011 29/01/2013 2 99 6 3 1 0 7 3
Both b15
Your Choice 
Your Voice 
(YCYV)
Scrumpylicious UK 50 - 100 4.5 0 2 0
Medium 
maturi ty
12+
health 
and 
fi tness
health 
and 
fi tness
0 07/10/2014 10/10/2014 4
Young 
people 
l iving in 
bromley
0 1 1 0 1 1
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Table 15: Additional information (iOS only) 
 
 
Platform App ID Title of App Developer
App allows 
interaction 
with a HCP*
Type of 
HCP
Contact via 
email
Contact via 
phone
Contact via 
app
Able to 
upload 
photo
Able to 
share info 
on SPs
iOS i1
Sexually 
transmitted 
disease (STD) 
triage 
iDoc24 AB Yes Doctor Yes No Yes Yes No
iOS i2 STD Guide ViralMesh No - - - - - No
iOS i3 STD Glossary
Space 
Monkeys 
LLC
No - - - - - No
iOS i4
iCondom 
Coventry
Raaza Ltd No - - - - - No
iOS i5 99 - The Talk
Oneapp 
Application 
Studio Inc
No - - - - - No
iOS i6 Safer Sex Jo Langford No - - - - - No
iOS i7 STD411 
Frank 
Strona
Yes Unknown Yes Yes Yes No No
iOS i8 Private Girl Tips KEYsci No - - - - - No
iOS i9 SWISH APP
MyOxygen 
Limited
No - - - - - No
iOS i10
Sex Health 
Dictionary & 
Sexual Health 
Video Lessons
WindyApp 
Studio
No - - - - - No
iOS i11 Safesex Guide
Mobile 
Identity 
Danmark 
Aps
Yes Unknown Yes No Yes No No
iOS i12 Safe sex ASD Soft No - - - - - No
iOS i13 SafeSex101
UCLA 
Student 
Media
No - - - - - No
iOS i14
SAFE - Safety 
Awareness for 
Everyone
Harish 
Subramma
niam
No - - - - - No
iOS i15
iSex - Sex 
Education and 
Terminology
Hassan 
Hosam
No - - - - - No
iOS i16
Girls's guide for 
sex myths
Soci 
solution
Yes Unknown Yes No No No No
iOS i17 CaSH 2 U ICE Yes Unknown No Yes No No No
iOS i18 Pap Test Lite
Elton 
Nallbati
No - - - - - No
iOS i19
Natural Yeast 
Infection 
Solutions
minervaz No - - - - - No
iOS i20
A woman's 
guide to yeast 
infections
Aimfire LLC No - - - - - No
NSU described as 'urethral catarrh'
Any other comments
Clinic locator not accurate or complete, only private clinics.  Service provision = send picture of skin concern and get answer from 
dermatologist within 24h plus clinic locator
Under definition of HPV they have the definition of HIV
Information on where to access condoms but no information on how, why & when you need to use them
Only basic facts on contraception: success rate, brief method of action, effective against STD/pregnancy. No side effects, how to use. 
States emergency contraceptive pill is two pills 12hours apart. Vaguely implies condoms are only method of preventing STIs
Simple information on STDs including symptoms. No diagnosis or management. 
States to be yeast infection must have itching AND white discharge, wrongly encourages use of baby powder 'down there'. 
Monistat** is the recommended treatment. States Pap smear to be done yearly (USA).
Very similar to Natural Yeast Infection Solutions by Minervaz
Although there isnt a facility to share with partners, the app does have a forum to speak to others about "topics" under a lesson 
section. Lessons & information section doen't work
In definitions it signposts you to terms that do not exist in the dictionary (e.g. genital herpes) or to a term that you are already in (e.g. 
diaphragm). In gonorrhoea it tells you about rare complications (without mentioning that they are rare) but doesn't mention 
common symptoms or the fact that it can be asymptomatic
Linked to SeX Factor ICE
Very wordy and opinionated. Implies that medical practitioners are likely to mismanage the condition and treat with antibiotics. 
Potentially dangerous in terms of treatment options.
*HCP, health care professional; SP, sexual partner; ** Monistat a brand name for miconazole vaginal cream 
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Table 16: Additional information (Android only) 
 
 
Platform App ID Title of App 
App allows 
interaction 
with a 
healthcare 
professional 
Type of 
healthcare 
professional
Contact via 
email
Contact via 
phone
Contact via 
app
Able to 
upload 
photo
Able to 
share info 
on SPs
Android a1
Abnormal 
Vaginal 
Discharge
No - - - - - Yes
Android a2
About Herpes 
Simplex 
Infection
No - - - - - No
Android a3 After Sex No - - - - - No
Android a4
Bacterial 
Vaginosis 
Disease
No - - - - - No
Android a5
Bacterial 
Vaginosis 
Guide 
No - - - - - No
Android a6
Bacterial 
Vaginosis 
Treatments
No - - - - - No
Android a7
Chlamydia 
Disease and 
Symptoms
No - - - - - No
Android a8
Chlamydia 
Know it 
Prevent it 
Treat it
No - - - - - No
Android a9
Deadly Herpes 
Virus Acyclovir
No - - - - - No
Android a10
Female 
Herpes
No - - - - - No
Android a11
Genital herpes 
guide
No - - - - - No
Android a12
Genital Herpes 
Information
No - - - - - No
Android a13
Genital Herpes 
Treatment
No - - - - - No
Android a14
Genital Herpes 
Treatment
No - - - - - No
Android a15
Genital Warts 
Guide
No - - - - - No
Android a16
Genital Warts 
Guide
No - - - - - No
Android a17
Genital warts 
info
No - - - - - No
Excellent accurate comprehensive app which includes what to expect when you see a healthcare professional, coping support, 
pregnancy, & episodic & suppressive treatment.
Comments
Very good. Links to a website for more information. 
Pictures/photos with text are incongruous - e.g. on page titled 'definition' there is a picture of a CT scanner
Links to external websites included in the app and to You Tube videos. 
Links to website. No content within actual app. 
Good information about herpes but then under treatment there are two links to websites selling remedies. Mainly discusses using 
culture for diagnosing HSV with only a brief mention of PCR
Has game at end. One section links to wikipedia with no obvious relevance. Poorly written and contains very little information. Only 
mentions HSV-2 as a cause of genital herpes.
Same info as genital herpes Ashi
Linked to genital herpes guide. Only mentions HSV-2 as a cause of genital herpes. Game at end
Scare-mongering e.g. 'Genital warts are bad. If they form in a bunch on your genitals, you will have a very bad time getting them 
treated and your relationships will shatter'. Same format as genital warts info.
Contains very little information. Same format and very similar to Havana app
Virus never leaves the body. Much easier to prevent transmission of the virus than to deal with the virus after you have caught it. 
Multiple inaccuracies & scare-mongering. Link to more information (wikipedia) doesn't work. Game at end. 
Able to click to send email containing the information to someone else. Focus on fertility treatments as well as abnormal discharge 
which seems strange as the two are not necessarily related. 
Quite a lot of scare mongering. Makes herpes sound really horrendous. 
Quite scaremongering. Lots of suggestions for natural remedies and natural prevention methods.
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Table 16 continued
 
Platform App ID Title of App 
App allows 
interaction 
with a 
healthcare 
professional 
Type of 
healthcare 
professional
Contact 
via email
Contact 
via phone
Contact 
via app
Able to 
upload 
photo
Able to 
share info 
on SPs
Android a18
Genital 
Warts Info
No - - - - - No
Android a19
Genital 
Warts Info
No - - - - - No
Android a20
Genital  
Warts 
Information
No - - - - - No
Android a21
Get Rid of 
Bacterial 
Vaginosis
No - - - - - No
Android a22
Get Rid of 
Yeast 
Infection 
Now !
No - - - - - No
Android a23
Gonorrhea 
Disease & 
Symptoms
No - - - - - No
Android a24
Guide to 
STDs
No - - - - - No
Android a25
Herpes 
Knowledge
No - - - - - No
Android a26
Herpes Lupus 
Psoriasis 
Eczema
No - - - - - No
Android a27
Herpes 
Treatment
No - - - - - No
Android a28
HPV Infection 
Information
Android a29 iGirl No - - - - - No
Android a30
Knowledge of 
Herpes
No - - - - - No
Android a31 No Worries Yes Unknown No Yes No No No
Android a32 NORISKS Yes Unknown No Yes No No No
Android a33
Painful 
urination in 
men
No - - - - - No
Android a34
Pelvic 
inflammatory 
disease
No - - - - - No
Comments
Exactly the same as Genital Warts Info by Havana apps
Similar format to Genital warts info by Havana apps. Link to extra information takes you to a wikipedia 'Today's 
featured article' page
Scare mongering. Suggested management includes douching with grapefruit seed extract or hydrogen peroxide. 
Recommends accessing the bacterial vaginosis freedom guide for further info.
Very similar to itune yeast apps
When something is sexually transmitted, it means that it has a very significant possibility of being transmitted 
being animals or human beings through sexual behaviour'. 'By sexual behaviour it does not only mean having 
vaginal intercourse. In fact, homosexuals can obtain this dreaded disease too through anal and oral sex'. 'Actually, 
it was only around the 1990's when scientists and medical professionals decided to call sexually transmitted 
diseases as the venereal diseases'. Refers to STDs as 'a disease' as opposed to individual infections that cause 
disease. 'Most of the strains of the human papillomavirus cause the onset of cervical cancer...' 'Once women are 
left untreated with Chlamydia, they become highly likely of acquiring HIV or the human immunodeficiency virus'. 
Re gonorrhoea: 'a huge percentage of the men who have acquired the infection do not exhibit symptoms.' 'Leaving 
gonorrhea untreated will only affect the infected person's joints and heart valves'. Re Trichomonas: 'The great 
thing about this disease is that it is the number one most curable sexually transmitted disease in the whole world' 
& 'Many believe that performing a natural douche once in a day while having a warm bath is very helpful. Actually, 
they are right. But this method will be much more effective is the juice of a single lemon is added as it increases 
the liquid's parasite-killing power'. 'Those who usually get infected with the genital herpes virus are the poor, 
those who are addicts with cocaine, those with multiple sexual mates, and also those who are uneducated'.
Very similar format to Ashi. Discusses genital herpes only being caused by HSV-2. Infers that you get it by having 
'careless casual sex with strangers'. Information on how HSV is transmitted is ambiguous. Read more tab links to 
herpes simplex page on wikipedia. Game at end. 
Describes HSV-3 (zooster/shingles)
Both the prescription drug Valtrex and some medicinal herbs have been proven to reduce herpes viral shedding in 
clinical studies..' 'Certain medicinal herbs may also be beneficial in creating a strong immune resistance against 
HSV in non-infected partners'. Incubation period 2-12 days. Women with HSV-2 genital herpes the chance of 
spreading the virus to a man if they abstain from having sex during outbreaks is approx 3% in a year; for a man to 
woman - 8%. Video. Estimated 1:4 people in the UK are diagnosed with genital herpes. Genital herpes usually 
caused by HSV-2. Diet and certain foods can trigger outbreaks. Herpes virus does not pass through latex condoms. 
If you know that you have come into contact with the virus in the past few minutes or so then simple act of washing 
the infected area with soap and warm water can help to sweep away the virus from your hands and other areas. 
By doing this you can help avoid the virus from spreading further. Doesn't mention PCR testing (does mention viral 
culture, serologic tests and antigen tests). Discusses dietary habits and herbal remedies as ways of managing the 
infection. Although this app contains a lot of information that is accurate it also contains a lot of information that 
they claim is backed by evidence and it isn't 
Excellent comprehensive app. Crashed on 2 occasions. Centres based in Uganda.
Comprehensive coverage of certain STIs and contraceptive methods including emergency contraception. Only app 
to mention both Ellaone and the IUD as methods of emergency contraception. Also discusses pros and cons of 
certain contraceptive methods.
Exactly the same as Herpes Knowledge by Gooplay Apps. Very similar format to Ashi. Discusses genital herpes only 
being caused by HSV-2. Infers that you get it by having 'careless casual sex with strangers'. Information on how HSV 
is transmitted is ambiguous. Read more tab links to herpes simplex page on wikipedia. Game at end. 
Uses the term venereal diseases. Able to answer questions re symptoms but repeatedly got pop up box stating 
'This application is not licensed. Please purchase it from Android Market' even though I'd paid £4.11 for the app. 
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Table 16 continued
 
Platform App ID Title of App 
App allows 
interaction 
with a 
healthcare 
professional 
Type of 
healthcare 
professional
Contact 
via email
Contact 
via phone
Contact 
via app
Able to 
upload 
photo
Able to 
share info 
on SPs
Android a35
Protection - 
Sex
No - - - - - No
Android a36
Pubic Lice 
Crabs 
Information 
No - - - - - No
Android a37 SAFE No - - - - - No
Android a38 Safer sex No - - - - - No
Android a39
Samedaydoctor 
- STD Testing
Yes Yes Yes Yes Yes No No
Android a40
Sexual 
Education
No - - - - - No
Android a41
Sexually 
transmitted 
Stds
No - - - - - No
Android a42 Sheffield SH No - - - - - No
Android a43 STD glossary No - - - - - No
Android a44
Stop Vaginal 
Odor
No - - - - - No
Android a45
Syphilis 
Disease and 
Symptoms
No - - - - - No
Android a46
The Big Book - 
Symptoms of 
STD
No - - - - - No
Android a47
The Sex 
Guide
No - - - - - No
Android a48
Treat Genital 
Herpes 
Naturally
No - - - - - No
Android a49
Trichomoniasis 
information
Unknown - - - - - No
Android a50 UCT Safe Sex No - - - - - No
Android a51
Yeast 
Infection
No - - - - - No
Android a52
Yeast 
Infection 
Home 
Remedy
No - - - - - No
Initial facts and figures quoted area out of date (references date from 2001) & they have NHS direct number at end 
rather than 111. In format of leaflet which is not particularly easy to scroll through 
Comments
Exactly the same as iTunes SAFE app.
Not obvious that you need to scroll through it. Clearly designed as  leaflet/booklet and has just been transferred 
straight in to an app. 
Coitus interuptus - can work to prevent pregnancy if done right'
Cervical & STI screening is for USA  not UK
The symptoms they describe could also be HSV - e.g. 'burning and tingling sensation' 'make walking, switching 
positions, urinating and sexual intercourse difficult'. 'Sufferers are more likely to develop allergies inhaling 
airborne mold. Damp, dark locations can make them feel worse. They may also display a craving for sugar, breads, 
carbohydrates  & alcohol, though sufferers may not necessarily be tolerant to alcohol. But even then these 
symptoms altogether may make you a candidate for another infection called bacterial vaginosis, which merits its 
own article.' 'Also, when left unchecked, thrush may cause dangerous side-effects, such as endometriosis, ovarian 
dysfunction and the release of toxins which may further jeopardize your immune system'. 'But if the yeast in our 
bodies reach more than the normal levels, that's when yeast infection strikes. Yeast infection causes our bodies 
to produce too much yeast and is triggered by a fungus called Candida albicans'. 'Vaginal yeast infection happens 
more to women after menopause'. Treatment and prevention includes dietary advice, apple cider vinegar 
solution, garlic, cranberry pills, olive leaf and grapefruit seed extract mixed together, raw garlic juice, hydrogen 
peroxide. Article based on book 'yeast infection no more' by Linda Allen. Repetitive & very lengthy. 
Candida (found in yeast infections) can infect your blood, causing an overload of toxins to disrupt your system, 
wreaking havoc on your mind and body. App finishes by saying that there is a really helpful guide/report but not 
stating which one this is and not discussing how vulvovaginal candiasis can be treated. 
Offer of free video if you provide email address. Very small font. 
Information on condoms links to a You Tube video. Able to send a text to order a chlamydia test kit via the app
Contains errors - e.g. definition of male condom = itch; Definition of CT discusses trachoma but fails to discuss 
genital infection; Doesn't mention that doxycycline is used to treat chlamydia; dysplasia - uses an example of 
retinal dysplasia to describe term rather than cervical. Only mentions HSV-2 in terms of genital herpes. Under HPV 
it gives you information on HIV. LN2 - doesn't mention that it is a treatment for warts. Accurate information on LGV. 
'Lice do not have feet designed to walk or hold onto smooth surfaces such as toilet surfaces'. 
The result of PID is a heavy discharge with an extremely noticeable bad smell'. Re Gonorrhea - 'this sexually 
transmitted disease causes a pus-like discharge that is accompanied with a rotten odor. It's possible to become 
re-infected even after each partners has been treated for it'. Re Chlamydia - it can also pass to an unborn baby 
during pregnancy'. Advises using tea tree oil, garlic & panty liners
Contact numbers for different services are out of date
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Table 17: Additional information (available in both platforms) 
Platform App ID Title of App 
App a l lows  
interaction 
with a  
healthcare 
profess ional  
Type of 
healthcare 
profess ion
al
Contact via  
emai l
Contact via  
phone
Contact via  
app
Able to 
upload 
photo
Able to 
share 
information 
with sexual  
partners
Both b1
C&SH 
Somerset
2 99 99 99 99 99 2
Both b2
Conifer Sex 
Health
1 Unknown 2 1 2 2 2
Both b3
FPA - Find a  
Cl inic
2 99 99 99 99 99 2
Both b4 FREE 2 B ME 1 Unknown 2 2 1 2 2
Both b5
Get Them 
Tested
1 Unknown 1 1 2 2 1
Both b6 Kent C Card 2 99 99 99 99 99 2
Both b7 KIS-SK 2 99 99 99 99 99 2
Both b8
KYSH - Know 
Your Sexual  
Health
2 99 99 99 99 99 2
Both b9
My Sex 
Doctor
2 99 99 99 99 99 2
Both b10 NeedTayKnow 2 99 99 99 99 99 2
Both b11 SexPos i tive 2 99 99 99 99 99 2
Both b12
Sexual  
Health 
Guide
2 99 99 99 99 99 2
Both b13
Sexual  
Health 
Liverpool
2 99 99 99 99 99 2
Both b14
Your rapid 
diagnos is  
STD
4 99 99 99 99 99 2
Both b15
Your Choice 
Your Voice 
(YCYV)
4 99 99 99 99 99 2
Diagnostic tests mentioned as swabs, bloods or urine sample. Treatments mentioned only as antibiotics, 
antivirals, creams etc. Sources listed at end. Extensive list of contraceptives,  dis/advantages, contraindications, 
success rates, MoA
Brief sentence each for different types of  contraception. Very extensive list of available sexual health services. 
Does not mention what happens in STI testing, diagnostic tests or management of STIs. Briefly mentions 
chlamydia.
No specific information on CT despite being the commonest STI. Drug managements are not specific to UK; dosage, 
routes, first-line etc incorrect. Incorrectly states warts are caused by HPV 1, Gardasil vaccine protects against 
HPV1 (not 11) and is approved for use in girls 9-26. Vaccine 100% effecitve in preventing infection with HPV types 
16,18, 1 & 6. Herpetic urethritis occurs in 30-40% of affected men. Re candida vulvovaginitis: 'although 
transmission is thought to be mainly sexual, non-sexual infection can also occur'. Yeast may be visualised directly 
under the microscope using a KOH preparation'; 'ensure partner is treated to prevent reinfection'. Re NSU: 
'Treatment should cover NG as this organism is present in about 50% of cases. ELISA test for CT. When doing the 
risk assessment, chlamydia doesn't come up as an option.
The app links to a web application that provides people with more information on STIs and contraception. Able to 
join C card and order a chlamydia test online. BV, thrush and NSU are all discussed under the same section 
together e.g. 'If left untreated they can cause reduced fertility, inflammation of the joints, urethra and eyes, long-
term pelvic pain, ectopic (outside the womb) pregnancy, blocked fallopian tubes, testicle and prostate infection'. 
Re HSV: 'This is called asymptomatic shedding or viral shedding and is extremely contagious'
Cites 'is your wee dark, or does it smell bad?' as a reason to get tested for STIs. Doesn't mention asymptomatic 
infection. Location of clinic services, condom dispensers. Contact information of services.
Doesn't mention copper coil role in EC. Doesn't mention IUS. % quoted aren't accurate. Questions/answers on 
contraception & safe sex. Clinic finder for contraception & STIs. States OCP is taken everyday, no mention of 7day 
break. States patch worn for 7day, replaced weekly. Success rates of some contraceptive methods are much lower 
than those stated in NHS choices
Descriptions of STIs basic eg few example symptoms. Only mentions antivirals for herpes, no management for 
other STIs. No mention of avoiding STI, use of condom, safe sex. General info on tests - bloods, swabs, urine.
Drug management is not specifically named, simply as antibiotics. Description of NGU: 'Acronym for 
nongonococcal urethritis, an infection caused by bacteria. The areas primarily affected by NGU are the cervix and 
the urethra. Typical symptoms are discharge from the penis or vagina and a burning sensation during urination. 
The infection can be sexually transmitted'
Specific treatment names not mentioned; only antibiotcs, antivirals, cream. Does not mention cervical cancer risk 
of HPV. No mention of how often to get tested. Diagnostic tests not explained further than generalised 'pee in a 
pot', swabs and blood.
Link from herpes page doesn't work. Information on chlamydia inaccurate and scaremongering. Risk tool not 
accurate. STD description included transmission, symptoms and complications. Nothing on diagnosis or 
management. Doesn't specify how often you should get STD check. 
Additional  comments/Notes
Partner notification and treatment is only mentioned with regards to pubic lice, scabies and gonorrhoea. Specific 
names of drug treatments not mentioned. Provides information on where to acquire condoms and GUM services, 
but does not emphasise importance of regular check up
Information an all STIs not actually in app but in downloadable leaflets. I have included this information as it was 
very easy to download the leaflets within the app. 
NHS branded app. Vaguely mentions condoms are only method of preventing STIs. STIs described generally 
specifically mentioned in examples only. Diagnostic tests not expanded further than swabs and urine tests. No 
management. 'Without treatment, some STIs such as Chlamydia, HIV, Herpes, HPV and Hepatitis may stop you 
having a baby naturally' 'Most STIs can be treated easily with medicine. But, you should always use a condom as 
some STIs such as HIV, Herpes, HPV and Hepatitis have no cure, and if the symptoms are left untreated could 
cause infertility"
Unable to access partner notifciation module unless you have attended their clinic.  Incorrectly states HPV is 
bloodborne
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The following pages contain summary tables. 
Table 18: Summary of basic details 
 
 
 
NB:  for the apps that were available in both platforms, where different results were available 
for the individual platform (e.g. theme) I had to make an arbitrary decision as to which set of 
results to use. I chose to use the results for the Android version rather than iOS.  
 
iOS n=20 
(%)
Android n= 
52  (%)
Both n=15 
(%)
Tota l  n=87 
(%)
Country of origin
Austra l ia 0 0 1 (7) 1 (1)
Canada 0 0 1 (7) 1 (1)
Denmark 1 (5) 0 0 1 (1)
Ireland 0 0 1 (7) 1 (1)
Malays ia 0 1 (2) 0 1 (1)
Singapore 0 0 1 (7) 1 (1)
Sweden 1 (5) 0 0 1 (1)
Uganda 0 1(2) 0 1 (1)
UK 3 (15) 4 (8) 10 (67) 17 (20)
US 6 (30) 1 (2) 1 (7) 8 (9)
Unknown 9 (45) 45 (87) 0 54 (62)
Ratings
Unrated 19 (95) 27 (52) 1 (7) 47 (54)
0 s tars 0 0 1 (7) 1 (1)
1 s tar 0 1 (2) 0 1 (1)
2 s tars 0 0 0 0
3 s tars 0 3 (6) 0 3 (3)
4 s tars 1 (5) 11 (21) 7 (47) 19 (22)
5 s tars 0 7 (14) 6 (40) 13 (15)
Theme
Books 1 (5) 6 (12) 0 7 (8)
Education 2 (10) 1 (2) 2 (13) 5 (6)
Health & 
Fi tness
10 (50) 25 (48) 7 (47) 42 (48)
Li festyle 2 (10) 4 (8) 2 (13) 8 (9)
Medica l 5 (25) 16 (31) 4 (27) 25 (29)
Price
Free 12 (60) 43 (83) 14 (93) 69 (79)
Paid 8 (40) 9 (17) 1 (7) 18 (21)
£0.00-£0.99 2 (10) 4 (8) 0 6 (7)
£1.00- 6 (30) 5 (10) 1 (7) 12 (14)
Table x: General & additional information 
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Table 18 continued  
  
iOS n=20 
(%) 
Android 
n= 52 (%) 
Both 
n=15 (%) 
Total 
n=87 (%) 
Updated since 
Sept 2013 
        
Yes 6 (30) 35 (67) 3 (20) 44 (51) 
No 14 (70) 17 (33) 12 (80) 43 (49) 
Target 
audience 
        
General public 14 (70) 43 (83) 3 (20) 60 (69) 
People with 
STI/infection 
1 (5) 1 (2) 2 (13.3) 4 (5) 
Parents 1 (5) 0 0 1 (1) 
Other 4 (20) 8 (15) 10 (67) 22 (25) 
App allows 
interaction 
with a HCP  
        
          
Yes 5 (25) 3 (6) 3 (20) 11 (13) 
No 15 (75)  49 (94) 12 (80) 66 (87) 
Type of HCP  (n=5) (n=3) (n=3) (n=11) 
Doctor 1 (20) 1 (33) 0 2 (18) 
Unknown 4 (80)  2 (67) 3 (100) 8 (82) 
Method of 
contact with 
HCP  
(n=5) (n=4) (n=3) (n=12) 
Email 4 (80)  1 (25) 1 (33) 6 (50) 
Phone 2 (40) 3 (75) 2 (67) 7 (58) 
App 3 (60) 1 (25) 1 (33) 5 (42) 
Upload photo 1 (20) 0 0 1 (8) 
Able to share 
info with 
sexual 
partners 
        
Yes 0 1 (2) 1 (7) 2 (2) 
No 20 (100) 51 (98) 14 (93) 85 (98) 
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Table 19: Age restriction for different platforms 
Age 
restriction 
iOS n=20 
(%) 
Android 
n= 52  (%) 
Both 
n=15 (%) 
Total (%) 
iOS and 
Android 
      (n=87)  
No age 
restriction 
0 24 (46) 1 (7) 25 (28.7) 
iOS        (n=35) 
4+ 2 (10) - 2 (13) 5 (14) 
9+ 2 (10) - 0 2 (6) 
12+ 7 (35) - 10 (67) 17 (49) 
17+ 9 (45) - 2 (13) 11 (31) 
Android       (n=42) 
Low 
maturity 
- 10 (19) 2 (13) 
12 (29) 
Medium 
maturity 
- 13 (25) 8 (53) 21 (50) 
High 
maturity 
- 5 (10) 4 (27) 
9 (21)  
 
Table 20: Comparison of age restriction for apps available on both platforms 
 
Android age restriction 
iOS age restriction 
Total 
4+ 12+ 17+ 
Everyone 0 0 1 1 
Low maturity 2 0 0 2 
Medium maturity 0 7 1 8 
High maturity 0 3 1 4 
Total 2 10 3 15 
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5.2 ADAPTED HON CRITERIA 
 
Tables 21, 22 and 23 describe to what extent each app meets each criterion and whether the 
app is approved by NHS choices. A search of the NHS Choices Health Apps Library found 10 
apps under the Sexual Health section. Four of these are targeted at patients with HIV, including 
information on contraception and drug adherence, one is aimed at helping people find out 
where they can get tested for HIV, and one is classified as ‘alcohol’. Of the four apps related to 
sexual health, two have been downloaded and analysed in this review (My Sex Doctor and 
Kent C Card), one was excluded ((Well Happy) see Appendix I), and one was not found using 
the search terms applied (Freetest.me)(210).   
 
Table 24 summarises the data by each criterion. 30% (26/87) of apps have a named author 
with only three (3%) apps and two (2%) apps having the author’s training and qualification 
stated respectively. Whereas a larger proportion of Android apps clearly stated that the 
information provided was supportive and not a replacement for clinical care, a far higher 
proportion of iOS apps and apps available in both platforms had the app mission, purpose and 
audience stated. Only 18% (16/87) of apps provided details on the organisation behind the 
app. Information on the privacy policy was unavailable for the majority of apps with only three 
(3%) apps addressing this. Likewise, only three (3%) apps had any sort of referencing and 
dating of the documentation and only four apps (5%) backed claims with scientific evidence, 
and these were all only assessed as being partially complete. No apps displayed the medical 
content date of creation and modification. 
 
84% (73/87) of apps were assessed as having correct grammar and spelling. However, this 
varied depending on app platform with 93% (14/15) of apps available in both platforms, 90% 
(18/20) of iOS apps and 79% (41/52) of Android apps having correct spelling and grammar. In 
89% (77/87) of the apps, the information was deemed to be accessible and clearly stated. 
84 
 
Again this varied according to platform with 85% (17/20) of iOS apps, 94% (49/52) of Android 
apps and 73% (11/15) of apps available in both platforms meeting this criterion. 97% (85/87) 
were operational.   
 
Whereas 90% (47/52) of Android apps had a method of contacting the app publisher within 
the app description provided in the Googleplay store, only 40% (8/20) of iOS apps and 60% 
(9/15) of apps available in both platforms provided this information. Very few (4/87 (5%)) apps 
had information on the source of funding for the app. Only one app (1%) addressed conflicts of 
interest and external influences within a disclaimer, and only one (3%) app out of the 34 with 
paying banners provided an advertising policy. 
 
When looking at the number of HON criteria met by each app stratified by platform (see Tables 
25 and 26), it can be seen that overall the apps met a median of 4 (IQR 2; 21%) of the 19 
criteria. Both iOS (median = 5; IQR 3) and apps that were available on both platforms (median 
=5; IQR 2) met more criteria than Android apps (median = 4; IQR 1.5). 71% (62/87) of apps met 
five or less criteria, 28% (24/87) met between 6 and 10, and only 1% (1/87) met between 11 
and 15. No apps met more than 11 criteria.  
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Platform App ID
Title of 
App 
Author 
named
Training 
stated
Qualificat
ion clearly 
stated
Clearly 
stated that 
info is 
supportive 
and not a 
replaceme
nt
App 
mission, 
purpose & 
audience 
stated
Organisati
on behind 
app  
described, 
incl 
purpose & 
mission
Privacy 
policy incl 
info on 
how 
emails are 
managed 
if used
Document
ed, 
referenced 
& dated
Medical 
content 
date of 
creation 
present
Medical 
content 
date of 
modificati
on present
Grammar 
& spelling 
correct
All claims 
backed up 
with 
scientific 
evidence
App 
operation
al
Informatio
n 
accessible 
& clearly 
stated
Method of 
contacting 
app 
publisher
Source/s 
of funding 
stated
Conflicts 
of interest 
& external 
influences 
clearly 
stated in 
disclaimer
Those with 
paying 
banners 
have 
advertisin
g policy
Any 
conflict of 
interest 
explained
No of HON 
criteria 
met
Approved 
by NHS 
choices
iOS i1
Sexually 
transmitte
d disease 
(STD) 
triage 
Yes Yes No Yes Yes Yes Yes No No No Yes No Yes Yes Yes Yes No N/A N/A 11 No
iOS i2 STD Guide No No No Yes Yes No No No No No No No Yes Yes No No No N/A N/A 4 No
iOS i3
STD 
Glossary
No No No No Partial No No No No No Yes No Yes Yes No No No N/A N/A 3 No
iOS i4
iCondom 
Coventry
No No No Partial Yes Yes Partial No No No Yes No Yes Yes Yes Yes No N/A N/A 7 No
iOS i5
99 - The 
Talk
Yes Yes Yes No Yes Yes No No No No Yes No Yes Yes Yes N/A N/A N/A N/A 9 No
iOS i6 Safer Sex Yes No No No No No No No No No Yes No Yes Yes No No No N/A N/A 4 No
iOS i7 STD411 Yes No No No Yes Yes No No No No Yes No Yes Yes Yes No No N/A N/A 7 No
iOS i8
Private 
Girl Tips
Yes Yes Yes No Yes No No No No No Yes No Yes No No No No No N/A 6 No
iOS i9
SWISH 
APP
No No No No Yes Yes No No No No Yes No Yes Yes No No No N/A N/A 5 No
iOS i10
Sex Health 
Dictionary 
& Sexual 
Health 
Video 
Lessons
No No No No No No No No No No Yes No Yes Yes No No No No N/A 3 No
iOS i11
Safesex 
Guide
No No No No No No No No No No No No Yes No Yes No No N/A N/A 2 No
iOS i12 Safe sex No No No No No No No No No No Yes No Yes Yes No No No N/A N/A 3 No
iOS i13
SafeSex10
1
No No No No No No No No No No Yes No No No No No No N/A N/A 1 No
iOS i14
SAFE - 
Safety 
Awareness 
for 
Everyone
Yes No No No No No No No No No Yes No Yes Yes No No No N/A N/A 4 No
iOS i15
iSex - Sex 
Education 
and 
Terminolo
gy
Yes No No No Yes No No No No No Yes No Yes Yes No No No No N/A 5 No
iOS i16
Girls's 
guide for 
sex myths
No No No No Partial No No No No No Yes No Yes Yes Yes No No N/A N/A 4 No
iOS i17 CaSH 2 U Yes No No No No Partial No No No No Yes No Yes Yes Yes No No N/A N/A 5 No
iOS i18
Pap Test 
Lite
No No No Yes Yes No Yes No No No Yes No Yes Yes No No No N/A No 6 No
iOS i19
Natural 
Yeast 
Infection 
Solutions
No No No Yes Yes Yes No No No No Yes No Yes Yes Yes No No N/A N/A 7 No
iOS i20
A woman's 
guide to 
yeast 
infections
No No No Yes Yes No No No No No Yes No Yes Yes No No No N/A N/A 5 No
Table 21: Adapted HON criteria (iOS only) 
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Platform App ID Title of App 
Author 
named
Training 
stated
Qualificatio
n clearly 
stated
Clearly 
stated that 
info is 
supportive 
and not a 
replacemen
t
App 
mission, 
purpose & 
audience 
stated
Organisatio
n behind 
app  
described, 
incl 
purpose & 
mission
Privacy 
policy incl 
info on 
how emails 
are 
managed if 
used
Documente
d, 
referenced 
& dated
Medical 
content 
date of 
creation 
present
Medical 
content 
date of 
modificatio
n present
Grammar & 
spelling 
correct
All claims 
backed up 
with 
scientific 
evidence
App 
operational
Informatio
n accessible 
& clearly 
stated
Method of 
contacting 
app 
publisher
Source/s of 
funding 
stated
Conflicts of 
interest & 
external 
influences 
clearly 
stated in 
disclaimer
Those with 
paying 
banners 
have 
advertising 
policy
Any conflict 
of interest 
explained
No of HON 
criteria met
Approved 
by NHS 
choices
Android a1
Abnormal 
Vaginal 
Discharge
No No No Absent Partially Absent Absent Absent No No No Absent Yes Yes No No No N/A N/A 2 No
Android a2
About Herpes 
Simplex 
Infection
Yes No No Completely Partially Partially Absent Absent No No No Absent Yes Yes No No No N/A N/A 4 No
Android a3 After Sex No No No Absent Partially Absent Absent Absent No No Yes Absent Yes Yes No No No N/A N/A 3 No
Android a4
Bacterial 
Vaginosis 
Disease
Yes No No Partially Partially Absent Absent Absent No No Yes Absent Yes Yes Yes No No No N/A 5 No
Android a5
Bacterial 
Vaginosis 
Guide 
Yes No No Completely Partially Absent Absent Absent No No Yes Absent Yes Yes Yes No No N/A N/A 6 No
Android a6
Bacterial 
Vaginosis 
Treatments
No No No Partially Partially Absent Absent Absent No No Yes Absent Yes Yes Yes No No No N/A 4 No
Android a7
Chlamydia 
Disease and 
Symptoms
Yes No No Completely Completely Absent Absent Absent No No Yes Absent Yes Yes Yes No No No N/A 6 No
Android a8
Chlamydia 
Know it 
Prevent it 
Treat it
No No No Absent Absent Absent Absent Absent No No No Absent Yes Yes No No No No No 2 No
Android a9
Deadly Herpes 
Virus Acyclovir
No No No Absent Absent Absent Absent Absent No No Yes Absent Yes Yes No No No N/A N/A 3 No
Android a10 Female Herpes No No No Completely Absent Absent Absent Absent No No Yes Absent Yes Yes Yes No No No No 5 No
Android a11
Genital herpes 
guide
No No No Completely Absent Absent Absent Absent No No No Absent Yes Yes Yes No No N/A N/A 4 No
Android a12
Genital Herpes 
Information
Yes No No Completely Partially Absent Absent Absent No No Yes Absent Yes Yes Yes No No No N/A 6 No
Android a13
Genital Herpes 
Treatment
No No No Completely Absent Absent Absent Absent No No No Absent Yes Yes Yes No No N/A N/A 4 No
Android a14
Genital Herpes 
Treatment
No No No Completely Absent Absent Absent Absent No No No Absent Yes Yes Yes No No No N/A 4 No
Android a15
Genital Warts 
Guide
No No No Completely Absent Absent Absent Absent No No No Absent Yes Yes Yes No No No N/A 4 No
Android a16
Genital Warts 
Guide
No No No Completely Absent Absent Absent Absent No No No Absent Yes Yes Yes No No No N/A 4 No
Android a17
Genital warts 
info
No No No Absent Absent Absent Absent Absent No No Yes Absent Yes Yes Yes No No No N/A 4 No
 
Table 22: Adapted HON criteria (Android only) 
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Platform App ID Title of App 
Author 
named
Training 
stated
Qualificat
ion clearly 
stated
Clearly 
stated that 
info is 
supportive 
and not a 
replaceme
nt
App 
mission, 
purpose & 
audience 
stated
Organisati
on behind 
app  
described, 
incl 
purpose & 
mission
Privacy 
policy incl 
info on 
how 
emails are 
managed 
if used
Document
ed, 
referenced 
& dated
Medical 
content 
date of 
creation 
present
Medical 
content 
date of 
modificati
on present
Grammar 
& spelling 
correct
All claims 
backed up 
with 
scientific 
evidence
App 
operation
al
Informatio
n 
accessible 
& clearly 
stated
Method of 
contacting 
app 
publisher
Source/s 
of funding 
stated
Conflicts 
of interest 
& external 
influences 
clearly 
stated in 
disclaimer
Those with 
paying 
banners 
have 
advertisin
g policy
Any 
conflict of 
interest 
explained
No of HON 
criteria 
met
Approved 
by NHS 
choices
Android a18
Genital Warts 
Info
No No No Absent Absent Absent Absent Absent No No Yes Absent Yes Yes Yes No No No N/A 4 No
Android a19
Genital Warts 
Info
No No No Absent Absent Absent Absent Absent No No No Absent Yes Yes Yes No No No N/A 3 No
Android a20
Genital  
Warts 
Information
Yes No No Completely Partially Absent Absent Absent No No Yes Absent Yes Yes Yes No No N/A N/A 6 No
Android a21
Get Rid of 
Bacterial 
Vaginosis
Yes No No Absent Partially Absent Absent Absent No No Yes Absent Yes No Yes No No No N/A 4 No
Android a22
Get Rid of 
Yeast 
Infection Now 
!
No No No Absent Absent Absent Absent Absent No No Yes Absent Yes Yes Yes No No No N/A 4 No
Android a23
Gonorrhea 
Disease & 
Symptoms
Yes No No Completely Partially Absent Absent Absent No No Yes Absent Yes Yes Yes No No N/A N/A 6 No
Android a24 Guide to STDs No No No Completely Partially Absent Absent Absent No No Yes Absent Yes Yes Yes No No N/A No 5 No
Android a25
Herpes 
Knowledge
No No No Absent Absent Absent Absent Absent No No Yes Absent Yes Yes Yes No No No N/A 4 No
Android a26
Herpes Lupus 
Psoriasis 
Eczema
Yes No No Absent Partially Absent Absent Absent No No No Absent Yes Yes Yes No No No N/A 4 No
Android a27
Herpes 
Treatment
No No No Absent Partially Absent Absent Absent No No Yes Absent Yes Yes Yes No No No N/A 4 No
Android a28
HPV Infection 
Information
Yes No No Completely Partially Absent Absent Absent No No Yes Absent Yes Yes Yes No No N/A N/A 6 No
Android a29 iGirl No No No Absent Partially Absent Absent Absent No No Yes Absent Yes Yes Yes No No N/A N/A 4 No
Android a30
Knowledge of 
Herpes
No No No Absent Absent Absent Absent Absent No No Yes Absent Yes Yes Yes No No No N/A 4 No
Android a31 No Worries Yes No No Absent Partially Absent Absent Absent No No Yes Absent Yes Yes Yes No No N/A N/A 5 No
Android a32 NORISKS No No No Absent Completely Absent Absent Absent No No Yes Absent Yes No Yes No No N/A N/A 4 No
Android a33
Painful 
urination in 
men
No No No Completely Partially Absent Absent Absent No No Yes Absent No Yes Yes No No N/A N/A 4 No
Android a34
Pelvic 
inflammatory 
disease
Yes No No Completely Completely Absent Absent Absent No No Yes Absent Yes Yes Yes No No N/A N/A 7 No
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Platform App ID Title of App 
Author 
named
Training 
stated
Qualificat
ion clearly 
stated
Clearly 
stated that 
info is 
supportive 
and not a 
replaceme
nt
App 
mission, 
purpose & 
audience 
stated
Organisati
on behind 
app  
described, 
incl 
purpose & 
mission
Privacy 
policy incl 
info on 
how 
emails are 
managed 
if used
Document
ed, 
referenced 
& dated
Medical 
content 
date of 
creation 
present
Medical 
content 
date of 
modificati
on present
Grammar 
& spelling 
correct
All claims 
backed up 
with 
scientific 
evidence
App 
operational
Information 
accessible 
& clearly 
stated
Method of 
contacting 
app 
publisher
Source/s 
of funding 
stated
Conflicts 
of interest 
& external 
influences 
clearly 
stated in 
disclaimer
Those with 
paying 
banners 
have 
advertisin
g policy
Any 
conflict of 
interest 
explained
No of HON 
criteria 
met
Approved 
by NHS 
choices
Android a35
Protection - 
Sex
No No No Absent Completely Partially Absent Partially No No Yes Partially Yes Yes Yes No No N/A N/A 5 No
Android a36
Pubic Lice 
Crabs 
Information 
Yes No No Completely Partially Absent Absent Absent No No Yes Absent Yes Yes Yes No No No N/A 6 No
Android a37 SAFE No No No Absent Partially Absent Absent Absent No No Yes Absent Yes Yes Yes No No N/A N/A 4 No
Android a38 Safer sex No No No Absent Completely Partially Absent Partially No No Yes Partially Yes Yes Yes No No N/A N/A 5 No
Android a39
Samedaydoct
or - STD 
Testing
No No No Absent Partially Partially Absent Absent No No Yes Absent Yes Yes Yes No No N/A N/A 4 No
Android a40
Sexual 
Education
No No No Absent Partially Absent Absent Absent No No Yes Absent Yes Yes Yes No No N/A N/A 4 No
Android a41
Sexually 
transmitted 
Stds
Yes No No Completely Completely Partially Absent Absent No No Yes Absent Yes Yes Yes No No No N/A 7 No
Android a42 Sheffield SH No No No Absent Completely Completely Absent Absent No No Yes Absent Yes Yes Yes Yes Yes N/A No 8 No
Android a43 STD glossary No No No Absent Partially Absent Absent Absent No No Yes Absent Yes Yes Yes No No N/A N/A 4 No
Android a44
Stop Vaginal 
Odor
No No No Absent Partially Absent Absent Absent No No Yes Absent Yes Yes Yes No No No N/A 4 No
Android a45
Syphilis 
Disease and 
Symptoms
Yes No No Completely Completely Absent Absent Absent No No No Absent Yes Yes Yes No No No No 6 No
Android a46
The Big Book - 
Symptoms of 
STD
No No No Partially Completely Absent Absent Absent No No Yes Absent Yes Yes Yes No No No N/A 5 No
Android a47 The Sex Guide No No No Absent Completely Partially Absent Absent No No Yes Absent Yes Yes Yes No No N/A N/A 5 No
Android a48
Treat Genital 
Herpes 
Naturally
No No No Absent Partially Absent Absent Absent No No Yes Absent Yes Yes Yes No No No N/A 4 No
Android a49
Trichomonias
is 
information
Yes No No Completely Completely Absent Absent Absent No No Yes Absent Yes Yes Yes No No N/A N/A 7 No
Android a50 UCT Safe Sex Yes No No Absent Absent Completely Absent Absent No No Yes Absent Yes Yes Yes No No N/A N/A 6 No
Android a51
Yeast 
Infection
No No No Absent Partially Absent Absent Absent No No Yes Absent Yes No Yes No No No N/A 3 No
Android a52
Yeast 
Infection 
Home Remedy
Yes No No Partially Partially Absent Absent Absent No No Yes Absent Yes Yes Yes No No No N/A 5 No
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Table 23: Adapted HON criteria (apps available in both platforms) 
 
Platform App ID Title of App 
Author 
named
Tra ining 
s tated
Qual i ficati
on clearly 
s tated
Clearly 
s tated that 
info i s  
supportive 
and not a  
replaceme
nt
App 
miss ion, 
purpose & 
audience 
s tated
Organisati
on behind 
app  
described, 
incl  
purpose & 
miss ion
Privacy 
pol icy incl  
info on 
how 
emai ls  are 
managed i f 
used
Documente
d, 
referenced 
& dated
Medica l  
content 
date of 
creation 
present
Medica l  
content 
date of 
modificati
on present
Grammar 
& spel l ing 
correct
Al l  cla ims  
backed up 
with 
scienti fic 
evidence
App 
operation
al
Informatio
n 
access ible 
& clearly 
s tated
Method of 
contacting 
app 
publ isher
Source/s  
of funding 
s tated
Confl icts  
of interest 
& external  
influences  
clearly 
s tated in 
discla imer
Those 
with 
paying 
banners  
have 
advertis in
g pol icy
Any 
confl ict of 
interest 
expla ined
No of HON 
cri teria  
met
Approved 
by NHS 
choices
Both b1
C&SH 
Somerset
No No No Absent Absent Completely Absent Absent No No Yes Absent Yes Yes No No No
Not 
appl icable
Not 
appl icable
4 No
Both b2
Conifer Sex 
Health
No No No Partia l ly Completely Partia l ly Absent Absent No No Yes Absent Yes Yes Yes No No
Not 
appl icable
Not 
appl icable
5 No
Both b3
FPA - Find a  
Cl inic
No No No Partia l ly Completely Completely Absent Absent No No Yes Partia l ly Yes Yes Yes No
Not 
appl icable
Not 
appl icable
Not 
appl icable
6 No
Both b4 FREE 2 B ME No No No Absent Completely Partia l ly Absent Absent No No Yes Absent Yes Yes No No No
Not 
appl icable
Not 
appl icable
4 No
Both b5
Get Them 
Tested
No No No Completely Completely Completely Partia l ly Absent No No Yes Absent Yes Yes Yes No No
Not 
appl icable
Not 
appl icable
7 No
Both b6 Kent C Card No No No Absent Completely Completely Absent Absent No No Yes Absent Yes No No No No
Not 
appl icable
Not 
appl icable
4 Yes
Both b7 KIS-SK No No No Completely Completely Partia l ly Partia l ly Absent No No Yes Absent Yes Yes No No No
Not 
appl icable
Not 
appl icable
5 No
Both b8
KYSH - Know 
Your Sexual  
Health
No No No Absent Completely Partia l ly Absent Absent No No Yes Absent Yes Yes Yes No No
Not 
appl icable
Not 
appl icable
5 No
Both b9
My Sex 
Doctor
No No No Completely Completely Completely Completely Partia l ly No No Yes Partia l ly Yes Yes Yes No
Not 
appl icable
Yes
Not 
appl icable
9 Yes
Both b10 NeedTayKnow No No No Absent Completely Completely Absent Absent No No Yes Absent Yes No No No No
Not 
appl icable
Not 
appl icable
4 No
Both b11 SexPos i tive No No No Absent Completely Completely Partia l ly Absent No No Yes Absent Yes Yes Yes Yes
Not 
appl icable
Not 
appl icable
Not 
appl icable
7 No
Both b12
Sexual  
Health 
Guide
No No No Absent Partia l ly Partia l ly Absent Absent No No No Absent Yes Yes Yes No No
Not 
appl icable
Not 
appl icable
3 No
Both b13
Sexual  
Health 
Liverpool
No No No Absent Absent Partia l ly Absent Absent No No Yes Absent Yes No Yes No No
Not 
appl icable
Not 
appl icable
3 No
Both b14
Your rapid 
diagnos is  
STD
No No No Completely Completely Completely Absent Absent No No Yes Absent Yes No Yes No No
Not 
appl icable
Not 
appl icable
6 No
Both b15
Your Choice 
Your Voice 
(YCYV)
No No No Absent Completely Partia l ly Absent Absent No No Yes Absent Yes Yes No No No
Not 
appl icable
Not 
appl icable
4 No
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The following tables summarise the HON criteria: 
Table 24: Summary of each HON criterion
 
 
Yes Partially No Yes Partially No Yes Partially No Yes Partially No
Author named 
(%)
8 (40) - 12 (60) 18 (35) - 34 (65) 0 - 15 (100) 26 (30) - 61 (70)
Training stated 
(%)
3 (15) - 17 (85) 0 - 52 (100) 0 - 15 (100) 3 (3) - 2 (84)
Qualification 
clearly stated 
(%)
2 (10) - 18 (90) 0 - 52 (100) 0 - 15 (100) 2 (2) - 85 (98)
Clearly stated 
information 
supportive & 
not 
replacement 
(%)
5 (25) 1 (5) 14 (70) 20 (38) 4 (8) 28 (54) 4 (27) 2 (13) 9 (60) 29 (33) 7 (8) 51 (59)
App mission, 
purpose & 
audience 
stated (%)
10 (52.6) 2 (10.5) 7 (36.8) 11 (21) 26 (50) 25 (29) 12 (80) 1 (7) 2 (13) 34 (39) 29 (33) 24 (28)
Organisation 
behind app 
described, 
including 
purpose & 
mission (%)
6 (30) 1 (5) 13 (65) 2 (4) 6 (12) 44 (85) 8 (53) - 7 (47) 16 (18) 14 (16) 57 (66)
Privacy policy 
including 
information on 
how emails are 
managed if 
used (%)
2 (10) 1 (5) 17 (85) 0 0 52 (100) 1 (7) 3 (20) 11 (73) 3 (3) 4 (5) 80 (92)
Documented, 
referenced & 
dated (%)
0 0 20 (100) 0 2 (4) 50 (96) 0 1 (7) 14 (93) 0 3 (3) 84 (97)
Medical 
content date 
of creation 
present (%)
0 - 20 (100) 0 - 52 (100) 0 - 52 (100) 0 - 87 (100)
Medical 
content date 
of modification 
present (%)
0 - 20 (100) 0 - 52 (100) 0 - 52 (100) 0 - 87 (100)
Grammar & 
spelling correct 
(%)
18 (90) - 2 (10) 41 (79) - 11 (21) 14 (93) - 1 (7) 73 (84) - 14 (16)
iOS n=20 (%) Android n=52 (%) Both n=15 (%) Total n=87 (%)
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Table 24 continued 
Yes Partially No
Not 
applicable
Yes Partially No
Not 
applicable
Yes Partially No
Not 
applicable
Yes Partially No
Not 
applicable
All claims 
backed up 
with 
scientific 
evidence
0 0 20 (100) - 0 2 (4) 50 (96) - 0 2 (13) 13 (87) - 0 4 (5) 83 (95) -
App 
operation
al
19 (95) - 1 (5) - 51 (98) - 1 (2) - 15 (100) - 0 - 85 (97) - 2 (2) -
Informatio
n 
accessible 
& clearly 
stated
17 (85) - 3 (15) - 49 (94) - 3 (6) - 11 (73) - 4 (27) - 77 (89) - 10 (11) -
Method of 
contacting 
app 
publisher
8 (40) - 12 (60) - 47 (90) - 5 (10) - 9 (60) - 6 (40) - 64 (74) - 23 (26) -
Source/s 
of funding 
stated
2 (10) - 18 (90) 0 1 (2) - 51 (98) 0 1 (7) - 14 (93) 0 4 (5) - 83 (95) 0
Conflicts 
of interest 
& external 
influences 
clearly 
stated in 
disclaimer
0 - 19 (95) 1 (5) 1 (2) - 51 (98) 0 0 - 12 (80) 3 (20) 1 (1) - 82 (94) 4 (5)
Those 
with 
paying 
banners 
have 
advertisin
g policy
0 - 3 (15) 17 (85) 0 - 26 (50) 26 (50) 1 (7) - 0 14 (93) 1 (1) - 29 (33) 57 (66)
Any 
conflict of 
interest 
explained
0 - 1 (5) 19 (15) 0 - 5 (10) 47 (90) 0 - 0 15 (100) 0 - 6 (7) 81 (93)
Approved 
by NHS 
choices
0 - 20 (100) - 0 - 52 (100) - 2 (13) - 13 (87) - 2 (2) - 85 (98) -
iOS n=20 (%) Android n=52 (%) Both n=15 (%) Total n=87 (%)
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Table 25: Summary of number of HON criteria met according to app platform 
 
 No of HON 
criteria met 
(n=19) 
iOS (%) n=20 
Android (%) 
n=52 
Both 
(%) 
n=15 
Total (%) n=87 
2 1 (5) 2 (4) 0 3 (3) 
3 3 (15) 4 (8) 2 (13) 9 (10) 
4 4 (20) 24 (46) 5 (33) 33 (38) 
5 4 (20) 9 (17) 3 (20) 16 (18) 
6 2(10) 9 (17) 2 (13) 13 (15) 
7 3 (15) 3 (6) 2 (13) 8 (9) 
8 0 1 (2) 0 1 (1) 
9 1(5) 0 1 (7) 2 (2) 
10 0 0 0 0 
11 1(5) 0 0 1 (1) 
Median 
(IQR) 
5 (3) 4 (1.5) 5 (2) 4 (2) 
 
Table 26: Summary of number of HON criteria met according to app platform divided into 
strata 
 
 
  
No of HON 
criteria met
iOS (%) 
n=20
Android (%) n=52
Both (%) 
n=15
Total (%) 
n=87
0-5 13 (65) 39 (75) 10 (67) 62  (71)
6-10 6 (30) 13 (25) 5 (33) 24 (28)
11-15 1 (5) 0 0 1 (1)
16-19 0 0 0 0
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5.3 COMPREHENSIVENESS OF APPS 
 
As described on page 53, the FPA, NHS Choices and BASHH patient information webpages 
provide comprehensive coverage of all elements of routine STI/genital infection management. 
In contrast, we found great variability in coverage and comprehensiveness of these elements 
in the apps reviewed.  
I will first describe the coverage and comprehensiveness of the content parameters (i.e. safe 
sex, testing, diagnosis, information about STIs/infection, management, partner notification, 
ePrescribing, contraception and service provision). I will then describe the coverage and 
comprehensiveness of the individual STI/infections (e.g. chlamydia, gonorrhoea).  
Content parameters  
Fully comprehensive coverage 
A minority of apps provided fully comprehensive information on individual content parameters 
with an overall median of 1 (IQR 2) content parameter covered fully per app (median 1 (IQR1) 
for IOS apps; median 0 (IQR 1) for Android apps; median 2 (IQR 1) for apps available in both 
platforms) (see Table 34).  
We found that there was marked variability depending on the parameter we were assessing 
and the platform the app was from (see Tables 27 to 33 below).  Whereas 47% (13/15) of apps 
available in both platforms provided fully comprehensive information on safe sex, only 5% 
(1/20) of iOS apps did and only 10% (5/52) Android apps did. This pattern of a greater 
proportion of apps available in both platforms providing fully comprehensive information, 
compared to iOS apps and Android apps, was present in all areas of STI management to 
greater and lesser degrees.   
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Partially comprehensive coverage 
A much higher proportion of apps provided partial information on the content parameters 
compared to providing fully comprehensive information, with the exception of service 
provision (24% (21/87) fully comprehensive; 10% (11/87) partially comprehensive). This was 
particularly striking with Android apps which provided fully comprehensive information on a 
median of 0 content parameters, and partially comprehensive information on a median of 4 
(IQR 2) content parameters (see Table 35).  
Overall coverage 
A median of 5 (IQR 3) content parameters were covered per app, with iOS apps covering a 
median of 4 (IQR 4), Android apps covering a median of 5 (IQR 3) and apps available in both 
platforms covering a median of 6.5 (IQR 4). The wide IQR reflect the variability in terms of 
content parameters covered, with between 1 (n=4) and 8 (n=6) content parameters being 
covered per individual app (see Table 36).  
Eighty nine percent (78/87) of apps provided information about STIs/infections (including 
about aetiology, pathogenesis, symptoms, prevention, transmission, and natural history where 
appropriate). However, the majority of apps (71% (62/87)) provided only partially 
comprehensive information.  
Overall 21% failed to provide any information on safe sex and, of particular concern, 67% did 
not provide any information on partner notification. iOS apps were particularly poor at 
providing information on the latter with 80% (16/20) of apps providing no information.  
Six percent (5/87) of apps solely focussed on accessing STI testing, although overall only 64% 
(54/87) of apps covered this parameter. No apps covered electronic prescribing. Although 
coverage of contraception was poor, particularly for iOS apps and apps available in both 
platforms, we only used one search term (‘contraception’) to search for this.  
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STI/genital infections  
Fully comprehensive coverage 
Only 18% (median 0 (IQR 0) of apps provided fully comprehensive information on the STI/s or 
genital infection/s that they were covering (see Table 37). This equated to no more than 7 apps 
(8%) providing information for each STI/infection at this level of detail. 
Coverage of STIs and provision of information did not reflect prevalence of STIs within the UK. 
Despite chlamydia being the commonest bacterial genital infection within the UK, with up to 
10% of 16-24 year olds infected (211), only three apps (3%) provided fully comprehensive 
information. A higher proportion of apps (8% (7/87)) provided fully comprehensive 
information on gonorrhoea.  Likewise, 8% (7/87) of apps provided fully comprehensive 
information on genital herpes, the most common infection covered overall. 
Partially comprehensive coverage 
As with coverage of content parameters, a much higher proportion of individual STI/genital 
infections were covered partially as opposed to fully (see Table 38). The condition that was 
covered most commonly was genital herpes, with 46% (40/87) providing partial information. 
Overall coverage 
Content coverage was highly variable with 34/87 (39%) covering one or two infections, 47% 
(16/34) of which were ebooks, predominantly about genital herpes or candidiasis. 46% (40/87) 
of apps covered three or more infections (see Table 39). 
Fifty seven percent (50/87) of the eligible apps provided no information on chlamydia, There 
was wide variability of coverage when comparing iOS and Android apps with, for example, 55% 
(11/20) of iOS apps providing information on chlamydia compared with 27% (14/52) of 
Android apps. A higher proportion of iOS apps, compared to Android apps, provided 
information on all the different STIs/infections with the exception of bacterial vaginosis and 
96 
 
pelvic inflammatory disease. Bacterial vaginosis and vaginal candidiasis were covered in 22% 
(19/87) and 23% (26/87) of apps respectively.  
As with areas of STI management, for the majority of STIs/infection, apps that were available 
in both platforms covered more STIs/infections and provided more comprehensive 
information compared with iOS apps and Android apps. 
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Table 27: Comprehensiveness of content type and STI/infection type for each app (iOS only) 
 
 
 
 
Platform App ID Title of App Safe sex Testing Diagnosis
Informatio
n about 
STIs/infect
ion
Managem
ent
Partner 
notificatio
n
ePrescribi
ng
Contracep
tion
Service 
provision
Chlamydia
Gonorrhoe
a
Syphilis
Genital 
warts
HPV
Genital 
herpes
Pubic l ice
Trichomon
as 
vaginalis
Vaginal 
candidiasi
s
Bacterial 
vaginosis
NGU
Pelvic 
inflammat
ory 
disease
Epididymit
is
iOS i1
Sexually transmitted disease 
(STD) triage 
Partial Complete Absent Complete Partial Partial Absent Absent Partial Partial Partial Partial Partial Partial Partial Absent Absent Partial Absent Absent Absent Absent
iOS i2 STD Guide Partial Partial Partial Partial Partial Partial Absent Absent Partial Complete Complete Complete Complete Complete Complete Absent Complete Absent Absent Absent Absent Absent
iOS i3 STD Glossary Partial Partial Partial Partial Absent Complete Absent Partial Absent Partial Partial Partial Partial Partial Partial Partial Partial Partial Absent Partial Partial Absent
iOS i4 iCondom Coventry Absent Absent Absent Absent Absent Absent Absent Absent Complete Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent
iOS i5 99 - The Talk Partial Partial Complete Complete Partial Absent Absent Complete Absent Partial Partial Partial Complete Complete Partial Partial Partial Partial Partial Partial Partial Partial
iOS i6 Safer Sex Partial Absent Absent Absent Absent Absent Absent Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent
iOS i7 STDPartial11 Partial Partial Absent Partial Absent Absent Absent Partial Complete Partial Partial Partial Absent Absent Partial Absent Absent Absent Absent Absent Absent Absent
iOS i8 Private Girl Tips Partial Partial Absent Partial Partial Partial Absent Absent Absent Partial Partial Partial Partial Partial Partial Partial Partial Partial Absent Absent Absent Absent
iOS i9 SWISH APP Absent Absent Absent Absent Absent Absent Absent Absent Complete Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent
iOS i10
Sex Health Dictionary & Sexual 
Health Video Lessons
Partial Partial Partial Partial Partial Absent Absent Partial Absent Partial Partial Partial Partial Partial Partial Partial Partial Partial Partial Absent Partial Partial
iOS i11 Safesex Guide Partial Absent Absent Partial Partial Absent Absent Partial Absent Partial Partial Partial Partial Partial Partial Partial Partial Partial Absent Partial Absent Absent
iOS i12 Safe sex Partial Absent Absent Absent Absent Absent Absent Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent
iOS i13 SafeSex101 Partial Complete Partial Partial Partial Absent Absent Partial Complete Partial Partial Partial Partial Partial Partial Partial Partial Absent Absent Absent Absent Absent
iOS i14
SAFE - Safety Awareness for 
Everyone
Partial Partial Absent Complete Partial Absent Absent Partial Partial Partial Partial Partial Partial Partial Partial Absent Absent Absent Absent Absent Absent Absent
iOS i15
iSex - Sex Education and 
Terminology
Partial Absent Absent Partial Absent Absent Absent Partial Absent Partial Partial Partial Partial Partial Partial Partial Absent Partial Absent Absent Partial Partial
iOS i16 Girls's guide for sex myths Complete Absent Absent Partial Absent Absent Absent Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent
iOS i17 CaSH Complete U Absent Partial Absent Absent Absent Absent Absent Absent Complete Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent
iOS i18 Pap Test Lite Absent Partial Partial Partial Absent Absent Absent Absent Partial Absent Absent Absent Absent Partial Absent Absent Absent Absent Absent Absent Absent Absent
iOS i19
Natural Yeast Infection 
Solutions
Partial Absent Absent Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Complete Absent Absent Absent Absent
iOS i20
A woman's guide to yeast 
infections
Partial Absent Partial Partial Complete Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Complete Absent Absent Absent Absent
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Table 28: Comprehensiveness of content type and STI/infection type for each app (Android only) 
 
 
Platform App ID
Title of 
App 
Safe sex Testing Diagnosis
Information 
about 
STIs/infection
Management
Partner 
notification
ePrescribing Contraception
Service 
provision
Chlamydia Gonorrhoea Syphilis
Genital 
warts
HPV
Genital 
herpes
Pubic lice
Trichomonas 
vaginalis
Vaginal 
candidiasis
Bacterial 
vaginosis
NGU
Pelvic 
inflammatory 
disease
Epididymitis
Android a1 Abnormal 
Vaginal 
Discharge
Partial Absent Absent Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Partial Partial Partial Absent Partial Absent
Android a2 About 
Herpes 
Simplex 
Infection
Partial Absent Absent Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Partial Absent Absent Absent Absent Absent Absent Absent
Android a3 After Sex Partial Partial Partial Partial Partial Partial Absent Absent Partial Partial Partial Partial Partial Partial Partial Partial Partial Partial Partial Absent Partial Absent
Android a4 Bacterial 
Vaginosis 
Disease
Partial Partial Partial Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Complete Absent Partial Absent
Android a5 Bacterial 
Vaginosis 
Guide 
Partial Partial Partial Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Complete Absent Partial Absent
Android a6 Bacterial 
Vaginosis 
Treatment
s
Absent Absent Absent Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Partial Absent Partial Absent
Android a7 Chlamydia 
Disease 
and 
Symptoms
Partial Partial Partial Partial Partial Complete Absent Absent Absent Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Partial Partial
Android a8 Chlamydia 
Know it 
Prevent it 
Treat it
Absent Partial Absent Partial Absent Absent Absent Absent Absent Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Partial Absent
Android a9 Deadly 
Herpes 
Virus 
Acyclovir
Absent Partial Partial Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Partial Absent Absent Absent Absent Absent Absent Absent
Android a10 Female 
Herpes
Partial Partial Partial Partial Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent Complete Absent Absent Absent Absent Absent Absent Absent
Android a11 Genital 
herpes 
guide
Partial Absent Absent Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Partial Absent Absent Absent Absent Absent Absent Absent
Android a12 Genital 
Herpes 
Informatio
n
Partial Partial Partial Partial Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent Partial Absent Absent Absent Absent Absent Absent Absent
Android a13 Genital 
Herpes 
Treatment
Partial Partial Partial Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Partial Absent Absent Absent Absent Absent Absent Absent
Android a14 Genital 
Herpes 
Treatment
Partial Partial Partial Partial Partial Absent Absent Absent Absent Partial Partial Partial Partial Partial Partial Partial Partial Partial Partial Partial Partial Partial
Android a15 Genital 
Warts 
Guide
Complete Partial Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent
Android a16 Genital 
Warts 
Guide
Partial Absent Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent
Android a17 Genital 
warts info
Partial Absent Absent Partial Partial Partial Absent Absent Absent Absent Absent Absent Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent
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Table 28 continued 
 
 
Platform App ID
Title of 
App 
Safe sex Testing Diagnosis
Information 
about 
STIs/infection
Management
Partner 
notification
ePrescribing Contraception
Service 
provision
Chlamydia Gonorrhoea Syphilis
Genital 
warts
HPV
Genital 
herpes
Pubic lice
Trichomonas 
vaginalis
Vaginal 
candidiasis
Bacterial 
vaginosis
NGU
Pelvic 
inflammatory 
disease
Epididymitis
Android a18 Genital 
Warts Info
Complete Partial Partial Complete Partial Partial Absent Absent Absent Absent Absent Absent Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent
Android a19 Genital 
Warts Info
Absent Partial Partial Partial Partial Absent Absent Absent Absent Absent Absent Absent Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent
Android a20 Genital  
Warts 
Informatio
n
Partial Partial Partial Partial Complete Absent Absent Absent Absent Absent Absent Absent Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent
Android a21 Get Rid of 
Bacterial 
Vaginosis
Absent Absent Absent Partial Complete Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Partial Absent Absent Absent
Android a22 Get Rid of 
Yeast 
Infection 
Now !
Absent Absent Absent Complete Complete Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Complete Absent Absent Absent Absent
Android a23 Gonorrhea 
Disease & 
Symptoms
Partial Partial Partial Partial Partial Complete Absent Partial Partial Absent Complete Absent Absent Absent Absent Absent Absent Absent Absent Absent Partial Partial
Android a24 Guide to 
STDs
Partial Partial Partial Partial Partial Absent Absent Absent Absent Partial Partial Partial Partial Partial Partial Partial Partial Absent Partial Absent Partial Absent
Android a25 Herpes 
Knowledge
Absent Absent Absent Complete Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Partial Absent Absent Absent Absent Absent Absent Absent
Android a26 Herpes 
Lupus 
Psoriasis 
Eczema
Complete Complete Complete Complete Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Partial Absent Absent Absent Absent Absent Absent Absent
Android a27 Herpes 
Treatment
Partial Partial Partial Complete Complete Partial Absent Absent Absent Absent Absent Absent Absent Absent Partial Absent Absent Absent Absent Absent Absent Absent
Android a28 HPV 
Infection 
Informatio
n
Partial Partial Partial Partial Partial Absent Absent Absent Absent Absent Absent Absent Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent
Android a29 iGirl Partial Complete Complete Partial Partial Complete Absent Partial Complete Partial Partial Partial Partial Partial Partial Partial Partial Absent Partial Absent Partial Absent
Android a30 Knowledg
e of 
Herpes
Absent Absent Absent Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Partial Absent Absent Absent Absent Absent Absent Absent
Android a31 No 
Worries
Partial Complete Complete Complete Complete Partial Absent Partial Partial Partial Partial Partial Absent Absent Partial Partial Absent Absent Absent Partial Absent Absent
Android a32 NORISKS Absent Absent Absent Absent Absent Absent Absent Absent Complete Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent
Android a33 Painful 
urination 
in men
Partial Absent Partial Partial Partial Absent Absent Absent Absent Absent Partial Partial Absent Absent Partial Partial Absent Absent Absent Partial Absent Absent
Android a34 Pelvic 
inflammat
ory 
disease
Partial Partial Partial Partial Partial Partial Absent Partial Absent Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Complete Absent
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Table 28 continued 
 
 
 
Platform App ID
Title of 
App 
Safe sex Testing Diagnosis
Information 
about 
STIs/infection
Management
Partner 
notification
ePrescribing Contraception
Service 
provision
Chlamydia Gonorrhoea Syphilis
Genital 
warts
HPV
Genital 
herpes
Pubic lice
Trichomonas 
vaginalis
Vaginal 
candidiasis
Bacterial 
vaginosis
NGU
Pelvic 
inflammatory 
disease
Epididymitis
Android a35 Protection - 
Sex
Complete Partial Partial Partial Partial Partial Absent Absent Partial Partial Partial Partial Partial Absent Partial Absent Absent Absent Absent Partial Absent Absent
Android a36 Pubic Lice 
Crabs 
Informatio
n 
Partial Partial Partial Partial Partial Complete Absent Absent Absent Absent Absent Absent Absent Absent Absent Complete Absent Absent Absent Absent Absent Absent
Android a37 SAFE Partial Complete Partial Complete Complete Absent Absent Complete Absent Partial Partial Partial Absent Partial Partial Absent Absent Absent Absent Absent Absent Absent
Android a38 Safer sex Partial Absent Absent Partial Absent Absent Absent Absent Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent
Android a39 Samedayd
octor - STD 
Testing
Absent Complete Complete Absent Absent Absent Absent Absent Partial Partial Partial Partial Partial Partial Partial Absent Partial Absent Partial Partial Absent Absent
Android a40 Sexual 
Education
Partial Absent Absent Partial Absent Absent Absent Partial Absent Absent Absent Absent Absent Absent Absent Absent Partial Partial Partial Absent Partial Absent
Android a41 Sexually 
transmitte
d Stds
Complete Partial Partial Partial Partial Complete Absent Absent Absent Partial Partial Partial Absent Partial Partial Absent Partial Absent Absent Absent Absent Absent
Android a42 Sheffield 
SH
Partial Absent Absent Partial Absent Absent Absent Partial Complete Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent
Android a43 STD 
glossary
Partial Absent Partial Partial Partial Partial Absent Absent Absent Partial Partial Partial Partial Partial Partial Partial Partial Partial Absent Partial Partial Absent
Android a44 Stop 
Vaginal 
Odor
Partial Partial Partial Partial Partial Absent Absent Absent Absent Partial Partial Absent Absent Absent Partial Absent Absent Partial Partial Absent Partial Absent
Android a45 Syphilis 
Disease 
and 
Symptoms
Partial Partial Partial Partial Partial Partial Absent Absent Absent Absent Absent Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent
Android a46 The Big 
Book - 
Symptoms 
of STD
Partial Absent Absent Partial Partial Partial Absent Absent Absent Partial Partial Partial Partial Partial Partial Partial Partial Absent Partial Absent Partial Absent
Android a47 The Sex 
Guide
Partial Absent Absent Partial Absent Absent Absent Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent
Android a48 Treat 
Genital 
Herpes 
Naturally
Partial Partial Partial Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Complete Absent Absent Absent Absent Absent Absent Absent
Android a49 Trichomon
iasis 
informatio
n
Partial Partial Partial Partial Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Complete Absent Absent Absent Absent Absent
Android a50 UCT Safe 
Sex 
Partial Absent Absent Absent Absent Absent Absent Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent
Android a51 Yeast 
Infection
Absent Absent Absent Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Partial Absent Absent Absent Absent
Android a52 Yeast 
Infection 
Home 
Remedy
Absent Partial Partial Partial Partial Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Complete Absent Absent Absent Absent
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Table 29: Comprehensiveness of content type and STI/infection type for each app (apps available in both platforms) 
 
Platform App ID
Title of 
App 
Safe sex Testing Diagnos is
Informatio
n about 
STIs/infect
ion
Managem
ent
Partner 
noti ficatio
n
ePrescribi
ng
Contracept
ion
Service 
provis ion
Chlamydia
Gonorrhoe
a
Syphi l i s
Genita l  
warts
HPV
Genita l  
herpes
Pubic l ice
Trichomon
as  
vaginal is
Vaginal  
candidias i
s
Bacteria l  
vaginos is
Non-
speci fic 
urethri tis
Pelvic 
inflammat
ory 
disease
Epididymit
is
Both b1
C&SH 
Somerset
Complete Partia l Partia l Partia l Partia l Partia l Absent Partia l Complete Partia l Partia l Partia l Partia l Absent Partia l Partia l Partia l Absent Absent Absent Absent Absent
Both b2
Conifer 
Sex Health
Partia l Complete Partia l Complete Complete Partia l Absent Complete Complete Absent Absent Absent Absent Partia l Absent Absent Absent Partia l Absent Absent Absent Absent
Both b3
FPA - Find 
a  Cl inic
Complete Complete Complete Complete Complete Partia l Absent Complete Complete Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Partia l Partia l
Both b4
FREE 2 B 
ME
Partia l Partia l Partia l Partia l Absent Absent Absent Absent Complete Partia l Partia l Absent Absent Partia l Partia l Absent Absent Absent Absent Absent Absent Absent
Both b5
Get Them 
Tested
Partia l Complete Partia l Complete Partia l Partia l Absent Absent Complete Partia l Partia l Absent Partia l Partia l Partia l Absent Absent Absent Partia l Partia l Absent Absent
Both b6
Kent C 
Card
Partia l Absent Absent Partia l Absent Absent Absent Partia l Complete Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent
Both b7 KIS-SK Absent Absent Absent Absent Absent Absent Absent Complete Complete Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent
Both b8
KYSH - 
Know Your 
Sexual  
Health
Absent Complete Partia l Partia l Partia l Absent Absent Absent Complete Partia l Absent Partia l Partia l Absent Partia l Partia l Absent Absent Absent Absent Absent Absent
Both b9
My Sex 
Doctor
Complete Complete Partia l Complete Partia l Complete Absent Complete Absent Partia l Absent Absent Absent Absent Absent Absent Absent Absent Absent Partia l Absent Absent
Both b10
NeedTayK
now 
Complete Partia l Partia l Partia l Partia l Absent Absent Complete Complete Partia l Partia l Partia l Partia l Partia l Partia l Absent Absent Absent Absent Absent Absent Absent
Both b11
SexPos itiv
e
Complete Partia l Absent Partia l Absent Absent Absent Partia l Absent Partia l Partia l Partia l Partia l Partia l Partia l Absent Absent Absent Absent Absent Absent Absent
Both b12
Sexual  
Health 
Guide
Complete Complete Partia l Complete Partia l Complete Absent Complete Complete Partia l Partia l Partia l Partia l Partia l Partia l Partia l Partia l Partia l Absent Absent Absent Absent
Both b13
Sexual  
Health 
Liverpool
Complete Partia l Absent Partia l Absent Absent Absent Partia l Complete Partia l Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent
Both b14
Your rapid 
diagnos is  
STD
Partia l Complete Complete Complete Complete Complete Absent Absent Complete Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent
Both b15
Your 
Choice 
Your Voice 
(YCYV)
Partia l Partia l Absent Partia l Partia l Absent Absent Partia l Complete Partia l Partia l Partia l Partia l Partia l Partia l Partia l Partia l Partia l Partia l Partia l Partia l Absent
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The following tables summarise this information: 
 
Table 30: comprehensiveness of different parameters 
 
 
 
 
 
Platform
Any 
coverage
Completely 
comprehensive
Partially 
comprehensive
Absent
iOS n=20 16 (80) 1 (5) 15 (75) 4 (20)
Android 
n=52
40 (77) 5 (10) 25 (48) 12 (23)
Both n=15 13 (87) 7 (47) 6 (40) 2 (13)
Tota l  n=87 69 (79) 13 (15) 56 (64) 18 (21)
iOS n=20 11 (55) 2 (10) 9 (45) 9 (45)
Android 
n=52
32 (62) 5 (10) 27 (52) 20 (38)
Both n=15 13 (87) 7 (47) 6 (40) 2 (13)
Tota l  n=87 56 (64) 14 (16) 42 (48) 31 (36)
iOS n=20 8 (40) 1 (5) 7 (35) 12 (60)
Android 
n=52
34 (66) 4 (8) 30 (58) 18 (35)
Both n=15 10 (66) 2 (13) 8 (53) 5 (33)
Tota l  n=87 52 (60) 7 (8) 45 (52) 35 (40)
iOS n=20 15 (75) 3 (15) 12 (60) 5 (25)
Android 
n=52
49 (94) 7 (13) 42 (81) 3 (6)
Both n=15 14 (93) 6 (40) 8 (53) 1 (7)
Tota l  n=87 78 (89) 16 (18) 62 (71) 9 (10)
iOS n=20 10 (50) 1 (5) 9 (45) 10 (50)
Android 
n=52
41 (79) 6 (12) 35 (67) 11 (21)
Both n=15 10 (67) 3 (20) 7 (47) 5 (33)
Tota l  n=87 61 (70) 10 (11) 51 (59) 26 (30)
iOS n=20 4 (20) 1 (5) 3 (15) 16 (80)
Android 
n=52
18 (35) 5 (10) 13 (25) 34 (65)
Both n=15 7 (47) 3 (20) 4 (27) 8 (53)
Tota l  n=87 29 (33) 9 (10) 20 (23) 58 (67)
iOS n=20 0 0 0 20 (100)
Android 
n=52
0 0 0 52 (100)
Both n=15 0 0 0 15 (100)
Tota l  n=87 0 0 0 87 (100)
iOS n=20 11 (55) 1 (5) 10 (50) 9 (45)
Android 
n=52
9 (17) 1  (2) 8 (15) 43 (83)
Both n=15 11 (73) 6 (40) 5 (33) 4 (27)
Tota l  n=87 30 (34) 8 (9) 22 (25) 57 (66)
iOS n=20 9 (45) 5 (25) 4 (20) 11 (55)
Android 
n=52
9 (18) 3 (6) 6 (12) 43 (83)
Both n=15 13 (87) 13 (87) 0 2 (13)
Tota l  n=87 31 (35) 21 (24) 10 (11) 56 (64)
ePrescribing 
(%)
Contraception 
(%)
Service 
provision (%)
Safe sex (%)
Testing (%)
Diagnosis (%)
Information 
about 
STIs/infection 
(%)
Management 
(%)
Partner 
notification 
(%)
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Table 30 continued 
 
  
STI/infection Platform
Any 
coverage
Completely 
comprehensive
Partially 
comprehensive
Absent STI/infection Platform
Any 
coverage
Completely 
comprehensive
Partially 
comprehensive
Absent
iOS (n=20) 11 (55) 1 (5) 10 (50) 9 (45) iOS (n=20) 7 (35) 1 (5) 6 (30) 13 (65)
Android 
(n =52)
14 (27) 0 14 (27) 38 (73)
Android 
(n =52)
10 (19) 1 (2) 9 (17) 42 (81)
Both 
(n=15)
12 (80) 2 (13) 10 (67) 3 (20)
Both 
(n=15)
7 (47) 4 (27) 3 (20) 8 (53)
Tota l  
(n=87)
37 (42) 3 (3) 34 (39) 50 (57)
Tota l  
(n=87)
24 (28) 6 (7) 18 (21) 63 (72)
iOS (n=20) 11 (55) 1 (5) 10 (50) 9 (45) iOS (n=20) 9 (45) 2 (10) 7 (35) 11 (55)
Android 
(n =52)
14 (27) 1 (2) 13 (25) 38 (73)
Android 
(n =52)
8 (16) 2 (4) 6 (12) 44 (85)
Both 
(n=15)
12 (80) 5 (33) 7 (47) 3 (27)
Both 
(n=15)
6 (40) 3 (20) 3 (20) 9 (60)
Tota l  
(n=87)
37 (42) 7 (8) 30 (34) 50 (57)
Tota l  
(n=87)
23 (26) 7 (8) 16 (18) 64 (74)
iOS (n=20) 11 (55) 1 (5) 10 (50) 9 (45) iOS (n=20) 2 (10) 0 2 (10) 18 (90)
Android 
(n =52)
12 (23) 0 12 (23) 40 (77)
Android 
(n =52)
12 (23) 2 (4) 10 (19) 40 (77)
Both 
(n=15)
11 (73) 5 (33) 6 (40) 4 (27)
Both 
(n=15)
5 (35) 3 (20) 2 (15) 10 (65)
Tota l  
(n=87)
34 (39) 6 (7) 28 (32) 53 (61)
Tota l  
(n=87)
19 (22) 5 (6) 14 (16) 68 (78)
iOS (n=20) 10 (50) 2 (10) 8 (40) 10 (50) iOS (n=20) 3 (15) 0 3 (15) 17 (85)
Android 
(n =52)
14 (27) 0 14 (27) 38 (73)
Android 
(n =52)
5 (10) 0 5 (10) 47 (90)
Both 
(n=15)
11 (73) 4 (27) 7 (47) 4 (27)
Both 
(n=15)
5 (33) 2 (13) 3 (20) 10 (67)
Tota l  
(n=87)
35 (40) 6 (7) 29 (33) 52 (60)
Tota l  
(n=87)
13 (15) 2 (2) 11 (13) 74 (85)
iOS (n=20) 11 (55) 2 (10) 9 (45) 9 (45) iOS (n=20) 4 (20) 0 4 (20) 16 (80)
Android 
(n =52)
15 (29) 0 15 (29) 37 (71)
Android 
(n =52)
15 (29) 1 (2) 14 (27) 37 (71)
Both 
(n=15)
11 (74) 4 (27) 7 (47) 4 (27)
Both 
(n=15)
4 (27) 2 (13) 2 (13) 11 (73)
Tota l  
(n=87)
37 (43) 6 (7) 31 (36) 50 (57)
Tota l  
(n=87)
23 (26) 3 (3) 20 (23) 64 (74)
iOS (n=20) 11 (55) 1 (5) 10 (50) 9 (45) iOS (n=20) 3 (15) 0 3 (15) 17  (85)
Android 
(n =52)
24 (46) 2 (4) 22 (42) 28 (54)
Android 
(n =52)
2 (4) 0 2 (4) 50 (96)
Both 
(n=15)
12 (80) 4 (27) 8 (53) 3 (20)
Both 
(n=15)
1 (7) 0 1 (7) 14 (93)
Tota l  
(n=87)
47 (54) 7 (8) 40 (46) 40 (46)
Tota l  
(n=87)
6 (7) 0 6 (7) 81 (93)
iOS (n=20) 7 (35) 0 7(35) 13 (65)
Android 
(n =52)
8 (15) 1 (2) 7 (13) 44 (85)
Both 
(n=15)
8 (53) 4 (27) 4 (27) 7 (47)
Tota l  
(n=87)
23 (26) 5 (6) 18 (21) 64 (74)
Epididymitis
Genital 
herpes (%)
Pubic lice (%)
Vaginal 
candidiasis
Bacterial 
vaginosis
NSU
PID 
Chlamydia 
(%)
Gonorrhoea 
(%)
Syphilis (%)
Genital warts 
(%)
HPV (%)
Trichomonas 
vaginalis (%)
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Table 31: summary table of comprehensiveness of apps (iOS) 
  
Platform App ID Title of App 
Number of 
content 
parameters 
fully 
comprehensive
Number of 
STI/infections 
fully 
comprehensive
Number of 
content 
parameters 
partially 
comprehensive
Number of 
STI/infections 
partially 
comprehensive
No of content 
parameters 
covered total
Number of 
STI/infections 
covered total
iOS i1
Sexually 
transmitted 
disease (STD) 
triage 
2 0 4 7 6 7
iOS i2 STD Guide 0 7 7 0 7 7
iOS i3 STD Glossary 1 0 5 11 6 11
iOS i4
iCondom 
Coventry
1 0 0 0 1 0
iOS i5 99 - The Talk 3 2 3 11 6 13
iOS i6 Safer Sex 0 0 2 0 2 0
iOS i7 STD411 1 0 4 4 5 4
iOS i8
Private Girl 
Tips
0 0 5 9 5 9
iOS i9 SWISH APP 1 0 0 0 1 0
iOS i10
Sex Health 
Dictionary & 
Sexual Health 
Video Lessons
0 0 6 12 6 12
iOS i11 Safesex Guide 0 0 4 11 4 11
iOS i12 Safe sex 0 0 2 0 2 0
iOS i13 SafeSex101 2 0 5 9 7 9
iOS i14
SAFE - Safety 
Awareness for 
Everyone
1 0 5 6 6 6
iOS i15
iSex - Sex 
Education and 
Terminology
0 0 3 10 3 10
iOS i16
Girls's guide 
for sex myths
1 0 2 0 3 0
iOS i17 CaSH 2 U 1 0 1 0 2 0
iOS i18 Pap Test Lite 0 0 4 1 4 1
iOS i19
Natural Yeast 
Infection 
Solutions
0 1 3 0 3 1
iOS i20
A woman's 
guide to yeast 
infections
1 1 3 0 4 1
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Table 32: summary table of comprehensiveness of apps (Android) 
 
 
Platform App ID Title of App 
Number of 
content 
parameters 
fully 
comprehensive
Number of 
STI/infections 
fully 
comprehensive
Number of 
content 
parameters 
partially 
comprehensive
Number of 
STI/infections 
partially 
comprehensive
No of content 
parameters 
covered total
Number of 
STI/infections 
covered total
Android a1
Abnormal 
Vaginal 
Discharge
0 0 3 4 3 4
Android a2
About Herpes 
Simplex 
Infection
0 0 3 1 3 1
Android a3 After Sex 0 0 7 11 7 11
Android a4
Bacterial 
Vaginosis 
Disease
0 1 5 1 5 2
Android a5
Bacterial 
Vaginosis 
Guide 
0 1 5 1 5 2
Android a6
Bacterial 
Vaginosis 
Treatments
0 0 2 2 2 2
Android a7
Chlamydia 
Disease and 
Symptoms
1 0 5 3 6 3
Android a8
Chlamydia 
Know it 
Prevent it Treat 
it
0 0 2 2 2 2
Android a9
Deadly Herpes 
Virus Acyclovir
0 0 4 1 4 1
Android a10 Female Herpes 0 1 6 0 6 1
Android a11
Genital herpes 
guide
0 0 3 1 3 1
Android a12
Genital Herpes 
Information
0 0 6 1 6 1
Android a13
Genital Herpes 
Treatment
0 0 5 1 5 1
Android a14
Genital Herpes 
Treatment
0 0 5 1 5 1
Android a15
Genital Warts 
Guide
1 0 3 2 4 2
Android a16
Genital Warts 
Guide
0 0 3 2 3 2
Android a17
Genital warts 
info
0 0 4 2 4 2
Android a18
Genital Warts 
Info
2 0 4 2 6 2
Android a19
Genital Warts 
Info
0 0 4 2 4 2
Android a20
Genital  Warts 
Information
1 0 4 2 5 2
Android a21
Get Rid of 
Bacterial 
Vaginosis
1 0 1 1 2 1
Android a22
Get Rid of 
Yeast Infection 
Now !
2 1 0 0 2 1
Android a23
Gonorrhea 
Disease & 
Symptoms
1 1 5 2 6 3
Android a24 Guide to STDs 0 0 5 10 5 10
Android a25
Herpes 
Knowledge
1 0 1 1 2 1
Android a26
Herpes Lupus 
Psoriasis 
Eczema
4 0 1 1 5 1
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Table 32 continued 
 
 
 
 
 
 
 
Platform App ID Title of App 
Number of 
content 
parameters 
fully 
comprehensive
Number of 
STI/infections 
fully 
comprehensive
Number of 
content 
parameters 
partially 
comprehensive
Number of 
STI/infections 
partially 
comprehensive
No of content 
parameters 
covered total
Number of 
STI/infections 
covered total
Android a27
Herpes 
Treatment
2 0 4 1 6 1
Android a28
HPV Infection 
Information
0 0 5 2 5 2
Android a29 iGirl 4 0 4 10 8 10
Android a30
Knowledge of 
Herpes
0 0 2 1 2 1
Android a31 No Worries 4 0 4 6 8 6
Android a32 NORISKS 1 0 0 0 1 0
Android a33
Painful 
urination in 
men
0 0 4 5 4 5
Android a34
Pelvic 
inflammatory 
disease
0 1 7 2 7 3
Android a35
Protection - 
Sex
1 0 6 6 7 6
Android a36
Pubic Lice 
Crabs 
Information 
1 1 5 0 6 1
Android a37 SAFE 4 0 2 5 6 5
Android a38 Safer sex 0 0 3 0 3 0
Android a39
Samedaydocto
r - STD Testing
2 0 1 9 3 9
Android a40
Sexual 
Education
0 0 3 4 3 4
Android a41
Sexually 
transmitted 
Stds
2 0 4 6 6 6
Android a42 Sheffield SH 1 0 3 0 4 0
Android a43 STD glossary 0 0 5 11 5 11
Android a44
Stop Vaginal 
Odor
0 0 5 6 5 6
Android a45
Syphilis 
Disease and 
Symptoms
0 0 6 1 6 1
Android a46
The Big Book - 
Symptoms of 
STD
0 0 4 10 4 10
Android a47 The Sex Guide 0 0 4 0 4 0
Android a48
Treat Genital 
Herpes 
Naturally
0 1 5 0 5 1
Android a49
Trichomonias is  
information
0 1 6 0 6 1
Android a50 UCT Safe Sex 0 0 2 0 2 0
Android a51 Yeast Infection 0 0 1 1 1 1
Android a52
Yeast Infection 
Home Remedy
0 1 4 0 4 1
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Table 33: summary table of comprehensiveness of apps (Both) 
 
 
Table 34: number of content parameters (e.g. diagnosis) covered fully comprehensively by 
platform 
Platform 
No of content parameters fully comprehensive (n=9) 
0 1 2 3 4 5 6 7 Median (IQR) 
iOS (n=20) 9 8 2 1 0 0 0 0 1 (1) 
Android (n=52) 33 10 5 0 4 0 0 0 0 (1) 
Both (n=15) 0 4 4 2 0 2 2 1 2 (4) 
Total (n=87) 42 22 11 3 4 2 2 1 1 (2) 
 
 
 
 
 
 
Platform App ID Title of App 
Number of 
content 
parameters 
fully 
comprehensive
Number of 
STI/infections 
fully 
comprehensive
Number of 
content 
parameters 
partially 
comprehensive
Number of 
STI/infections 
partially 
comprehensive
No of content 
parameters 
covered total
Number of 
STI/infections 
covered total
Both b1 C&SH Somerset 2 1 6 7 8 8
Both b2
Conifer Sex 
Health
5 7 3 2 8 9
Both b3
FPA - Find a 
Clinic
7 11 1 2 8 13
Both b4 FREE 2 B ME 1 0 4 4 5 4
Both b5
Get Them 
Tested
3 1 4 7 7 8
Both b6 Kent C Card 1 0 3 0 4 0
Both b7 KIS-SK 2 0 0 0 2 0
Both b8
KYSH - Know 
Your Sexual 
Health
2 1 3 5 5 6
Both b9 My Sex Doctor 5 10 2 2 7 12
Both b10 NeedTayKnow 3 0 4 6 7 6
Both b11 SexPositive 1 0 3 6 4 6
Both b12
Sexual Health 
Guide
6 0 2 9 8 9
Both b13
Sexual Health 
Liverpool
2 0 3 1 5 1
Both b14
Your rapid 
diagnosis STD
6 11 1 0 7 11
Both b15
Your Choice 
Your Voice 
(YCYV)
1 0 5 12 6 12
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Table 35: number of content parameters (e.g. diagnosis) covered partially comprehensively 
(by platform) 
Platform 
No of content parameters partially comprehensive (n=9) 
0 1 2 3 4 5 6 7 Median (IQR) 
iOS (n=20) 2 1 3 4 3 5 1 1 3 (3) 
Android (n=52) 2 5 5 8 13 12 5 2 4 (2) 
Both (n=15) 1 2 2 5 3 1 1 0 3 (2) 
Total (n=87) 5 8 10 17 19 18 7 3 4 (3) 
Table 36: number of content parameters (e.g. diagnosis) covered total (by platform) 
Platform 
No of content parameters covered total (n=9) 
0 1 2 3 4 5 6 7 8 Median (IQR) 
iOS (n=20) 0 2 3 3 3 2 4 3 0 4 (4) 
Android (n=52) 0 2 7 7 9 11 11 3 2 5 (3) 
Both (n=15) 0 0 1 0 2 3 1 4 4 6.5 (4) 
Total (n=87) 0 4 11 10 14 16 16 10 6 5 (3) 
Table 37:  number of STI/infections covered fully 
Platform 
No of STI/infections covered fully comprehensively (n=13) 
0 1 2 3 4 5 6 7 8 9 10 11 Median 
iOS (n=20) 16 2 1 0 0 0 0 1 0 0 0 0 0 (0) 
Android (n=52) 42 10 0 0 0 0 0 0 0 0 0 0 0 (0) 
Both (n=15) 8 3 0 0 0 0 0 1 0 0 1 2 0 (1) 
Total (n=87) 66 15 1 0 0 0 0 2 0 0 1 2 0 
Table 38: number of STI/infections covered partially 
Platform 
No of STI/infections covered partially comprehensively (n=13) 
0 1 2 3 4 5 6 7 8 9 10 11 12 Median 
iOS (n=20) 9 1 0 0 1 0 1 1 1 1 2 2 1 1 (9) 
Android (n=52) 11 13 11 1 2 2 4 0 0 1 3 2 0 2 (5) 
Both (n=15) 3 1 3 0 1 1 2 2 0 1 0 0 1 3 (5) 
Total (n=87) 23 17 14 1 4 3 7 3 1 3 5 4 2 2 (6) 
 
Table 39: number of STI/infections covered total 
Platform 
No of STI/infections covered  total (n=13) 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 Median 
iOS (n=20) 6 3 0 0 1 0 1 2 1 1 2 1 1 1 4 (9) 
Android (n=52) 5 19 11 3 2 2 4 0 0 1 3 2 0 0 2 (3) 
Both (n=15) 2 1 0 0 1 0 3 0 2 2 0 1 2 1 7 (8) 
Total (n=87) 13 23 11 3 4 2 8 2 3 4 5 4 3 2 2 (6) 
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5.4 ACCURACY OF APPS 
As with the comprehensiveness and coverage of apps, there was wide variability in accuracy in 
terms of parameter measured, app and platform. Only 15% (13/87) of apps were found to be 
completely accurate and 32% (28/87) of apps were assessed as being partially accurate. Just 
over half of the apps assessed (53%) provided information that was found to be ‘majority 
accurate’, i.e. errors were found in one aspect of the information or no more than two minor 
errors were present throughout (see Table 40).  
When looking at individual parameters (see Table 41), a far greater proportion of apps 
available in both platforms, compared to iOS apps and Android apps, were found to be 
completely accurate, with the exception of bacterial vaginosis, where a greater proportion of 
iOS apps were accurate.  However, there were only a small number of apps covering bacterial 
vaginosis.  
Content parameters (safe sex, testing, diagnosis, information about sti/genital 
infection, management, partner notification, eprescribing, contraception, 
and service provision) 
 
Most apps were found to be majority accurate when assessing the individual content 
parameters. The accuracy of apps was notably low for information about STIs/infection (only 
19% (15/78) completely accurate), management (only 16% (10/61) completely accurate) and 
partner notification (only 20 % (6/30) completely accurate). The only parameter measured to 
be completely inaccurate was management, where one app was assessed as such. The content 
parameter which was portrayed most accurately was service provision, with 72% (21/29) apps 
providing completely accurate information on this parameter. 
Overall, the median content type accuracy percentage was 77% (IQR 27.7) (see Table 42). This 
varied from 95.9% (IQR 8.3) for apps available in both platforms, to 69.5% (IQR 29.6) for 
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Android apps, with iOS apps having a median content type accuracy percentage of 76.5% (IQR 
30). 
STI/Genital infections 
As with the other parameters, there was wide variability in terms of the accuracy dependent 
on app and platform. Of the five STIs that Public Health England identify as being of particular 
interest: 
Chlamydia: The information provided on chlamydia was assessed as being completely accurate 
in only 27% (10/87) of apps. As with other parameters, this did vary according to platform, 
with 67% (8/12) apps available in both platforms providing completely accurate information, 
as opposed to no Android apps. The majority of apps covering chlamydia were found to be 
‘majority accurate’ (n=23 (62%)). Only one app was found to contain fully comprehensive, 
completely accurate information on chlamydia. 
Gonorrhoea: Accuracy of information on gonorrhoea was found to similar to that on 
chlamydia, with 27% (10/37) of apps providing completely accurate information, 65% (24/37) 
providing majority accurate information and 8% (3/37) providing partially accurate 
information. Again, there were no Android apps that provided completely accurate 
information, whereas 58% (7/12) of apps available in both platforms did.   
Syphilis: The information on syphilis was of a slightly higher quality, with 35% (12/34) apps 
providing completely accurate information on this infection. The discrepancy of quality of 
information between different platforms continued with 73% (8/11) of apps available in both 
platforms providing completely accurate information, whilst 27% (3/11) of iOS apps did and 
only 8% (1/12) of Android apps did.  
Genital warts: The accuracy of information on genital warts was slightly lower than the 
information on chlamydia and gonorrhoea: Twenty two percent (8/36) of apps provided 
completely accurate information; 58% (21/36) of apps provided information that was majority 
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accurate; 19% (7/36) provided information that was partially accurate. Again, apps available in 
both platforms were the most accurate with 64% (7/11) providing completely accurate 
information, as opposed to no Android apps.  
Genital herpes: Only 21% (10/47) provided completely accurate information, whereas 30% 
(14/47) were partially accurate. Again, no Android apps provided completely accurate 
information.   
Android apps provided particularly poor quality information in several parameters with 60% 
(9/15) of apps providing information on HPV, 50% (12/24) of apps providing information on 
genital herpes, 63% (5/7) of apps providing information on vaginal candidiasis and 45% (5/11) 
of apps providing information on bacterial vaginosis being graded as only partially accurate.  
The overall median STI/infection type accuracy percentage was 81% (IQR 36) (see Table 43). As 
with content type accuracy, this varied from 90.8 (IQR 12) for apps available in both platforms, 
to 73.5% (IQR 33.3) for Android apps. 
Overall accuracy  
Both reviewers of each app made an assessment of the overall accuracy of the app (see Table 
41). 15% (13/87) were rated as being completely accurate, 53% (46 /87) as being partially 
accurate and 32% (28/87) as being partially accurate. No android apps were rated as 
completely accurate, whereas 30% (6/20) of iOS apps were and 47% (7/15) of apps available in 
both platforms were.  
The total overall median accuracy percentage was 75.2% (IQR 30.5) (see Table 43). Reflecting 
content type accuracy and STI/infection type accuracy, apps available in both platforms had 
the highest overall accuracy percentage (94.6% (IQR 6)), whilst Android apps had the lowest 
overall accuracy percentage (66.7 (IQR 29.7)).  
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Platform App ID Title of App Safe Sex Testing Diagnosis
Information 
about 
STIs/infection
Management
Partner 
notification
ePrescribing Contraception
Service 
provision
Chlamydia Gonorrhea Syphilis
Genital 
warts
HPV
Genital 
herpes
Pubic l ice
Trichomonas 
vaginalis
Vaginal 
candidiasis
Bacterial 
vaginosis
Non-specific 
urethritis
Pelvic 
inflammatory 
disease
Epididymitis
Overall  
content 
accuracy
iOS i1
Sexually 
transmitted 
disease (STD) 
triage 
Completely Completely - Completely Completely Completely - - Majority Completely Completely Completely Majority Completely Completely - - Completely - - - - Completely
iOS i2 STD Guide Partially Partially Partially Partially Majority Majority - - Partially Partially Partially Partially Majority Majority Majority - Partially - - - - - Partially
iOS i3 STD Glossary Partially Partially Partially Majority - Majority - Partially - Majority Majority Majority Majority Partially Majority Majority Majority Majority - Majority Majority - Majority
iOS i4
iCondom 
Coventry
- - - - - - - - Completely - - - - - - - - - - - - - Completely
iOS i5 99 - The Talk Completely Completely Majority Completely Completely - - Completely - Majority Completely Completely Completely Completely Completely Completely Completely Completely Completely Completely Completely Completely Completely
iOS i6 Safer Sex Majority - - - - - - Majority - - - - - - - - - - - - - - Majority
iOS i7 STD411 Completely Completely - Completely - - - Completely Completely Completely Completely Completely - - Completely - - - - - - - Completely
iOS i8
Private Girl 
Tips
Majority Majority - Majority Majority Majority - - - Majority Majority Majority Majority Majority Majority Majority Majority Majority - - - - Majority
iOS i9 SWISH APP - - - - - - - - Completely - - - - - - - - - - - - - Completely
iOS i10
Sex Health 
Dictionary & 
Sexual Health 
Video Lessons
Completely Majority Majority Majority Majority - - Majority - Majority Majority Majority Majority - Partially Majority Majority Majority Majority - Majority Majority Majority
iOS i11 Safesex Guide Majority - - Majority Majority - - Majority - Majority Majority Majority Majority Majority Majority Majority Majority Partially - Majority - - Majority
iOS i12 Safe sex Majority - - - - - - Majority - - - - - - - - - - - - - - Majority
iOS i13 SafeSex101 Majority Completely Majority Completely Majority - - Majority Completely Majority Majority Partially Majority Majority Majority Completely Majority - - - - - Majority
iOS i14
SAFE - Safety 
Awareness for 
Everyone
Completely Partially Majority Majority Majority - - Majority Completely Majority Majority Majority Majority Majority Majority - - - - - - - Majority
iOS i15
iSex - Sex 
Education and 
Terminology
Majority - - Majority - - - Partially - Majority Majority Majority Majority Majority Majority Completely - Majority - - Majority Completely Majority
iOS i16
Girls's guide 
for sex myths
Majority - - Majority - - - Majority - - - - - - - - - - - - - - Majority
iOS i17 CaSH 2 U - Completely - - - - - - Completely - - - - - - - - - - - - - Completely
iOS i18 Pap Test Lite - Majority Majority Majority - - - - Majority - - - - Majority - - - - - - - - Majority
iOS i19
Natural Yeast 
Infection 
Solutions
Majority - - Partially Not accurate - - - - - - - - - - - - Partially - - - - Partially
iOS i20
A woman's 
guide to yeast 
infections
Completely Majority Majority Partially Partially - - - - - - - - - - - - Partially - - - - Partially
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Platform App ID Title of App Safe sex Testing Diagnosis
Information 
about 
STIs/infection
Management
Partner 
notification
ePrescribing Contraception
Service 
provision
Chlamydia Gonorrhoea Syphilis
Genital 
warts
HPV
Genital 
herpes
Pubic lice
Trichomon
as vaginalis
Vaginal 
candidiasis
Bacterial 
vaginosis
Non-
specific 
urethritis
Pelvic 
inflammatory 
disease
Epididymitis
Overall 
content 
accuracy
Android a1
Abnormal 
Vaginal 
Discharge
Completely - - Majority Majority - - - - - - - - - - - Partially Majority Partially - Majority - Partially
Android a2
About Herpes 
Simplex 
Infection
Majority - - Majority Partially - - - - - - - - - Partially - - - - - - - Partially
Android a3 After Sex Majority Majority Majority Majority Majority Majority - - Majority Majority Majority Majority Majority Partially Majority Majority Majority Majority Majority - Majority - Majority
Android a4
Bacterial 
Vaginosis 
Disease
Majority Majority Majority Majority Majority - - - - - - - - - - - - - Majority - Majority - Majority
Android a5
Bacterial 
Vaginosis 
Guide 
Majority Partially Partially Partially Partially - - - - - - - - - - - - - Partially - Majority - Partially
Android a6
Bacterial 
Vaginosis 
Treatments
- - - Majority Partially - - - - - - - - - - - - - Partially - Majority - Partially
Android a7
Chlamydia 
Disease and 
Symptoms
Majority Completely Majority Completely Majority Majority - - - Majority - - - - - - - - - - Majority Majority Partially
Android a8
Chlamydia 
Know it 
Prevent it 
Treat it
Majority Majority Majority Majority - - - - - Majority - - - - - - - - - - Majority - Majority
Android a9
Deadly 
Herpes Virus 
Acyclovir
- Majority Majority Partially Partially - - - - - - - - - Partially - - - - - - - Partially
Android a10
Female 
Herpes
Majority Partially Partially Majority Partially Majority - - - - - - - - Majority - - - - - - - Majority
Android a11
Genital 
herpes guide
Majority - - Partially Majority - - - - - - - - - Partially - - - - - - - Partially
Android a12
Genital 
Herpes 
Information
Majority Majority Majority Majority Majority Majority - - - - - - - - Majority - - - - - - - Majority
Android a13
Genital 
Herpes 
Treatment
Majority Partially Partially Majority Majority - - - - - - - - - Partially - - - - - - - Partially
Android a14
Genital 
Herpes 
Treatment
Majority Partially Partially Partially Majority - - - - - - - - - Partially - - - - - - - Partially
Android a15
Genital Warts 
Guide
Majority - Majority Partially - - - - - - - - Partially Partially - - - - - - - - Partially
Android a16
Genital Warts 
Guide
Majority - Majority Partially - - - - - - - - Partially Partially - - - - - - - - Partially
Android a17
Genital warts 
info
Partially - - Partially Partially Partially - - - - - - Partially Partially - - - - - - - - Partially
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Platform App ID Title of App Safe sex Testing Diagnosis
Information 
about 
STIs/infection
Management
Partner 
notification
ePrescribing Contraception
Service 
provision
Chlamydia Gonorrhoea Syphilis
Genital 
warts
HPV
Genital 
herpes
Pubic lice
Trichomonas 
vaginalis
Vaginal 
candidiasis
Bacterial 
vaginosis
Non-
specific 
urethritis
Pelvic 
inflammatory 
disease
Epididymitis
Overall 
content 
accuracy
Android a18
Genital Warts 
Info
Majority - - Partially Partially Partially - - - - - - Partially Partially - - - - - - - - Partially
Android a19
Genital Warts 
Info
- Partially Partially Partially Partially - - - - - - - Partially Partially - - - - - - - - Partially
Android a20
Genital  
Warts 
Information
Majority Majority Majority Majority Majority Majority - - - - - - Majority Majority - - - - - - - - Majority
Android a21
Get Rid of 
Bacterial 
Vaginosis
- - - Partially Partially - - - - - - - - - - - - - Partially - - - Partially
Android a22
Get Rid of 
Yeast 
Infection Now 
!
- - - Partially Partially - - - - - - - - - - - - Partially - - - - Partially
Android a23
Gonorrhea 
Disease & 
Symptoms
Majority Majority Majority Majority Majority Completely - - - - Majority - - - - - - - - - Completely Completely Majority
Android a24 Guide to STDs Majority Majority Majority Partially Partially - - - - Partially Partially Majority Partially Partially Majority Majority Partially - Majority - Majority - Partially
Android a25
Herpes 
Knowledge
- - - Partially Majority - - - - - - - - - Partially - - - - - - - Partially
Android a26
Herpes Lupus 
Psoriasis 
Eczema
Completely Completely Completely Completely Majority - - - - - - - - - Majority - - - - - - - Majority
Android a27
Herpes 
Treatment
Majority Majority Partially Majority Partially Majority - - - - - - - - Partially - - - - - - - Partially
Android a28
HPV Infection 
Information
Majority Majority Majority Majority Majority - - - - - - - Majority Majority - - - - - - - - Majority
Android a29 iGirl Majority Majority Majority Majority Majority Majority - Majority - Majority Majority Majority Majority Majority Majority Majority Majority - Majority - Majority - Majority
Android a30
Knowledge of 
Herpes
- - - Partially Partially - - - - - - - - - Partially - - - - - - - Partially
Android a31 No Worries Majority Majority Majority Majority Majority Majority - Majority Completely Majority Majority Majority - - Majority Majority - - - Majority - - Majority
Android a32 NORISKS - - - - - - - - Completely - - - - - - - - - - - - - Majority
Android a33
Painful 
urination in 
men
Majority Majority Majority Majority Majority - - - - - Majority Partially - - Partially Majority - - - Majority - - Majority
Android a34
Pelvic 
inflammatory 
disease
Majority Majority Majority Majority Majority Majority - Majority - Majority Majority - - - - - - - - - Majority - Majority
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Platform App ID Title of App Safe sex Testing Diagnosis
Information 
about 
STIs/infection
Management
Partner 
notification
ePrescribing Contraception
Service 
provision
Chlamydia Gonorrhoea Syphilis
Genital 
warts
HPV
Genital 
herpes
Pubic lice
Trichomonas 
vaginalis
Vaginal 
candidiasis
Bacterial 
vaginosis
Non-
specific 
urethritis
Pelvic 
inflammatory 
disease
Epididymitis
Overall 
content 
accuracy
Android a35
Protection - 
Sex
Completely Completely Completely Majority Majority Completely - - Completely Majority Majority Majority Majority - Majority - - - - Partially - - Majority
Android a36
Pubic Lice 
Crabs 
Information 
Majority - Majority Majority Majority Majority - - - - - - - - - Majority - - - - - - Majority
Android a37 SAFE Majority Majority Partially Majority Majority - - Majority - Majority Majority Majority Majority Majority Partially - - - - - - - Majority
Android a38 Safer sex Completely - - Majority - - - - Majority - - - - - - - - - - - - - Majority
Android a39
Samedaydoct
or - STD 
Testing
- Majority Majority - - - - - Majority Majority Majority Majority Majority Majority Majority - Majority - - Majority - - Majority
Android a40
Sexual 
Education
Majority - - Majority - - - Partially - - - - - - - - Majority Partially Majority - Majority - Majority
Android a41
Sexually 
transmitted 
Stds
Majority Majority Majority Majority Majority Majority - - - Majority Majority Majority - Partially Majority - Majority - - - - - Majority
Android a42 Sheffield SH Majority - - Completely - - - Completely Completely - - - - - - - - - - - - - Majority
Android a43 STD glossary Majority - Majority Majority Majority Majority - - - Majority Majority Majority Partially Partially Majority Majority Majority Completely - Majority Majority - Majority
Android a44
Stop Vaginal 
Odor
Majority Partially Partially Partially Partially - - - - Partially Partially - - - Partially - - Partially Partially - Partially - Partially
Android a45
Syphilis 
Disease and 
Symptoms
Majority Majority Majority Majority Majority Majority - - - - - Majority - - - - - - - - - - Majority
Android a46
The Big Book - 
Symptoms of 
STD
Majority - - Majority Majority Majority - - - Majority Majority Completely Majority Majority Majority Majority Majority - Majority - Majority - Majority
Android a47 The Sex Guide Majority - - Majority Majority - - Majority Partially - - - - - - - - - - - - - Majority
Android a48
Treat Genital 
Herpes 
Naturally
Majority Partially Partially Majority Majority - - - - - - - - - Partially - - - - - - - Partially
Android a49
Trichomonias
is 
information
Majority Majority Majority Majority Majority Majority - - - - - - - - - - Majority - - - - - Majority
Android a50 UCT Safe Sex Majority - - - - - - Majority - - - - - - - - - - - - - - Majority
Android a51
Yeast 
Infection
- - - Partially - - - - - - - - - - - - - Partially - - - - Partially
Android a52
Yeast 
Infection 
Home Remedy
- Majority Majority Partially Partially - - - - - - - - - - - - Partially - - - - Partially
 
Table 40 continued 
 
116 
 
 
  
Platform App ID
Title of 
App 
Safe sex Testing Diagnos is
Informatio
n about 
STIs/infect
ion
Managem
ent
Partner 
noti ficatio
n
ePrescribi
ng
Contracept
ion
Service 
provis ion
Chlamydia
Gonorrhoe
a
Syphi l i s
Genita l  
warts
HPV
Genita l  
herpes
Pubic l ice
Trichomon
as  
vaginal is
Vaginal  
candidias i
s
Bacteria l  
vaginos is
Non-
speci fic 
urethri tis
Pelvic 
inflammat
ory 
disease
Epididymit
is
Both b1
C&SH 
Somerset
Complete Partia l Partia l Partia l Partia l Partia l Absent Partia l Complete Partia l Partia l Partia l Partia l Absent Partia l Partia l Partia l Absent Absent Absent Absent Absent
Both b2
Conifer 
Sex Health
Partia l Complete Partia l Complete Complete Partia l Absent Complete Complete Absent Absent Absent Absent Partia l Absent Absent Absent Partia l Absent Absent Absent Absent
Both b3
FPA - Find 
a  Cl inic
Complete Complete Complete Complete Complete Partia l Absent Complete Complete Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Partia l Partia l
Both b4
FREE 2 B 
ME
Partia l Partia l Partia l Partia l Absent Absent Absent Absent Complete Partia l Partia l Absent Absent Partia l Partia l Absent Absent Absent Absent Absent Absent Absent
Both b5
Get Them 
Tested
Partia l Complete Partia l Complete Partia l Partia l Absent Absent Complete Partia l Partia l Absent Partia l Partia l Partia l Absent Absent Absent Partia l Partia l Absent Absent
Both b6
Kent C 
Card
Partia l Absent Absent Partia l Absent Absent Absent Partia l Complete Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent
Both b7 KIS-SK Absent Absent Absent Absent Absent Absent Absent Complete Complete Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent
Both b8
KYSH - 
Know Your 
Sexual  
Health
Absent Complete Partia l Partia l Partia l Absent Absent Absent Complete Partia l Absent Partia l Partia l Absent Partia l Partia l Absent Absent Absent Absent Absent Absent
Both b9
My Sex 
Doctor
Complete Complete Partia l Complete Partia l Complete Absent Complete Absent Partia l Absent Absent Absent Absent Absent Absent Absent Absent Absent Partia l Absent Absent
Both b10
NeedTayK
now 
Complete Partia l Partia l Partia l Partia l Absent Absent Complete Complete Partia l Partia l Partia l Partia l Partia l Partia l Absent Absent Absent Absent Absent Absent Absent
Both b11
SexPos itiv
e
Complete Partia l Absent Partia l Absent Absent Absent Partia l Absent Partia l Partia l Partia l Partia l Partia l Partia l Absent Absent Absent Absent Absent Absent Absent
Both b12
Sexual  
Health 
Guide
Complete Complete Partia l Complete Partia l Complete Absent Complete Complete Partia l Partia l Partia l Partia l Partia l Partia l Partia l Partia l Partia l Absent Absent Absent Absent
Both b13
Sexual  
Health 
Liverpool
Complete Partia l Absent Partia l Absent Absent Absent Partia l Complete Partia l Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent
Both b14
Your rapid 
diagnos is  
STD
Partia l Complete Complete Complete Complete Complete Absent Absent Complete Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent
Both b15
Your 
Choice 
Your Voice 
(YCYV)
Partia l Partia l Absent Partia l Partia l Absent Absent Partia l Complete Partia l Partia l Partia l Partia l Partia l Partia l Partia l Partia l Partia l Partia l Partia l Partia l Absent
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Table 41: Accuracy of different parameters 
 
Platform
Completely 
accurate
Majority 
accurate
Partially 
Accurate
Not 
accurate 
iOS (n=16) 6 (38) 8 (50) 2 (13) 0
Android 
(n =41)
4 (10) 36 (88) 1 (2) 0
Both 
(n=13)
13 (100) 0 0 0
Tota l  
(n=70)
23 (31) 44 (63) 3 (4) 0
iOS (n=12) 5 (42) 4 (33) 3 (25) 0
Android 
(n =30)
3 (10) 20 (67) 7 (23) 0
Both 
(n=13)
12 (92) 1 (8) 0 0
Tota l  
(n=55)
20 (36) 25 (45) 10 (18) 0
iOS (n=8) 0 6(75) 2 (25) 0
Android 
(n =34)
2 (6) 23 (68) 9 (27) 0
Both (n=9) 7 (78) 1 (11) 1 (11) 0
Tota l  
(n=51)
9 (18) 30 (59) 12 (24) 0
iOS (n=15) 4 (27) 8 (53) 2 (20) 0
Android 
(n =49)
3 (6) 29 (59) 17 (35) 0
Both 
(n=14)
8 (57) 5 (36) 1 (7) 0
Tota l  
(n=78)
15 (19) 42 (54) 21 (27) 0
iOS (n=10) 2 (20) 6 (60) 1 (10) 1 (10)
Android 
(n =42)
0 27 (64) 15 (36) 0
Both (n=9) 8 (89) 1 (11) 0 0
Tota l  
(n=61)
10 (16) 34 (56) 16 (26) 1 (2)
iOS (n=4) 1 (25) 3 (75) 0 0
Android 
(n =19)
2 (11) 15 (79) 2 (11) 0
Both 3 (43) 4 (57) 0 0
Tota l  
(n=30)
6 (20) 22 (73) 2 (7) 0
iOS 0 0 0 0
Android 0 0 0 0
Both 0 0 0 0
Tota l 0 0 0 0
iOS (n=11) 2 (18) 7 (64) 2 (18) 0
Android 
(n =8)
1 (13) 6 (75) 1 (13) 0
Both(n=11) 10 (91) 1 (9) 0 0
Tota l  
(n=30)
13 (42) 14 (47) 3 (10) 0
iOS (n=9) 6 (67) 2 (22) 1 (11) 0
Android 
(n =8)
4 (50) 3 (38) 1 (13) 0
Both 
(n=12)
11 (92) 1 (8) 0 0
Tota l  
(n=29)
21 (72) 6 (21) 4 (14) 0
ePrescribing 
(%)
Contraception 
(%)
Service 
provision (%)
Safe sex (%)
Testing (%)
Diagnosis (%)
Information 
about 
STIs/infection 
(%)
Management 
(%)
Partner 
notification 
(%)
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STI/infection Platform
Completely 
accurate
Majority 
accurate
Partially 
Accurate
Not 
accurate 
STI/infection Platform
Completely 
accurate
Majority 
accurate
Partially 
Accurate
Not 
accurate 
iOS (n=11) 2 (18) 8 (73) 1 (9) 0 iOS (n=7) 1 (14) 5 (71) 1 (14) 0
Android 
(n =14)
0 12 (86) 2 (14) 0
Android 
(n =10)
0 8 (80) 2 (20) 0
Both 
(n=12)
8 (67) 3 (25) 1 (8) 0 Both (n=7) 5 (71) 2 (29) 0 0
Tota l  
(n=37)
10 (27) 23 (62) 4 (11) 0
Tota l  
(n=24)
6 (25) 15 (63) 3 (13) 0
iOS (n=11) 3 (27) 7 (64) 1 (9) 0 iOS (n=9) 2 (22) 4 (44) 3 (33) 0
Android 
(n =14)
0 12 (86) 2 (14) 0
Android 
(n=8)
1 (13) 2 (26) 5 (63) 0
Both(n=12) 7 (58) 5 (41) 0 0 Both (n=6) 3 (50) 1 (17) 2 (33) 0
Tota l  
(n=37)
10 (27) 24 (65) 3 (8) 0
Tota l  
(n=23)
6 (26) 7 (30) 10 (43) 0
iOS (n=11) 3 (27) 6 (55) 2 (18) 0 iOS (n=2) 1 (50) 1 (50) 0 0
Android 
(n =12)
1 (8) 10 (83) 1 (8) 0
Android 
(n =11)
0 6 (55) 5 (45) 0
Both 
(n=11)
8 (73) 2 (18) 2 (18) 0 Both (n=5) 2 (40) 2 (40) 1 (20) 0
Tota l  
(n=34)
12 (35) 18 (53) 4 (12) 0
Tota l  
(n=18)
3 (17) 9 (50) 6 (33) 0
iOS (n=10) 1 (10) 9 (90) 0 0 iOS (n=3) 1 (33) 2 (67) 0 0
Android 
(n =15)
0 8 (53) 7 (47) 0
Android 
(n =5)
0 4 (80) 1 (20) 0
Both 
(n=11)
7 (64) 4 (36) 0 0 Both (n=5) 2 (40) 1 (20) 2 (40) 0
Tota l  
(n=36)
8 (22) 21 (58) 7 (19) 0 Tota l 3 (23) 7 (54) 6 (46) 0
iOS (n=10) 2 (20) 7 (70) 1 (10) 0 iOS (n=4) 1 (25) 3 (75) 0 0
Android 
(n =15)
0 6 (40) 9 (60) 0
Android 
(n =15)
1 (7) 13 (87) 1 (7) 0
Both 4 (36) 7 (64) 0 0 Both (n=4) 2 (50) 2 (50) 0 0
Tota l  
(n=36)
6 (17) 20 (57) 10 (27) 0
Tota l  
(n=23)
4 (17) 18 (78) 1 (4) 0
iOS (n=11) 3 (27) 7 (64) 1 (9) 0 iOS (n=20) 2 (67) 1 (33) 0 0
Android 
(n =24)
0 12 (50) 12 (50) 0
Android 
(n =2)
1 (50) 1(50) 0 0
Both 
(n=12)
7 (58) 4 (33) 1 (8) 0 Both (n=1) 1 (100) 0 0 0
Total  
(n=47)
10 (21) 23 (49) 14 (30) 0 Tota l  (n=6) 4 (67) 2 (33) 0 0
iOS (n=7) 3 (43) 4 (57) 0 0 iOS (n=20) 6 (30) 11 (55) 3 (15) 0
Android 
(n =8)
0 8 (100) 0 0
Android 
(n =52)
0 28 (54) 24 (46) 0
Both (n=8) 7 (88) 1 (13) 0 0
Both 
(n=15)
7 (47) 7 (47) 1 (7) 0
Tota l 10 (43) 13 (57) 0 0
Tota l  
(n=87)
13 (15) 46 (53) 28 (32) 0
NSU
PID 
Epididymitis
Overall
Genital 
herpes (%)
Pubic lice (%)
Chlamydia 
(%)
Gonorrhoea 
(%)
Syphilis (%)
Genital warts 
(%)
HPV (%)
Trichomonas 
vaginalis 
(%)
Vaginal 
candidiasis
Bacterial 
vaginosis
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 Table 42: Summary of accuracy scores  
 
 
 
 
 
 
Platform App ID Title of App 
Sum of 
content 
type 
accuracy 
scores
Content 
type 
accuracy % 
Sum of 
STI/infection 
accuracy 
scores
STI/infection 
accuracy %
Overall 
Accuracy 
score
Overall 
Accuracy %
iOS i1
Sexually 
transmitted 
disease (STD) 
triage 
13 97 15 97 28 97
iOS i2 STD Guide 37 45 39 40 76 43
iOS i3 STD Glossary 28 77 36 83 64 80
iOS i4
iCondom 
Coventry
2 100 - - - -
iOS i5 99 - The Talk 13 97 27 99 40 98
iOS i6 Safer Sex 8 67 - - - -
iOS i7 STD411 10 100 8 100 18 100
iOS i8 Private Girl Tips 17 76 29 80 46
iOS i9 SWISH APP 2 100 - - -
iOS i10
Sex Health 
Dictionary & 
Sexual Health 
Video Lessons
17 87 35 80 52 83
iOS i11 Safesex Guide 16 67 46 69 62 68
iOS i12 Safe sex 8 67 - - - -
iOS i13 SafeSex101 20 85 32 75 52 80
iOS i14
SAFE - Safety 
Awareness for 
Everyone
24 76 21 75 45 75
iOS i15
iSex - Sex 
Education and 
Terminology
12 67 31 81 43 74
iOS i16
Girls's guide for 
sex myths
10 77 - - - -
iOS i17 CaSH 2 U 4 100 - - - -
iOS i18 Pap Test Lite 16 67 4 67 20 67
iOS i19
Natural Yeast 
Infection 
Solutions
16 44 6 37 22 39
iOS i20
A woman's 
guide to yeast 
infections
22 60 6 37 28 47
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Table 42: Summary of accuracy scores 
 
Platform App ID Title of App 
Sum of 
content 
type 
accuracy 
scores
Content 
type 
accuracy % 
Sum of 
STI/infection 
accuracy 
scores
STI/infection 
accuracy %
Overall 
Accuracy 
score
Overall 
Accuracy %
Android a1
Abnormal 
Vaginal 
Discharge
10 78 18 63 28 67
Android a2
About Herpes 
Simplex 
Infection
12 67 6 33 18 58
Android a3 After Sex 23 79 35 80 58 80
Android a4
Bacterial 
Vaginosis 
Disease
15 83 6 83 21 83
Android a5
Bacterial 
Vaginosis Guide 
26 47 8 67 34 52
Android a6
Bacterial 
Vaginosis 
Treatments
10 50 9 58 19 54
Android a7
Chlamydia 
Disease and 
Symptoms
17 86 9 83 26 85
Android a8
Chlamydia 
Know it Prevent 
it Treat it
16 67 6 83 22 72
Android a9
Deadly Herpes 
Virus Acyclovir
16 67 6 33 22 60
Android a10 Female Herpes 24 67 3 83 27 69
Android a11
Genita l  herpes  
guide
14 56 5 50 19 54
Android a12
Genita l  Herpes  
Information
19 81 3 83 22 81
Android a13
Genita l  Herpes  
Treatment
24 53 5 50 29 53
Android a14
Genita l  Herpes  
Treatment
25 50 5 50 30 50
Android a15
Genita l  Warts  
Guide
13 61 11 43 24 53
Android a16
Genita l  Warts  
Guide
12 67 10 50 22 60
Android a17
Genita l  warts  
info
23 38 12 33 35 36
Android a18
Genita l  Warts  
Info
22 47 12 33 34 39
Android a19
Genita l  Warts  
Info
23 38 12 33 35 36
Android a20
Genita l   Warts  
Information
18 83 6 83 24 83
Android a21
Get Rid of 
Bacteria l  
Vaginos is
12 33 6 33 18 33
Android a22
Get Rid of Yeast 
Infection Now !
12 33 6 33 18 33
Android a23
Gonorrhea 
Disease & 
Symptoms
17 86 7 95 24 89
Android a24 Guide to STDs 23 57 44 64 67 64
Android a25
Herpes 
Knowledge
10 50 5 50 15 50
Android a26
Herpes  Lupus  
Psorias is  
Eczema
11 97 3 83 14 94
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Table 42: Summary of accuracy scores 
 
 
 
 
Platform App ID Title of App 
Sum of 
content 
type 
accuracy 
scores
Content 
type 
accuracy % 
Sum of 
STI/infection 
accuracy 
scores
STI/infection 
accuracy %
Overall 
Accuracy 
score
Overall 
Accuracy %
Android a27
Herpes  
Treatment
24 67 5 50 29 64
Android a28
HPV Infection 
Information
15 83 6 83 21 83
Android a29 iGirl  21 83 34 77 55 80
Android a30
Knowledge of 
Herpes
11 42 5 50 16 44
Android a31 No Worries 23 85 18 83 41 85
Android a32 NORISKS 2 100 - - - -
Android a33
Painful  
urination in 
men
16 80 20 67 36 73
Android a34
Pelvic 
inflammatory 
disease
21 83 9 83 30 83
Android a35 Protection - Sex 17 93 21 75 38 85
Android a36
Pubic Lice Crabs  
Information 
16 67 3 83 19 81
Android a37 SAFE 22 72 21 75 43 74
Android a38 Safer sex 8 89 - - - -
Android a39
Samedaydoctor - 
STD Testing
11 72 26 79 37 80
Android a40
Sexual 
Education
14 56 15 63 29 64
Android a41
Sexually 
transmitted Stds
21 75 21 75 42 75
Android a42 Sheffield SH 9 83 - - - -
Android a43 STD glossary 16 80 42 70 58 73
Android a44
Stop Vaginal 
Odor
28 40 35 72 63 38
Android a45
Syphi l i s  Disease 
and Symptoms
18 83 3 83 21 83
Android a46
The Big Book - 
Symptoms of 
STD
12 83 31 82 43 82
Android a47 The Sex Guide 18 73 - - - -
Android a48
Treat Genita l  
Herpes  
Natura l ly
19 63 5 50 24 67
Android a49
Trichomoniasis 
information
18 83 3 83 21 83
Android a50 UCT Safe Sex 6 83 - - - -
Android a51 Yeast Infection 5 50 5 50 10 50
Android a52
Yeast Infection 
Home Remedy
19 54 6 33 25 50
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Table 42: Summary of accuracy scores 
 
Table 43: Median accuracy percentage 
Platform 
Content 
type 
accuracy % 
median 
(IQR) 
STI/infection 
accuracy % 
median 
(IQR) 
Overall 
Accuracy % 
median 
(IQR)  
iOS 76.5 (30) 77.5 (16) 76.7 (16.7) 
Android 69.5  (29.6) 73.5 (33.3) 66.7 (29.7) 
Both 95.9 (8.3) 90.8 (12) 94.6 (6) 
Total 77 (27.7) 81 (36) 75.2 (30.5) 
Platform App ID Title of App 
Sum of 
content 
type 
accuracy 
scores
Content 
type 
accuracy % 
Sum of 
STI/infection 
accuracy 
scores
STI/infection 
accuracy %
Overall 
Accuracy 
score
Overall 
Accuracy %
Both b1 C&SH Somerset 19 94 18 96 37 95
Both b2
Conifer Sex 
Health
18 96 19 98 37 97
Both b3
FPA - Find a  
Cl inic
16 100 26 100 42 100
Both b4 FREE 2 B ME 13 90 16 89 29 89
Both b5
Get Them 
Tested
13 97 19 94 32 95
Both b6 Kent C Card 10 92 0 - - -
Both b7 KIS-SK 6 83 0 - - -
Both b8
KYSH - Know 
Your Sexual  
Health
9 96 12 100 21 98
Both b9 My Sex Doctor 14 100 32 89 46 94
Both b10 NeedTayKnow 14 100 12 100 26 100
Both b11 SexPos itive 9 96 17 86 26 91
Both b12
Sexual  Health 
Guide
17 98 23 91 40 94
Both b13
Sexual  Health 
Liverpool
10 100 3 83 13 92
Both b14
Your rapid 
diagnos is  STD
24 76 43 68 67 72
Both b15
Your Choice Your 
Voice (YCYV)
10 100 44 72 54 86
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6 DISCUSSION  
6.1 MAIN FINDINGS 
This is the first review of the content and accuracy of apps to assist people concerned about 
STIs and genital infections.  
Number of apps and search findings 
Although in the initial search for apps that contained information on sexual health I found 
thousands of hits, only a small proportion of these were eligible when taking the perspective 
of a member of the public seeking information on STIs and genital infections.  The majority of 
the search terms when put in to Google play came up with 250 hits for each term. We found, 
when searching through these hits, that eligible apps were dispersed throughout these 250 
hits, and it was necessary to search through all 250 in order to find all relevant apps. Searching 
using the same search terms in the iOS store found similar issues however there were fewer 
hits per search term, and fewer eligible apps. Even once the researchers had distilled the 
eligible apps by applying the eligibility criteria to the developer’s description of the app, once 
the apps were downloaded and a full evaluation was conducted, 35% of the apps were found 
to be ineligible. 
It is therefore difficult for a member of general public who is looking for an app on STIs and 
genital infections to search and find an app that meets their needs, irrespective of whether 
that app is comprehensive and accurate.    
Basic details and additional information  
It was not possible to discern in which country the majority of apps were developed. This has 
implications in terms of interpreting the content and accuracy of the information provided as 
different countries have different guidelines. For example, within the UK it is standard practice 
for cervical cytology to be performed on a three yearly basis for all women aged between 25 
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and 55 years of age, whereas in other countries these guidelines differ. In addition, definitions 
and terminology differ between countries, with latent syphilis being defined as two years post-
infection in the UK, as opposed to one year post-infection in the US, and cervical cytology 
being referred to as ‘pap smear’ in the US whereas in the UK it is normally referred to as just 
‘smear’ or ‘cervical cytology/smear’. Brand names of medications also differ between 
countries, with at least one app referring to a drug by its brand name in that country which is 
different to the brand name of the drug in the UK. All of these can potentially cause confusion 
amongst consumers looking for information.  
Only 51% of apps had been updated within the past year and therefore almost half could 
contain out of date information.  
Age restriction criteria differed between platforms with iOS having an age cut off and Google 
play describing the age restriction as different levels of maturity. It is not clear what the 
maturity rating for Android apps actually means and how it is decided.  
HON criteria  
Only 1 app met more than 50% of the HON criteria, with 71% meeting five or less. No apps 
contained references or documentation of where the information came from; this means that 
it is impossible for people to assess the reliability of the information.  
Range of coverage 
Content coverage ranged from apps that only provided information on one content parameter 
(e.g. testing) and no information on STIs or genital infections, to apps that covered multiple 
content parameters and multiple STIs and genital infections. Apps available in both platforms 
were more comprehensive in terms of the number of content parameters covered and 
number of STI and genital infections covered.  
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Comprehensiveness of content 
Compared to patient information webpages provided by FPA, NHS Choices and BASHH, the 
majority of apps provided incomplete information on the parameters that they covered, 
although there was wide variability in terms of parameters covered, apps and platforms 
assessed.  There was particularly poor coverage of safe sex and partner notification, which is of 
concern from a public health perspective. 
Of concern, only 18% of apps provided fully comprehensive information on the STI/genital 
infections on which they focussed. Despite the prevalence and incidence of genital chlamydia, 
and the presence of a national screening programme for 16-24 year olds, only 43% provided 
any sort of information on this infection, with the majority of these providing only partially 
comprehensive information.  
Accuracy of content 
As with coverage and comprehensiveness of content, accuracy of content was highly variable 
between apps and between platforms. Only a small proportion of apps were found to contain 
completely accurate information, whereas 32% contained only partially accurate (i.e. errors in 
more than one aspect of the information or more than two minor errors).  
Potentially harmful content 
There was a large degree of variability of content and accuracy between apps and between 
different platforms with no quality accredited system to enable the public to determine which 
apps to trust.  
Although none of the apps assessed actually make a clinical diagnosis, with the exception of 
“STD triage”, and none of them would be categorised as medical devices, the inaccurate 
information provided, particularly related to management of the condition, means that some 
of them could be deleterious to health, e.g. some of the managements suggested for vaginal 
candidiasis and bacterial vaginosis. Perhaps more importantly, some of the apps are 
potentially psychologically damaging.  The psychological effects of infections such as HPV and 
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HSV frequently outweigh the physical effects, and this has been backed up by the literature 
(212-216). Several of the apps reviewed that contained information on these infections were 
both condemning and scaremongering. 
However, some apps provided excellent information on one of both of these infections, e.g. 
Genital Herpes Information by Naster Solomon.  
6.2 FINDINGS OF OTHER STUDIES 
Muessig et al conducted a review of the characteristics and content of HIV and STI prevention 
and care apps. They found 55 apps that fitted their inclusion criteria. Of these, 49% had been 
updated within the previous 12 months.  36% of eligible apps contained information on STI 
testing, as opposed to 64% of apps in our review. Likewise, a far higher proportion (79%) of the 
apps we reviewed provided information on safe sex, with Muessig et al finding only 24% of the 
apps in their reviewed contained information on this parameter. Muessig et al did not assess 
comprehensiveness and accuracy of the apps. (64) 
Of the 10 apps that have been approved by NHS Choices health apps library under the sexual 
health section, only four concern   STIs (one of which we found to be non-functioning); five are 
related to specifically to HIV and one to alcohol(210). It is difficult to make an assessment as to 
how up-to-date this information is with the NHS Choices health apps library neither having a 
creation date nor an updated date on its web pages. Furthermore, there is no mention as to 
when the individual apps were approved. The HON Code of Conduct for medical and health 
Web sites (HONcode) recommends that ‘all medical content has to have a specific date of 
creation and a last modification date’(217). The HONcode is provided by a non-government 
organisation with the aim of addressing the reliability and credibility of medical and health 
information on the internet(209).  Although it is not mandatory, if a NHS-backed website that 
hosts the health apps library has failed to meet this basic requirement, it brings in to question 
the validity and usefulness of the recommendations it is providing. Knowledge and information 
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within the medical field develops and changes frequently and it is important for users to know 
when the information on both the NHS choices health apps website and the individual apps 
were last reviewed and updated.   
Within other fields of medicine 
Fifty percent of apps for the prevention, detection and management of cancer were free to 
download (review conducted 2012). Few incorporated ‘features that could facilitate 
communication with the health care team’ and the reviewers felt that the apps ‘did not take 
advantage of the smartphone’s technical capability’ (218).  
As found in this review, a significant proportion of medical apps fail to provide information on 
authorship, references, and are not updated on a regular basis (64;66;76). In addition, only a 
minority of apps have input from an appropriately qualified healthcare professional (66;76). 
Sunyaev et al examined the proportion of mobile medical apps which had privacy policies, 
finding that only 30.5% (183) of the 600 apps reviewed had privacy policies. These also found 
that 66.1% of these policies were not specifically relevant to the app(219).   
Huckvale et al found similar issues to us in terms of limited comprehensiveness and breadth of 
information provided in their systematic review of apps for self-management of asthma(66). 
Arnhold et al, although not directly assessing content, found in their review of apps for people 
with diabetes that the majority of apps were limited in terms of the number of functions that 
they performed and that the apps offered similar functionality(201).  
6.3 STRENGTHS/WEAKNESS/LIMITATIONS 
Although I have designed and conducted a comprehensive review, it has not been possible to 
eliminate the subjective element. Because of the need for more than one person to conduct 
the review, the length of time it took to search for and evaluate each app, and the timing of 
the review, it was necessary to have three other researchers involved at different points in 
time. This meant that the subjectivity is likely to be increased, whilst potentially reducing the 
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accuracy of the scoring of individual apps and the ability to compare these apps. Because of 
the way I designed and conducted the review, I chose not to calculate the kappa coefficient of 
agreement between researchers. In addition, I did not use an independent third reviewer to 
resolve any differences in scores for the apps which could have led to significant bias.  
In the future I would choose to conduct the review with one or two other suitably qualified 
researchers, who reviewed all of the apps and who did not change during the review process. I 
would use an independent third reviewer to resolve any differences in scores.  By doing so I 
could also calculate the kappa coefficient of agreement between the researchers meaningfully.  
Because of the scope of the review, and following the findings of the initial phase one search 
process, it was necessary to employ stringent inclusion and exclusion criteria. Therefore, it is 
possible that we have missed apps that should have been included within this review.  
As noted by Lewis in his paper on self-certification of medical apps(209), this review was also 
limited by the need to assess a broad range of apps that focussed on different aspects of 
sexual health and which had very different interfaces. This meant that any direct comparison 
between individual apps was impossible and that the parameters had to be kept broad.  
Ten apps were excluded because they required a subscription or a username and password. 
They either required one to have attended a clinic before being able to access the app or asked 
for personal information including contact details. As the researchers were using their own 
personal smartphones to access the apps, the decision was made to exclude these apps. This 
could have led to a significant bias through excluding either higher or lower quality apps.  
However, this is a large review that has been rigorously conducted, and includes STI and 
genital infection apps from the main mobile phone platforms and from a wide range of 
countries.  
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6.4 STRENGTHS/WEAKNESSES IN RELATION TO OTHER STUDIES 
Powell et al criticised the quality of published reviews of mobile medical apps, suggesting that 
many of them have failed to perform a systematic, evidence-based assessment of the apps in 
question(220).  I have adapted and developed a framework for reviewing mobile medical apps 
that is timely and comprehensive.  Whilst it is specific to sexual health, this framework could 
be easily amended to meet the needs of other specialities.  
It is difficult for any review of this magnitude to be conducted, analysed and written up within 
a timeframe that ensures that it isn’t out of date by the time it is published(209). However, 
although the assessment of an individual app may not be completely accurate at the time of 
publishing, the overall findings of the survey can be helpful in providing evidence on the 
quality of mobile medical apps and informing the need for changes in the regulation and 
accreditation of apps.  
6.5 MEANING AND IMPLICATIONS 
 
Sexual health is still a stigmatised area and therefore people maybe more likely to seek 
information online. The fact that a high proportion of apps contain inaccurate information is of 
great concern.   
It is clear that accuracy and quality of currently available mobile medical apps is highly variable 
and at the moment there is no easy way for the consumer to recognise which apps to trust and 
which apps to avoid. 
The US Food and Drug Administration (FDA) have taken the approach of only attempting to 
regulate those mobile apps that they define as medical devices. They refer to these apps as 
medical mobile apps and , similar to the MHRAs classification of medical devices(221), 
categorise medical mobile apps as ‘low risk’, ’moderate risk’ or ‘high risk’. Their guidance only 
applies to those apps that are classified as ‘moderate’ or ‘high risk’. The vast majority of 
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available mobile medical apps do not fall into these categories and therefore remain 
unregulated (222;223).  
In the US, Happtique Health App Certification Standards provided certification for those apps 
available in the US that met their standards on a variety of criteria including content quality, 
usability, connectivity, security and privacy (205;209). However, this process was suspended 
towards the end of 2013 following the discovery that several apps that had previously received 
certification contained issues with security(224). This, along with other reasons discussed 
below, has made several authors question the feasibility and usefulness of accreditation of 
medical and health apps (205;224-226). It is a time-expensive process, with Happtique taking 
18 months to certify 16 apps(224). In addition, with the number and diverse origin of available 
apps, any certification process is going to have to be voluntary and is likely to only ever be 
taken up by a small proportion of the market(225). There is also a fear that regulation will limit 
innovation through unnecessary bureaucracy, increased cost and delay in time to market 
(226;227). 
Instead Boulos et al and Chan and Misra argue that we should be focussing on educating 
consumers on how to assess whether an app is a reliable source of information, and 
recommending (or even prescribing) those apps that are known to be accurate and 
accessible(205;225).  They do not discuss how this can actually be achieved, and, as with 
regulation, education in terms of apps may need to differ depending on who the app is 
targeting and an assessment of the potential harm from individual apps. 
Implications for the eSTI2 Chlamydia Online Clinical Care Pathway 
Although the first point of access for young people looking to find information on sexual health 
is the internet, qualitative research conducted by other researchers within the eSTI2 
consortium suggests that young people prefer to access this information via a web application 
than a native app (181;228). Reasons for this include concerns with regards to privacy, with the 
fear that a friend or parent will see that they have a sexual health app on their 
131 
 
phone(181;228).  It is acknowledged that young people are faster to adopt but also potentially 
faster to reject new technology(6). However, Helsper raises the potential implications of 
assuming that young people are digital experts, are intrinsically better at filtering information 
and aware of the risks associated with the internet(229).  
The findings from the qualitative research (181;228), along with the large variability in terms of 
coverage, comprehensiveness and accuracy of apps, with no way for people to easily identify 
apps that are relevant and accurate, found by this review led us to decide to develop a web 
application as opposed to a native app for the Chlamydia-OCCP. Other factors that led us to 
make this decision included the complexity of the pathway which, although designed so that 
people could use it on their smartphone, would be easier to complete on a larger screen (i.e. a 
tablet, laptop or PC), and allowing people that had mobile phones which were not 
smartphones to access the pathway.   
6.6 RECOMMENDATIONS  
As well as assessing whether an app is high risk in terms of potential physical harm, 
psychological harm should also be taken in to consideration, particularly in the context of 
sexual health apps.  
A more transparent accreditation process by NHS Choices, preferably with the involvement of 
the British Association of Sexual Health and HIV (BASHH), with clear guidelines on what needs 
to be achieved could be a useful way forward and then publicising this. 
However, I do not believe it will be possible, and is perhaps not necessary, to regulate all 
sexual health apps. Instead, I support Boulos et al’s argument that educating the consumer is 
more important and feasible. Signposting people to apps that have been accredited or come 
from a reputable source is a priority.  
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6.7 UNANSWERED QUESTIONS AND FUTURE RESEARCH 
In terms of sexual health, the global diffusion and dissemination of smart phones has been 
advocated by Swendeman and Rotheram-Borus as a method of delivering interventions aimed 
at STI prevention and support(230).  Nearly five years after their paper was published, we are 
still a long way from attaining this goal with this review showing that currently available apps 
are highly variable in coverage, comprehensiveness and accuracy.  
I chose to only focus on apps that are designed for the general public and cover sexual health 
(excluding HIV). There haven’t been any reviews conducted that examine the content and 
accuracy of sexual health apps designed for health care professionals, or those that cover HIV. 
In addition, further research is needed to examine the efficacy of these apps in increasing 
knowledge and bring about behaviour change. 
Concerns related to mobile medical apps as a whole include the potential for breach of patient 
confidentiality(76;231), lack of validated medical information (70;200;218;232), errors 
produced by faulty clinical decision making apps or calculators(76), and lack of evidence of 
mobile medical app efficacy to deliver health behaviour changes and improve patient 
outcomes (71;75;218;227;233-235;235). Pandey et al, in their review of apps for cancer, found 
a significant difference in scientific validity between apps aimed at the general population 
when compared to those developed for healthcare professionals(200). 
Buijink et al state ‘the field of medical apps is currently one of the most dynamic in medicine, 
with real potential to change the way evidence-based healthcare is delivered in the 
future’(76). Whilst true, we are unlikely to see this potential reached, at least in terms of 
medical apps designed for patients and the public, unless there is clear guidance in the UK as 
to which apps need accreditation before being made freely available, and we find a way of 
guiding users on how to assess the reliability of the app they are looking at or directing them 
towards those apps that have undergone voluntary or mandatory certification.  
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Chapter 3: Review of electronic 
prescribing in the UK to inform the 
design of the Chlamydia Online 
Clinical Care Pathway 
 
 
 
 
 
 
 
 
1. RATIONALE  
As part of my routine Queen Mary University of London work, I conducted a review of legal, 
regulatory, organisational, ethical and perceptual barriers pertinent to the introduction of a 
Sexual Health online clinical care pathway into the NHS. Whilst conducting this it became 
apparent that, despite the volume of literature on electronic prescribing (39), there have been 
no reviews on electronic prescribing in the UK and that there were particular difficulties 
surrounding the introduction of an electronic prescription service which bridges primary and 
secondary care.   
I therefore chose to conduct a comprehensive review of electronic prescribing in the UK. This 
would enable me to explore options and solutions for the introduction of an electronic 
This chapter is composed of the following components: 
1. Rationale 
2. Background 
3. Methods 
4. Results 
5. Discussion 
6. ePrescribing within the eSTI2 Chlamydia Online Clinical Care 
Pathway 
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prescribing service, using an automated online clinical consultation to assess safety and 
appropriateness of treatment, for azithromycin 1g stat to patients diagnosed with chlamydia 
which could be issued in secondary care and dispensed in a community pharmacy.  
2. BACKGROUND 
2.1 DEFINITIONS 
 
Prescriptions, whether paper or electronic, are a method whereby a physician, or a suitably 
qualified healthcare professional, enables a patient, or a patient’s representative, to collect the 
medication that the healthcare professional has recommended from an onsite or external 
dispensary or pharmacy.  
Electronic prescribing, defined as ‘the utilisation of electronic systems to facilitate and 
enhance the communication of a prescription or medicine order, aiding the choice, 
administration and supply of a medicine through knowledge and decision support and 
providing a robust audit trail for the entire medicines use process’(89) is a key part of the 
larger eHealth landscape.  
eHealth, defined as the utilisation of evolving information and communication technology to 
develop and improve the organisation and delivery of health services and healthcare(11;12), 
eHealth has assumed increasing importance within the NHS over the past 20 years. 
Computerized Provider Order Entry systems:  Outside the UK, electronic prescribing systems 
are known as computerized provider (previously physician) order entry systems (CPOEs). 
CPOEs have been defined by Kaushal et al as ‘a variety of computer-based systems that share 
the common features of automating the medication ordering process and that ensure 
standardized, legible, and complete orders’(236). There are subtle differences between 
electronic prescribing systems and CPOE systems. However, for the purposes of this chapter, I 
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have chosen to use electronic prescribing to describe electronic prescribing systems, and for 
this to be synonymous with CPOE systems. 
Clinical Decisions Support Systems are defined as “any electronic or non-electronic system 
designed to aid directly in clinical decision making, in which characteristics of individual 
patients are used to generate patient-specific assessments or recommendations”(237). The 
majority of electronic prescribing systems incorporate clinical decision support systems which 
vary in complexity from providing basic advice about drug dosage and mode of delivery to the 
ability to check for drug allergies, drug-drug interactions, laboratory results (including adjusting 
for renal impairment), and relevant guidelines(30;236).  
The NHS Spine is the ‘essential national infrastructure that stores patient information and 
enables electronic messaging’(238). The Spine ‘holds the demographic information of 80 
million people, as well as controlling the messaging between key applications used in the 
delivery of patient care, for example, the Electronic Prescription Service, Summary Care Record 
and Choose and Book’(238). The contract for the Spine was due to expire in June 2013(239). 
However, the Health and Social Care Information Centre concluded that it was imperative for 
this service to continue. This was accomplished, with an extension of contract which covered 
the transition to the new ‘Spine 2’ project(240). The new Spine infrastructure (‘Spine 2’) was 
implemented on 23rd and 24th August 2014(241). 
Grey literature is defined by Khoja et al as ‘any literature that is not published in academic 
peer-reviewed journals and is not available through indexed databases for review’(242).  
2.2 POLITICAL MILIEU 
There has been growing political influence on development of eHealth, visible since 1998 with 
the Department of Health’s strategy document Information for Health(83). This pledged 
lifelong electronic health records for patients, along with 24 hour online access to medical 
records and best practice guidance for all NHS clinicians(5;83).This theme has continued, 
136 
 
including the more recently published strategies and consultations:  Building the Information 
Core: Implementing the NHS Plan(243);Delivering 21st century IT support for the NHS: national 
strategic programme(87); Better information, better choices, better health: Putting information 
at the centre of health(88); Liberating the NHS: An Information Revolution(85); Keeping your 
online health and social care records safe and secure(244); The Power of Information: putting 
us all in charge of the health and care information we need(84); Safer Hospitals, Safer 
Wards(89).  
The NHS National Programme for Information Technology, launched in October 2002, aimed to 
establish the infrastructure and setting to deliver a comprehensive electronic health record 
(NHS Care Records Service) for patients utilising an national network (N3) and database (the 
Spine), an integrated electronic prescription service and an electronic hospital appointment 
service (Choose and Book)(5). Despite an £11.4 billion programme of investment, it was 
fraught with difficulties and received negative reportage (245-249). 
 In 2004 the Department of Health, as part of its reconfiguration of Arm’s Length Bodies, 
created NHS Connecting for Health. This new organisation was given responsibility for both 
delivering the National Programme for Information Technology and managing the information 
technology (IT) component of the NHS Information Authority(5;250).  In 2012, as part of the 
Health and Social Care Act(251), it was announced that Connecting for Health would be 
incorporated into the newly formed Health and Social Care Information Centre. Despite the 
troubles associated with the National Programme for Information Technology, the Electronic 
Health Record (EHR) systems in use in General Practice in the UK have received both national 
and international recognition as an example of successful implementation of a National EHR 
system(246;252).  
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2.3 PROFESSIONAL REGULATORS 
In 2009, the General Medical Council commissioned an in depth investigation exploring the 
type of prescribing errors made by Foundation Year 1 (new qualified) doctors in the UK, 
relating this to their medical education, in order to make ‘evidence-based recommendations’. 
The research found that there was an error rate of 8.9% in the 124,260 medication orders that 
were reviewed(253). Recommendations were made but these have been criticised for lacking 
an evidence base and for not considering systems that have worked in other countries or 
electronic prescribing as a solution (254-257). 
 
Motulsky et al, in their review of second-generation electronic prescribing, highlight the fact 
that there appear to be no standards on communication in electronic prescribing, with 
heterogeneity being the rule rather than the exception(258). In addition, they failed to find a 
study that looked at process security or process quality(258).  
2.4 CURRENT STATE OF PLAY 
Electronic prescribing has been introduced into both primary and secondary care within the 
UK. General practice and hospitals have been treated as separate entities and the approach 
taken in both cases has been markedly different, with secondary care lagging behind 
primary(249).  For the purposes of this review, I have used the terms primary care, community 
and general practice, and secondary care and hospitals, synonymously.  
3. METHODS 
I conducted a comprehensive literature search on electronic prescribing, which was initially 
conducted in the medical literature and then expanded to include grey literature. I 
independently developed the following method for approaching this type of disparate 
literature which needed to included policy, legislation, regulations, trials and other literature. I 
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have described my methodology employing the structure described by Greenhalgh and 
Peacock(259) (which divided it into protocol driven search, snowballing, and personal 
knowledge). However, I found that belatedly having completed the work using similar 
methodology which I devised independently. 
3.1 PROTOCOL DRIVEN SEARCH 
Using NHS Evidence, I performed an electronic search of MEDLINE, EMBASE and the Cochrane 
Library. 
The search was conducted of articles published between 1993 and 2013, as the first electronic 
prescribing systems were introduced 20 years ago, using NHS Evidence database thesaurus 
terms and free text search terms. Table 44 below describes the NHS Evidence database 
thesaurus terms used. 
Table 44: NHS Evidence database thesaurus terms for ePrescribing literature review 
Drug therapy, computer assisted Legislation, medical 
Electronic prescribing Medical order entry systems 
England Medication errors 
Great Britain Organization and administration 
Inappropriate prescribing Pharmaceutical services, online 
Jurisprudence Reference standards 
Legislation as topic Utilization review 
 
Appendix II illustrates the search strategy I conducted using the above NHS Evidence thesaurus 
terms and free text. I searched official Government, NHS and professional association 
websites, including existing professional guidance (summarised in Table 45 below). 
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Table 45: Government, NHS & professional association websites searched 
Type of website URL 
Government http://www.legislation.gov.uk/;  
 http://www.hscic.gov.uk/;   
NHS  http://www.nhsbsa.nhs.uk/; 
http://webarchive.nationalarchives.gov.uk/20130502102046/http://w
ww.connectingforhealth.nhs.uk/ 
https://www.england.nhs.uk/ 
Professional  http://www.gmc-uk.org/ 
http://psnc.org.uk/ 
http://www.rpharms.com/home/home.asp 
 
 
 I then searched Google and Google Scholar to capture both medical and grey literature that 
had been missed in the above searches. 
3.2 ‘SNOWBALLING’ 
I used reference and citation tracking to widen the scope of relevant sources found. 
3.3 PERSONAL KNOWLEDGE 
This included articles that I found whilst searching for other topics (serendipitous discovery) 
and personal contacts and academic networks. 
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4. RESULTS 
 
As mentioned in the introduction, there is a large amount of diverse literature on electronic 
prescribing, present in both medical and grey literature. I classified relevant literature under 
two main headings, as this formed a natural subdivision of the literature found in the search: 
legal and regulatory and organisational.  
4.1 LEGAL AND REGULATORY  
 
Table 46 summarises the relevant literature I found on electronic prescribing legislation and 
regulations.  
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Table 46: Summary of the relevant literature on the legal and regulatory aspects of electronic prescribing 
Ref First Author/Source Year 
published 
Source focus Source type Findings and Recommendations 
1 British National 
(260)Formulary 
2013 BNF November 2013 Guidance Provides guidance on what details are required on computer 
issued prescriptions 
2 General Medical 
Council(261) 
2013 Good practice in 
prescribing and managing 
medicines and devices 
Professional 
guidance 
Provides guidance on safe prescribing, including remote 
prescribing.  
3 Legislation.gov.uk 
(262) 
2001 Prescription Only 
Medicines (Human Use) 
(Electronic 
Communication) Order 
Legislation Article 15 of the PoM Order 1997 amended. Permits 
prescriptions to be transmitted electronically and the use of 
electronic signatures.  
4 Legislation.gov.uk(263) 1997 The Prescription on 
Medicines (Human Use) 
Order 1997 
Legislation Provides details of what information prescriptions need to 
contain 
5 Legislation.gov.uk(264) 2013 NHS (Pharmaceutical and 
Local Pharmaceutical 
Service) Regulations 
Legislation Updated legislation governing the provision of 
pharmaceutical services in England. Defines ePrescribing. 
6 NHS Business Service 
Authority (NHS 
Prescription 
Services)(265) 
2013 Current and Out of Date 
Prescription Form Versions 
Guidance Summary of current and out of date prescription forms 
7 NHS Information 
Governance(266) 
2008 Guidelines on use of 
encryption to protect 
person identifiable and 
sensitive information 
Guidance Provides guidance on the use of encryption to ensure patient 
confidentiality 
8 Pharmaceutical 
Services Negotiating 
Committee(267) 
2013 Valid Prescription Forms Guidance Summary of valid prescription forms 
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This content can be divided into the following areas: 
Prescriptions 
The Prescription Only Medicines (Human Use) Order 1997 states that prescriptions need to 
contain the following information(263):  
 
 
 
 
 
 
 
With increasing shared responsibility of patient care, the Department of Health released a 
circular making it clear that in the case of shared care between hospitals and General Practice, 
the legal responsibility for prescribing is with the doctor who signs the prescription(268) 
The recently updated General Medical Council guidelines Good practice in prescribing and 
managing medicines and devices make clear the need to take an adequate drug history, 
including adverse drug reactions, recent use of medicines including over the counter and illicit 
drugs, and other medical conditions(261). 
There is a natural divide in the UK between hospital and community prescribing. The majority 
of hospital prescriptions, whether inpatient or outpatient, are dispensed in an onsite inpatient 
or outpatient hospital pharmacy. Prescriptions generated from General Practice are either 
dispensed in an onsite dispensary or by a community pharmacy. If a hospital practitioner 
wishes to write a prescription that will be dispensed in a community pharmacy then they need 
Address of the Practitioner 
Appropriate date 
Title of the Practitioner 
Name of patient 
Address of patient 
If under 12, the age of the patient 
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to write the prescription on a specific form called a FP10.   The Pharmaceutical Services 
Negotiating Committee (PSNC) provides a list of valid prescription forms(267).   
Electronic prescriptions 
The 2001 Prescription Only Medicines (Human Use) (Electronic Communication) Order permits 
the use of electronic prescriptions. This includes the electronic form being signed with an 
electronic signature and dispensed via electronic means. It does not put any restrictions on 
which service or software is used to enable this(262).   
The British National Formulary provides guidance, based on the Joint GP Information 
Technology Committee recommendations, on what details are required on computer issued 
prescriptions. 
 
 
 
 
 
 
 
 
This guidance has been developed in conjunction with General Practitioners and with first-
generation e-prescribing systems (stand-alone systems producing a printed prescription which 
is handed to the patient or faxed to a pharmacy) in mind. In second-generation e-prescribing 
systems, where the electronic prescription is transmitted electronically to the ‘spine’ (the 
central server), these guidelines are not necessarily fit for purpose. The GMC Good practice in 
prescribing and managing medicines and devices guideline stipulates that the prescribing 
The computer must print out the: 
· Date 
· Patient’s surname 
· One forename 
· Other initials 
· Age (mandatory if <12 or >60 years) 
· Address 
· The doctor’s name at the bottom of the 
prescription form 
· The doctor’s surgery address, reference 
number, and primary care trust, & the  
surgery telephone number 
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doctor’s name and GMC number are sufficient when prescribing remotely.(261). Likewise, we 
as Healthcare professionals (HCPs) are encouraged to minimise the transfer of patient 
identifiable information, wherever possible, with NHS Information Governance publishing 
Guidelines on use of encryption to protect person identifiable and sensitive information in 2008 
(266). This is particularly important in the scenario of electronic transmission of information 
related to sexual health. It is common practice in Genitourinary Medicine (GUM) and Sexual 
Health clinics in the UK to use a unique clinic number and date of birth to identify a patient on 
a written prescription, but this is when using a hospital pharmacy. Whether it would be 
permitted in a community setting has not been tested. The address is required to identify 
which Local Authority the patient is from for reimbursement and for surveillance purposes, 
and only the first four digits of a postcode is required to do this.  
 
In the Good practice in prescribing and managing medicines and devices GMC guidelines 
(2013) there is a specific section on remote prescribing which states that doctors need to be 
able to obtain the patient’s consent for this. This includes providing the patient with 
information about the proposed treatment,  how and when to take the medicine or use a 
medical device, how long they need to continue it for, and what follow-up, if any, is required. 
As well as explaining the rationale for using the treatment, any risks or side effects need to be 
explained along with what to do if the patient suffers an adverse effect or the condition they 
are being treated for recurs. It then needs to be confirmed that the patient understands the 
information. The guidance recognises the difficulties of being able to convey this amount of 
information in a limited amount of time, and suggests involving other HCPs to help with this, as 
well as using patient information leaflets(261).  Section 61 of the Good practice in prescribing 
and managing medicines and devices guidelines (2013) highlights specific details that need to 
be considered when prescribing remotely. These include the limitations of the method of 
communication that a clinician is using, whether the patient needs a physical examination or 
other investigations, and whether the clinician has access to the medical records of the 
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patient. Where the latter is not available, the patient has not been referred by their GP and 
one has never met the patient face-to-face then, if prescribing online, a named doctor and 
GMC number are required on the prescription. The legal responsibility for prescribing will lie 
with this doctor(261).  
 
Summary of the requirements for information on a prescription 
 
A prescription needs to convey which treatment the patient requires, how it will be applied 
(e.g. oral, intramuscular), how often it needs to be taken, how long it needs to be taken for, a 
method by which that patient can be identified, and who is prescribing the medication. In 
addition, in the UK, there needs to be sufficient information so that the correct local authority 
can be billed for the prescription. Table 47 below summarises what the various regulatory 
bodies stipulate should be on a prescription, and illustrates the marked lack of consensus
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Table 47: Summary of the information required on a prescription by different regulatory bodies 
Requirements 
Regulatory bodies 
Genitourinary 
Medicine PoM
1 Order 
1997(263) 
NHS BSA2(269) 
(FP10) 
PoM Order 2001 
(electronic 
prescribing)(262) 
BNF3 (electronic 
prescribing)(260) 
GMC4 (remote 
electronic 
prescribing)(261) 
Details of 
prescriber 
Address of the 
practitioner 
‘HOSPITAL PRESCRIBER’ 
to be printed at top of 
form 
Address of the 
practitioner 
The Doctor’s name at the 
bottom of the prescription form 
Doctor’s name Doctor’s name  
 
  Name and initials of 
Doctor. Hospital Unit 
name and address. NHS 
Trust name and code  
 The Doctor’s surgery address, 
reference number and primary 
care trust, and the surgery 
telephone number 
Named Doctor’s 
GMC number 
 
 Title of the 
practitioner 
 Title of the 
practitioner 
   
Date 
prescribed 
Appropriate 
date 
 Appropriate date Date  Date 
1st patient 
identifier 
Name of 
patient 
Name of patient (format 
to be agreed between 
the user and the system 
supplier) 
Name of patient Patient’s surname 
One forename 
Other initial 
 Patient’s unique 
clinic number 
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Table 47 continued 
 
Requirements 
Regulatory bodies 
Genitourinary 
Medicine PoM
1 Order 
1997(263) 
NHS BSA2(269) 
(FP10) 
PoM Order 2001 
(electronic 
prescribing)(262) 
BNF3 (electronic 
prescribing)(260) 
GMC4 (remote electronic 
prescribing)(261) 
2nd patient identifier 
and billing information 
Address of 
patient 
Address of 
patient 
Address of patient Address of patient  Patient’s 
postcode 
Age/Date of birth If under 12, the 
age of patient 
Age and Date 
of birth of 
patient 
If under 12, the age of 
patient 
Age (mandatory if <12 
or >60 years) 
 Date of birth 
Signature Yes Yes Yes (electronic) Not stipulated No Yes 
Details of drug 
prescribed5 
Medication generic name, dose, method of administration and length of prescription 
1 Prescription only Medicines; 2 NHS Business Services Authority; 3 British National Formulary; 4 General Medical Council; 5 with the exception of controlled drugs 
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Electronic Prescription Service 
The NHS (Pharmaceutical and Local Pharmaceutical Service) Regulations 2013(264), which 
came into effect on 1st April 2013, replaced the National Health Service (Pharmaceutical 
Services) Regulations 2012 and Chapter 1 of Part 7 of the National Health Service Act 2006, 
which covers provision of local pharmaceutical services. The 2005 NHS (Pharmaceutical 
Services) Regulations define, and the 2013 NHS (Pharmaceutical and Local Pharmaceutical 
Service) regulations continue to define, electronic prescribing as follows: 
‘“electronic prescription” means an electronic prescription form or an electronic repeatable 
prescription; 
“electronic prescription form” means data created in an electronic form for the purpose of 
ordering a drug or appliance, which: 
 … is transmitted as an electronic communication to a nominated dispensing contractor 
by the Electronic Prescription Service’ 
This has been interpreted as meaning that only the NHS Electronic Prescription Service (EPS) 
can be used to transmit an electronic prescription to a community pharmacy, although there is 
nothing explicit within these regulations that covers the scenario that we are describing (270).  
 
4.2 ORGANISATIONAL 
 
Table 48 below summaries the literature found on the organisation of electronic prescribing 
within the NHS in the UK. 
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Ref First 
Author/Source 
Year 
published 
Country Source focus Source type Findings and Recommendations 
1 NHS Connecting for 
Health(271) 
2009 UK Electronic prescribing 
in hospitals. 
Challenges and 
lessons learned 
Report Hospital prescribing systems need updating and 
electronic prescribing offers the potential to 
address current issues. Although a high 
proportion of GP practices have electronic 
prescribing, a much smaller proportion hospitals 
have such systems. There is wide variability of 
existing hospital electronic prescribing systems.   
Communication and engagement of the 
multidisciplinary team are key to implementing a 
new system.  
2 Cornford(249) 2010 UK Learning lessons from 
electronic prescribing 
implementations in 
secondary care 
Review and 
study 
Describes findings from a literature review and 
questionnaire study conducted to review lessons 
learned from implementation of electronic 
prescribing systems in hospitals in the UK. Not 
many hospitals have comprehensive, hospital-
wide electronic prescribing systems, in contrast 
to the primary care Electronic Prescription 
Service. Importance of role of senior managers, 
champions, clinical input and user involvement, 
the latter of which must be multi-disciplinary. 
Importance of establishing good communication 
between the project, software and database 
teams. Need for rapid transition from piloting to 
rolling out full system. Consider sustainability and 
need for resources to develop and adapt the 
system.  
 
 
 
Table 48: summary of the literature on the organisation of electronic prescribing in the UK 
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Table 47 continued 
Ref First 
Author/Source 
Year 
published 
Country Source focus Source type Findings and Recommendations 
3 NHS England(89) 2013 UK Safer hospitals, safer 
wards: achieving an 
integrated digital care 
record 
Guidance  Discusses benefits of ePrescribing and provides 
guidance on the different types of systems 
available and how they can be implemented 
4 Cresswell(272) 2013 UK  Investigating and 
Learning Lessons from 
Early Experiences of 
Implementing 
ePrescribing Systems 
into NHS Hospitals: A 
Questionnaire Study  
Questionnaire 
Study 
78.7% response rate (85/108 NHS staff). Low 
rates (18%) of NHS Trusts had implemented 
electronic prescribing systems. 55% were 
planning to implement an electronic prescribing 
system. There was a diverse range of electronic 
prescribing systems that had been implemented 
or were planning on being implemented.  
5 Ahmed(273) 2013 UK The Use and 
Functionality if 
Electronic Prescribing 
Systems in English 
Acute NHS Trusts: A 
Cross-sectional 
Survey 
Cross-
sectional 
postal survey 
61% response rate from chief pharmacists. 
70/101 acute NHS hospital trusts had some form 
of electronic prescribing. 56% of these had more 
than one type of electronic prescribing system in 
use, with 60 diverse systems described (40% 
developed in-house).  
6 Health and Social 
Care Information 
Centre(239;274) 
2013-15 UK The national provider 
of information, data 
and IT systems for 
health and social care  
Online Superseded NHS Connecting For Health. Detailed 
description of the Electronic Prescribing System.  
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Community-based electronic prescribing: Electronic Prescription Service (EPS) 
NHS Connecting for Health introduced the EPS into primary care in England in 2005 in the 
format of EPS Release 1. With EPS release 1, an electronically generated prescription with a 
barcode on it is printed off by a general practitioner and handed to the patient as a paper 
prescription. When issued, the EPS receives an electronic copy of the information which is 
accessible to dispensers who have implemented EPS Release 1; when they scan the barcode 
the stored electronic information is automatically retrieved and downloaded on to the 
dispenser’s computer. Those dispensers who are not EPS Release 1 enabled can process the 
prescription in the traditional way(275). 
EPS has, in part, been superseded by EPS Release 2(270), which confers additional benefits. 
These include the ability for a patient to nominate a pharmacy from which to collect their 
prescription, the capability for a pharmacy to download a prescription generated by a GP from 
‘the spine’, the ability for a GP to generate repeat prescriptions and to cancel a prescription 
online, and for pharmacist reimbursement to occur electronically.  Further advantages include 
the ability to trace whether a patient has collected their prescription from their chosen 
pharmacy, and to contact patients where it is clinically important to do so. Studies have shown 
that electronic prescribing per se does not improve patient compliance with collecting 
prescriptions(276) and, in Sweden, the introduction of electronically transmitted prescriptions 
paradoxically led to an increase in the number of prescriptions not collected at 
pharmacies(277). However, an electronic system allows healthcare professionals to track who 
has collected their medication and who has not. This increased visibility of patients’ adherence 
to medication collection allows problems with individual patients to be identified and 
interventions to be introduced to improve the situation(278).  This has had proven success, 
either as the sole measure taken or as part of a number of interventions to improve adherence 
and clinical outcomes(279), although an electronic prescription database was found to be 
inferior to pill counts as a method of detecting non-adherence in Denmark. The main reasons 
for this was inaccuracies on the database due to erroneous prescription information(280).  
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The large percentage of GP surgeries with existing electronic health records, provided by a 
limited number of commercial providers, and overseen by Primary Care Trusts, facilitated the 
introduction and uptake of EPS release 1. In addition, EPS Release 1 was inserted into the GP 
contract and, as mentioned above, legislation for commercial pharmacies. Pharmacies were 
offered financial incentives for offering EPS (281).  At this time, smartphones did not exist, with 
Apple’s iPhone first being introduced in 2007(282), and it was difficult conceive that anyone 
other a GP would send an electronic prescribing to a community pharmacy (281). 
 
EPS Release 2 initially met with limited success, with low levels of uptake reported(270). This 
may be due, in part, to the complexity of the authorisation which is required by Local 
Authorities, pharmacies and individual GP surgeries. In addition, new or updated software is 
required by GP surgeries and pharmacies. Finally, some GP practices have a dispensary on site 
that they are already electronically transmitting prescriptions to, whilst others may be satisfied 
with the EPS Release 1 system that they are currently using. 
 
As of 13th March 2015, 51% (n=4143) GP practices in the UK were live with EPS 2 and 97% 
(n=11445) of pharmacies were live(283). 84,563,387 Release 2 prescriptions had been sent, 
with 12,264,876 patients having a community pharmacy nomination(283).  
 
As with any Health and Social Care Information Centre service, in order to access this system, 
NHS staff require a smartcard and personal identification number (PIN)(239). A smartcard is a 
secure identification card, which is similar to a chip and PIN credit card. It allows individual 
staff access to patients records to be restricted according to what is appropriate for the role 
and grade, and allows a record to be kept of who has accessed which records(284). The 
smartcard and PIN are also used by General Practitioners to generate an electronic signature 
for the prescription(285). Although a ‘prescription token’ can be provided to a patient for them 
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to collect their prescription with, patients do not require one and can simply attend their 
chosen pharmacy and confirm their identity verbally to collect it(239). 
 
There have been reports of slow download times of electronic prescribing from ‘the spine’ 
when pharmacists attempt to access prescriptions. When the new Spine system (Spine 2) was 
introduced in August 2014, batches of prescriptions were blocked because of a prescription 
validation error, which meant pharmacists were not able to process the prescriptions, and 
invalid digital signatures were an issue (286).  
 
In addition, patients are required to nominate one pharmacy to which all of their electronic 
prescribing will be sent.  Those patients who have denied their records being uploaded on to 
the patient demographic service are marked as ‘sensitive’ and are unable to utilise the EPS. 
The demographics and characteristics of this group of ‘sensitive’ patients are not defined. 
 
The Prescribing Systems Compliance Specification March 2012(287), specifies the functionality 
required to support the EPS in England. It has been written for system suppliers. Users of the 
EPS are required to interact with the National Care Record Service Spine via the national 
communications infrastructure (currently known as N3). The National Care Record Service 
includes the Personal Demographic Service, the Personal Spine Information Service, and 
Information Governance.   A system wishing to use any of the services provided by the 
National Care Record Service must first be compliant with these core services and all 
appropriate legislation, regulations, national and international laws related to healthcare 
systems (288).  
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Hospital-based electronic prescribing 
 
Hospital-based electronic prescribing is very different from electronic prescribing in the 
community and the latest government strategy, Safer Hospitals, Safer Wards, reflects this(89).  
A £260 million Safer Hospitals, Safer Wards technology fund, administered and delivered by 
NHS England, was revealed in May 2013. This proposes investing in solutions that are best 
suited and adapted to individual organisations, as long as they meet national standards in data 
security and interoperability. The main stipulation is that the primary identifier of individual 
patients is their NHS number, and NHS England proposes that the widespread transformation 
to digital healthcare is a ‘focus for innovation and enterprise and a driver of economic growth, 
particularly among smaller business and their sector organisations’(89). 
Chapter 5 of Safer Hospitals, Safer wards describes a matrix of five domains (prescribing, 
medicines management, administration, decision support and interoperability) composed of  
building blocks which NHS providers can select from to build the system that works best for 
their situation, rather than stipulating how electronic prescribing should be introduced and 
which systems should be used. It is emphasised that this matrix is neither prescriptive nor 
exhaustive and should be interpreted fluidly(89). Although stating the benefits of electronic 
prescribing it does not reference this or give examples where electronic prescribing has 
worked in practice.  
Electronic prescribing in hospitals in the UK has been implemented in a piecemeal fashion, 
with individual hospitals using different systems, some of which are incorporated into, or 
integrated with, electronic health records and clinical decision support systems, and others 
that are stand-alone. Uptake of electronic prescribing has varied from hospital to hospital, and 
it is acknowledged that ‘NHS providers in hospitals are at different stages of digital maturity 
and many still have substantial work to do’(89;249;271). An example of the variety of different 
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electronic prescribing systems in use, and functionality of these systems, is illustrated in figure 
3 below: 
Figure 5: Example of the variety of different electronic prescribing systems in use (adapted 
from Connecting for Health Electronic prescribing in hospitals; Challenges and lessons learned 
page 21)(271)  
ePx
hospital 
systems in 
use
Limited to 1 
clinical 
speciality
Include 
electronic 
administration 
record
Include  ward 
stock supply & 
control
Limited to 1 
stage of 
prescribing 
process
Hospital-wide 
system
Developed in-
house
Stand-alone 
product
Linked to 
clinical decision 
support 
systems
Linked to 
laboratory 
systems
Integrated into 
EHR system
Commercially 
produced 
software
  
Some systems are used solely for inpatients, others for outpatients and some for discharge 
purposes; some systems cover all three areas(271). 
In 2011 Ahmed et al conducted a cross-sectional postal survey of the current use of electronic 
prescribing in acute NHS Hospital Trusts in England (response rate 61% (101 Trusts)). They 
found that only 13% (13 Trusts) had inpatient electronic prescribing systems in place that were 
used in both adult medical and surgical wards(273). Their findings confirmed the diversity of 
type and uptake of electronic prescribing systems, both within hospitals and between 
hospitals, in use in the NHS in England at the present time(273). Cresswell conducted a 
questionnaire survey which was targeted at delegates attending a national conference on 
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implementing electronic prescribing within NHS hospitals in 2012. This was a scoping study 
designed to give an overview of, and lessons learned from, implementation of electronic 
prescribing within hospitals in England(272). Although they had a higher response rate than 
Ahmed et al(273) (79% (85/108 NHS staff attending conference), only 55/168 (33%) Trusts 
were represented by responders. Cresswell found that a proportion of these trusts had already 
implemented (18%), were currently implementing (20%) or were planning on implementing 
(55%) electronic prescribing systems. As with Ahmed et al’s(273) findings, the type and 
spectrum of the electronic prescribing systems in use, or planning to be implemented, was 
highly variable(272). Both Ahmed et al’s and Cresswell’s et al studies were subject to 
responder bias, and Cresswell et al’s studies was limited by selection bias as the survey sample 
were attending a conference on electronic prescribing.  
It has been recognised that some departments in hospitals are unique in terms of the 
implementation of electronic prescribing systems and that they may not suit being integrated 
into a hospital-wide electronic prescribing system(271). Examples highlighted by Connecting 
for Health, in their review of the challenges and lessons learned from electronic prescribing in 
hospitals, include Emergency Departments and Intensive Care Units(271). It would seem logical 
for GUM clinics to be included as one of the areas where it is more complex due to issues of 
confidentiality, privacy and stigma, or where it may not be appropriate, to incorporate them 
into a generalised hospital system. 
Traditionally, GUM clinics have been run separately, and frequently differently, to other 
hospital departments, as discussed in Chapter 1. In terms of prescribing, it is standard practice 
for doctors and appropriately qualified nurses, to access a range of standard antibiotics, 
contraception and associated pharmaceutical products from a secure pharmacy stock room 
within the GUM department. It is up to that individual to check the expiry date on the box, and 
adhere to local guidelines. In other clinics, the prescription (be it written in the notes, on a 
prescription or on an electronic system) is ‘handed’ to a Registered Nurse for that nurse to give 
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the medication to the patient. The type, or dosage, of medication used in Sexual Health Clinics 
is often different to those used in other departments (e.g. Azithromycin 1g PO stat; 
Metronidazole 2g PO stat; Ceftriaxone 500mg I.M. Stat). 
 
5. DISCUSSION 
 
Electronic prescribing has become a common component of eHealth increasingly used in 
everyday practice by healthcare professionals in the UK. Acknowledged as an important 
component of eHealth,  Black et al, in their systematic overview of the impact of eHealth on 
the quality and safety of eHealth, found that electronic prescribing was the most commonly 
studied intervention(39). However, there was large variation in the quality and generalisability 
of these interventions(39).  Study evaluation depends on definition and spectrum of electronic 
prescribing – i.e. the term electronic prescribing includes everything from a stand-alone 
system, without a clinical decision support system,  that produces a printed paper prescription 
for a patient to take to a pharmacy,  to a sophisticated electronic prescribing system, including 
a clinical decision support system, where drugs can be prescribed, with an electronic signature,  
dispensed, repeat prescriptions produced, cost reimbursed and stocks resupplied (249). 
Cornford et al, in their review of lessons to be learned from the implementation of electronic 
prescribing systems in Secondary Care in the UK, state ‘contemporary eP [ePrescribing] 
systems serve wider purposes in prescribing, supply, administration and recording functions, 
as well as audit and review’(249). For the purposes of this review I have chosen to focus on the 
prescribing and implementation of electronic prescribing systems. However, it has been 
important to bear these other factors in mind.  
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Electronic prescribing has been billed as improving safety, quality and efficiency of prescribing 
through: increased legibility (255); the ability to alter drug prescriptions without having to go 
back to the ward a patient is on to do so (255); facilitating microbiologists to monitor, guide 
and evaluate antibiotic usage (254;255) 
However, some studies have found that electronic prescribing systems introduce their own set 
of difficulties and challenges(236).  Electronic prescribing systems in use in hospitals vary in 
complexity and functionality, with some being without clinical decision support tools so that, 
for example, the capability to prevent doctors prescribing incorrect doses or ability to pick up 
on potential drug interactions is absent (254;255).  Conversely some systems have been 
criticised for being over sensitive with doctors continually receiving pop-up warnings. This 
overexposure to warnings means that these often go ignored through alert fatigue. Bignardi et 
al concluded in 2010 that electronic prescribing will never reach its potential unless it has a fit 
for purpose clinical decision support tool. They suggest that local healthcare professionals 
need to be involved in the design and implementation of these systems(254). This correlates 
with the finding that 25% of studies come from four US centres of excellence who have 
introduced in-house eHealth systems in a gradual, iterative process with engagement of 
clinical staff(5). Likewise, although of questionable generalizability to the UK, Abramson et al 
found, in their small case study of physicians in the US, that transitioning between electronic 
prescribing systems may pose important safety threats(289). They examined the perspectives 
of physicians who experienced the transition from a locally developed EHR, with a basic clinical 
decision support system, to a commercial EHR with a more advanced clinical decision support 
system. Despite intensive input by the information systems team, the latter was felt to be 
overly complex and was perceived to reduce efficiency(289).  
Abdel-Qatar et al, in their retrospective observational study of pharmacists’ interventions in an 
electronic prescribing system at hospital discharge, found that prescribing errors were 
common even when using an electronic prescribing system. They concluded that it was 
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imperative that pharmacists were aware of the limitations and strengths of the electronic 
prescribing system in use so that they targeted the weaknesses and complemented, as 
opposed to duplicating, the systems strengths(290).  
Although there is limited evidence, there may be differences between the collection rate of 
electronic prescriptions between different age groups and this needs to be explored further 
(277) 
As I have described, there is a large disparity between electronic prescribing in primary and 
secondary care within the UK. The EPS is geared towards use by general practitioners and for 
patients with stable, chronic conditions(291). A completely different approach has been taken 
with the introduction and roll out of electronic prescribing in secondary care(89). Legislation 
and regulations have developed with these two separate entities in mind. It is therefore a 
major challenge trying to come to a solution, which we can use in a research context trial 
situation, which bridges the existing gap between primary and secondary electronic 
prescribing systems. Changing a statute requires a bill to Parliament, which is unlikely to 
achieve a favourable outcome within a feasible time frame, to change what can be described 
as a limiting clause billed at time when things were very different to the current climate. We 
have reached a solution for the exploratory pilot but this is not feasible for the roll out of a 
larger trial.  
In the following section I describe how I applied review findings to ePrescribing within eSTI2 to 
develop a robust, regulation-compliant ePrescribing solution: 
6. ePRESCRIBING WITHIN THE eSTI2 CHLAMYDIA 
TRACHOMATIS CLINICAL CARE PATHWAY 
Within the eSTI2 exploratory study we aimed to manage a group of people that had a specific 
diagnosis, genital Chlamydia trachomatis, for which, when uncomplicated, the first line 
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treatment is a single dose of azithromycin (1g PO). The online clinical consultation was 
designed to act as a decision making tool to ensure that only the people for whom it was 
appropriate and safe to prescribe azithromycin, for a known diagnosis of chlamydia, received 
treatment this way; as such it has similarities to a patient group direction. A patient group 
direction however, was not deemed suitable for this study as it would involve patients being 
asking additional questions at the pharmacy and would add no benefit to access testing via 
existing internet postal testing and pharmacy testing.  In practice, the investigator of the eSTI2 
study was the named doctor on the e-prescription and her GMC number was supplied. In order 
to minimise the patient identifiable data used, we would have ideally followed the same 
practice that occurs in some GUM clinics and use a unique patient number and the patient’s 
date of birth as methods of identification on the electronic prescription. This was unlikely to be 
acceptable to community pharmacists (264;267;292) and so, for the purposes of the 
exploratory study, users name and date of birth were provided. The address collected from 
patients was the first four digits of the postcode only. 
 
6.1 MEETING GMC REQUIREMENTS FOR REMOTE PRESCRIBING 
When patients accessed their results via the eSTI2 results service (see Chapter 5), information 
was provided to users on chlamydia, why it needed to be treated, and the treatment itself. 
Links to patient information documents on the diagnosis and treatment were provided for 
those who required more information. Those who required clarification of this information, 
who encountered problems completing the online clinical consultation, or who suffered 
adverse effects from the treatment were advised to ring the clinical helpline number (available 
09.00-17.00 Monday to Friday). In the case of symptoms suggestive of anaphylaxis, users were 
advised to seek immediate medical attention. Patients were assessed for the need to be 
examined as part of the online clinical consultation. They were provided with a patient 
information leaflet and standard written information on azithromycin in addition to the 
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information they were provided with online. We believe that this meets GMC requirements for 
prescribing and remote prescribing (261). However, the actual implementation of an electronic 
prescribing system in the NHS, for azithromycin 1g PO stat, from a secondary care based 
service to a community pharmacy proved more challenging.   
6.2 IMPLEMENTING ePRESCRIBING IN THE eSTI2 CHLAMYDIA ONLINE 
CLINICAL CARE PATHWAY  
 
Options for the electronic prescribing component of the online clinical consultation are 
summarised in Table 49 below. We decided that email authorisation was the only viable option 
at this stage. In line with the guidance described above, I designed the email to include the 
patient’s name, date of birth, description of the drug to be authorised, name of doctor 
prescribing the drug and the GMC number of that doctor.  In order for us to be able to verify 
that the medication had been given to the patient, I included a link on the email which the 
pharmacist was instructed to click when they gave out the medication. This then produced a 
time-stamped record on our system.  
Figure 6 illustrates the information sent in the email authorisation to the pharmacy chosen by 
the patient. 
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Table 49: ePrescribing options for the eSTI2 chlamydia clinical care pathway 
 
Option Feasible Comments 
Texting Quick Response 
code to patient 
No Resolution of currently available mobile phones; 
The NHS (Pharmaceutical and Local Pharmaceutical 
Service) Regulations 2013 
Electronic prescription 
service 
No The EPS requires the prescribing system to interact with 
the National Care Record Service Spine via the national 
communication infrastructure; involves patient being 
registered on the Personal demographic service with 
identifiable data transferred including: name, address, 
date of birth and NHS number. Goes against NHS 
Sexually Transmitted Diseases Regulations 2000(139). 
Develop new electronic 
prescribing service 
No The NHS (Pharmaceutical and Local Pharmaceutical 
Service) Regulations 2013 
Email NHS prescription 
(FP10) to pharmacy 
Not at 
present 
The NHS (Pharmaceutical and Local Pharmaceutical 
Service) Regulations 2013. ‘FP10 SS can only be used by 
hospitals if the hospital prescribing system has been 
accredited to do so by NHS Business Services 
Authority’(265). This is currently being explored as a 
potential solution for a future trial. 
Pharmacy download 
FP10 from webtool 
Not at 
present 
The NHS (Pharmaceutical and Local Pharmaceutical 
Service) Regulations 2013. ‘FP10 SS can only be used by 
hospitals if the hospital prescribing system has been 
accredited to do so by NHS Business Services 
Authority’(265). This is currently being explored as 
potential solution for a future trial. 
Private prescription No If a drug is available via an NHS prescription for a NHS 
patient then it is not possible to use a private 
prescription for that drug (293). 
Fax prescription Yes Goes against the ethos of what we are trying to achieve 
Email authorisation to 
px1- selected pharmacy 
and provide pharmacies 
with pre-packed 
azithromycin to give out  
Yes Similar to a Patient Specific Direction(294;295), with 
patients being assessed on an individual basis. 
Prescribing doctor’s name and GMC number present, but 
with the absence of an electronic signature.  Current 
solution for the exploratory trials, and has worked for 
the APT2 trial. However, not a feasible solution if the 
online clinical consultation is rolled out to an RCT/larger 
trial/incorporated into NHS practice. 
1 patient; 2 Accelerated Partner Therapy (296) 
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Figure 6: Email authorisation  
 
 
 
The final ePrescribing pathway is shown in Figure 7 below. 
 
 
Figure 7: Schematic diagram of the eSTI2 prescribing pathway 
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Chapter 4: Methodology for the 
development of a remote online 
clinical care pathway for the 
management of genital chlamydia 
 
 
 
 
 
 
1 INTRODUCTION 
As part of my role within the eSTI2 consortium, I was required to develop an online clinical 
consultation which would form part of the online clinical care pathway to managepeople 
diagnosed with genital chlamydia. NHS England and the Department of Health have advocated 
eHealth and patient centred care (9;84-87;89;90;297). However, despite extensive literature 
searching, I was unable to identify any validated tools or methods to guide the development of 
a remote online automated clinical care pathway nor any similar pathways from any branch of 
medicine. There is no process by which an online care pathway can be quality marked or 
accredited. In view of the novelty of this type of care pathway, we needed to ensure 
developmental rigour.  Although there is no specific guidance for online pathways there is, 
however, a substantial amount of information available that can be used to indirectly inform 
the development of such a pathway. The use and adaptation of existing standards and 
materials was at the heart of my approach here.  
This chapter is composed of the following sections: 
1. Introduction 
2. Methods for developing the remote online clinical care pathway  
3. Framework to inform the development of future online clinical care pathways 
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The last twenty years have seen the growing use of proformas (often for face to face care), 
algorithms, protocols and pathways within the NHS with the aim of improving quality of care, 
efficiency and patient safety. Advances in technology, developments in organisational 
structure and increasing multidisciplinary working have encouraged this expansion. Sexual 
health has been one of the first protagonists of this. With a standard set of questions being 
required in most sexual health consultations (298), and the multidisciplinary nature and 
increased role of nurse-delivered care, patient history proformas have been rapidly adopted.  
These were initially in paper format but are now increasingly in electronic format. Where 
clinics are based within a hospital, this has been aided by Genitourinary Medicine (GUM) clinic 
notes being separate from the remainder of the hospital’s clinical records(139). This has 
allowed the implementation of electronic health records (EHRs) to occur without being 
dependent on the rest of the hospital in terms of timing of implementation, or software used. 
Uptake of EHRs has been driven by the need for a computerised database containing patient 
information for vital public health surveillance purposes(95), which are more demanding than 
required in most other medical specialities,  and for audit, with the speciality having well-
organised national and regional audit networks(299). 
There is widely available professional guidance and comprehensive information available on 
the care and management of patients in traditional sexual health settings. Notably, this 
includes British Association for Sexual Health and HIV (BASHH) guidelines and 
recommendations on how a sexual history consultation should be conducted(298), what it 
should contain, and how to manage genital Chlamydia trachomatis(300). 
In this chapter I describe how I used what was relevant and available from existing literature 
and in traditional clinical practice, to develop the methods to enable the development of an 
online clinical care pathway for the management of Chlamydia trachomatis, and highlight and 
justify the decisions made.     
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As outlined in my introduction, although this is a substantive piece of original research, it does 
not lend itself to any of the commonly used research reporting structures. I have adopted a 
different write up format which best fits the nature of this study.  
1.1 DEFINITIONS 
Clinical protocols are defined as "a comprehensive set of rigid criteria outlining the 
management steps for a single clinical condition or aspects of organisation"(301).  In most 
sexual health clinics clinical protocols are in place for the management of several common 
conditions including, for example, chlamydia,  genital warts, women requiring emergency 
contraception, people who have being sexually assaulted, and for assessment and care of 
people requiring post-exposure prophylaxis of HIV.  
The eSexual Health Clinic is an online sexual health service. It includes all aspects of the 
patient journey, the clinical helpline, health promotion and all communication between 
different services (see Figure 36) 
Clinical care pathways have been defined as ‘structured, multidisciplinary plans of care 
designed to support the implementation of clinical guidelines and protocols’(302).  Examples 
of clinical pathways in Sexual Health include the management of women with post-coital 
bleeding and the management of pregnant women with HIV. 
The Chlamydia Online Clinical Care Pathway, which I developed, sits within the eSexual Health 
Clinic and encompasses the multiple pathways that patients can follow from receiving a text 
allowing them to access their result to the two week health adviser follow-up (for positive 
patients who consent (see Figure 36). 
The online clinical consultation is an “automated medical assessment” section of the 
chlamydia care pathway in which the patient is asked clinical and behavioural questions to 
determine whether it is safe to proceed to remote treatment, to collect partner notification 
information, and to conduct a risk assessment and identify other health needs (see Figure 36). 
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Partner notification is ‘the process of contacting the sexual partners of an individual with a 
sexually transmitted disease (STD) and advising them they have been exposed to 
infection’(303).  
 
1.2 eSTI2 CONSORTIUM REQUIREMENTS: 
As part of the eSTI2 consortium, an online clinical management pathway needed to be 
developed for use in the context of an exploratory study of remote management of genital 
chlamydia. The pathway aimed to enable people with genital chlamydia to receive their test 
result online, obtain information about the infection, complete an online clinical consultation, 
and progress to receive a remote prescription of antibiotic treatment in a safe, efficient 
manner. As part of this pathway, an online clinical consultation was required as a history-
taking and decision making tool to ensure that those people for whom remote care was 
appropriate were able to access treatment, and those people who were not suitable for this 
pathway were fast-tracked into clinic.  
The eSTI2 exploratory studies were conducted to test the safety and feasibility of the online 
clinical care pathway ((REC: 13/LO/1111; IRAS: 112513) see Appendix III for protocol). Two 
groups of patients were recruited: 
1. Chlamydia negative and positive users in six London boroughs who had accessed online 
National Chlamydia Screening Programme (NCSP) chlamydia postal self-sampling testing 
via the Checkurself website and met the inclusion criteria 
 
2. Chlamydia positive patients from Barts Health Sexual Health Centre and St George’s 
Courtyard Clinic who met the inclusion criteria  
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The inclusion criteria for patients recruited from GUM (those testing positive for genital 
chlamydia only) and NCSP sites (those testing positive or negative for genital chlamydia)  were: 
1. Patients 16 years of age and over; 2. Patients who tested positive for genital C.trachomatis 
3. Patients who were able to read and understand English. In addition, patients recruited from 
the NCSP sites needed to have accessed their test via the Checkurself internet-based postal 
testing website. Exclusion criteria included: 1. Co-infection with another STI; 2. Rectal 
C.trachomatis; 3. Patients who did not provide a mobile telephone number.  
For the duration of the study, patients at each of these sites underwent chlamydia testing in 
the customary manner and were then able to access their results via the eSTI2 results service, 
which formed part of the Chlamydia Online Clinical Care Pathway (Chlamydia-OCCP) (see 
Figure 8 below for overview of the exploratory study). For the six NCSP London boroughs, the 
eSTI2 results service (see page 188) replaced the standard method of receiving results for all 
users testing negative for genital chlamydia and all eligible patients testing positive for genital 
chlamydia for the duration of the study. Consent was not required for users testing negative.   
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Those patients who tested positive for genital Chlamydia trachomatis were then offered the 
chance to access treatment online. All patients who consented went through an online clinical 
consultation, partner notification process and, if appropriate, were able to choose one of 30 
participating pharmacies from which to collect their medication, without having any contact 
with a healthcare professional (see Figure 9 below and Appendix III). As is current practice in 
traditional services, clinical follow-up occurred at two weeks via a phone call from a Research 
Health Adviser. 
 
 
2 METHODS FOR DEVELOPING THE REMOTE ONLINE 
CLINICAL CARE PATHWAY 
I conducted a wide literature search to identify “validated” methodology, and examples of 
similar online care pathways, to inform the Chlamydia-OCCP. I was unable to find an example 
of methodology that could be used, or adapted, to develop an online clinical care pathway, 
taking people from diagnoses through to remote management, without contact with a 
healthcare professional. There are however, examples of where sections of comparable 
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pathways have been developed and implemented into clinical practice, and guidelines and 
standards in place which cover traditional care. Therefore I needed to develop new methods 
to underpin the Chlamydia-OCCP. I organised this literature into four broad categories: 
Review of literature concerning online clinical consultations 
Review of relevant proformas and protocols in contemporary sexual health use 
Review of current national standards in sexual transmitted infections 
Review of existing results service and sexual health questionnaires 
2.1 REVIEW OF LITERATURE FOR ONLINE CLINICAL CONSULTATION 
I used the methods described in Chapter 2 to conduct this literature review. I initially 
separated the pathway into its individual components (results service, clinical consultation, 
partner notification, treatment and prescribing). I then conducted a literature search on the 
development and content of these individual components. This included a search on clinical 
consultations with a focus on online, remote consultations, and self-completed history taking 
tools. I then conducted a search of the acceptability and effectiveness of online or remote 
clinical consultations. I then expanded this search to include results services and partner 
notification. The review of literature, legislation and regulations surrounding electronic 
prescribing and the methodology behind the development of the ePrescribing process being 
used in the exploratory study are described separately in Chapter 2. 
Protocol driven search 
I conducted an electronic search via NHS Evidence of MEDLINE, EMBASE, and The Cochrane 
Library using the NHS Evidence database thesaurus terms shown in Table 50. 
Appendix II illustrates the search strategy I conducted using the above NHS Evidence database 
thesaurus terms and free text. I searched official Government, NHS and professional 
association websites, including existing professional guidance. I then searched Google and 
Google Scholar to capture both medical and grey literature that had been missed in the above 
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searches. I used both reference and citation tracking to widen the scope of relevant sources 
found. 
Table 50: NHS Evidence database thesaurus terms for review of literature on online clinical 
consultation 
Ambulatory care facilities Internet 
Attitude to computers Medical history taking 
Cell phone Methods 
Chlamydia trachomatis Online systems 
Communication Organization and administration 
Computer Patient satisfaction 
Contact tracing Questionnaires 
Data collection Remote consultation 
Decision making Reproducibility of results 
Decision support systems Self-disclosure 
Electronic mail Sexually Transmitted Diseases/diagnosis 
Health promotion Social desirability 
Health survey Standards 
Interviews as topic Telemedicine 
Legislation and jurisprudence Text messaging 
 
I will discuss the findings of this literature and how they informed decisions about each 
element of the Chlamydia Online Clinical Care Pathway in Chapter 5. However, from this 
review of the literature, it became apparent that there was going to be several important 
components that needed to be included in the development process: 1. Expert review group; 
2. Cognitive testing. A key component of the development of a clinical care pathway is the 
presence of a multi-disciplinary group of experts, with expertise in the speciality and in the 
development of clinical decision systems(304).  Although informal discussion with other 
experts was carried out at all stages of development, I felt it was important to make expert 
review an integral part of the framework and for this review to take place as soon as the draft 
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online clinical consultation was in place.  This allowed the content and sequence of the 
consultation to be optimised prior to comprehension testing.  
With the absence of a health care professional to explain anything that is not clear or that is 
misunderstood, comprehension testing is a vital step in the creation of an online clinical care 
pathway or self-completed survey. For example, extensive cognitive testing was conducted as 
part of the methodology behind the National Survey of Sexual Attitudes and Lifestyles 
(NATSAL) (168). As well as ensuring that people’s interpretation of the questions were the 
same as the researchers, cognitive testing was used by the NATSAL team to check the overall 
flow of the questionnaire and understanding of certain terminology(169).  
2.2 REVIEW OF RELEVANT PROFORMAS AND PROTOCOLS IN 
CONTEMPORARY SEXUAL HEALTH USE 
 
I reviewed and analysed existing self-completion registration forms and basic history-taking 
proformas in use in several clinics with different approaches to user journeys within London 
and in a more rural setting. Ambrose King Clinic is in Tower Hamlets, serving a deprived, ethnic 
minority population.  Barts Sexual Health Clinic is an inner city clinic with a commuter 
population. Both of these clinics reside within Barts Sexual Health Centre. The Courtyard Clinic 
is in a deprived part of South East London, whilst West Suffolk Hospital is a rural district 
general hospital. These clinics use a mixture of paper-based and electronic notes. I used these 
clinics to provide an illustration of proformas and protocols in use.  I divided the content of 
these into sections, and I tabulated the content and questions to enable easy comparison (see 
Tables 51and 52 below). 
 
Registration 
 
Table 51 below illustrates the questions asked at registration by the different clinics. 
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Table 51: Questions asked at registration 
Clinic Hospital 
Type of 
notes 
Questions asked at registration 
Barts 
Sexual 
Health 
Centre 
St 
Bartholomew’s 
Hospital, 
London 
Electronic 
Contact 
details 
Demographics 
Reason for 
attendance/symptoms 
Risk assessment     
Courtyard 
Clinic 
St George’s 
Hospital, 
London 
Paper and 
electronic 
Contact 
details 
Demographics 
About you – testing 
history and basic 
sexual history 
HIV testing history 
Risk 
assessment 
Symptoms 
Vaccination 
against Hep B 
Feedback on 
questionnaire 
West 
Suffolk 
Hospital 
Bury St 
Edmunds, 
Suffolk 
Paper 
Contact 
details 
Demographics 
Permission to 
email/text/ phone 
Reason for 
attendance/ 
symptoms 
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Clinical consultation 
The Courtyard clinic has different proformas depending on the patient‘s gender and sexual 
behaviour (for men). The proforma for MSM has an additional section on mental health which 
includes questions on previous psychiatric history, depression and self-harming. In addition, 
there are more extensive questions on relationships/consent, blood borne virus risk 
assessment, chemsex, and consequences of drug or alcohol use.  West Suffolk hospital has 
separate proformas for women and men.  
Table 52 below illustrates the sequence of the history taken at each of the individual clinics.  
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Table 52: Sequence of history taken during consultation 
 
Clinic Sequence of history taken 
Barts 
Sexual 
Health 
Centre 
History of 
presenting 
complaint 
Sexual 
History 
Past medical 
history, 
medications 
Smoking, 
alcohol, 
drugs 
Allergies Risk 
assessment 
Reproductive 
history 
Contraception Domestic 
violence 
history 
Courtyard 
Clinic 
Presenting 
problem 
Allergies 
and Drug 
reactions 
Sexual 
History 
Past medical 
history, 
medications 
GU history Hep B 
vaccination 
history 
Alcohol, 
smoking, 
drugs, 
vulnerability 
Risk 
Assessment 
HIV 
testing 
history 
West 
Suffolk 
Hospital 
Presenting 
complaint 
and history 
of 
presenting 
complaint 
Past 
medical 
history, 
medication 
and 
allergies 
Reproductive 
history 
Sexual 
history  
Risk 
assessment 
Drug, 
alcohol and 
smoking 
Immunisation 
history 
Testing 
history 
Family 
history 
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2.3 REVIEW OF CURRENT NATIONAL STANDARDS 
To ensure that both the pathway and online clinical consultation met a satisfactory standard in 
terms of content, patient care and safety, and satisfy existing guidance and recommendations, 
I examined the following national guidelines and guidance: 
British Association of Sexual Health and HIV (BASHH)(305) 
2006 UK National Guideline for the Management of Genital Tract Infection with Chlamydia 
trachomatis 
UK National Guideline for the Management of Pelvic Inflammatory Disease 2011 (updated June 
2011) 
UK National Guidelines for HIV Testing 2008  
Guideline for consultations requiring sexual history taking 2013  
UK National guidelines on safer sex advice [2012] 
Management of STIs and related conditions in children and young people [2010]  
Standards for comprehensive sexual health services for young people under 25 years 2002  
BASHH Statement on Partner Notification for Sexually Transmissible Infections [2012] 
UK National Guidelines on the Management of Adult and Adolescent Complainants of Sexual  
Assault 2011  
BASHH patient information leaflets: a guide to - Safer Sex 
European guidelines(306) 
2010 European guideline for the management of Chlamydia trachomatis infections 
European guideline for the organization of a consultation for sexually transmitted infections, 
2012 
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General Medical Council(307) 
Consent  
Good Medical Practice [2013] 
Good practice in prescribing and managing medicines and devices [2013] 
0–18 years: guidance for all doctors 
Protecting children and young people: the responsibilities of all doctors 
Medical foundation for HIV and Sexual Health (MEDFASH) 
Recommended standards for sexual health services [2005](121) 
Standards for the management of sexually transmitted infections [2010] (updated January 
2014)(308) 
Faculty of sexual and reproductive health(309) 
Combined Hormonal Contraception missed pill guidance (2011) 
Emergency contraception guidance (2011)     
  
2.4 REVIEW OF EXISTING SERVICES AND STUDIES 
Within sexual health the use of both mobile phone technology and the internet has increased 
(25;310). Despite this, at present in the England there are no online NHS pathways for STIs 
taking a person from testing to result, with the possibility of diagnosis and remote 
management, without contact with a health care professional. There are, however, an 
increasing number of private providers of online STI testing including Dr Thom(192), 
test.me(311) and Superdrug(161). 
 
Private providers all provide a variety of different testing options, at differing prices, and allow 
patients to access treatment online. However, they are not constrained by the same rules and 
regulations as NHS services, although they can be  regulated by the Care Quality Commission 
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(for example Dr Thom is). There is a certain amount of controversy in terms of tests offered, 
with test.me offering a ’10 STI test’ option which includes tests for Mycoplasma hominis (non-
pathogenic) and Haemophilus ducreyi (extremely rare in the UK)(311).  In addition no 
information  is provided on the importance of partner notification and, in the case of 
DrThom(312), all patient-completed health proformas are reviewed by a doctor prior to that 
doctor emailing the patient a private prescription.  
 
In 2014 Spielberg et al published the findings of their study, conducted in California, exploring 
the acceptability and feasibility of an online system for the testing, management and 
integration of care of STIs (188). This paper was published after the methodology described in 
this chapter had been implemented. The study involved only small numbers of participants 
and required a clinician to fax a prescription to a pharmacy. However, it has provided a useful 
comparison to the eSTI2 study and is discussed at the end of this chapter.   
 
The information synthesised by applying these four categories to my literature search, 
combined with my clinical expertise as a specialist GUM doctor, provided me with the 
knowledge base for the Chlamydia Online Clinical Care Pathway.  Having reviewed and 
analysed this information, I concluded that there was no method I could directly apply and that 
I needed a method and structure within which to develop the online pathway, which could be 
flexible and comprehensive enough to meet the needs of a complex clinical care pathway, such 
as this for management of genital chlamydia, but if possible would be adapted to other 
STIs/sexual health conditions or the wider medical field. For this reason I designed the eClinical 
Care Pathway Framework (see Figure 10 below).  
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3. FRAMEWORK FOR THE DEVELOPMENT OF AN 
ONLINE CLINICAL CARE PATHWAY 
 
Figure 10: The eClinical Care Pathway Framework (eCCPF) 
 
The Framework has nine steps. Although Figure 10 depicts the eCCPF as a linear process, it is 
very much an iterative process that is difficult to describe in a linear format. For example, steps 
four to nine all resulted in amendments to previous steps at different points in time.   
The eCCPF was based on a synthesis of different methods used in diverse studies.  Steps one to 
three were a natural outcome of the evidence gathered in section 2, where it became clear 
that I would need to establish what we trying to achieve, then examine the sequence of how 
we were going to do it as an online pathway, and then develop the central component, the 
online clinical consultation. As with the standard set by NHS pathways, every clinical question 
and every piece of advice given in the online clinical consultation should be evidence-based, 
with clinical safety being the priority(304).  
Step 9: Piloting the online clinical care pathway 
Step 8: Usability testing and further comprehension testing 
Step 7: Specification development 
Step 6: User-centred interface testing 
Step 5: Comprehension testing 
Step 4: Expert review 
Step 3: Draft the online clinical consultation 
Step 2: Define the functional units & their sequence within the 
clinical care pathway 
Step 1: Define the aims of the online clinical care pathway 
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Steps four to nine were derived from the evidence base described above and in Chapter five. 
Although usability testing is relatively late in this framework, at Steps 6 and 8, qualitative 
research on the acceptability of an online clinical care pathway for the management of genital 
chlamydia was conducted at an early stage of the project, prior to the development of the 
framework and Chlamydia Online Clinical Care Pathway (228). If the eCCPF is to be applied to 
different clinical conditions in the future, and engagement with potential users has not 
occurred prior to the development, then it would be prudent to either move Step 6 further up 
the framework or to conduct similar preliminary qualitative work prior to applying the eCCPF.  
I applied the framework to develop the Chlamydia Online Clinical Care Pathway which is 
discussed in Chapter 5. 
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Chapter 5: Development of the 
Chlamydia Online Clinical Care 
Pathway using the eClinical Care 
Pathway Framework 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
In this chapter I will describe how I used the knowledge base and applied the Clinical Care 
Pathway Framework described in Chapter 4 to develop the Chlamydia Online Clinical Care 
Pathway. 
STEP 1: AIMS OF THE ONLINE CLINICAL CARE PATHWAY 
Informed by existing literature and guidance, along with knowledge of the eSTI2 clinical 
pathway and aims of the consortium, I clarified the aims of the Chlamydia-OCCP. These are 
listed in Figure 11 below. 
This chapter is composed of the following components: 
1. Introduction 
2. Step 1: Aims of the online clinical care pathway 
3. Step 2: Defining the functional units and their sequence within 
the online clinical care pathway 
4. Step 3: Draft of the online clinical consultation 
5. Step 4: Expert review 
6. Step 5: Comprehension testing 
7. Step 6: User centred interface design 
8. Step 7: Specification development 
9. Step 8: Usability testing and further comprehension testing 
10. Step 9: Piloting of the online clinical care pathway 
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STEP 1 STEP 2 STEP 3 STEP 4 STEP 5 STEP 6 STEP 7 STEP 8 STEP 9
 
Figure 11: Aims of the Chlamydia Online Clinical Care Pathway 
 
1. To ensure that the online clinical pathway appropriately predicts the clinical situations for 
which  azithromycin is the appropriate drug to use (i.e. uncomplicated chlamydia) 
2. To ensure that all patients are provided with sufficient, comprehensible,  information on 
chlamydia and health promotion 
3. To ensure that patients who are more medically or psychologically complex, or require 
further input, speak to, or are seen by, an appropriate health care professional in a timely 
manner 
4. To ensure that it is safe to prescribe azithromycin for any particular individual patient using 
the on-line pathway  
5. To identify the number of sexual partners for whom partner notification is appropriate 
6. To explain partner notification to the index patient, and offer support 
7. To provide a process whereby sex partners can access the eSTI2 clinical care pathway if 
desired, or to identify alternative options, for management as a contact of chlamydia. 
STEP 2: DEFINING THE FUNCTIONAL UNITS AND THEIR 
SEQUENCE WITHIN THE ONLINE CLINICAL CARE PATHWAY 
I led a small team of experienced clinicians and researchers within the eSTI2 consortium to 
draft the initial clinical care pathway. As currently there is not a point of care test for STIs that 
can be used at home and interact with other information communication technology, we  
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STEP 1 STEP 2 STEP 3 STEP 4 STEP 5 STEP 6 STEP 7 STEP 8 STEP 9
 
decided to concentrate on the pathway from the point of diagnosis, results provision, and 
management of infection through to health adviser follow-up. 
We chose to use chlamydia as it is the commonest bacterial STI in the UK, is tested for in the 
community through the NCSP, and has a single dose of oral antibiotics as first line treatment 
(300). The online clinical care pathway has been tested in the exploratory pilot study (see page 
110 and Appendix III). The pathway was based on existing practices in specialist GUM services, 
and was adapted to meet the needs of a remote pathway. 
Crucial differences between this remote consultation and other consultation methods in 
existing use (e.g. traditional face-to-face interviews and computer assisted self-interviews) 
were highlighted as part of this process. Whichever point a person chooses to access care, a 
certain amount of information needs to be collected in terms of identifying factors and 
demographics. However, in the case of a completely remote pathway where someone 
accesses a self-sampling test via, for example, the internet or uses a self-test at home, the 
amount of information that needs to be taken has not been quantified. I have therefore 
chosen to design a common pathway which goes beyond this, so that it does not matter where 
somewhere originally accessed their test, we still collect the information that is required for 
clinical, surveillance, and reimbursement purposes.  Figure 12 shows the traditional clinical 
care pathway sequence whereby a patient comes in to clinic, a history is taken, examination 
performed, investigations conducted, results given and patient managed. Some studies have 
shown that the addition of clinical examination to the management of asymptomatic patients 
is likely to yield only minimal additional diagnoses or changes in management (142;313), and 
the current national advice is that, apart from where someone has been sexually assaulted, 
examination is not required in asymptomatic patients (298). 
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Figure 12: Sequence of elements of care within a traditional clinical care pathway
 
Figure 13 illustrates the online clinical care pathway. Patients recruited from the NCSP (see 
page 168 and Appendix III), having accessed postal testing via the internet, will not have had 
any contact with health care professionals. Therefore we will have a diagnosis for these 
patients without knowing their medical, drug and sexual histories. Even those patients 
recruited from clinic, if they have gone through asymptomatic screening, will have had only 
minimal history recorded. The sequence of elements of care which I identified as being optimal 
for managing a patient with a diagnosis but with no or very little history known, was 
investigation, results, taking a focussed history and then deciding the appropriate 
management.  
 
 
 
 
 
 
History taken Examination Investigations Results Management 
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Figure 13: Sequence of elements of care within an eclinical care pathway
 
This is a radical departure from the sequence of traditional care and has major implications in 
terms of the content, phrasing, logic and order of the questions asked in the history taking 
section and the information that needs to be provided at each stage.   
Figures 14 and 15 below illustrate the patient user journeys which I developed for the eSTI2 
chlamydia clinical care pathway trial.  
Investigation Results History taken Management 
186 
 
Figure 14: NCSP User Journey 
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Figure 15: GUM User Journey 
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STEP 3: DRAFT OF THE ONLINE CLINICAL CONSULTATION  
I will now discuss the development of the results service and online clinical consultation. 
RESULTS SERVICE 
Objective: 
To develop an efficient and acceptable method for patients to access their results that takes in 
to account the need for confidentiality, privacy and the ability to continue on the online clinical 
care pathway if appropriate.  
Evidence from the literature:  
The method whereby GUM patients are informed of the results of their investigations has 
changed over the past 10-15 years. We have progressed from the situation where the majority 
of clinics worked on a ‘no news is good news’ policy, where the service only contacts people 
who have tested positive for an infection, to the routine use of short messaging service (SMS). 
The latter was initially implemented with a designated health care professional (HCP) texting 
individual patient’s, using a mobile phone. This then developed to the use of web-based SMS 
systems, which enable HCPs to contact multiple patients simultaneously with a template email 
message, or lab-linked systems whereby as soon as the laboratory gets the result of the test/s 
a message is automatically sent to the patient. As well as potentially increasing patient 
satisfaction, reducing the burden of phone calls being handled by members of the GUM clinic 
team, and increasing efficiency, both increasing patients’ receipt of results and subsequent 
treatment rates have been cited as reasons for implementing alternative eHealth results 
services(314).   
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Combining my clinical experience and the literature, I have identified the following methods of 
notifying people of the results of their investigations which have been used in Sexual Health 
services in the UK:  1. ‘No news is good news’: the service only contacts people who have 
tested positive for an infection; 2. Face-to-face (patient returns to clinic to get result); 3. 
Telephone (either patient is given an appointment to ring for their results or a HCP rings them 
on an ad hoc basis); 4. Telephonetics (whereby a patient rings up an automated service at a 
pre-determined time (e.g. one week) and accesses their results by inputting a unique number 
and date of birth); 5. SMS; 6. Email; 7. Online Results Service.  
No news is good news 
Brown et al conducted a quantitative questionnaire-based survey of 202 Genitourinary 
Medicine patients and 542 community based patients to evaluate their preference for 
obtaining test results amongst other outcomes.  They offered the following options for 
receiving results: ‘no news is good news’; face-to face; by telephone; SMS/text; email; 
internet. The most unpopular option was the ‘no news is good news’ option, which has been 
commonly in use until recent times(315). Likewise Llewelyn et al found that this option was 
deemed highly unsatisfactory by participants in their qualitative study of patients’ choices for 
attending sexual health clinics (316).  
Face-to-face 
Brown et al found that 41% (n=304) of the people that responded to their survey preferred to 
receive their STI test results face-to-face(315).  Likewise, in a study of patients preferences for 
receiving STI or HIV test results conducted in Sydney Sexual Health Centre, Martin et al found 
that 40% of patients preferred to receive their results in person if they had a positive  
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STI result(317). Labacher and Mitchell, in their paper-based survey of students in South Africa 
and Canada, found that 78% (n=90/116) of the South African students and 57% of Canadian 
students (n=105/183) preferred to receive their STI results face-to-face respectively (318).  
However, the current conflict between patients’ wishes and service delivery within an austere 
financially-guided, target-driven environment means that providing every person who tests for 
STIs  with their results  face-to-face is not a realistic or feasible option(182). 
Telephone 
Forty percent (n= 295) of participants in Brown et al’s questionnaire survey chose telephone as 
their preferred method of receiving test results(315). A lower proportion of patients at the 
Sydney Sexual Health Centre chose this as their preferred option, with approximately 13% 
indicating that this would be their first choice(317).  In the survey of South African and 
Canadian students, mobile phone as the preferred option for receiving STI results was more 
popular with Canadian students (36% (n=66/183)) compared to South African students (9% 
(n=10/116)). Providing all results via telephone is not a viable option for Sexual Health Services 
in the UK. 
Telephonetics 
Patients at a small number of services including Barts Sexual Health Centre receive their STI 
results via a telephonetic service. This involves the patient, one week after having been tested, 
ringing up a designated phone number, and providing their unique results number (given at 
first attendance) and date of birth to access the results. Despite there being evidence that this 
an effective, efficient method of providing results(319;320), I did not consider this to be a 
viable option for the Chlamydia-OCCP as it would be difficult to then link the patient in to 
online care.  
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Short Message Service (SMS) 
Lim et al describe the benefits of SMS in their review of SMS usage in sexual health(310): as 
the name suggests, it is mobile and therefore not dependent on landlines or fixed equipment;  
messages are received by patient almost instantaneously; the patient can choose when they 
want to read the message; low cost; convenient for provider; messages can be sent either 
from a mobile phone, computer or web application; it is possible to send a message to multiple 
recipients simultaneously; ubiquity of mobile phones; popularity as a method of 
communication.  
 
However, there is currently a lack of a strong evidence base for the acceptability of texting 
people with their results directly displayed on the SMS (e.g. with ‘your chlamydia test is 
positive’). Brown et al found that less than 5% of people preferred to receive their results by 
SMS(315). 2% (3/183) of Canadians and 9% (10/116) of South Africans preferred to receive this 
results this way (318), whilst approximately 33% of clients’ at Sydney Sexual Health Centre 
would be happy to receive negative results via SMS and approximately 14% would be happy to 
receive positive results this way(317). 
 
Contacting those people who test negative for STIs via text message is an acceptable option for 
providers and, although perhaps not the preferred method of contact, is a feasible option for 
informing patients of their results (310;315). The ambiguity lies with those who test positive. 
Lim et al showed that use of mobile phone technology reduced the time to treatment for 
chlamydia(182).  
 
 
192 
 
STEP 1 STEP 2 STEP 3 STEP 4 STEP 5 STEP 6 STEP 7 STEP 8 STEP 9
 
However, Fuller et al highlighted that privacy is a major concern for young people when testing 
for STIs, with the fear that one of their friends or a parent may pick up their phone and read 
the text message (228). In addition, despite concerns about confidentiality and 
embarrassment, when given a positive diagnosis people wish to be able to discuss this with an 
‘expert’ in order to gain the reassurance they need in terms of what the diagnosis means and 
how it can be managed (315). It also provides an opportunity to discuss how to inform sexual 
partners, and how to prevent the same thing happening again. Sending someone a text 
informing them of a positive diagnosis, or using a telephonetics system to provide results, 
could only achieve these other elements of care if linked to clinic resources but it clearly goes 
nowhere near to replacing a face-to-face or telephone service. 
 
A review conducted by the NCSP failed to find any literature on the phrasing of test results text 
messages(321).  They conducted an internal review, finding that there was great variation in 
the wording of text messages between different chlamydia screening offices. As part of a 
Health Protection Agency web-based survey of young people conducted in 2012, three 
questions were included to help establish acceptability of the phrasing of results messages. 
Amongst other findings, they found that 7% of young people misinterpreted the statement 
‘your test result is positive’ and 25% misinterpreted ‘your test result is negative’.  From this, 
the NCSP recommended several different options for the wording of chlamydia test result text 
messages.   
Email 
In previously conducted surveys, email has been an unpopular method of contact for provision 
of test results (315;317;318). The reason for this was not explored by the authors, although  
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Brown et al suggest that it might be due to the inability to interact directly on a real time basis 
with a healthcare professional (315).   
Online results services 
Although, in surveys of peoples’ preferences, only a small proportion would opt to get their 
results via a secure internet site (315;317), there are several examples where online results 
services have been introduced into clinical practice. 
An online STI results service was implemented in San Francisco in 2004 in an attempt to relieve 
the pressure on staffing of an existing results phone line and to improve patient satisfaction. 
Initial patient acceptability was suboptimal with only 40% of patients opting to create a 
password to use the service(322).  
In 2007, an online STD clinic was launched online in Amsterdam for syphilis and HIV testing. 
Patients were able to download a referral letter that they could use to access testing at a 
laboratory free of charge.  Their results were then made available online. This service was 
mainly targeting men who have sex with men (MSM) and, proving a popular option with this 
population, it was expanded to including testing for other STIs(323). 
 The first paper evaluating an online test results system in a predominantly heterosexual 
population was published in 2010 by Ling et al. Denver Metro Health STI Clinic introduced a 
web-based results system in June 2008. They conducted an evaluation comparing the 
proportion of test results accessed, and how these results were accessed over three different 
time periods: (A) in the six months prior to implementation of the online service; (B) during the 
six month period where patients had to create their own passcode to access their results; (C) 
the four month period after passcodes were automatically generated and assigned to patients. 
Findings included a 41% (1616/3931) uptake of the online results service in period (B), with a 
statistically significant (p<0.0001) higher proportion of patients actually receiving their results  
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during this period (74%, 1198/1616) compared to those who opted for phone results (62%, 
1431/2315).  There was no significant difference between the proportions of patients actually 
receiving their results during the three time periods. However there was a significant 
(p<0.0001) decrease in the proportion of patients phoning the clinic between the three 
different time periods, from 67% (2446/3624) in period (A), to 51% (1985/3931) in period (B), 
to 36% (537/1501) in period (C).The primary reason for people choosing to access their results 
online was the ability to access their results any time of the day. Reasons for people still opting 
to access their results by phone included  preferring this option and limited internet 
access(314). 
Decisions for eSTI2 results service 
Method 
Various points needed to be considered in choosing the method to be used for the Chlamydia-
OCCP. These included how a user gained access to their results (such as using a username and 
password), and the information that needed to be conveyed. The aim of the eSexual Health 
clinic is for appropriate patients to be managed remotely without needing direct contact, 
either by phone or face-to-face with a healthcare professional. In order to facilitate patients’ 
access to the online clinical consultation it was important to choose the most feasible method 
of receiving results that could then lead directly on to this.  
Synthesising these findings, I concluded that SMS was the modality of choice in terms of 
initially contacting patients with regards to their results. However, in the interest of privacy the 
text message needed to be nondescript but credible. In the qualitative work conducted by 
Fuller et al (228), the NHS as a brand held confidence and trust, therefore we decided that the 
text  
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message needed to be sent via the NHS SMS and webmail system, NHS.net, which entitles 
texts with ‘NHS no reply’.  
As patients in the exploratory study would be coming from different GUM clinics and NCSP 
sites, it was important to understand the pre-existing results management processes within 
each service before considering each possible option in terms of its feasibility and relevance. 
Figure 16 shows details of how I operationalised the results service within each setting.  
 
Figure 16: a schematic of the eSTI2 Results service
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As can be seen in Figure 16, I, with input from a senior researcher, had to develop a process 
whereby the results from the relevant laboratory were loaded on to our system and patients 
received a text message informing them that the results were ready. This was a relatively 
simple process for the GUM patients, with a results administrator at each clinic identifying 
eligible patients and then manually entering them on to the system via the results  
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administrator portal (see Figure 17 below).  As someone was entering details manually, there 
was a risk of transcription error.  This was minimised by: 1. the research health adviser having 
the ability to change the date of birth if a patient contacted them as they were unable to login; 
2.The correct number of digits needed to be entered for both mobile number and results 
number; 3.A valid UK mobile number had to be entered.  This didn’t remove all potential for 
errors to be made but all patients who had not accessed their results within seven days were 
fed back to the clinic they tested at so they could be contacted by the clinic. If an error had 
been made it would be picked up at this point.  
For NCSP patients, we initially arranged for the NCSP to continue to provide the results texts to 
these patients. However, they were only able to do this in real time which meant that patients 
would receive their text message as soon as the result became available, i.e. it could be at any 
time of the day or night. In addition, all the results for the preceding 24 hours were sent to 
Epigenesys (the software company who developed and hosted the website) at 04.00 which 
meant that patients would have their results before their details had been entered onto the 
system. Instead, we arranged for the results to be sent out by Epigenesys at 10.00 every 
morning. The rationale behind a 10.00 timing was that the clinical helpline was open from 
10.00-18.00. During the first month of the study, I monitored the times at which patients 
accessed the system and the health adviser monitored the times at which patients called the 
helpline. From this data, we recommended that the helpline hours be changed to 09.00-17.00.  
Those patients accessing Barts Sexual Health Centre are routinely provided with a results 
number (a unique 6 digit code) to access their results via a telephonetics service. The same 
login was used for these patients in the exploratory study, along with their date of birth. Those 
patients accessing their results from the NCSP and St George’s used their mobile phone 
number and date of birth to login.  
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We chose not to include an option whereby a participant could inform their GP of their result 
for the following reasons: 
1. This a proof of concept trial and interacting with established GP EHR was outside our 
remit 
2. This is not standard practice in GU clinics where anonymity remains an important 
factor for people accessing this service  
3.  Although this practice is being increasingly encourage for patients who are HIV 
positive, and therefore have been diagnosed with a chronic illness and are likely to be 
on medications that will interact with other medications that the GP will prescribe, this 
is not the case with other STIs. 
4. One of the main points in offering online care is to be able to offer access to testing 
and treatment which removes interaction with a healthcare professional, and thereby 
increase accessibility to testing, streamline care, and reduce wastage 
I will discuss the online partner notification option offered to index patients on page 238, 
however I will discuss the method by which sexual partners could access the online clinical 
consultation here as it follows the discussion of the different pathways by which a patient can 
access their results depending on which service they initially accessed. 
 Sexual partners of index patients, who had been passed on a personal identification number 
(PIN) by the index partner, initially accessed the online clinical consultation using this PIN. 
Once they entered the online clinical consultation, they were asked to provide their mobile 
number and date of birth, and thereafter used these details to enter the online clinical 
consultation. In order to provide a separate identification for each sexual partner of an index 
patient, as soon as a sexual partner logged on they were assigned a unique code which is the 
index patients system identifier along with the number sexual partner they are to use that PIN. 
For example, if index patient AKC123456 had two sexual partners who chose to use the PIN 
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that they have been sent to log in, then they were assigned system identifier SPAKC123456001 
and SPAKC123456002 respectively.   
Figure 17: Results administrator portal  
 
 
 
Message 
In line with the NCSP findings and recommendations, I decided that the text message for both 
positive and negative results should not include the word chlamydia or STI. It was then  
necessary to design the message so that it was credible and recipients would know that it 
related to their tests (see Table 53below). This was tested as part of the comprehension 
testing described in Step 5. 
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Table 53: summary of the text messages sent to index patients 
 
Clinic/NCSP Text message 
Ambrose King 
Centre/Barts Sexual 
Health Centre 
Your test results are ready. Your results number is xxxxxx. Access your 
results online here: https://eSH.bartshealth.nhs.uk/patient_login 
 
Courtyard Clinic Your Courtyard Clinic test results are ready. Access your results online 
here: https://eSH.bartshealth.nhs.uk/SGC_login 
 
NCSP Your Checkurself test results are ready. Access your results online 
here: https://eSH.bartshealth.nhs.uk/NCSP_login 
 
 
 
Results page 
Based on my clinical experience and Duncan et al’s findings in their qualitative study of women 
who had been diagnosed with genital chlamydia(324), I believed that it was important that 
patients accessing a positive result received the same information that they would be given in 
clinic, i.e. a basic explanation of what chlamydia is, how they might have acquired the infection 
and how it can be managed. This was cognitively tested (see Step 5). For patients requiring 
further information, I provided a link to the Family Planning Association (FPA) chlamydia 
leaflet. 
Figure 18 below shows the Chlamydia-OCCP results page. ‘Click here’ links to the Family 
Planning Association (FPA) chlamydia leaflet. 
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Figure 18: Results page 
 
ONLINE CLINICAL CONSULTATION 
I then developed an initial version of the online clinical consultation drawing on my own 
clinical experience together with the knowledge base described in Chapter 4. As well as the 
Chlamydia-OCCP having a different structure to a traditional care pathway, different factors 
needed to be taken into account with the structure of the online clinical consultation 
compared to a tradition clinical consultation. An example of the standard structure of a 
traditional clinical consultation is shown in Figure 19 below (298). 
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Figure 19: traditional clinical consultation 
 
The order in which the history is actually elicited for the latter five components varies 
depending on clinic, individual HCP and individual patient. However, the first three 
components are constant and at some point all of the remaining components would be 
covered.  
When developing the structure of the online clinical consultation, I considered the following 
aspects: 
· Need to establish personal details  
· Where people were likely to ‘fall off’ the pathway and need to be fast tracked into 
clinic. I decided that it was better if people fell off at the beginning of the pathway so 
that they did not get frustrated by being unable to access treatment even though they 
had completed the majority of the consultation 
· Acceptability of, and comfort with answering, the questions. In a traditional clinic 
consultation, I would not start by asking someone their sexual history. I would first 
establish a rapport with the patient. The same can be applied online; although it isn’t 
possible to establish a rapport per se, it is possible to start with questions people are  
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more likely to be comfortable answering (i.e. less intrusive), and to give a brief 
explanation as to why we are asking these questions.   
· Issue of  confidentiality and privacy in terms of both the online clinical consultation 
and any  SMS or email sent to the patient  
· Flow of questions 
The structure of the online clinical consultation that I chose to adopt is illustrated in Figure 
20 below: 
Figure 20: components of online clinical consultation 
 
 
 
I will now discuss the development of each of the components in Figure 20 in turn. 
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Personal details 
Objective 
To gather the minimum amount of information to enable us to contact the patient, issue an 
electronic authorisation for antibiotics, and have information on basic demographics to inform 
both this study, a future full scale trial and for surveillance purposes. 
Evidence  
The grey literature is mainly concerned with minimising use of personal information, which I 
have attempted to do. There is a wealth of legislation and regulations relating to data 
protection, the storage and retrieval of data and patient’s rights in terms of access to their 
data. Some of this is generally applicable whilst some are specific to healthcare and sexual 
health. Table 54 below summarises this. 
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Table 54: Legislation and regulation relating to data protection 
Type Legislation 
General Common Law Duty of Confidentiality 
Copyright Designs and Patents Act 1988 
Children’s Act 1989 
Copyright Regulations 1992 
Crime and Disorder Act 1998 
Data protection Act 1998 
Human Rights Act 1998 
Computer Misuse Act 1990 
Data protection (Processing of sensitive data) order 2000 
Electronic Communications Act 2000 
Freedom of Information Act 2000 
The Privacy and Electric communications (EC Directive) Regulations 2003 
Information Security Management: NHS Code of Practice 2007 
2008 Cabinet Office Data Handling Review Report 
Healthcare Access to Medical Reports Act 1998 
Access to Health Records Act 1990 
Health and Social Care Act 2011 
Public Interest Disclosure Act 1998 
Sexual Health NHS Sexually transmitted diseases regulations 2000 
 
The majority of these have been written before electronic health records (EHRs) were 
introduced or in common use in healthcare. The Information Governance toolkit(325) is a 
useful adjunct to help apply, check and ensure compliance with this myriad of legislation and 
regulations surrounding data storage, management and transfer.  
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Professional Guidance 
Published guidance from the NHS, GMC and other professional bodies includes: 
Caldicott Report and Caldicott Principles 1997 
Information Security Management – Part 1: Code of practice for information security 
management (BS7799-1:1999) 
Ensuring Security and Confidentiality in NHS Organisations, protecting the security of 
information in NHS organisations, NHS Executive’s Security and Data Protection Programme 
For the Record, HSC 1999/012 
Confidentiality: NHS Code of Practice 2003 
GMC Confidentiality: protecting and providing information 
Department of Health: The Caldicott Guardian Manual 2010 
Information Commissioner: Data Protection Audit Manual 2001 
 
The number and size of each of these makes reading, digesting and utilising them a laborious 
and lengthy process. This is compounded by the fact that they are frequently duplicative. 
However, having reviewed the available literature, and from my personal clinical experience, I 
concluded that several factors were important to include. These included: 1.Ensuring that we 
had two methods of contacting each patient as mobile phones can get lost, stolen or 
replaced(326;327); 2. Ensuring patients register with their name and contact details before 
testing if we conduct a future trial with patients self-testing using a POC test at home and then 
accessing the online clinical consultation. Bracebridge et al, in their evaluation of an NCSP 
postal screening service in Essex, found that 488 people who undertook testing were not  
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registered and were therefore unable to be contacted. Of these 4.5% (n=22) tested positive for 
chlamydia (328).  
Decision 
 
Surveillance data for Public Health England (PHE) for the chlamydia clinical care pathway 
exploratory trials  was collected from the initial testing site (i.e. Barts Sexual Health Services, 
The Courtyard Clinic at St George’s Hospital and the NCSP). However, in  a future trial it is likely 
that we will need to collect and communicate surveillance data directly to PHE. In developing 
the online clinical consultation, as well as referring to the Public Health England guidance on 
surveillance data, I have liaised with members of the Public Health England surveillance team 
in order to capture all of the data items required. In England, there are two different sets of 
data collected for chlamydia diagnoses:  
1. Chlamydia Testing Activity Database (CTAD) (329)– collected from primary care and 
community services 
2. Genitourinary medicine clinic activity dataset (GUMCAD)(95) – collected from GUM 
clinics 
The data collected via the system we have designed can be used to provide the relevant data 
for both of these datasets.  
 
The data collected has been balanced against the need for collecting a minimal amount of 
identifiable information for security and confidentiality reasons. As is the case in traditional 
sexual health clinics, patients do not need to give their real name or date of birth. In order to  
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try and prevent underage use, as well as asking for patients’ date of birth we also ask for their 
age. If someone states that they are under 16 then they are advised to contact the clinical 
helpline to be fast tracked into clinic. We require patients’ postcode for reimbursement 
purposes.  As a full postcode is potentially identifiable, when one takes other potentially 
identifiable data into account, we only request the first four digits of the postcode.  
Figure 21 is a screenshot of the ‘My details’ page of the online clinical consultation.  
Figure 21: My details section of the online clinical consultation 
 
 
 I chose to use email as the second contact detail for the following reasons: 
1. It is possible to set up an NHS.net account so that outgoing emails will be secure and 
so that the emails contain the word “NHS” (so it is not mistaken for junk mail). 
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2. Home phone numbers are not necessarily personal to that individual and could lead to 
awkward questions for the patient. In addition, the research Health Adviser would be 
working office hours when the patient is less likely to be at home to receive the call.    
3. As with a home phone number, the patient is likely to be sharing accommodation, 
potentially with parents or partner, which could lead to awkward questions if we were 
to contact them via post. In addition, I was trying to minimise the identifiable patient 
collected data for security and confidentiality reasons. Finally, written correspondence 
can easily fall into ‘the wrong hands’, would delay any communication needed, and 
would be reliant on the patient making contact with the health adviser. 
 
Symptoms 
Objective 
To ensure that patients who report symptoms suggestive of complicated chlamydial infection, 
and who may require examination and an antibiotic other than azithromycin, are directed off 
the pathway and into traditional services in a safe and efficient manner. 
Evidence 
When taking a history of presenting complaints from a patient, it is standard practice, to check 
that they do not have a number of symptoms that could indicate infection and/or need for 
examination even if a patient does not spontaneously report symptoms. In the case of the 
Chlamydia-OCCP, we already have an established microbiological diagnosis and therefore the 
rationale behind the questions we need to ask is different. Issues with using any form of 
protocol include the balance between being safe and being overly restrictive, and being 
comprehensive without being overly protracted.  This is particularly important when the  
209 
 
STEP 1 STEP 2 STEP 3 STEP 4 STEP 5 STEP 6 STEP 7 STEP 8 STEP 9
Personal 
details
rs l 
t ils
Symptoms
Medications 
and allergies
Relevant 
medical 
history
Sexual history
Partner 
notification
Reproductive 
history
Risk 
assessment
Health 
promotion
Health adviser 
follow-up
 
protocol is being used as an automated decision-making tool without HCP input. I therefore 
analysed each of the symptoms asked in a traditional clinical consultation and assessed 
whether, if someone reported the presence of that symptom, it would indicate that they: 
1. need to be examined before being treated and/or 
2. need an alternative medication to azithromycin (i.e. complicated infection) 
or 
3. need to be examined in the near future but are safe to continue on the 
online clinical consultation 
Decision 
Having ascertained which symptoms we needed to ask patients about, I then decided which of 
them, if disclosed, would mean that a patient would fall off the pathway and need to be fast-
tracked into clinic, and which symptoms it would be acceptable for patients to continue on the 
pathway with but that would need to be discussed at the two week health adviser follow-up. 
This is summarised in Table 54 below. 
In order to ensure that patients who are symptomatic but are able to continue online are 
flagged up by this system, followed-up and, if necessary seen, appropriately, I ensured that the 
answers to these questions fed in to the health advisers’ follow-up screens and triggered 
additional questions.  
As I wanted to keep the number of questions asked to a minimum and to only ask patient a 
questions relevant to the individual, at this stage I decided that the female and male online 
clinical consultations needed to be developed as separate entities, and I employed a skip 
pattern of questioning.  
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Table 55: Symptom inclusion decision-making summary 
Symptom Assessment 
Need to ask in 
consultation 
Safe to continue 
Dysuria Would not change 
treatment 
No N/A 
Discharge Would not change 
treatment (as majority 
of patients tested for 
chlamydia and 
gonorrhoea and 
gonorrhoea is rare in 
community settings) 
No N/A 
Abdominal pain Patient needs to be 
examined 
Yes No 
Post-coital bleeding Patient needs to be 
examined 
Yes No 
Dyspareunia Patient needs to be 
examined 
Yes No 
Testicular pain Patient needs to be 
examined 
Yes No 
Anal pain Patient needs to be 
examined 
Yes No 
Genital skin lumps Patient needs to be 
examined 
Yes Yes 
Genital rash, sores or 
blisters 
Patient needs to be 
examined 
Yes Yes 
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The female symptoms screen is shown in Figure 22 below.  
Figure 22: Female symptom screenshot
 
 
Medications and allergies 
Objective 
To ensure that any patients for whom it is not suitable to be treated with azithromycin, 
because of known allergies or concurrent medication, are directed off the pathway into 
traditional care in a safe and efficient manner 
Evidence 
I examined current national and regional Patient Group Directives for the prescription of 
azithromycin 1g stat PO for people diagnosed with Chlamydia to inform the development of 
the electronic prescribing assessment component of the online clinical consultation. Of note,  
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the NCSP Patient Group Direction for azithromycin for Chlamydia trachomatis has not been 
updated since November 2012(330).  
I aligned this material with the information gathered from the azithromycin Summary of 
Products Characteristics(331) and the British National Formulary (BNF) (260). Tables 56 and 57 
below summarises the list of drugs that interact with azithromycin and conditions where 
azithromycin is contraindicated or caution advised.  
Table 56: Azithromycin drug interactions 
Drug Interaction Reference 
Addressed in online 
clinical consultation 
(OCC) 
Antacids Reduces absorption of  
Azithromycin (advise to take at 
least 1 hour before or 2 hours after 
the antacids)  
BNF(260)  No – Will be 
provided on 
label of 
azithromycin 
packet 
Artemether with 
Lumefantrine 
Avoidance of macrolides advised 
by manufacturer 
BNF Yes 
Bromocriptine Macrolides possibly increase 
plasma concentration of 
bromocriptine 
BNF Yes 
Cabergoline Macrolides possibly increase 
plasma concentration of 
cabergobline 
BNF 
Ciclosporin Macrolides possibly inhibit 
metabolism of ciclosporin – levels 
require monitoring 
BNF/AzSPC(331) Yes 
Colchicine Possible increased risk of 
colchicine toxicity 
BNF  Not in SPC and 
patient unlikely 
to be on it 
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Table 56 continued 
Drug Interaction Reference 
Addressed in online clinical 
consultation (OCC) 
Coumarins Possible enhancement of 
anticoagulant effect of 
coumarins (causal relationship 
not established) 
BNF /AzSPC Yes 
Digoxin Macrolides increase plasma 
concentration of digoxin 
BNF Yes 
Disopyramide Possible increase plasma 
concentration of disopyramide 
BNF  Yes – advice re cardiac 
arrhythmias 
Droperidol Avoidance of macrolides 
advised by manufacturers of 
droperidol (risk of ventricular 
arrhythmias) 
BNF Yes 
Ergotamine Increased risk of ergotism 
when macrolides given with 
ergotamine 
BNF/AzSPC Yes 
Mizolastine Macrolides possibly inhibit 
metabolism of mizolastine. 
Mizolastine has weak 
potential to prolong the QT 
interval in a few individuals.  
BNF/MzSPC(332) Yes 
Piperaquine 
with 
Artenimol 
Avoidance of macrolides 
advised by manufacturer 
(possible risk of ventricular 
arrhythmia)  
BNF Yes 
Reboxetine Avoidance of macrolides 
advised by manufacturer 
BNF Yes 
Rifabutin Increased risk of side effects 
including neutropenia (but a 
causal relationship to 
azithromycin has not been 
established) 
BNF/AzSPC No - I don’t think we 
need to ask about this 
Ritonavir Possible increase in plasma 
concentration of azithromycin 
BNF No - I don’t think we 
need to ask about this 
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Table 57: Other cautions 
Condition or drug Reference Addressed in online 
clinical consultation 
Avoid in severe liver disease BNF and AzSPC Yes 
Avoid if GFR <10 BNF and AzSPC 
Avoid if known or risk of prolonged 
cardiac repolarisation and QT interval 
(incl: 
· Class 1A antiarrhythmics 
· Class III antiarrhythmics 
(dofetilide, amiodarone, 
sotalol) 
· Terfenadine (no evidence for 
latter) 
· Antipsychotics e.g. pimozide 
· Antidepressants e.g. 
citalopram 
· Fluoroquinolones e.g. 
moxifloxacin and levofloxacin 
 
 
AzSPC 
AzSPC 
AzSPC 
AzSPC 
AzSPC 
AzSPC 
Come off pathway if tick 
they are on Cisapride or 
tick that they have been 
told by a doctor that 
they have a cardiac 
arrhythmia. 
If tick they on 
citalopram, pimozide or 
ciprofloxacin they come 
off the pathway. 
Moxifloxacin and 
levofloxacin rarely used 
in the community. 
With electrolyte disturbance (e.g. 
hypokalaemia or hypomagnaesaemia) 
AzSPC No 
With clinically relevant bradycardia, 
cardiac arrhythmias or severe cardiac 
insufficiency 
AzSPC Yes – see above 
Myasthenia gravis BNF and AzSPC Yes 
 
Azithromycin was believed to have fewer drug interactions than other macrolide antibiotics 
due to its inability to interact with the cytochrome P450 IIIA enzyme system(333). Prolongation 
of the QT interval, with the potential risk of torsades de pointes, was thought to  
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be only of minimal risk with the use of azithromycin until recent years(334).  Following a 
review of available evidence in 2011, the Food and Drug Administration (FDA) altered 
information provided on azithromycin product labels relating to risks of QT interval 
prolongation (335). In 2012, Ray et al published a large cohort study evaluating the use of 5 
days of azithromycin in Tennessee Medicaid patients. They found a small increase in absolute 
risk of cardiovascular event, with those patients at pre-existing highest risk of cardiovascular 
disease most likely to be affected (336). In 2013 Svanstrom et al concluded that there was no 
evidence of ‘an increased risk of death from cardiovascular causes in a general population of 
young and middle-aged adults’ in their national retrospective cohort study(337). From this 
information base it is possible to conclude that the population that we are expecting to use the 
online clinical consultation are at very low risk of prolongation of the QT interval. However, 
account needs to be taken of other drugs that patient may be taking that prolong the QT 
interval, even if the population risk remains low, as the potential severity of an adverse 
outcome to an individual is high.  
Having reviewed the evidence, I then examined the optimal way to ask these questions so that 
patients who were not taking any medications and did not have any drug allergies could pass 
quickly through the section, but those patients who were on medications which were 
contraindicated with azithromycin or who were allergic to azithromycin, soya or peanuts, or 
had a medical condition that contraindicated the use of azithromycin, were taken off the 
pathway.  
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Decision 
It was clear early on that the traditional sequence and content of the drug history would not 
be feasible both in terms of the functioning of the automated clinical decision system and in 
terms of the number of questions required.  I approached this by asking the patients as few 
questions as possible for a safe outcome with respect to prescribing.  
Rather than asking patients to list all the medications they are on, I decided it would be safer 
to ask patients whether they were taking any of a list of medications that are contraindicated 
with azithromycin. I felt that this removed the need for patients to recall, without prompting, 
which medications they were on and how to spell them. Figure 23 below shows the wording of 
this question. 
Figure 23: Screenshot of My Medications and Allergies screen 
 
 
One of the main findings from the comprehension testing (described in Step 5 below) was that 
members of the public do not know what azithromycin is or they get it confused with  
217 
 
STEP 1 STEP 2 STEP 3 STEP 4 STEP 5 STEP 6 STEP 7 STEP 8 STEP 9
Personal 
details
l 
t il Symptoms
t
Medications 
and allergies
Relevant 
medical 
history
l t 
i l 
i t
Sexual 
history
l 
i t
Partner 
notification
t  
tifi ti
Reproductive 
history
r ti  
i t
Risk 
assessment
i  
t
Health 
promotion
lt  
ti
Health 
adviser 
follow-up
lt  
i  
f ll -  
erythromycin. As a proportion of people who take erythromycin suffer gastrointestinal side-
effects (338), which they may mistakenly believe means they are allergic to the medication, I 
felt it was first necessary to ask a set of questions about this to avoid patients being 
inappropriately precluded. This is described in Table 58 below along with the decision as to 
whether it is safe for the patient to continue or not.  
Table 58: Allergy decision-making section 
Question 
Safe to 
continue 
1. Are you allergic to any medications? Yes/No 
        
If ticks No 
2. If yes to 1: Are you allergic to azithromycin? Yes/No/Don’t know 
 
If ticks No 
3. If yes to 2: Azithromycin is an antibiotic which belongs to the same family as 
Erythromycin and Clarithromycin. Have you taken any of these before and 
had: ( tick all that apply) 
 
a. Itchy rash, throat or facial swelling, or difficulty breathing 
b. Nausea ( feeling sick), vomiting (being sick), diarrhoea 
c. Other reaction 
d. No 
 
 
 
 
 
No 
Yes 
No 
Yes 
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Relevant medical history 
 
Objective 
To ensure that any patients for whom it is not suitable to be treated with azithromycin 
because of existing medical conditions are directed off the pathway into traditional care in a 
safe and efficient manner 
Evidence 
The rationale behind the decision of which questions to ask in this section of the online clinical 
consultation is described in the Medication & allergies section above. In summary, 
azithromycin is contraindicated if a person has severe liver disease, severe renal impairment, 
has a history of, or is at risk of, cardiac arrhythmia, or has myasthenia gravis.  
Decision 
Although it is important to ask these questions as the risk of harm is potentially high, the 
majority of patients are likely to be young and healthy. To limit the amount of time this section 
would take users to complete, I combined the medical conditions into two questions, shown in 
Figures 24 and 25 below.  
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Figure 24: Screenshot of the cardiac-related questions 
 
 
Figure 25: Screenshot of other medical conditions screen 
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Sexual history 
Objective 
To assess sexual behaviour, identify patients who are at higher risk of other infections or 
getting recurrent infections in the future and to identify sexual partners who need contacting 
and treating. 
Evidence  
I reviewed the literature on recording sexual history in a variety of contexts: face to face; paper 
questionnaire; self or clinician completed computer assisted questionnaire; sexual behaviour 
surveys.  I appraised complete self-completion questionnaires from the third National Survey 
of Sexual Attitudes and Lifestyles study(339) and an Australian sexual health centre’s 
Computer Assisted Structured Interview (CASI). The latter was used, with kind permission from 
Prof Kit Fairley, as Melbourne Sexual Health Centre is at the forefront of research in to Sexual  
Health and the health service in Australia is similar to that in the UK. I then reviewed national 
and international guidance and proformas in use in contemporary sexual health services. 
Three themes emerged from my review of this literature: 
1. Content 
2. Bias associated with asking these types of question 
3. Validity (discussed in chapter 6) 
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Content 
 
There are no validated sexual history questions that are designed to be used in an online 
clinical consultation. I therefore drew on my own clinical experience, proformas in use within 
sexual health clinics, national(298) and international(340) guidelines, existing validated sexual 
behavioural questionnaires that have been designed for either online use(190) or computer 
assisted self-interviews(339), and a computer assisted self-interview in use in a sexual health 
clinic. These questions went through expert review and comprehension testing as described on 
page 264 and 265 respectively.  
Bias 
 
There are various type of bias that are associated with asking questions in both a sexual history 
taking context and non-sexual history taking context. Some of these are found irrespective of 
the method used to take the history, whilst others are more of an issue with certain methods. I 
have collated and summarised the issues in Table 59 below.  
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Table 59: Summary of types of bias associated with sexual history taking 
Type of bias1 Summary of issues Actions taken to reduce bias 
in this research 
Design bias With an online clinical consultation there is a 
risk that users may answer questions incorrectly 
because of lack of understanding or 
misinterpretation of what is being asked. There 
is also the risk that the consultation may not be 
asking the right questions for an individual 
patient because of lack of ability to adapt to the 
individual patient or because the individual 
scenario had not been considered in the design.  
Patient inputted data will be compared 
with data collected by clinicians in clinic 
both for GUM patients who consent and 
for patients who drop off the pathway 
and are directed into clinic. It is 
acknowledged that more complex lines of 
questioning may be ‘more suited to face-
to-face [FTF]interviews than computer-
assisted self-interviews(152)’.  
Evaluation bias By placing people in the situation of being 
questioned, they become anxious and this may 
influence their ability to answer.   
By being able to enter the information 
where they want and when they want, 
evaluation bias could potentially be less of 
an issue than the situation of a face-to-
face interview. How in a FTF interview or 
on the phone, a HCP may sense that a 
patient is anxious and seek to assuage this 
anxiety. This is not possible with an 
automated online system.  
Patient inputted data will be compared 
with data collected by clinicians in clinic 
both for GUM patients who consent and 
for patients who drop off the pathway 
and are directed into clinic (see Chapter 
6). 
 
Interviewer bias As long as the questions asked in an online 
clinical consultation are not leading, interviewer 
bias is likely to be reduced in this situation 
compared to a face-to-face interview 
Patient inputted data will be compared 
with data collected by clinicians in clinic 
both for GUM patients who consent and 
for patients who drop off the pathway 
and are directed into clinic (see Chapter 
6). 
Questions specifically designed so they do 
not lead patients. 
Mood bias This is likely to be an issue irrespective of 
whether an interview is conducted face-to-face 
or using a computer/mobile phone interface 
remotely. 
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Table 59 continued 
Type of 
bias1 
Summary of issues Actions taken to reduce 
bias in this research 
Observer 
bias 
This is likely to be less of an issue with an online clinical consultation 
than a face-to-face interview 
 
Recall bias An issue with both face-to-face interviews and online clinical 
consultation. Theoretically an online clinical consultation may give 
people more time to think about their answer without feeling under 
pressure. Furthermore, Aicken et al found that the majority of 
participants completing cognitive interviews on a CASI were able to 
accurately report information about their sexual partners(169). 
Patient inputted data will be 
compared with data collected by 
clinicians in clinic both for GUM 
patients who consent and for 
patients who drop off the pathway 
and are directed into clinic (see 
chapter 4). 
 
Reporting 
bias  
It is possible that people will not reveal certain information 
irrespective of method used to interview them. However, in several 
studies respondents admitted to a high proportion of risky behaviour 
when questioned via a self-completion questionnaire compared to a 
face-to-face interview with a clinician (40;151;156;157;341).   
Patient inputted data will be 
compared with data collected by 
clinicians in clinic both for GUM 
patients who consent and for 
patients who drop off the pathway 
and are directed into clinic (see 
chapter 4). 
 
Response 
style bias 
It is possible that participants using the online clinical consultation will 
respond to a question in a ‘yes-saying’ manner.  
I have tried to phrase the questions, 
and have arranged the format of the 
questions to deter people from ‘yes-
saying’ whilst balancing this with 
making the consultation easy to use. 
Social 
desirability 
The greater disclosure of sensitive information seen when computer 
assisted self-interviews are used has been postulated as being 
secondary to a reduction in social desirability bias when using this 
history-taking method.(151-153;155). However, Richens et al, with the 
findings of their randomised controlled trial, dispute this, arguing that 
it is the structure framework and mandatory answering of sensitive 
questions which leads to greater disclosure of information (40). 
 
1Adapted from (342) p172-175 
Decision 
 
In many traditional clinics, when a patient initially presents a history is taken of a patient’s 
sexual behaviour over the past three months or of their last sexual partner if it longer than 
three months since they last had sexual intercourse. As we already have a diagnosis with the  
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patients who are been asked these questions as part of the online clinical consultation, and the 
majority of these patients are asymptomatic, I chose to use a six month sexual history instead 
so that this data could inform partner notification. The information gathered also needed to 
identify higher risk sexual behaviour, so that the health advisers can provide appropriate 
advice, and to provide an idea of the sexual practices of those people using the Chlamydia-
OCCP to inform a future large scale trial. For example, if a proportion of females reported anal 
intercourse in the sexual history section, and they had come through the NCSP or had not 
reported this in clinic, then this would indicate an area that needed to be developed as if they 
had rectal chlamydia as well as genital chlamydia they should be treated with doxycycline 
100mg b.d. for a week(298;300). 
Initially patients are asked whether they have had chlamydia before. If they answer yes to this 
question, they are then asked when they were last diagnosed with chlamydia. As well as 
informing us as to the STI history of patients using the online consultation, it also helps us to 
detect those patients who have tested positive within the past 6 weeks and who have tested 
again too soon.  As is recommended in the BASHH guidelines, patients are also questioned as 
to whether they have ever tested for HIV, when was the last time they tested and what was 
the result(298).  
I developed the sexual behaviour section separately for women, men who have sex with 
women, men who have sex with men, and men who have sex with men and women.  An 
example of the logic behind one of the questions is illustrated in Figures 26, 27 and 28 below. 
As well as asking the number of sexual partners a patient has had in the last six months, they 
are also asked the number of new partners the patient has had in the last six months. Change 
in sexual partner and having more than one partner concurrently are risk factors for chlamydia  
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infection (300;343). I have designed the online clinical consultation so that all patients are 
asked the appropriate questions for gender of partner/s, type of sex and condom use. The 
questions asked in the sexual history section of the online clinical consultation are shown in 
Tables 60 and 61 below.  
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Figure 26: an example of the questions asked as part of the 
female sexual history 
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What type of sex 
have you had in the 
last 6 months
1. Oral
2. Vaginal +/or
3. Anal with a 
female
4. Anal with a 
man – active 
(top)
5. Anal with a 
man – passive 
(bottom)
Yes or no
no
no
Anal with a man 
– active top
yes
Anal with a man 
– passive 
bottom
no
8g
no
9.b
Anal with a 
man- passive 
(bottom)
yes
8h
no
8i
8hyes 8i 8j
8k8h
Anal with a man 
– passive 
(bottom)
yes
yes
Men who have sex 
with men and 
women
yes
no
no
 
Figure 27: An example of the questions asked for 
MSM&W 
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Figure 28:   An example of the questions asked for MSW and MSM 
An example of the questions asked for MSW and MSM
M
SW
M
SM
Phase
10d. What type of 
sex have you had in 
the last 6 months 
(tick all that apply)
1. Vaginal
2. Oral
3. Anal
10g. How often 
have you used a 
condom in the last 6 
months
1. Never
2. Sometimes
3. Most of the 
time
4. Always
Q11a
Q10e. What type of 
sex have you had in 
the last 6 months (tick 
all that apply)
1. Oral
2. Anal – active 
(top)
no
3. Anal – passive 
(bottom)
no
Anal – active 
(top)
yes
Anal-passive 
(bottom)
Anal- passive
(bottom)
yes
no
Q10g
no
Q11b
Q10i
Q10iyes Q10J Q10K
yes
yes
yesno
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Table 60: Sexual history section (Female) of the online clinical consultation 
Data 
Item 
Description Field Name Response categories and coding structure 
6 
 
 
 
 
 
 
 
Female: Previous 
chlamydia infection 
FPRECHL 
 
Text: Finally, we are going to ask you some 
standard questions we ask in clinic about your 
sexual health.  
 
Have you ever had chlamydia? 
1. Yes If ticked yes to chlamydia proceed 
to 6a 
2. No  go to 7 
 
6a Timing of previous 
Chlamydia infection 
TIMEPVCHL Text: When were you last diagnosed with 
chlamydia? 
1. 0-6 weeks  
2. 6 weeks - 6 months  
3. 7-12 months 
4. More than a  year ago 
7 Previously tested for 
HIV 
PREHIV Text: Have you ever been tested for HIV? 
 
1. Yes ( it ticked  drop down to  7a and 7b 
before  8) 
2. No 
3. Don’t know 
(2 and 3 if ticked auto generates to 8ai) 
7a Last HIV test HIVTEST When was the last time you were tested? 
1. Within the last 6 months 
2. 6-12 months ago 
3. More than a year ago 
 
7b Result of previous HIV 
test 
PREHIVRST What was the result of the test? 
1. Negative (you don’t have HIV) 
2. Positive ( You do have HIV) 
3. Don’t know 
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Data 
item 
Description Field Name Response categories and coding 
structure 
8ai 
 
 
 
 
 
 
 
 
 
 
 
 
8aii 
Number of sex 
partners in last 
6/12 
 
 
 
 
 
 
 
 
 
 
 
Partner 
notification text 
or e-mail 
requested 
SEXPART 
 
 
 
 
 
 
 
 
 
 
 
 
PARTNER 
NOTIFICATIONREQUEST 
How many people have you had sex 
(vaginal, oral or anal) with in the last 6 
months?  - - Number populated to 
Health adviser follow up screen. If put 0 
auto generates to 8f any other number 
auto generates to 8b after 8aii pop up 
box saying following: 
For 0  The last person you had sex with 
has 
For 1 person: This person has 
For more than 1 These people have 
a high chance of having chlamydia too. 
It is important to let them know. We 
can send a text or an e-mail to you with 
a number and a link you can give to 
them so they can log on and get 
treatment this way too. Don’t worry 
they will not be able to access any 
information about you.  
Select which way you want to get the 
number: 
1.Text 
2.e-mail 
3. Neither  
When ticked automatically generates a 
text/e-mail to the person. 
 
8b Number of first 
time  sex partners 
in last 6/12  
NEWSXPART Of these people, how many of them 
have you had sex with for the first time 
in the last 6 months? -- 
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Data 
item 
Description Field Name Response categories and coding 
structure 
8 c Previous sex with 
women or men or 
both 
GENDERSXPART  Text :In the last 6 months have you 
had sex with  
1. Men only 
2. Both men and women 
3. Women only 
8d Type of sex TYPESEX What type of sex have you had in the 
last 6 months ( tick all that apply) 
1. Vaginal 
2. Oral 
3. Anal 
8e Condom use CONDOM How often have you used a condom in 
the last 6 months? 
1. Never 
2. Sometimes 
3. Most of the time 
4. Always 
Move on to Q9a  
8f  Over 6 months sex 
partners 
 
SIXSEXPART 
 
FSEXMAN 
FSEXBIWO 
 
 
 
FSEXWOMAN 
FSEXBIMAN 
This question  is only for those who put  
0 to Q8ai 
When you last had sex did you have sex 
with a 
1. Man  if tick drops down box  
Have you ever had sex with a woman  
1.Yes  (to 9a) 
2.No    (to 9a)  
2. Woman if tick drops down box  
Have you ever had sex with a man  
1.Yes (to 9a) 
2.No  ( if ticked go to 9b) 
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Table 61: Sexual history section (male) of online clinical consultation 
 
Data 
Item 
Description Field Name Response categories and coding 
structure 
6 
 
 
 
 
 
 
 
Male: Previous chlamydia infection MPREVCHL 
 
 
 
 
 
 
 
Text:  Finally, we are going to ask you 
some standard questions we ask in 
clinic about your sexual health.  
 
Have you ever had chlamydia? 
1. Yes If ticked yes  proceed to 
6a 
2. No  go to 7 
 
 
6a Timing of previous chlamydia 
infection 
MTIMEPVCHL When were you last diagnosed with 
chlamydia? 
 
1. 0-6 weeks 
2. 6 weeks -6 months 
3. 7-12 months 
4. More than a year ago 
 
 
Data 
item 
Description Field Name Response categories and coding 
structure 
7 Previously tested for HIV MPREHIV Text: Have you ever been tested for 
HIV? 
 
1. Yes ( it ticked drop down 
box to 7a) 
2. No 
3. Don’t know 
(2 and 3 if ticked auto generates to 
8ai) 
7a Last HIV test MHIVTEST When was the last time you were 
tested? 
 
1. Within the last 6 months 
2. 6-12 months ago 
3. More than a year ago 
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7b Result of previous HIV test MPREHIVRST What was the result of the test? 
1. Negative (you don’t have 
HIV) 
2. Positive ( You do have HIV) 
3. Don’t know 
 
 
 
Data 
item 
Description Field Name Response categories and coding 
structure 
8ai 
 
 
 
 
 
 
 
 
 
 
 
8aii 
Number of sex partners in last 
6/12  
 
 
 
 
 
 
 
 
 
 
Partner notification text or e-
mail requested 
MSEXPART 
 
 
 
 
 
 
 
 
 
 
 
MPARTNER 
NOTIFICATIONREQUEST 
How many people have you had 
sex (vaginal, oral or anal) with in 
the last 6 months?  - - Number 
populated to health adviser 
follow up screen. 
If put 0 auto generates to 8f any 
other number auto generates to 
8b after 8aii pop up box saying 
following: 
For 0  The last person you had 
sex with has 
For 1 person: This person has 
For more than 1 These people 
have 
a high chance of having 
chlamydia too. It is important to 
let them know. We can send a 
text or an e-mail to you with a 
number and a link you can give 
to them so they can log on and 
get treatment this way too. 
Don’t worry they will not be 
able to access any information 
about you.  
  
Tick which way you want to get 
the number: 
1.Text 
2.e-Mail 
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3. Neither  
When ticked automatically 
generates a text/e-mail to the 
person.  
8b Number of first time  sex 
partners in last 6/12  
MNEWSXPART Of these people, how many of 
them have you had sex with for 
the first time in the last 6 
months? (numerical) - - - 
8 c Previous sex with women or 
men or both 
MGENDERSXPART  Text :In the last 6 months have 
you had sex with  
(Tick box) 
1. Women only If ticked  
go to Question 8d and 
8g then move to Q9a 
2. Men only If ticked  go to 
8e then go to 8i or 8j 
3. Both men and Women If 
ticked  go to 8f then 8h 
8d Type of sex Women only MTYPESEX What type of sex have you had 
in the last 6 months ( tick all 
that apply) 
1. Vaginal 
2. Oral 
3. Anal 
8 e Type of sex  Men only  What type of sex have you had 
in the last 6 months? (tick all 
that apply) 
1. Oral  Yes/No If yes to 
oral and no to 2and3 go 
to 8g then 9b 
2. Anal-active (top) 
Yes/No... 
3. Anal-passive (bottom) 
Yes/No  
If answers yes to 8e2 and no to 
8e3 then goes to 8i and then 9b. 
If answers yes to 8e2 and yes to 
8e3 then goes to through 8i-8k 
and then 9b 
If answers no to 8e2 and yes to 
8e3 then goes to 8j to 8k and 
then 9b 
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Data 
item 
Description Field Name Response categories and coding 
structure 
8f Type of sex Men and Women  MBISEX What type of sex have you had in 
the last 6 months ( tick all that 
apply) 
1. Oral  Yes/No 
2. Vaginal Yes/No 
3. Anal with a female Yes/No 
4. Anal with a man – active 
(top)  Yes/No 
5. Anal with a man -passive 
(bottom) Yes/No  
If yes to any combination of 1-3 
and no to 4 and 5 then goes to 8g 
and then 9b 
If yes to any combination of 2-3 
and yes to 4 and no to 5 then goes 
to 8h and then 8i and then 9b 
If yes to any combination of 2-3 
and yes to 4 and 5 then goes to 
8h, 8i, 8j, 8k and then 9b 
If yes to any combination of 2-3 
and no to 4 and yes to 5 then goes 
to 8h then 8j, 8k and then 9b 
If yes to 4 and no to 2,3 and 5 
then goes to 8i and then 9b 
If yes to 4and5 and no to 2-3 then 
goes through 8i-8k and then to 9b 
If yes to 5 and no to 2-4 then goes 
to 8j, then 8k and then 9b 
8g Condom use MCONDOM How often have you used a 
condom in the last 6 months? 
1. Never 
2. Sometimes 
3. Most of the time 
4. Always 
 
 
 
236 
 
Data 
item 
Description Field Name Response categories and coding 
structure 
8h Condom use Men and Women CONMENandWOM How often have you used a 
condom in the last 6 months 
when you had vaginal sex? ( tick 
box) 
1. Never 
2. Sometimes 
3. Most of the time 
4. Always 
 
8i Condom use men only -active CONMENACT How often have you used a 
condom in the last 6 months 
when you were active (top)? (tick 
box) 
1. Never 
2. Sometimes 
3. Most of the time 
4. Always 
 
8j Condom use men only passive CONMENPASS How often have you used a 
condom in the last 6 months 
when you were passive (bottom)? 
( tick box) 
1. Never 
2. Sometimes 
3. Most of the time 
4. Always 
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Data 
item 
Description Field Name Response categories and coding 
structure 
8k Passive Men Only Condom use PASSMENCON Thinking about when you have 
been passive (bottom), how many 
partners have you not used a 
condom with in the last 6 months? 
 
(numerical) - - - 
8L  Over 6 months sex partners 
 
MSIXSEXPART 
 
MSEXWOMAN 
MSEXBIMAN 
 
 
MSEXMAN 
MSEXBIWO 
 
 
 
 
 
This question  is only for those who 
put  0 to Q8a 
When you last had sex did you 
have sex with a 
1. Woman if tick drops down 
box  
Have you ever had sex with a man  
1.Yes 
2.No 
 
2. Man  if tick drops down 
box  
Have you ever had sex with a 
woman  
1.Yes 
2.No 
 On to 9b 
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Partner notification 
Objective 
To advise patients of the need to contact sexual partners to inform them that they are a 
contact of chlamydia and to provide a method whereby sexual partners can access 
epidemiological treatment online via the Chlamydia-OCCP. 
Evidence 
It remains unclear which is the optimal method of partner notification for people diagnosed 
with Chlamydia trachomatis (344). Currently only 40-60% of relevant named sexual partners 
are managed appropriately (345). In England, the most common method used by patients to 
inform their partners of their potential exposure to an STI is via ‘patient referral’, in which 
patients inform their sexual partners that they may have been in contact with an infection and 
need to access medical care (346). Although new mechanisms of informing partners are 
available, for example by text or SMS, these have been found to be less popular than may have 
been anticipated (347). 
Expedited partner therapy, one form of which is patient delivered partner therapy, is the 
method whereby an index patient is given treatment to give to sexual partners who may have 
been in contact with the infection with which they have been diagnosed. It has been trialled 
with indexes who have been diagnosed with genital Chlamydia trachomatis, Trichomonas 
vaginalis and Neisseria gonorrhoea, and has been shown to be a successful method of treating 
partners of indexes in countries outside the UK (344;348). However, current UK prescribing 
guidance recommends that a medical assessment is conducted for a person prior to them 
being prescribed Azithromycin (260;261;296). In addition, both a recent Cochrane 
Collaboration Intervention review of strategies for partner notification for sexually transmitted  
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infections, and a health technology assessment conducted by Althaus et al, found that 
although patient delivered partner therapy was superior to patient referral for reducing rates 
of reinfection in the index patient, it did not surpass enhanced patient referral in efficacy 
(344;349). They found that there is currently insufficient evidence to discern the most effective 
method of enhanced partner referral for specific settings (349).  
Decision 
In our exploratory study we agreed among the research team that we wanted to explore 
partner notification via an online model but that it was not the primary outcome of the study. 
We adopted a pragmatic approach, keeping the partner notification offered as patient referral, 
whilst acknowledging the potential for the Chlamydia-OCCP to provide “provider” 
referral/anonymised partner notification in the future). In the UK, a different form of 
expedited partner therapy has been developed, “Accelerated Partner Therapy (APT)” which is 
showing promise in preliminary studies (296). For the purposes of this trial, it was decided to 
use a simplified version of a method already being used in an existing trial (APT trial (UKCRN 
numbers 2564 and 10123)) to facilitate partner notification, along with website guidance. It is 
beyond the scope of the exploratory trials to send participants’ sexual partners an anonymous 
text. Instead, participants will be emailed or text (depending on their preference) a message 
containing a link and unique number (to that participant) that sexual partners will be able to 
use to access the online clinical consultation and potentially treatment online. This will be 
followed up, as is standard practice in the UK, by a phone call from a health advisor at two 
weeks. 
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In order to optimise the flow of the online consultation, we chose to include the partner 
notification section straight after the first sexual health question: ‘How many people have you 
had sex with in the last six months?’ 
Those patients who have been diagnosed with chlamydia and have not had sex in the last six 
months need to contact the last person they have had sex with. Therefore, anyone answering 
zero to the above question, is still directed to the partner notification page and is then asked 
the following set of questions: 
When you last had sex did you have sex with a  
3. Man (if tick drops down box)  
Have you ever had sex with a woman? 
1.Yes  2.No     
2.   Woman (if tick drops down box)  
Have you ever had sex with a man?  
1.Yes  2.No   
Figure 29 is a screenshot of the partner notification screen. 
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Figure 29: Screenshot of partner notification screen 
 
 
I adjusted the wording of the first sentence for the combinations illustrated in Table 62. 
Table 62: Wording of partner notification page 
No of sexual partners in the last 6 
months 
Wording of first sentence 
0 The last person you had sex with has a high chance of 
having chlamydia too 
1 This person has a high chance of having chlamydia too 
2 or more These people have a high chance of having chlamydia 
too 
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Early evaluation, conducted three months into the study, revealed that few index patients 
were choosing to have a partner notification text or email sent to them and only three sexual 
partners had accessed the online service. I collated the data collected from the health adviser 
follow-up interviews, health adviser notes and discussed the issue with the qualitative 
researcher. I then arranged to meet with a senior researcher and the human computer 
interface researcher so that we could revise the partner notification page and the partner 
notification text/email message. We decided to reduce the wording and introduce a diagram 
to illustrate what we were trying to convey. I revised the text message and cognitively tested 
(see Step 5) several versions with clinic patients. The final partner notification screen is shown 
below in Figure 30.  
Figure 30: Screenshot of the final partner notification screen 
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The revised partner notification message that was sent to the index patient via SMS or email 
was:  
‘To access free online NHS treatment enter 034542 to login 
https://esh.bartshealth.nhs.uk/sexualpartner’ 
A couple of weeks after implementing this, the research health adviser raised concerns that 
patients still did not fully understand how this worked. I therefore revised the health adviser 
follow-up questions so that we could capture this information. In the five months following the 
change in the partner notification screen, 25 sexual partners accessed the online consultation. 
A process evaluation using the quantitative and qualitative data (see Chapter 6) will be 
conducted to inform a full-scale trial.   
Reproductive history 
Objective 
For the purposes of the Chlamydia-OCCP study, a reproductive history was required to identify 
those patients who are pregnant or breast feeding 
Evidence 
A reproductive history is taken from females when they attend a sexual health clinic to 
identify(298;340): 
1. those women who are pregnant which may alter management of conditions diagnosed 
2. those women who may be pregnant and who need a pregnancy test and an 
assessment for emergency contraception 
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3. whether a female needs contraception and what are her options from a medical 
perspective 
4. whether a female is using the contraception method she is using correctly 
5. women with abnormal menstrual patterns and changes in pattern who require further 
investigation 
6. Women who are not up-to-date with their cervical cytology or have a history of 
abnormal cervical smears 
Decision 
I initially drafted an assessment to establish if a woman had unmet contraceptive needs, was 
at risk of pregnancy or was eligible for emergency contraception. However, we decided that 
this was outside the remit of our proof of concept Chlamydia-OCCP exploratory study. Instead I 
chose to ask whether a female patient whether she is pregnant or breast-feeding. Although 
these women could potentially be managed online, as this is an exploratory study, we decided 
that these would be directed off the pathway and into clinic (shown in Figure 31 below). 
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Figure 31: Screenshot from patient who has fallen off the pathway because she is pregnant 
or breast-feeding. 
 
 
Risk assessment 
Objective 
To conduct a risk assessment to identify patients who are at higher risk of other infections or 
getting recurrent infection in the future.  
Evidence 
All patients who are screened for STIs are recommended to undergo a risk assessment for 
blood borne viruses(298). Those patients who are recruited from the GUM clinics will have had 
a risk assessment at their initial appointment however those patients recruited from the NCSP 
will not have had one.  There is also evidence to suggest that people are more likely to be 
candid when answering sensitive questions in a computer assisted structured interview than in 
a face-to-face interview (40;151;152;155). 
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Decision 
Table 63 below shows which questions I chose to include in the online clinical consultation and 
how I have phrased them. 
Table 63: Risk assessment questions  
Gender Question 
Female Have any of your male partners had sex with a man? 
Male(MSW only) Have you ever had sex (oral or anal) with a man? 
Female and Male Have you ever injected drugs or had sex with someone who has injected 
drugs? 
Female Have you ever received money or paid money for sex? 
Male Have you ever paid money or received money for sex? 
Female and Male Have you ever had sex with someone from a different country (outside of 
the UK and Ireland)? If yes, please list the country or countries here 
Female and Male Have you ever been vaccinated against Hepatitis B? 
 
 
As part of the health adviser two week follow-up, all patients who answered yes to any of 
these questions were asked additional questions as part of the follow-up. In addition, health 
advisers were able to see patients responses to the online consultation and were therefore 
able to identify high risk individuals who may benefit from one-to-one interventions, along 
with young people who were in a relationship with a much older partner.  
All patients should be asked if they have ever had non-consensual sex and be assessed as to 
whether they are in a physically or mentally abusive relationship, use recreational drugs or 
have alcohol problems. The expert group and the members of the public involved in cognitive 
testing both felt that it would be too emotive to ask about non-consensual sex in an online  
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consultation. Instead, I chose to add information about where to access help for this in the 
health promotion section. Asking about recreational drug and alcohol use was beyond the 
scope of the study, which is a limitation, however it should be included in a future large scale 
trial.  
Health promotion 
Objective 
To provide users with information about sexual health, safe sex and contraception.   
Evidence 
Although the incidence of STIs in the UK decreased by 0.6% between 2012 and 2013, diagnoses 
of some STIs continues to increase, and young people and MSM remain disproportionately 
affected(97). Lim et al, in their survey of young people attending a music festival in Melbourne, 
found only a small improvement in STI knowledge between 2006 and 2011. The statements 
that were most frequently answered incorrectly were to do with diagnosis and treatment, with 
65% of young people believing that pap smears can diagnose all the main STIs, only 53% aware 
that chlamydia can be diagnosed using a urine test and 51% aware that gonorrhoea, chlamydia 
and syphilis can all be treated with antibiotics(350).  
There has been a call to improve sexual health promotion interventions and to use the internet 
and mobile phones to reach young people (350-352). A 2011 Cochrane review found that 
interactive computer-based interventions are an effective way of educating young people on 
sexual health and can have a beneficial effect on sexual behaviour. However, it concluded that 
further evidence was required to demonstrate cost-effectiveness, impact on biological 
outcomes, and how these interventions might work(353). Since then, a number of studies have 
used the internet, social media, and SMS to provide sexual health promotion to young people  
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(190;354-356). Jones et al undertook a systematic review of the impact of health education 
provided via social media or SMS on the sexual behaviour of young people. As with the 2011 
Cochrane review, they found that the studies provided evidence on benefit of STI prevention 
knowledge in this group, but only weak evidence of other benefits, and that many of the  
studies contained limitations which inhibited their usefulness. They concluded that further 
research is needed in this field (355).   
Decision 
Health promotion forms a vital part of service provision in sexual health. Designing a novel 
health promotion section was outside the remit of the study and my PhD. However, I wanted 
to ensure that we provide patients with the same opportunities to access information on the 
major components of health promotion as happens within clinic. As patients were to be 
recruited from both a clinic setting and the NCSP, and would therefore been exposed to 
different levels of health promotion, I decided to attempt to provide accurate and useful 
information on all the basic components by using links to existing NHS and accredited Sexual 
Health sites.  Initially I included tailored health promotion information for patients testing 
positive using the information they entered in the online clinical consultation to guide what 
additional information was provided. However, it was not feasible to implement this in our 
proof of concept study.  
Figure 32 below shows the health promotion page in the online consultation, which is available 
to people testing positive and negative for chlamydia. 
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Figure 32: Screenshot of health promotion page 
 
The websites that patients are directed to are listed in Table 64 below. 
Table 64: Web links for health promotion page 
Health Promotion 
Heading 
Web link  
Find out more about 
chlamydia 
http://www.fpa.org.uk/helpandadvice/sexuallytransmittedinfectio
nsstis/chlamydia 
 
Get checked for other 
infections 
www.nhs.uk/ServiceDirectories/Pages/ServiceSearchAdditional.as
px?ServiceType=SexualHealthService 
How to keep yourself 
safe 
http://www.bashh.org/documents/4239.pdf 
 
Contraception www.fpa.org.uk 
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Table 64 continued 
Health Promotion 
Heading 
Web link  
Had sex against your 
will 
www.rapecrisis.org.uk/Referralcentres2.php   
Find Sexual Health 
Services 
www.nhs.uk/ServiceDirectories/Pages/ServiceSearchAdditional.aspx
?ServiceType=SexualHealthService 
 
Patients testing negative for chlamydia are provided with information about the window 
period for chlamydia testing and are advised that they need to repeat the test if they have had 
sex with a new sexual partner in the preceding two weeks. As the NCSP patients will not have 
been tested for HIV, syphilis and, in some cases gonorrhoea, negative patients are also advised 
that they may be at risk of other STIs and are directed to the health promotion page for 
information on other STIs, contraception, and safe sex. 
Health-adviser follow-up consultation 
 
This is the last unit and is the only section aimed at completion by a healthcare professional 
and not directly by the patient.  
Objective 
To develop a health adviser follow-up consultation that covers all elements of a traditional 
consultation, adapted to the needs of a remote consultation.  
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Evidence 
There are clear guidelines on the content of a health adviser consultation with a patient 
diagnosed with genital chlamydia (300;357-359). These include ensuring that the patient has 
had effective treatment, has not had sexual intercourse within a week of treatment or with an 
untreated partner, and a discussion around partner notification(300).  
Decision 
Although the health adviser follow-up is conducted by phone, it is part of the eSexual Health 
Clinic and the health adviser is able to access their own screens and reports. The follow-up is 
an electronic proforma that forms part of each patient’s electronic health record. Each person 
who tests positive for chlamydia and consents to the study will be followed up two weeks after 
their results text is sent to them.  
I designed the proforma so that it captured all the information necessary to ensure that the 
patient had been successfully treated, had not been potentially re-exposed to infection, and 
that we had details and outcomes on all sexual partners that needed to be notified. As well as 
requiring this information to ensure appropriate management of all patients and sexual 
partners, we also needed to feedback this information to the relevant GUM clinic or NCSP site.  
If patients had reported that they had genital lumps or genital sores, rash or blisters, then an 
additional screen appeared in the health adviser follow-up so that the health adviser could 
discuss these symptoms and arrange a clinical review if necessary. Likewise, if patients 
answered yes to any of the questions in the risk assessment then an additional screen 
appeared so that the health adviser could discuss this and direct them to clinical services if 
necessary.  
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The quantitative service evaluation, discussed in Chapter 6, was added onto the end of the 
health adviser follow-up consultation. 
Table 65 below shows the original health adviser follow-up, with Table 66 showing the health 
follow-up after adjustments had been made on the partner notification section (as discussed 
on page 239). 
Table 65: Original health adviser follow-up 
Data 
item 
Description Field name Response categories and 
coding structure 
1 Date of index follow up IDATEFU HA inserts ID number 
1 DD/MM/YYYY 
2 DD/MM/YYYY 
3 DD/MM/YYYY 
Start and end Time of 
consultation auto-generated 
stops automatically when 
closed (3 attempts for follow up 
will be made to each index, so 
need date, start and end time 
for each) 
2.   Index treated 
 
 
INEXTREATED  1. Yes (if yes automatically 
feeds to 2.i)  
 2. No (if no automatically feeds 
to 2.vii) 
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Data 
item 
Description Field name Response categories and 
coding structure 
2.i When index treated IWHENTREAT Drop down box with: 
1. Same day as received 
result 
2. 1 day after received result 
3. 2 days after receiving 
result 
4. 3 days after receiving 
result 
5. 4 days after receiving 
result 
6. 5 days after receiving 
result 
7. 6 days after receiving 
result 
8. 7 days after receiving 
result 
9. More than 1 week after 
receiving result 
 
2.ii Where index treated IWHERETREAT Drop down box with: 
1. Via online clinical 
consultation at chosen 
pharmacy 
2. In a sexual health clinic 
3. At GPs 
4. At pharmacy  
5. Family Planning 
Clinic/CASH 
6. Other – free text 
2.iii Vomited within 2 hours of 
taking azithromycin 
IVOMIT 1. Yes (if yes automatically 
feeds to 2.iiia) 
2. No (if no automatically 
feeds to 2.iv) 
2.iiia Has patient been retreated IRETREAT 1. Yes (if yes automatically 
feeds to 2.iv) 
2. No (if no automatically 
feeds to 2.vii) 
2.iv Any other problems/side-
effects with treatment 
ISIDEEF 1. Yes (if yes drop down box 
with free text then feeds to 
2.v)  
2. No (if no automatically 
feeds to 2.v) 
2.v Any sexual intercourse (incl 
oral sex) within 1 week of 
treatment 
IINTERCOUR 1. Yes (if yes automatically 
feeds to 2.vii) 
2. No (if no automatically 
feeds to 2.vi) 
2.vi Any sexual intercourse (incl 
oral sex) with 
INTERUNTRPT 1. Yes (if yes automatically 
feeds to 2.vii) 
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untreated/inadequately 
treated partner 
2. No (if no automatically 
feeds to 3) 
2.vii When will they go for (re-
)treatment and where 
IWHERERETREAT Free text  
(Then automatically feeds to 3) 
3. ONLY IF FLAGGED ON ONLINE 
CONSULTATION 
 
Symptoms ticked on online 
consultation 
IHEALTHPROM Automatically filled from online 
consultation data item Female 
4a, Male 4a. 
Tick all that apply: 
1. Rash, sores or blisters in 
the genital area 
2. Skin lumps in the genital 
area 
 
 
3.1  Symptoms resolved?  ISYMRESOLVED 1. Yes 
2. No 
3. Some improvement but 
still present 
3.2 Advice sought? IADVICE 1. Yes (if yes, automatically 
feeds to 3.3) 
2. No (if no, automatically 
feeds to 3.4) 
3.3 Where was advice sought? IWHEREADVI 1. Sexual Health Clinic 
2. GP 
3. 111 telephone service 
4. Clinical helpline 
5. Other – free text 
3.4 Other information 
gathered/advice given 
IANYADVICE Free text 
4. ONLY IF FLAGGED ON ONLINE 
CONSULTATION 
Discussion about risk 
factors/HIV/STS/Hep B 
testing 
IDISCUSSHIV Free text 
Fed from Females and Male  9a 
-9d 
 
 
 
 
 
 
 
255 
 
5.  Number of partners in last 6 
months 
INOPARTNER 1. Number of sexual partners - -  
Number of partners populated 
from index consultation. Females 
8ai and males 8ai 
  All questions from 5.1a to 6 to 
be asked of each sexual partner 
5.ia [Partner 1] partner notified 
by index 
PARTNOT 1. Yes (if yes automatically 
feeds to 5.ib) 
2. No (if no automatically feeds 
to 5.if) 
. 
5.ib When index notified by 
partner  
WHENNOT Drop down box with: 
1. Same day as received result 
2. 1 day after received result 
3. 2 days after receiving result 
4. 3 days after receiving result 
5. 4 days after receiving result 
6. 5 days after receiving result 
7. 6 days after receiving result 
8. 7 days after receiving result 
9. More than 1 week after 
receiving result 
 
5.ic How index notified by 
partner 
HOWNOT Tick all that apply: 
1. Face –face 
2. Phone call 
3. Text message  
4. Email  
5. Facebook 
6. Other – free text 
5.id Did index give PIN and link 
to online clinical 
consultation to partner 
PINGIVEN 1. Yes (if yes automatically 
feeds to 5.if) 
2. No (if no automatically feeds 
to 5.ie) 
5.ie Reason why PIN and link not 
given to partner 
REASPINNOT 1. Deleted text prior to 
informing partner 
2. Too embarrassed 
3. Partner not interested in 
online method 
4. Forgot to forward text  
5. Forgot to forward email 
6. Other 
5.if Partner treated (as reported 
by index) 
PARTTREATINDEX 1. Yes (if yes automatically 
feeds to 5.ig) 
2. No  ( go to 6) 
3. Don’t know (go to 6) 
 
256 
 
5.ig Where partner treated (as 
reported by index) 
WHEREPARTREAT 1. Don’t know 
2. Via online clinical 
consultation  
3. GP practice 
4. Sexual Health clinic 
5. Family planning clinic 
6. NCSP office 
7. Pharmacy 
8. Other…. Please state where 
5.ih When partner treated (as 
reported by index) 
WHENPARTREAT 1  Already received treatment 
Same day  
2     1 day after informed 
3     2 days after informed 
4     3 days after informed 
5     4 days after informed 
6     5 days after informed 
7     6 days after informed 
8     7 days after informed 
9     8 days after informed 
10   9 days after informed 
11  10 days after informed 
12  11 days after informed 
13  12 days after informed 
14  13 days after informed 
15  14 days after informed 
16  Don’t know 
5.ii Reason why partner not 
notified 
REASPARTNOTNOT 1. Unable to contact 
2. Too embarrassed 
3. Not wanting to contact 
partner 
4. Forgot to contact partner 
5. Index didn’t think they 
needed to contact 
partner 
6. Other reason – free text  
6. Any other points 
discussed/information given 
DISCUSSION 1. Yes …..Free text box 
2. No 
Move to next partner and ask 
same questions, after all   same 
questions have been asked 
about all partners, move to Q7 
24 Suitable for qualitative 
interview 
QUALINT 1. Yes – automatically feeds 
to 25 
2. No – system closes date 
and time recorded 
25 Permission to follow-up by 
researcher 
PERMFURESEA 1. Yes 
2. No 
If yes, drop down text 
box: best time to call for 
interview 
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Table 66: Revised Health adviser follow-up from Q5a onwards 
Data 
item 
Description Field name Response categories and 
coding structure 
5a Did index give PIN and 
link to online clinical 
consultation to 
partner/s 
PINGIVEN 1. Yes (if yes automatically feeds 
to 5.ai) 
2. No (if no automatically feeds 
to 5.bi) 
3. Dropped off consultation 
before PARTNER 
NOTIFICATION section 
(automatically feeds to 5.cia) 
4. Chose not to receive PIN and 
link (automatically feeds to 
5.biii) 
5ai Did index patient 
understand how the 
PIN and link was to be 
used (i.e. they should 
send it to partners so 
they could receive 
treatment online too?) 
PINUNDERSTAND 1. Yes (automatically feeds to 
5bi) 
2. No  (automatically feeds to 
5aii) 
5aii How did the index 
patient think the PIN 
and link worked 
PINUNDERSTANDDET Free text box 
5bi Reason why PIN and 
link not given to 
partner/s 
REASPINNOT 1. Deleted text/email prior to 
informing partner 
2. Too embarrassed 
3. Partner not interested in 
online method 
4. Forgot to forward text  
5. Forgot to forward email 
6. Didn’t understand what PIN 
and link were for 
7. Other (automatically feeds to 
5bii) 
1-6 automatically feed to 5cia 
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Data 
item 
Description Field name Response categories and coding 
structure 
5bii Other reason why PIN 
and link not given to 
partner/s 
REASPINNOTOTH Free text 
5biii Reason why index 
decided not to get PIN 
and link? 
REASPINNOTGET 1. Didn’t understand how it 
would work 
2. Preferred to let partner/s 
know by other method 
3. Other (automatically feeds to 
5biv) 
1and 2 automatically feed to 
5biv 
5biv Other reason why 
index decided not to 
get PIN and link 
REASPINNOTGETOTH  Free text  
5.cia [Partner 1] partner 
notified by index 
PARTNOT 1. Yes (if yes automatically feeds 
to 5.ib) 
2. No (if no automatically feeds 
to 5.if) 
. 
5.cib When index notified by 
partner  
WHENNOT Drop down box with: 
1. Same day as received result 
2. 1 day after received result 
3. 2 days after receiving result 
4. 3 days after receiving result 
5. 4 days after receiving result 
6. 5 days after receiving result 
7. 6 days after receiving result 
8. 7 days after receiving result 
9. More than 1 week after 
receiving result 
5.cic How index notified by 
partner 
HOWNOT Tick all that apply: 
1. Face –face 
2. Phone call 
3. Text message  
4. Email  
5. Facebook 
6. Other – free text 
5.cie Partner treated (as 
reported by index) 
PARTTREATINDEX 1. Yes (if yes automatically feeds 
to 5.ig) 
2. No  ( go to 6) 
3. Don’t know (go to 6) 
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Data 
item 
Description Field name Response categories and 
coding structure 
5.cif Where partner treated 
(as reported by index) 
WHEREPARTREAT 1. Don’t know 
2. Via online clinical consultation  
3. GP practice 
4. Sexual Health clinic 
5. Family planning clinic 
6. NCSP office 
7. Pharmacy 
8. Other…. Please state where 
5.cig When partner treated 
(as reported by index) 
WHENPARTREAT 1.  Already received treatment 
Same day  
2     1 day after informed 
3     2 days after informed 
4     3 days after informed 
5     4 days after informed 
6     5 days after informed 
7     6 days after informed 
8     7 days after informed 
9     8 days after informed 
10   9 days after informed 
11  10 days after informed 
12  11 days after informed 
13  12 days after informed 
14  13 days after informed 
15  14 days after informed 
16  Don’t know 
5.cih Reason why partner 
not notified 
REASPARTNOTNOT 1. Unable to contact 
2. Too embarrassed 
3. 3. Not wanting to contact partner 
4. 4. Forgot to contact partner 
5. 5. Index didn’t think they needed 
to contact partner 
6. 6. Other reason – free text 
 
 
 
A screenshot illustrating the section for patients who report symptoms or high risk sexual 
behaviour is shown in Figure 33 below. 
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Figure 33: Screenshot of health adviser screen for symptomatic patients and high risk sexual 
behaviour 
 
 
We decided that there would be three attempts at follow-up before the patient passed into 
the ‘unsuccessful follow-up’ screen (see Figure 34 for screenshot). Figure 35 shows the 
screenshot of patients waiting to be followed up and who are in progress.  
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Figure 34: A screenshot of the unsuccessful follow-up screen 
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Figure 35: A screenshot of the waiting/in progress follow-up screen 
 
 
The online clinical consultation, and where it fits within the eSexual Health Clinic and 
Chlamydia-OCCP, is illustrated in Figure 36 below.
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Clinical care pathways
Online consultation
eSexual Health Clinic has no duty of care
Laboratory 
processes tests
Result sent to 
system via CSV file 
(for NCSP patients) 
or inputted via 
results 
administrator (GUM 
patients)
System generates & 
sends SMS to 
patient informing 
them their result is 
ready
Patient doesn’t log 
on
Patient logs on 
and accesses 
result
Chlamydia negative. Negative survey
Health promotion Chlamydia positive
Patient fed back to 
testing site (NSCP or 
GUM) for follow up
Patient consents to 
online management
Patient doesn’t 
consent
Patient enters 
personal & 
demographic details
Medication & 
allergies 
Symptoms
Relevant medical 
history
Sexual history
Partner notification
Risk assessment
Patient choses 
pharmacy
Due to symptoms or 
medical history 
patient needs to be 
seen in clinic
Due to medications 
or allergies patients 
needs to be seen in 
clinic
Clinical helpline
Fast track to clinic 
or seen by GP
System sends email 
to pharmacy
System sends text 
to patient with 
pharmacy details & 
clinical helpline 
number
Patient goes to 
pharmacy
Pharmacist confirms 
DOB and name and 
hands out 
treatment
Pharmacist clicks on 
link to confirm 
patient has 
collected treatment
Fed back to system
Health advisor 
follow-up at two 
weeks
Patient successfully 
treated & no further 
follow-up required
Health promotion
Patient needs 
retreating
Relevant 
information fed 
back to GUM and 
NCSP
Patient requests 
partner notification 
text or email
System sends text 
or email to patient
Patient forwards 
text or email to 
sexual partner/s
Sexual partner logs 
on to system with 
PIN
Informed contact of 
chlamydia and need 
for treatment
Ok to continue online
Figure 36: eSexual Health Clinic 
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STEP 4: EXPERT REVIEW 
The draft online clinical consultation was then reviewed by expert clinicians and non-clinicians 
within the eSTI2 consortium with respect to the content, phrasing and flow of questions and 
text.  The expert review panel consisted of consultant genitourinary medicine and public 
health physicians, academics in sexual health, public health, human computer interaction, 
bioethics, health economics and a research health adviser. Due to the multidisciplinary and 
multi-institutional nature of the expert group, this produced a large amount of discussion in 
terms of the questions being asked, how they were phrased, what to include and what was 
beyond the scope of this study (e.g. emergency contraception, drug and alcohol history). I 
therefore circulated the online clinical consultation, asked for individual feedback and then 
arranged to discuss this at the monthly work stream meeting so that we could come to a 
consensus.  Any issues where we unable to reach consensus, were specifically looked at as part 
of the comprehension (step 5) and usability testing (step 6) described below. Examples of 
questions that generated discussion included: 
 1. How to ask whether patients had previously had an STI and which STIs to specifically ask 
about. It was decided that it would be better to ask about specific STIs rather than whether 
they had a sexual health screen previously. The two STIs that I felt to be of most benefit to ask 
about were chlamydia (particularly as if they had been diagnosed within the preceding 6 weeks 
it could be that they were re-testing too soon) and HIV. The panel agreed with this.  
2. How to ask patients about sexual partners from outside the UK. Issues raised with this 
included how to phrase what are countries/areas of higher risk of HIV infection without 
appearing xenophobic, and not having to rely on peoples knowledge of geography in terms of 
area, along with  the best way to structure the question. It was decided that using a free text  
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box would result in people potentially misspelling countries and would be potentially difficult 
manually if using a smartphone, and a drop down list of different countries would also not be 
ideal due to the number of countries in the world. Instead we decided to go with a free text 
box that used predictive text. Revisions were made before moving on to step 5.  
STEP 5: COMPREHENSION TESTING 
In order to try and ensure that patients’ interpretation and comprehension of the text and 
questions asked within the online clinical consultation was the same as my own, I decided to 
conduct cognitive testing. Beatty and Willis define cognitive testing as ‘the administration of 
draft survey questions while collecting additional verbal information about the survey 
response, which is used to evaluate the quality of the response or to help determine whether 
the question is generating the information that its author intends’(360).  
I conducted cognitive interviews with patients at a GUM Clinic in Bury St Edmunds at an early 
stage of development to ensure that the initial draft of the questionnaire was comprehensible 
to users and that their interpretation of the question asked was the same as the researcher’s 
interpretation. I initially tested a print out of the questions with three patients. I asked each 
patient to read through the questions and text and to tell me what they thought the 
questions/text meant. I then asked probing questions as necessary.  One of the main findings 
from this was that people either did not know what azithromycin (a macrolide and first-line 
treatment for chlamydia (361)) was or confused it with erythromycin. This meant that they 
were unable to accurately interpret and answer the question relating to allergies. It was 
therefore necessary to develop a series of questions which allowed patients with no allergies 
to pass on to the next section whilst ensuring that any patients who were allergic to 
macrolides came off the online pathway and into clinic. 
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I then conducted two further rounds of testing using three patients for each round. By the 
third round all three patients were able to understand the questions and text and interpreted 
them correctly. I conducted further cognitive testing with members of the public using the 
same technique once the demonstration version of the web app was available in June 2014.  
At this stage no further amendments were necessary. More in-depth work was conducted on 
an ad hoc basis where it became apparent that patients were not using or did not understand 
a section of the pathway. For example, we noticed a couple of months into the study that not 
many index patients were not requesting the partner notification PIN to pass on to the sexual 
partners. In addition, even when index patients did request the PIN code, they were either not 
passing it on to their sexual partners or choosing not to use it. Information as to why this was 
happening was captured in the quantitative service evaluation which formed part of the health 
adviser follow-up interview at two weeks (discussed in Chapter 6). As an initial response, I, 
along with a Senior Researcher and a Human Computer Interface researcher, worked on 
revising the partner notification page. In addition the senior researcher and I revised the text 
and email message that was sent to the index patient. I then cognitively tested these with 
members of the public and we revised the system and messages accordingly.   
This revision provided some improvement in the uptake and usage of the PIN for sexual 
partners. However, the research health adviser still felt that some index patients did not 
understand how the PIN was to be used and that this had deterred them from requesting and 
using it. In order to evaluate this further, I amended the quantitative service evaluation (see 
Chapter 6). 
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STEP 6: USER CENTRED INTERFACE DESIGN 
Initial focus groups were conducted by a Human Computer Interaction researcher in university 
and secondary schools in order to establish user requirements(181). User interface design 
principles and guidelines were then used to design the interface to ensure optimal display of 
questions and response sets, along with facilitating user journey and flow of interaction (362). 
Lab-based user interface testing was conducted by the Human Computer Interaction 
researcher with wireframed prototypes. As part of this process comments were made and 
thoughts expressed about the content of the clinical consultation. Relevant findings have been 
incorporated into the online clinical consultation and amendments made where necessary.  
STEP 7: SPECIFICATION DEVELOPMENT 
As part of the iterative process in development of the online clinical consultation, I reviewed 
the literature and guidelines to ensure that the knowledge base on which the content of the 
online clinical consultation was based was optimal. Enquiries were made to various 
professional organisations including the Electronic Prescribing Service, and a number of 
pharmacies were contacted, with regards to the electronic prescribing component of the 
consultation.  
I endeavoured to balance the content and questions with what was mandatory in terms of 
current best practice guidelines and legislation, with what I considered needed to be included 
to ensure that the pathway was safe, supportive but feasible for a user to complete. I used skip 
patterns to facilitate patient flow through the pathway. The consultation was then reviewed 
again by a select group of expert clinicians and non-clinicians within and out with the eSTI2 
consortium. Following this, a Senior Researcher and I developed the specification for the  
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development of the online clinical consultation. As part of this process the pathway and online 
clinical consultation were revised and amended. 
The online clinical consultation was converted into the database specification in order for the 
software engineers to design the system according to our needs. We took the text, questions 
and logic and placed it into a spreadsheet, adding data item numbering and field names. We 
asked that each data item be time stamped and dated. This ensured that the database would 
capture the necessary information for the electronic health records and for quantitative and 
economic analysis. During the creation of the specification, I developed messages to pop-up on 
the screen providing information for the patient when they fell off or choose a certain option 
(e.g. the PIN for sexual partners). Figure 37 below illustrates an example of this. 
Figure 37: Example of a pop-up screen 
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Other functions that I ensured that the system had included the ability for a health adviser to 
put a patient back on the system if they had fallen off inappropriately and were assessed as 
being safe to continue.  
As well as developing the ‘front end’ of the system, with the database specification, I also 
helped develop the ‘back end’, with the software specification. The back end includes the 
programme manager, results administrator and health adviser interface along with the 
transfer of data from The Doctors Lab. In addition, it includes the export data sheet which I 
designed to capture all the data on the system. The codebook I developed, describing the 
export datasheet, is shown in Table 67 below. 
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Table 67: Export data sheet codebook
 
  
Section Parameter/Field Name Description Coding
Username
Results administrator (RA) email address User email address
Date logon Date RA logged on DD/MM/YY
Time logon Time RA logged on Time 
Date text message sent Date system sent text message DD/MM/YY
Time text message sent Time system sent text message Time
System identifier
Unique system identifier Index patients = site code + unique 6 digit PIN number e.g. 
AKC123456 ; sexual partners (SPs) = index patient's PIN 
number with additional numeral depending on logon 
sequence compared to other SPs e.g. AKC123456001
Site code/SP
Site code index patient originated from or SP for sexual 
partner. 
AKC= Ambrose King Centre; BHC= barts sexual health 
centre; SGC = St George's Clinic; CLEW= Lewisham; CBEX = 
Bexley; CBRM= Bromley; CGRE = Greenwich; CLAM = 
Lambeth; CSWK = Southwark; SP = sexual partner
Results number
Clinic results number or last 6 digits of NCSP unique 
number
6 digit 
RESDOB SPDOB RA entered date of birth DD/MM/YY
RESGEM RESGEF RA entered gender 1=  Female 2= Male
RESDATEST
RA entered date of chlamydia test DD/MM/YY
RESPOS RESNEG RA entered result of chlamydia test 1 =positive  2= negative
Date of log off Date RA logged off DD/MM/YY
Time of log off Time RA logged off time
Date of logon LOGON SPLOGON
Date index patient/SP logged on DD/MM/YY
Time of logon LOGON SPLOGON
Time index patient/SP logged on Time 
LOGON DOB Date of birth index patient logged on with DD/MM/YY
LOGONRSNUM Results number index patient logged on with 6 digit (except SGC - X+5digits)
Date every time px accesses 
results CLICKACCESSTST
Date index patient accesses results DD/MM/YY
Time every time px accesses 
results CLICKACCESSTST
Time index patient accesses results time
CLICKACCESSTST Index patient accesses results 1. Yes 2. No
Platform used Platform index patient/SP used to access system Platform (e.g. android)
INGUMFPALEAF/INNCSPFPALEA
F/SPCLINFO
Index patient/SPaccesses FPA leaflet on chlamydia on 
results page
1 = yes 2= no
INNCSPSEXCLINIC 
NCSP index patient accesses link on sexual health clinics 1 = yes 2= no
INGUMINFO/INNCSPINFO/SPCLI
CKINFO
Index patient/SP accesses PIL 1=yes 2=No
INGUMCONYES INNCSPCONYES 
SPCONYES
index patient/SP consents to continue online 1 = ticked 2 = not ticked
INGUMCONNO INNCSPCONNO 
SPCONNO
Index patient/SP does not consent to continue online 1 = ticked 2 = not ticked
INGUMCONYES/INNCSPCONYES
/SPCONYES
Date of consent DD/MM/YY
INGUMCONYES/INNCSPCONYES
/SPCONYES
Time of consent Time
Date everytime pt accesses 
online consultation
Date index patient/SP accesses online consultation DD/MM/YY
Time everytime pt accesses 
online consultation
Time index patient/SP accesses online consultation Time
Date evey time pt exits 
consultation
Date index patient/SP exits online consultation (by 
clicking log off)
DD/MM/YY
Time every time pt exits on line 
consultaiton
Time index patient/SP exits online consultation (by 
clicking log off)
Time
Data item patient exits on or 
comes off the system on
Data item index patient/SP exits the system on (by 
clicking log off)
Data item 
Date pt dropped off Date index patient/SP drops off the system DD/MM/YY
Time pt dropped off Time index patient/SP drops off the system Time
Question pt dropped off Question index patient/SP drops off the system Data item
Completed consultation within 
14 days
Index patient/SP completes the consultation with in 14 
days of their result being placed on the system
1=Yes 2=No
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Section Parameter/Field Name Description Coding
AGE Index patient/SP entered age Numerical
ETHNIC SPETHNIC Index patient/SP entered ethnicity ONS code (as provided)
POSTCD Index patient/SP entered postcode (first 4 digits only) First 4 digits of postcode
GENDER SPGENDER Index patient/SP entered gender 1=female 2=male
REGMEDS Index patient/SP on regular medications 1= yes 2=No
DRUGINTER
Index patient/SP taking one of the following: 
Ciprofloxacin (Ciproxin), Citalopram (cipramil) , Warfarin, 
Ergotamine (Migril), Bromocriptine (Parlodel), 
Cabergoline (Dostinex), Ciclosporin (Deximune, Neoral), 
Droperidol (Xomolix), Mizolastine (Mizollen), Pimozide 
(Orap), Reboxetine (Edronax), Artemether with 
Lumefantrine (Riamet), Piperaquine with Artenimol 
(Eurartesim), Theophylline (Nuelin SA, Slo-Phyllin, 
Uniphyllin Continus) 
1 = Yes 2 = No
CARDARRY
Index patient/SP reported history of cardiac arrhythmias 
or on medication for their heart
1 = Yes 2 = No
ALLMED Index patient/SP allergic to any medications 1 = Yes 2 = No
ALZITH Index patient/SP allergic to azithromycin 1 = Yes 2 = No 3= Don't know
ALGYSYM_1
Index patient/SP gets itch rash, throat or facial swelling or 
difficult breathing with macrolide antibiotics
1=ticked 2=not ticked
ALGYSYM_2
Index patient/SP gets nausea, vomiting or diarrhoea with 
macrolide antibiotics
1=ticked 2=not ticked
ALGYSYM_3
Index patient/SP gets another reaction with macrolide 
antibiotics
1=ticked 2=not ticked
ALGYSYM_4
Index patient/SP has none of these symptoms/reactions 
with macrolide antibiotics
1=ticked 2=not ticked
ALSOYPNT Index patient/SP allergic to soya or peanut 1= yes 2=no
MYASGRAV
Index patient/SP has Myasthenia gravis or severe liver or 
kidney problems
1= yes 2= no
FPRECHL MPREVCHL Index patient/SP has previously had chlamydia 1 = Yes 2 = No
TIMEPVCHL MTIMEPVCHL
When was index patient/SP previously diagnosed with 
chlamydia
1 = 0-6 weeks             2 = 6weeks -6/12         3= 7-12 
to12months               4 = > 1yr
PREHIV MPREHIV Index patient/SP previously been tested for HIV 1 = Yes 2 = No 3= Don't know
HIVTEST MHIVTEST
Last time index patient/SP was tested for HIV 1 = within the last 6months 2 = 6-12 months ago                       
3 = >1yr
PREHIVRST MPREHIVTEST Result of HIV test  1 = Negative 2 = positive 3 = don't know
SEXPART MSEXPART
Number of sex partners in the last 6 months ( index patient 
only )
Numerical 
PNREQUEST MPNREQUEST
Method index patient wants to get the PN PIN number 
(index patient only ) 
 1=Text  2=Email     3=Not now
NEWSXPART MNEWSXPART
Number of new sex partners in the last 6 months ( index 
patient only )
Numerical
GENDERSXPART 
MGENDERSXPART
Gender of sex partners in the last 6 months ( index patient 
only )
1 =women only            2 = men 3 = both men & women
INJDRUG MINJDRUG
Ever injected drugs or had sex with someone who has 
injected drugs
1 = yes 2 = no
PAIDSX MPAIDSX Ever received or payed money for sex 1 = yes 2= no
SXCOUNTRY MSXCOUNTRY
Ever had sex with someone from outside the UK or 
Ireland?
1 = yes 2= no
SXCOUNTRY_1 MSXCOUNTRY_1 
list countries
List of countries that index patient/SP's sexual partners 
originate from
List of countries
HEPB MHEPB Ever been vaccinated for Hepatitis B 1 = yes 2 = no 3 = don't know
PHRMNOM Name of pharmacy that index patient/SP has chosen Name of patient chosen pharmacy
PHRMNOM Date
Date that pharmacy was chosen (i.e. finished 
consultation)
DD/MM/YY
PHRMNOM Time
Time that pharmacy was chosen (i.e. finished 
consultation)
time
VERBPHARM
Verbal authorisation for pharmacist to give out treatment 
by HA
1=yes 2=No
DATVERBPHARM Date verbal authorisation given by HA DD/MM/YY
DATVERBPHARM Time verbal authorisation given time
VERBPHARMBY HA who gave verbal authorisation Text
DATPHARM
Date that link is clicked in pharmacy email to say that 
patient has collected treatment
DD/MM/YY
DATPHARM
Time link is clicked in pharmacy email to say that patient 
has collected treatment
time
PACKDIS Antibiotics dispensed 1 =Yes 2=no
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Section Parameter/Field Name Description Coding
USABSTARTDAT Date Index/SP accessed usability survey DD/MM/YY
USABSTARTDAT Date Index/SP completed usability survey DD/MM/YY
USABFINDAT Time started survey Time
USABFINDAT Time completed survey Time
USABQ1
I felt I received a high quality service through the esexual 
health clinic
1=strongly disagree, 2=disagree,3=neither agree or 
disagree,4=agree,5 strongly agree,6=NA
USABQ2
The appearance of the esexual health clinic was 
professional
1=strongly disagree, 2=disagree,3=neither agree or 
disagree,4=agree,5 strongly agree,6=NA
USABQ3
The esexual health clinc was easy to use 1=strongly disagree, 2=disagree,3=neither agree or 
disagree,4=agree,5 strongly agree,6=NA
USABQ4
It is easy to lose track of where you are in the esexual 
health clinic consultation
1=strongly disagree, 2=disagree,3=neither agree or 
disagree,4=agree,5 strongly agree,6=NA
USABQ5
Recovering from mistakes in the esexual health clinc was 
quick and easy
1=strongly disagree, 2=disagree,3=neither agree or 
disagree,4=agree,5 strongly agree,6=NA
USABQ6 It wasn't always clear what information I should enter 
within the esexual health clinic consultation
1=strongly disagree, 2=disagree,3=neither agree or 
disagree,4=agree,5 strongly agree,6=NA
USABQ7
It was clear how I could get help offline when using the 
esexual health clinic
1=strongly disagree, 2=disagree,3=neither agree or 
disagree,4=agree,5 strongly agree,6=NA
USABQ8
Overall I am satisfied with my experience of using the 
esexual health clinic
1=strongly disagree, 2=disagree,3=neither agree or 
disagree,4=agree,5 strongly agree,6=NA
INHEALTHPRO
Clicked to access health promotion on negative page 
(negative only )
1 = clicked 2 = not clicked
NEGINFOCHLAM Clicked link 'Find out more about chlamydia' (positive & negative )1 = external link clicked         2 = external link not clicked 
NEGINFOINFEC
Clicked link 'Get checked for other infections' (positive & 
negative )
1 = external link clicked         2 = external link not clicked 
NEGSAFE
Clicked link 'How to keep yourself safe' (positive & 
negative )
1 = external link clicked         2 = external link not clicked 
NEGCONT Clicked link 'Contraception' (positive & negative ) 1 = external link clicked         2 = external link not clicked 
NEGABUS
Clicked link 'Had sex against your will or in an abusive 
relationship' (positive & negative )
1 = external link clicked         2 = external link not clicked 
TICKNEGSURVEY Agree to answer short survey (negative only ) 1 = clicked 2 = not clicked
NEGSRTEST
Was this the first time you have been tested for 
chlamydia? (negative only )
1 = yes 2 = no 
NEGSRPVRES_1
Previously got test results via text message (negative 
only )
1= ticked             2 = not ticked
NEGSRPVRES_2 Previously got test results via phone call (negative only ) 1= ticked             2 = not ticked
NEGSRPVRES_3 Previously got test results via letter (negative only ) 1= ticked             2 = not ticked
NEGSRPVRES_4 Previously got test results via email (negative only ) 1= ticked             2 = not ticked
NEGSRPVRES_5
Previously got test results via other method (negative 
only )
1= ticked             2 = not ticked
NEGSRCOMPARE
Thought the way they got result this time was (negative 
only )
1 = Much better      2 = better                    3 = About the same                         
4 = worse                              5 = much worse
NEGSRFUT
Would you be happy to get your results this way in the 
future (negative only )
1 = yes 2 = no
NEGSRCOM
If you have any comments please write them in this box 
(negative only )
Text
NEGSRRSTXT
Were you happy with the way you were given your 
results? (negative only )
1 = yes 2 = no
NEGSRFUTRST
If your test showed you had chlamydia in the future, 
would you be happy to get your results this way if your 
test was positive (negative only )
1 = yes 2 = no
NEGSRPREF_1
Rather have got result via an email with a link to access 
results instead of text (negative only )
1 = yes 2 = no
NEGSRPREF_2
Rather have had a text saying 'the result of your chlamydia 
test is negative/positive. You do not/do have chlamydia 
(negative only )
1 = yes 2 = no
NEGSRPREF_3
Rather have had an email saying 'the result of your 
chlamydia test is negative/positive. You do not/do have 
chlamydia (negative only )
1 = yes 2= no
NEGSRPREF_4 Rather have had result via another way (negative only ) 1 = yes 2= no
NEGSRPREF_5
Way he/she would have preferred to get their result 
(negative only )
Text
NEGSRCOMENT
Other way px would have preferred to get result (only 
patients who have ticked NEGSRPREF_4 )
Text
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Section Parameter/Field Name Description Coding
Date logged on Date health adviser (HA) logged on  DD/MM/YY
Time logged on Time HA logged on Time
Date Logged off Date HA logged off DD/MM/YY
Time logged off Time HA logged off Time
Date follow-up started Date HA started follow-up DD/MM/YY
Time follow-up started Time HA started follow-up Time
Date clinical follow-up finished
Date HA finished clinical follow-up (i.e. answered 
DISCUSSION SPFREETEXT)
DD/MM/YY
Time clinical follow-up finished
Time HA finished clinical follow-up (i.e. answered 
DISCUSSION SPFREETEXT)
Time
Date follow-up finished
Date HA finished follow-up (i.e. answered QUALINT or 
PERMFURESEA)
DD/MM/YY
Time follow-up finished
Time HA finished follow-up (i.e. answered QUALINT or 
PERFURESEA)
Time
Name of HA doing follow-up Name of HA doing follow-up Name
Follow-up completed Completed follow-up 1= Yes 2=No
IDATEFU SPDATEFU Date of each separate followup call for a given followup.
DD/MM/YY
IDATEFU SPDATEFU Time of each separate followup call for a given followup.
Time
INEXTREATED SPTREATED Index patient/SP treated 1 Yes 2 No
IWHENTREAT SPWHENTREAT When index patient/SP treated
1 = Same day as received result 2 = 1 day after receiving 
result 3 = 2 days after receiving result 4 = 3 days after 
receiving result 5 = 4 days after receiving result 6 = 5 days 
after receiving results 7 = 6 days after receiving results 8 = 
7 days after receiving results 9 = >1/52 after receiving 
results 
IWHERETREAT SPWHERETREAT
Where index patient/SP treated 1 = Via online clinical consultation at chosen pharmacy 2 = 
in a sexual health clinic 3 = at GPs 4 = at pharmacy 5 = 
Family planning clinic/CASH 6 = Other - free text 
IWHERETREAT_6 
SPWHERETREAT_6
Where index patient/SP treated Text
IVOMIT SPVOMIT Vomited within 2 hours of taking Azithromycin 1 = yes 2 = no
IRETREAT SPRETREAT
Has patient been retreated 1 = yes 2= no
ISIDEEF SPSIDEFFECT Any other problems/side-effects with treatment 1 = Yes 2 = no
ISIDEEF_1 SPDESSEFFEC Nature of problem/side-effect Text
IINTERCOUR SPINTERCOUR Any sexual intervourse within 1 week of treatment 1 = yes 2 = no
INTERUNTRPT SPINTUNTREAT
Any sexual intercourse with untreated/inadequately 
treated partner 
1 = yes 2= no
IWHERERETREAT SPRETREAT When will they go for retreatment and where Free text
FURFUREQ Further follow-up required 1 = yes    2= no
SPMETHPN
Method contact notified by index 1 = Face to face 2 = By phone 3 = Txt only 4 = Email only 5 = 
Face to face & text 6 = Face to face & email 7 = By phone & 
text 8 = text & email 9 = facebook 10 = other - free text 
SPMETHPN_10 Other method used by index to contact index Text
IHEALTHPROM SPDISCUSS
Discussion around any symptoms ticked on online 
consultation  (only if symptoms ticked on online 
consultation )
 (data item 4a)  free text box
ISYMRESOLVED SPSYMRESOLVE
Symptoms resolved (only if symptoms ticked on online 
consultation )
1 = yes 2 = no 3 = some improvement but still present
IADVICE SPADVICE
Did index patient/SP seek advice on their symptoms  
(only if symptoms ticked on online consultation )
1=yes 2 -no
IWHEREADVI SPADVWHERE
Where index patient/SP sought advice on their symptoms 
(only if ticked yes to IADVICE SPADVICE )
1 = sexual health clinic 2 = GP 3 = 111 telephone service 4 = 
clinical helpline 5 = other - free text 
IWHEREADVI_5   
SPADVWHERE_5
Where index patient/SP sought advice on their symptoms - 
other (only if ticked yes to IADVICE SPADVICE )
 text
IANYADVI SPANYADVICE 
Other information gathered/advice given (only if ticked 
yes to IADVICE SPADVICE )
Text
IDISCUSSHIV SPDISCUSSHIV
Discussion about risk factors HIV/STS/Hep B testing (only 
if ticked yes to MSMPART, INJDRUG, PAIDSX, SXCOUNTRY, 
HEPB )
 text 
INOPARTNER
Number of sex partners in the last 6 months ( index patient 
only; populated from SEXPART MSEXPART )
Numerical 
PINGIVEN
Did index given PIN & link to online clinical consultation 
to partner/s
1=yes 2=no 3=Dropped off consultation before PN section 
4. Chose not to receive PIN & link
PINUNDERSTAND
(If yes to PINGIVEN ) Did index patient understand how 
the PIN & link was to be used
1=yes 2=no
PINUNDERSTANDDET If no to PINUNDERSTAND , free text box Text
REASONPINNOT
If no to PINGIVEN , reason why PIN and link not given to 
partner/s
1. Deleted text/email prior to informing partner; 2. Too 
embarrassed; 3. partner not interested in online method; 
4. Forgot to forward text; 5. Forgot to forward email; 6. 
Didn't understand what PIN and link were for; 7. Other 
REASONPINNOTOTH If 7 to REASONPINNOT , free text box Text
REASONPINNOTGET
If 4 to PINGIVEN , reason why index decided not to get PIN 
& link
1. Didn't understand how it would work; 2. Preferred to let 
partner/s know by other method; 3. Other
REASONPINNOTGETOTH If 3 to REASONPINNOTGET , free text box Text
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Section Parameter/Field Name Description Coding
TEXTOK_1 Index happy with result text message   1. Ticked 2. Not ticked
TEXTOK_2 Index would have preferred an email 1. Ticked 2. Not ticked
TEXTOK_3
Index would have preferred the text message told them 
their result
1. Ticked 2. Not ticked
TEXTOK_4 Text message wasn't clear (index patient only ) 1. Ticked 2. Not ticked
TEXTOK_5 Other reason index wasn't happy with text message Free text
PARTNER_TEXTOK_1
SP happy with the message he/she received informing 
him/her that he/she could access treatment online? 
1. Ticked 2. Not ticked
PARTNER_TEXTOK_2 SP felt that the text message wasn't clear 1. Ticked 2. Not ticked
PARTNER_TEXTOK_3 SP felt that the text message was too blunt 1. Ticked 2. Not ticked 
PARTNER_TEXTOK_4 Other reason SP wasn't happy with text message Free text
PARTNER_TEXTOK_5 Not applicable 1. Ticked 2. Not ticked
RESINFOAMT
When you accessed your results, did you think the amount 
of information you were given was 
1.       Not enough 2. About right 3. too much 4. not 
applicable
EASYOCC
How easy did you find the questions in the online clinic to 
complete?
1. Very Easy 2. Easy 3. Neither easy nor difficult 4. Difficult 
to understand 5. Very difficult to understand 6. Not 
applicable
COMFORTOCC
How comfortable did index/SP feel answering questions 1. Very comfortable 2. Comfortable 3. Neither 
Comfortable nor uncomfortable 4. Uncomfortable 5. Very 
uncomfortable 6. Not applicable
COMFOCCFTF
How comfortable index/SP was answering questions 
compared to answering face-to-face with a doctor or 
nurse
1.       Much more comfortable online compared to face-to-
face 2. more comfortable online compared to face-to-face 
3. About the same 4. Less comfortable online compared to 
face-to-face 5. Much less comfortable online compared to 
face-to-face 6. Not applicable
INFOOCCAMT
Index/SP thought that the amount of information given in 
the online clinic was
1.       Not enough 2. About right 3. too much 4. not 
applicable
INFOOCCOK
Index/SP felt that this information was 1. Very easy to understand 2. Easy to understand 3. 
Neither easy nor difficult to understand 4. Difficult to 
understand 5. Very difficult to understand 6. Not 
applicable
FREETXTOK Any other comments spontaneously made by index/SP Free text
CLINHELP Did index/SP use clinical helpline 1. Yes 2. No 
HELPFUL Did index/SP find clinical helpline helpful 1. Yes 2. No 3. Unable to remember
NOTHELPFUL
Why index/SP did not find clinical helpline helpful 1. Opening hours to restrictive 2. Unable to answer 
question/query 3. Other reason 
NOTHELPFUL_3
Other reason why index/SP did not find clinical helpline 
helpful
Free text
PREVCHLAM Has index/SP had chlamydia before this episode 1. Yes 2. No
OCCOMPARERES
How did the online results system compare to the last 
experience of getting results (index patient  only )
1. Much better 2. Better 3. About the same 4. Worse 5. 
Much worse
METHAGAIN
Would index patinet use this method of accessing their 
results again (index patient only )
1. Yes 2.No 3. Unsure
OCCOMPARETREAT
How did using the online clinic to get antibiotic treatment 
compare to your last experience of getting antibiotics 
(index patient & SP )
1. Much better 2.Better 3.About the same 4. Worse 5. 
Much worse 6. Not applicable
ACCESSAGAIN
Would you use this method of accessing your antibiotic 
treatment again? (index patient & SP )
1. Yes 2. No 3. Unsure
HOWACCOCC_1 Accessed online clinic using mobile phone 1. Ticked 2 Not ticked
HOWACCOCC_2 Accessed online clinic using desktop computer 1. Ticked 2 Not ticked
HOWACCOCC_3 Accessed online clinic using laptop 1. Ticked 2 Not ticked
HOWACCOCC_4 Accessed online clinic using tablet/ipad 1. Ticked 2 Not ticked
HOWACCOCC_5 Accessed online clinic using other combination 1. Ticked 2 Not ticked
HOWACCOCC_5_TEXT Other combination used to accesse online clinic Free text
PREFACE
Would you  rather have had a face-to-face consultation 
with a doctor or nurse
1. Yes 2. No 3. Unsure
PREFACE_1
Any comments on why index patient/SP would rather had 
a face-to-face consultation 
Free text
PROBPHARM Any problems getting treatment from pharmacy 1. Yes 2. No 3. Not applicable
PROPPHARM_1 Description of problems with pharmacy Free text
RECOMMEND
Would index patient/SP recommend the online clinic to 
friends?
1. Yes 2. No 3. Unsure
RATECARE
Overall, how would you rate the care you received via the 
online clinic
1. Excellent; 2. Very good; 3. Good; 4.Fair; 5. Poor;  6. Very 
poor
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The human computer interface researcher then converted the specification into a wireframe (a 
screen blueprint) to illustrate how we wanted the interface to look. The senior researcher and 
I were closely involved in the development of this, providing detailed feedback to ensure that 
the wireframe reflected the specification and our needs. During this time I assisted the senior 
researcher with the development of the software specification. The software  
 
Section Parameter/Field Name Description Coding
OLD_EASYOCC
How easy did you find the questions in the online clinic to 
complete?
1. Very Easy 2. Easy 3. Neither easy nor difficult 4. Difficult 
to understand 5. Very difficult to understand
OLD_COMFORTOCC
How comfortable did you feel answering these questions 
online
1. Very comfortable 2. Comfortable 3. Neither 
Comfortable nor uncomfortable 4. Uncomfortable 5. Very 
uncomfortable
OLD_INFOOCCAMT
Did you think the amount of information you were given 
throughout the online consultation was
1.       Not enough 2. About right 3. too much 
OLD_INFOOCCUND 
Did you thin the information you were given throughout 
the online consultation was
1. Very easy to understand 2. Easy to understand 3. 
Neither easy nor difficult to understand 4. Difficult to 
understand 5. Very difficult to understand 
OLD_FREETXTOCC
Any other comments spontaneously made by index 
patient on results service or online consultation
Free text
OLD_TEXTOK_1 Thought the text message was okay 1 = ticked 2 = not ticked
OLD_TEXTOK_2 Index patient would have preferred to have an email 1 = ticked 2 = not ticked
OLD_TEXTOK_3
Index patient would have preferred a text which told 
him/her the result
1 = ticked 2 = not ticked
OLD_TEXTOK_4 Text message wasn't clear (index patient only) 1 = ticked 2 = not ticked
OLD_TEXTOK_5
Other reason text message wasn't clear (index patient 
only)
Free text
OLD_PARTNER_TEXTOK_1
SP happy with the message he/she received informing 
him/her that he/she could access treatment online? 
1. Ticked 2. Not ticked
OLD_PARTNER_TEXTOK_2 SP felt that the text message wasn't clear 1. Ticked 2. Not ticked
OLD_PARTNER_TEXTOK_3 SP felt that the text message was too blunt 1. Ticked 2. Not ticked 
OLD_PARTNER_TEXTOK_4 Other reason SP wasn't happy with text message 1. Ticked 2. Not ticked
OLD_PARTNER_TEXTOK_5 Other reason SP wasn't happy with text message Free text
OLD_CLINHELP Did index/SP use clinical helpline 1. Yes 2. No 
OLD_HELPFUL Did index/SP find clinical helpline helpful 1. Yes 2. No 3. Unable to remember
OLD_NOTHELPFUL
Reason index/SP didn't find clinical helpline helpful 1. Opening hours to restrictive 2. Unable to answer 
question/query 3. Other reason 
OLD_NOTHELPFUL_3
Other reason index/SP didn't find clinical helpline helpful Free text
OLD_PREVCHLAM Has index/SP had chlamydia before this episode 1. Yes 2. No
OLD_OCCOMPARERES
How did using online clinical consultation compare to last 
experience of getting results (index patient only )
1. Much better 2. Better 3. About the same 4. Worse 5. 
Much worse
OLD_METHAGAIN
Would index patient use this method of accessing their 
results again (index patient only)
1. Yes 2.No 3. Unsure
OLD_OCCOMPARETREAT
How did using online clinical consultation compared to 
index patients's last experience of getting treatment 
(index patient only)
1. Much better 2.Better 3.About the same 4. Worse 5. 
Much worse
OLD_ACCESSAGAIN
Would index/SP use this method of accessing treatment 
again?
1. Yes 2. No 3. Unsure
OLD_HOWACCOCC
How did index/SP access the online consultation? 1. Mobile phone 2.Desktop computer/Laptop 3. 
Tablet/ipad 4. Combination
OLD_HOWACCOCC_4 Combination used to access online consultation Free text
OLD_PREFACE
Would index px/SP have preferred to have a face-to-face 
consultation with a doctor/nurse than use the online 
clinical consultation?
1. Yes 2. No 3. Unsure
OLD_PREFACEDETAILS
Why index px/SP would have preferred to have a face-to-
face consultation than use the online clinical consultation
Free text
OLD_PROBPHARM 
Did index patient/SP have any problems getting 
treatment at the pharmacy?
1. Yes 2. No 3. Not applicable
OLD_PROPPHARM_1 What problem/s did index patient/SP have at pharmacy Free text
OLD_RECOMMEND
Would index patient/SP recommend the eSexual Health 
Clinic to friends?
1. Yes 2. No 3. Unsure
OLD_RESINFOOK
Do you think this information was 1. Very easy to understand 2. Easy to understand 3. 
Neither easy nor difficult to understand 4. Difficult to 
understand 5. Very difficult to understand 6. Not 
applicable
Q
u
e
st
io
n
s 
th
a
t 
w
e
re
 a
m
e
n
d
e
d
 o
r 
re
m
o
ve
d
 d
u
ri
n
g
 t
h
e
 s
tu
d
y 
a
s 
p
a
rt
 o
f 
it
e
ra
ti
ve
 d
e
ve
lo
p
m
e
n
t
276 
 
STEP 1 STEP 2 STEP 3 STEP 4 STEP 5 STEP 6 STEP 7 STEP 8 STEP 9
 
specification included a description of the accessibility testing that we required the software 
engineers to undertake prior to deployment of the live system. 
Once we were happy with the wireframes and specifications, these were sent to the software 
engineers who developed a demonstration system for us to test. The human computer 
interface testing and further comprehension testing is described in Step 8 below. However, the 
senior researcher and I also needed to check that the screens were accurate, that the correct 
messages came up, that the logic was correct and that it was coding correctly. This was an 
iterative process which involved close communication with the software engineers.  
STEP 8: USABILITY TESTING AND FURTHER COMPREHENSION 
TESTING 
A high fidelity mobile application was developed from the finalised online clinical consultation 
by the human computer interface researcher. This was evaluated by laboratory-based usability 
testing with volunteers from Brunel University. Users were asked to work their way through 
the mobile application, without prompting, and to express their thoughts, questions and ideas 
aloud. The human computer interface researcher then fed back her findings and both the 
senior researcher and I made necessary amendments to the online clinical consultation. 
STEP 9: PILOTING OF THE ONLINE CLINICAL CARE PATHWAY 
The online clinical care pathway was piloted between 21st July 2014 to 13th March 2015 in an 
exploratory study of patients diagnosed with chlamydia in both a clinical and non-clinical  
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STEP 1 STEP 2 STEP 3 STEP 4 STEP 5 STEP 6 STEP 7 STEP 8 STEP 9
  
(internet-requested testing via the NCSP) setting.  Once the live system deployed, continued 
development of the front end and back end was required as different issues, which had not 
been foreseen, arose. Examples of these issues and the solutions I came up with are listed in 
Table 68 below. 
Table 68: Examples of issues that arose during the exploratory study. 
Issue Solution 
Health adviser interface not fit 
for purpose 
I worked closely with the research health adviser to make 
the necessary changes. This was an iterative process that 
continued for the majority of the study. The research 
health adviser supplemented the interface with additional 
excel spreadsheets. These will be incorporated into the 
back-end as part of any future trial.   
Two NCSP sites started dual 
testing for gonorrhoea,  which 
meant that 5 out of 6 sites were 
now providing dual testing 
I changed the results page so that patients received 
accurate information on the results of their test; this 
required different results pages depending on whether the 
patient had tested in a GUM clinic or NCSP site, and which 
NCSP site they had tested at.   
When St George’s GUM clinic 
came on board it became 
apparent that they had a 7 digit 
results number which they 
would not be able to log in with 
I arranged for St George’s patients to log in using the same 
method as the NCSP patients – i.e. with their mobile 
number and date of birth 
Pharmacists were having issues 
with not being able to log in to 
their nhs.net account to retrieve 
the authorisation email 
I suggested that the research health adviser provide verbal 
authorisation so that the patient could be given the 
treatment. In order for this to be recorded on our system, I 
asked the software engineers to add a tab on the health 
adviser screen that they could press if they verbally 
authorised treatment.  
Some patients coming off the 
pathway wanted to attend their 
GP or a non-study clinic  
I developed a letter that the HA could email to the patient 
which they could give to their GP or to the HCP in clinic. 
 
Every time that we changed anything with the system I updated the specification and export 
datasheet, and checked that the coding for the changes were correct on the demo system 
before it was deployed to the live system.  
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The Chlamydia-OCCP study will be evaluated using quantitative and qualitative methods which 
are discussed in Chapter 6.  
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Chapter 6: Development of 
methods to determine whether the 
eSTI2 Chlamydia online clinical 
care pathway is feasible, acceptable 
and safe, throughout an 
exploratory clinical study  
 
 
 
 
 
 
 
 
 
 
 
 
1. INTRODUCTION 
As previously described, the eSTI2 chlamydia online clinical care pathway pilot study is a proof 
of concept, exploratory study designed to evaluate the feasibility, safety and efficacy of a novel 
online care pathway for people testing for chlamydia and people who are found to have a 
positive chlamydia test result. It comprises an online results service, clinical consultation, 
partner notification and antibiotic authorisation to community pharmacies. It is a highly 
innovative model of care within the current NHS and offers the possibility for an entirely 
remote patient journey which involves diagnosis of a new condition and its subsequent 
This chapter is composed of the following sections: 
1. Introduction 
2. Literature review 
3. Proposed evaluation methods  
4. Quantitative evaluation tools 
5. Summary of patient involvement 
6. Discussion 
280 
 
management, including remote prescribing for a person not previously known to the 
responsible clinician. Although this has the potential to increase access to care, integrate care 
between different services, and facilitate patients to access appropriate management in an 
efficient manner, there is also the risk of harm (363;364). Thorough evaluation of the care 
pathway is therefore of paramount importance (363-365). The pathway is multi-faceted and 
evaluation must address each subunit of the pathway as far as is feasible(314). 
The design and evaluation of eHealth interventions, which are by their nature complex 
interventions(366), are multifarious and often expensive(367). It is therefore important that 
new eHealth intervention’s benefits outweigh any harm for patient-important outcomes 
(367;368). With the exception of some high quality behavioural interventions, both within 
sexual health and HIV (190;369-372) and in other specialities (190;366;373;373-378), many of 
the eHealth methods / interventions used within healthcare today have been introduced 
without robust evaluation and lack an evidence base to support their implementation and use 
(5;39). Atienza et al acknowledge that ‘research and evaluation methodologies have not kept 
pace with the rapid evolution and proliferation of health information and communication 
technologies’(379).  
Currently there is a dearth of appropriate fit-for-purpose standards and guidelines for 
development of online clinical care pathways and e-Health interventions (379;380), and there 
is no mode of accreditation. Although CONSORT-EHEALTH standards exist, they have been 
developed for online randomised controlled trials and are more applicable to behavioural 
interventions than clinical care pathways (366).   
The Chlamydia-OCCP has been developed in line with the Medical Research Council developing 
and evaluating complex interventions guidance(381). The second phase of the development-
evaluation-implementation process that the MRC guidance describes is the piloting and 
feasibility testing of the intervention. The guidance advises that the questions that need to be 
asked in this phase are: ‘Have you done enough piloting and feasibility work to be confident 
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that the intervention can be delivered as intended? Can you make safe assumptions about 
effect sizes and variability and rates of recruitment and retention in the main evaluation 
study?’(381). The sample size required to make assumptions about the second question was 
calculated by a statistician as part of the development of the protocol for the exploratory 
study.  
In this chapter, I describe how, using available evidence and guidance, I developed new 
methods to establish whether the Chlamydia-OCCP is feasible, acceptable and safe.  This 
evaluative methodology was a major component of my doctoral studies. Cost-effectiveness is 
clearly an important factor in terms of the feasibility of the Chlamydia-OCCP.  A cost-
consequence analysis is being performed by another eSTI2 PhD researcher and discussion of 
this is beyond the scope of my PhD.  
2. LITERATURE REVIEW 
 
A literature review failed to find any specific online guidance so I conducted a further search of 
the evaluation and validation of “traditional” clinical care pathways aiming to retain a focus on 
online or remote pathways as far as feasible. I conducted this using the same methods 
described in Chapter 2. Initially I searched the literature for evaluation and validation of clinical 
care pathways Only limited applicable literature was found using this strategy as, although 
there are some core principles of pathway development (e.g. incorporation of guidelines, and 
involvement of users at key stages) that need to be incorporated irrespective of whether the 
pathway is in a traditional clinical setting or online and therefore remote, online pathways are 
eHealth interventions and therefore are complex interventions which require a completely 
different approach as discussed below. Therefore,  I applied the same search strategy to each 
individual component of the pathway along with evaluation of eHealth interventions (see 
Appendix II). 
282 
 
Protocol driven search 
I conducted an electronic search of MEDLINE, EMBASE, and The Cochrane Library using the 
NHS Evidence database thesaurus terms in Table 69: 
Table 69: NHS Evidence database thesaurus terms for review of literature on online clinical 
consultation 
Ambulatory care/methods Health informatics 
Critical pathway Interview as topic 
Clinical protocol Medical history taking 
Computer Online systems 
Contact tracing Program evaluation 
Data collection Remote  consultation 
Decision making Reproducibility of results 
Decision support systems, clinical Sexually transmitted diseases/diagnosis 
Electronic prescribing Telemedicine 
Evaluation studies as topic Validation studies as topics 
 
Appendix II shows the search strategy conducted using the above NHS Evidence thesaurus 
terms and free text. I searched official Government, NHS and Professional Association 
websites, including existing professional guidance. I then searched Google and Google Scholar 
to capture both medical and grey literature that had been missed in the above searches. I used 
both reference and citation tracking to widen the scope of relevant, high quality, sources 
found.  
I was unable to find any suitable methods describing techniques, protocols or methods that 
could be directly applied to evaluate and validate the type of online care pathway we have 
developed. However, there was both medical and grey literature that covered evaluation of 
eHealth interventions. I will discuss this in turn below.   
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Mainstream literature 
 
The medical literature is divided into articles on clinical care pathways and articles on eHealth 
and complex interventions, with very little cross-over between the two. I found that the 
former held little information of relevance to the type of clinical care pathway that we have 
developed, i.e. an online STI pathway taking someone from a new diagnosis through to 
treatment, remote from traditional care. I have therefore focussed on the eHealth and 
complex intervention literature, which mainly contains articles from the UK and USA. These 
are summarised in Table 70 below.
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Table 70: Relevant literature on eHealth evaluation 
Ref First author Year 
published 
Country Source focus Source type Findings and recommendations 
1 Talmon(382) 1999 Netherlands, Spain, 
Germany, Finland, 
France 
The VATAM guidelines Review ‘Describes the background of the VATAM project and provides 
an account of the current state of the guidelines’(382) 
2 Ammenwerth 
(363) 
2003 Austria and 
Germany 
Evaluation of health 
information systems – 
problems and 
challenges 
Research article Defines the key problem areas with evaluation of health 
information technology and recommends the development of 
an evaluation framework 
 Ammenwerth(383) 2004 Austria, Denmark, 
Finland, Germany, 
UK, The 
Netherlands 
Visions and strategies to 
improve evaluation of 
health information 
systems 
Reflections and 
lessons based on 
the HIS-EVAL 
workshop in 
Innsbruck 
Describes typical evaluation questions, problems and barriers 
to evaluation. Summarises previous work addressing these 
issues. Suggests visions and strategies for the future and 
implementation activities.    
3 Gustafson (384) 2004 UK Evaluation of ehealth 
systems and services 
Editorial Discusses the need to evaluate users needs, the risks/benefits 
of the intervention/product, feasibility, usability, cultural 
sensitivities, acceptability and cost effectiveness.  
4 Dansky(385) 2006 USA A framework for 
evaluating eHealth 
research 
Framework based 
on two examples 
Describe four key, integrated, aspects of eHealth evaluation: 1. 
Design and methodology issues; 2. Challenges related to the 
technology itself; 3. Environmental issues that are not specific 
to eHealth but pose special problems for eHealth researchers; 
4. Logistic or administrative concerns of the evaluation 
methodology. 
5 May(386)  2006 UK A rational model for 
assessing and 
evaluating complex 
interventions in health 
care 
Research article Examine how complex interventions can become integrated 
into traditional clinical and organisational practice. Suggest the 
need to concurrently examine an intervention’s: workability; 
ability to be integrated; professional practice.  Article proposes 
the normalization process model to facilitate this.  
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Table 70 continued 
Ref First author Year 
published 
Country Source focus Source 
type 
Findings and recommendations 
6 Yusof(387) 2008 Malaysia 
UK 
Investigating evaluation 
frameworks for health 
information systems 
Review Review of evaluation frameworks in health informatics and information 
systems. Many evaluation studies either adopt a human and organizational 
issues approach or take a subjectivist approach. A more comprehensive and 
specific evaluation framework would be useful.  
7 Turner(388) 2008 UK An evaluation of the accuracy 
and safety of NHS pathways 
Report In appendices, discusses methods used to evaluate the accuracy and safety of 
pathways. This includes both internal and external clinical review, electronic 
pathways review tool, ‘bench testing’, feedback from users on content, 
user/site feedback on usability, scenario testing, piloting, and amendment 
process 
8 Catwell and 
Sheikh(389) 
2009 UK Evaluating eHealth 
Interventions:  the need for 
continuous systemic 
evaluation 
Framework  Schematic for simplified evaluation process that allows continuous evaluation 
of an eHealth intervention through the four stages of its lifecycle (inception; 
requirements and analyses; design, develop and test; implement and deploy) 
9 Lilford et al(390) 2009 UK Evaluating eHealth: How to 
make evaluation more 
methodologically robust 
Essay Evaluation of eHealth systems often requires both a quantitative and 
qualitative approach. Advice observations at patient and system level. Discuss 
internal and external assessment, formative and summative evaluation.  
Developed a schematic causal chain showing levels where IT may impact and a 
schematic representation of development and deployment of IT systems.  
10 Medical 
Research 
Council(381) 
2010 UK Developing and evaluating 
complex interventions 
Guidance Describe ‘The development-evaluation-implementation process’. Framework 
consisting of: 1. What makes an intervention complex; 2. The development-
evaluation-implementation process’; 3. Developing a complex intervention; 4. 
Accessing feasibility and piloting methods; 5. Evaluating a complex 
intervention; 6. Implementation and beyond  
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Table 70 continued 
Ref First author Year 
published 
Country Source focus Source type Findings and recommendations 
11 Cummings and 
Turner(391) 
2010 Australia Patients at the Centre: 
Methodological 
Considerations for 
Evaluating 
Evidence from Health 
Interventions Involving 
Patients Use of Web-
Based 
Information Systems 
 
Review Focus ‘on the socio-technical processes by which patients’ 
interests and outcomes are measured, defined and evaluated 
within health interventions that involve them using web based 
information systems’. They describe ‘an integrated approach that 
aims to generate evidence about the impact of these types of 
health interventions that are meaningful at both individual 
patient and patient cohort levels’. 
 
12 Nykanen(364) 2011 Finland, Denmark, 
The Netherlands, 
UK, France, Austria 
Guideline for good 
evaluation practice in 
health informatics 
Guidance Describe 6 phases of evaluation: 1. Preliminary outline; 2. Study 
design; 3. Operationalization; 4. Project planning; 5. Execution of 
the evaluation study; 6. Completion of the evaluation study  
13 Brender(365) 2013 Denmark, 
Netherlands, 
Finland, UK, 
Austria 
STARE-HI – Statement on 
Reporting of Evaluation 
Studies in Health 
Infromatics 
Explanation and 
exploration of 
STARE-HI guidance 
Provides examples and elaborates each component of the STARE-
HI statement 
14 Khoja(242) 2013 Kenya, 
Afghanistan, 
Canada 
Conceptual Framework 
for Development of 
Comprehensive e-Health 
Evaluation Tool 
Framework based 
on different theories 
of evaluation 
applicable to e-
Health 
Khoja-Durrani-Scott Framework for eHealth evaluation. 7 
evaluation themes identified: health service outcomes; 
technology outcomes; economic outcomes; behavioural and 
sociotechnical outcomes; ethical outcomes; readiness and 
change; policy outcomes. These were tabulated against the four 
stages of the eHealth life cycle (development; implementation; 
integration; sustained operation). From this, four separate 
evaluation tools were developed for the four stages of the 
eHealth life cycle (not covered in this article) 
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Table 70 continued 
Ref First 
author 
Year 
published 
Country Source focus Source type Findings and recommendations 
15 Kumar et 
al(392) 
2013 USA Mobile Health 
Technology 
Evaluation 
Summary of the mHealth 
Evidence Workshop 2011 
Three areas covered: 1. Evaluating assessments; 2. Evaluating interventions; 
3. Reshaping evidence generation using mHealth. 
Mobile technology define as wireless devices and sensors (including mobile 
phones) that are intended to be worn, carried, or accessed by the person 
during normal daily activities. 
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The MRC has developed guidance on developing and evaluating complex interventions. As 
mentioned, the Chlamydia-OCCP was developed following this guidance and it was an 
important source of information when evaluating the available evidence base. Although not 
specifically developed for use with eHealth interventions, as eHealth interventions are by their 
nature complex interventions, this guidance was a useful adjunct to other relevant literature. 
The guidance provides information on the development, evaluation and implementation 
process, with case studies to illustrate their points(381).  
Dansky et al state in their introduction to their paper entitled ‘a framework for evaluating 
eHealth research’ that ‘this article does not endorse specific designs, methods or approaches 
for conducting eHealth research’(385). The same can be said about much of the literature on 
evaluating eHealth interventions. One of the main reasons for this is the diverse nature of 
eHealth (363;364). Therefore, although there is guidance available, it is often non-specific with 
Yusof et al concluding that ‘existing evaluation methods do not provide explicit evaluation 
categories’(387) and  Cummings and Turner observing that ‘evaluation of different health 
information systems requires different methodologies’(391). Ammenworth et al recommend a 
flexible approach to evaluation, reflecting the length of time it can take to implement, adapt to 
and exploit novel IT systems, and the ‘moving evaluation target’ (the continued adaption of 
the evaluation object throughout the lifecycle of the implementation)(363;393;394).   
There is general agreement that ‘continuous systematic multifaceted evaluations’(389), which 
are in-depth and continued throughout the development, implementation and operation, of 
eHealth interventions are required(242;364;381;382;395). The most useful papers in terms of 
providing practical guidance as to how an evaluation of an online system can be undertaken 
was provided by Ammenwerth et al(363) and Turner et al(388). For the latter, paradoxically 
this information was in the appendices of their report on the evaluation of the accuracy and 
safety of NHS pathways in an ambulance service operational setting. They describe how 
different methods were employed in order to do this, including frequency that different 
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answers to questions were selected, timings, ‘bench-testing’, clinical review and service 
performance analysis(388).  Although these pathways are designed to be used via the 
telephone, and therefore involve human contact, the methods used can be extrapolated for 
use in evaluating an eHealth pathway. Ammenwerth et al take a pragmatic approach to 
reviewing the challenges of evaluating IT systems.  They first list the questions and problems 
commonly encountered when evaluating an eHealth study, and then describe, provide an 
analysis of, and possible solutions for, the three key problem areas they have identified: 
complexity of the evaluation object; complexity of the evaluation project; motivation for 
evaluation(363).  
Murray et al discuss the issues relating to data quality that are present in traditional studies 
and those that are specific to studies conducted online. The latter include the challenges of 
independently verifying the integrity of responses to information provided, including 
demographics, and the effect that changing the mode of delivery has on validated outcome 
measures. Both of these points can affect the validity of the data collected(396).   However, 
one advantage of using an online intervention is that it is possible to make questions 
mandatory which removes the issue of non-response(396).  
Talmon et al developed a set of guidelines (VATAM (validation of telematics applications in 
medicine)) for ‘the assessment of telematics applications in medicine’. Based on existing 
evidence, this was composed of two documents, one describing the VATAM approach, and the 
other providing a knowledge base for users(382). The VATAM website(397), launched in 1996 
to host this information, is no longer accessible. 
In 2011, two sets of guidelines were developed to provide good practice recommendations for 
developing and implementing evaluation studies (GEP-HI(364)) and a framework for reporting 
evaluation studies (STARE-HI(365;398)). In contrast to previous guidelines(387), the former 
was designed to provide guidance on evaluation of all aspects of the lifecycle of a broad 
spectrum of eHealth interventions(364). Nykanen et al propose six iterative phases of 
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evaluation (see Table 70) and stipulate multiple items that should be considered within each 
phrase(364). STARE-HI was developed to attempt to rectify the variability in quality of 
reporting of eHealth evaluation studies (365;398-401).  
In 2008, Black et al noted that there was no consensus as to how complex eHealth 
interventions should be evaluated(5). The field has developed since then and the general 
agreement is that it is vital to adopt a user-centred approach and evaluate all aspects of an 
eHealth intervention across all parts of its life cycle (5;363;364;382;388;391;392). A number of 
authors observe that it is important to take a mixed method approach when evaluating 
eHealth interventions(39;378;384;385;391;400;402;403), with the MRC advocating the same 
approach for complex interventions(381). In addition, the MRC state that it is important to 
both understand any barriers to implementation, as well as monitoring the delivery of and 
being aware of the possibility of unexpected consequences, of a complex intervention(381). 
As the majority of the literature on eHealth evaluations failed to provide the detail required to 
assess the feasibility, acceptability and safety of the Chlamydia-OCCP, I also searched the 
literature on questionnaire development. Prous et al(404) suggest that, as with any 
measurement instrument, a valid questionnaire needs: 
1. Feasibility  (simplicity, viability, patient, user and researcher acceptance) 
2. Reliability and precision (mistake free measurements) 
3. Content validity (adequate for the problem intended for measure) 
4. Construct validity (reflecting underlying theory in the phenomenon or concept to be 
measured)  
5. Sensitivity to change (capable of measuring change, both in different individuals as in 
the response of the same individual through time). 
Weston et al have developed and validated a sexual health clinic patient satisfaction survey. 
This has been designed to be used in traditional sexual health settings and the survey is not 
validated or adapted for use in an online setting. However, it does provide useful guidance in 
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terms of both content for a service evaluation of an online clinic, along with the methods 
employed to validate the survey(405).   
Grey literature 
 
There are several organisations, including the NHS(304) and NICE(304), who accredit clinical 
pathways.  
NHS Pathways is used within the NHS to provide ‘a clinical assessment tool designed to 
provide consistent assessment across all telephone access points’(304). The Health and Social 
Care Information Centre website pages describe how the pathways have been developed, and 
similar methods have been used in the development of this online clinical pathway. NHS 
Pathways is mainly geared towards urgent and emergency care provision, which clinically has 
both similarities and differences to the scenario we describe(304). Although developed to be 
used via phone conversations, the methodology behind the pathways, I believed that the 
methods could be adapted and extrapolated for use online. 
 NICE Pathways is ‘an online tool for health and social care professionals that brings together 
all related NICE guidance and associated products in a set of interactive topic-based 
diagrams’(304). It is designed to facilitate the finding and utilisation of NICE guidance. The only 
NICE guidance applicable to the clinical care pathway that we have developed is ‘Preventing 
Sexually Transmitted Infections and Under-18 Conceptions Overview’(406). NICE pathways do 
not provide any guidance on how to evaluate the interventions from an eHealth perspective.  
Synthesis of findings 
 
 I believed that the optimal approach would be to combine relevant findings from the 
literature search with application of techniques described by Pequegnat et al(407), Murray et 
al(396), Eysenbach(366),  Bailey et al(190), and Scherbatykh et al to strengthen the use of this 
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in an online scenario. Efficacy of the pathway will be established but is outside the remit of my 
doctoral research.  
As recommended by Catwell and Sheikh, the formative evaluation process has been an integral 
part of both the development and implementation of the Chlamydia-OCCP, and will continue 
when the pathway is rolled out in a full-scale trial. As described in chapter 5, the eClinical Care 
Pathway Framework is an iterative process with evaluation at various steps leading to changes 
to different components of the pathway which are then re-evaluated.  
3. PROPOSED EVALUATION METHODS 
 
Synthesising the recommendations from these sources, along with the objectives of the eSTI2 
pilot study, I concluded that the following seven components would provide a wide ranging 
robust approach to evaluating if the chlamydia-OCCP is fit for purpose:  
1. Assessment of acceptability to users  
2. Assessment of time taken to complete 
3. Assessment of the completion rate 
4. Assessment of usability 
5. Assessment of the content and structure of the online clinical consultation 
6. Assessment of users’ comprehension of the online clinical consultation and integrity of 
answers 
7. Safety-related outcomes and detection of adverse effects 
Table 71 below summarises the evidence base for each evaluation method. 
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Table 71: Summary of the evidence base for each evaluation method 
 
 Evaluation method Evidence to support its use  
1 Assessment of acceptability to 
users 
Ammenworth et al (393); Cummings and Turner(391); 
Prous et al (404); Shcherbatykh et al (367); Turner et al 
(388); Medical Research Council(381) 
2 Assessment of the length of 
time it takes users to complete 
the online clinical consultation  
Bowling(402); Lilford et al (390); Prous et al (404) 
3 Assessment of the completion 
rate 
Prous et al (404); Turner et al(388) 
4 Assessment of Usability Ammenworth et al (363); Brown et al (380); Cummings 
and Turner(391); Gustafson (384); Leloch et al(394); 
Shcherbatykh(367); Turner et al (388); Medical Research 
Council(381) 
5 Assessment of the content and 
structure of the online clinical 
consultation 
Gustafson (384); Karras et al (408); Lobach et al(394); 
May (386); Murray et al(396); Prous et al (404); Rothrock 
et al(368); Shcherbatykh et al(367); Turner et al (388); 
Weston et al; Medical Research Council(381)  
6 Assessment of users’ 
comprehension of the online 
clinical consultation and 
integrity of answers 
Ammenworth et al (363); Gustafson (384); Rothrock et 
al(368); Turner et al (388) 
7 Safety-related outcomes and 
detection of adverse effects 
Ammenworth et al (363)Catwell and Sheikh (389);Lilford 
et al (390) Shcherbatykh(367); Turner (388);Medical 
Research Council (381) 
 
Here, I will discuss each of the evaluation methods listed in Table 71, describing evidence for 
and methods used pre- and post- exploratory pilot study commencement. The detail of the 
evaluation approaches pre-implementation of the exploratory study are described in detail in 
Chapter 5. I will discuss the quantitative evaluation methods used post-exploratory study 
commencing in more detail in Section 4 of this Chapter. 
1. ASSESSMENT OF ACCEPTABILITY TO USERS  
Pre-exploratory study commencing 
Prior to the development of the Chlamydia-OCCP, two sets of qualitative research were 
conducted, by two other eSTI2 researchers. These were a planned part of work to which I 
contributed only indirectly. The acceptability of the pathway to young people, a target 
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population, was explored by an eSTI2 researcher using qualitative methodology for semi-
structured interviews at Further Education colleges. This included using an animated ‘mock-up’ 
of the basic pathway, developed by the human computer interface researcher, to give the 
young people an idea of how we envisaged people testing for STIs, accessing their results and 
being managed remotely (228). This information informed the development of the pathway 
and informed the patient important outcomes for evaluation. A human computer interface 
researcher conducted focus groups to inform the design of the mobile application 
interface(181).   
Post-exploratory study commencing  
As well as the methods described in Chapter 3, both quantitative and qualitative post trial 
evaluations of acceptability were conducted. This entailed four separate activities (qualitative 
interviews, quantitative human computer interface evaluation, service evaluation and 
quantitative survey of negative users), two (qualitative interviews and quantitative human 
computer interface evaluation) of which were conducted by other eSTI2 researchers and two 
of which I undertook.  
Qualitative evaluation 
Another eSTI2 PhD student conducted semi-structured qualitative interviews with 
approximately 40 users who consented to the online clinical consultation, focussing on 
acceptability and feasibility.  
Quantitative Human Computer Interface evaluation – patients testing positive for 
chlamydia 
 A human computer interface researcher designed a quantitative survey to evaluate the 
acceptability and usability of the web application interface. We incorporated this short survey 
at the end of the online clinical consultation. It was only completed by users who consented 
and were able to complete the consultation, and was therefore subject to selection bias. 
295 
 
However, as this was an online evaluation of an online intervention, it did help optimise the 
study’s external validity.    
Quantitative service evaluation – patients testing positive for chlamydia  
I designed a quantitative follow-up survey that was administered to all users who consented to 
the online clinical consultation. The development of this is discussed below. Although online 
evaluation of an online trial increases the external validity, and it is usually preferable for 
questionnaires to be self-administered(404), I chose to incorporate the questionnaire into the 
two week health adviser follow-up that was conducted by phone. Reasons for this decision 
included maximising the number of patients who completed the survey. High loss to follow-up 
is common with online surveys(396) with incentives increasing response (402). Although Bailey 
et al achieved a response rate of 72.2% to a three month post-intervention questionnaire, they 
offered financial incentives and this response rate required repeated attempts (maximum of 
five) at follow-up (190). As well as not having a budget to offer financial incentives, our user 
group had been diagnosed with an STI and required clinical follow-up; we felt that it wouldn’t 
be ethical to repeatedly contact them solely to complete an online service evaluation. In 
addition, although the research health adviser follow-up, and therefore the survey, was 
conducted potentially two weeks after the patients had used the system, and would therefore 
be subject to recall bias, in order to capture patients’ experiences of collecting antibiotics from 
pharmacies, and partner notification outcomes, it was necessary to have this time gap. Finally, 
these patients may already have been asked to complete the short human computer interface 
survey at the end of the consultation and, if they fit the sampling frame, would be offered a 
qualitative interview.  
Quantitative evaluation – patients testing negative for chlamydia 
I designed a short online survey for those patients who accessed the results service and tested 
negative for chlamydia. The development of this is discussed in section 4 below. 
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2. ASSESSMENT OF THE LENGTH OF TIME IT TAKES USERS TO COMPLETE THE 
ONLINE CLINICAL CONSULTATION 
 
Pre-exploratory study commencing  
This was assessed as part of the user-centred interface testing (conducted by the human 
computer interface researcher), described in Chapter 5 
Post-exploratory study commencing  
During the exploratory study, time-stamping(363;402) was used to capture the timing of 
various end points in order to inform the length of time that users took to complete the online 
clinical consultation. This was captured as part of the export data sheet and will be analysed in 
terms of both feasibility and cost-effectiveness. The latter will be conducted by the eSTI2 
health economics doctoral student.   
3. ASSESSMENT OF THE COMPLETION RATE  
Post-exploratory study commencing  
Patient outcomes(368;381) were included in the database specification and export data sheet 
(see Chapter 5) and the following was recorded and will be analysed: 
1. Proportion of patients (testing positive and negative for chlamydia) who accessed their 
results using the online results service 
2. Proportion of patients (testing positive for chlamydia) who consented to the online clinical 
consultation 
3. Proportion of patients who completed the online clinical consultation 
4. Proportion of patients who are known to have been treated (both online and in traditional 
services) 
5. Proportion of patients who were followed up by a research health adviser at two weeks 
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6. Partner notification outcomes 
Where participants, who consented, dropped off the pathway was recorded and audited at 
one month and then on a three monthly basis so that amendments could be made if 
necessary. These patients were still followed up at two weeks by a research health advisor and 
both treatment and partner notification outcomes were recorded. 
4. ASSESSMENT OF USABILITY 
 
Pre-exploratory study commencing  
Prior to the exploratory study commencing, a Human Computer Interface researcher 
undertook two qualitative studies to inform the development of the pathway. This is discussed 
in the background and development chapter. In addition, we had at least one human 
computer interface researcher as part of the expert group in the development and 
implementation of the exploratory study.  
Post-exploratory study commencing  
This was measured using the methods described under ‘Assessment of the acceptability to 
users’.   
5. ASSESSMENT OF THE CONTENT AND STRUCTURE OF THE ONLINE CLINICAL 
CONSULTATION 
Pre-exploratory study commencing 
The following methods were used to evaluate the different facets of the content and structure 
of the online clinical consultation: 
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a. Expert review  
As discussed in Chapter 5, both clinical and non-clinical experts have been involved at multiple 
stages with the development of the online clinical consultation. The clinical experts have 
judged that: the questions appear to be reasonable, relevant, unambiguous and clear; the 
content of the questions comprehensively cover what is required to ensure that the 
appropriate clinical outcome is ascertained and that it is safe and appropriate to 
prescribe(342;404).  
In addition, the chlamydia-OCCP has been presented to, and discussed with, sexual health 
clinicians, pharmacists, and other health care professionals, at different time points in the 
development process.  
b. Cognitive testing  (as described in Chapter 5) 
c. User-centred interface testing  (as described in Chapter 5) 
Post-exploratory study commencing: 
Comparison of data collected with data collected in clinic 
Data was collected from clinic records for all patients who had been diagnosed at Barts Sexual 
Health Centre and St George’s Sexual Health Clinic, and who had consented to online 
management. In addition data was collected for all patients (GUM and NCSP) who dropped off 
the pathway and were directed into Barts Sexual Heath Centre and St George’s Sexual Health 
Clinic. 
This data will be compared with the data inputted online to check the internal 
validity(342;404) of the online responses, and the appropriateness of diverting patients off of 
the pathway because of clinical reasons. This will be discussed in more detail below. 
Quantitative service evaluation 
I included questions in the service evaluation, conducted at the Health Adviser follow-up at 
two weeks, to establish whether patients felt that they understood the information given with 
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their results and throughout the online clinical consultation, and whether they felt that this 
information was sufficient.  
6. ASSESSMENT OF USERS’ ABILITY TO COMPREHEND THE ONLINE CLINICAL 
CONSULTATION AND THE INTEGRITY OF THEIR RESPONSES 
Pre-exploratory study commencing 
Cognitive testing (see chapter 5) was used to ensure that participants were able to 
comprehend and correctly interpret the online clinical consultation prior to the exploratory 
study commencing.  
Post-exploratory study commencing  
Comparison of patient inputted data with data collected in clinic will be used to as a surrogate 
marker of patients’ ability to comprehend the online clinical consultation and to assess the 
integrity of their online responses.  
Another approach would be to test the online clinical pathway pre and post consultation with 
patients diagnosed with chlamydia. However, this would require a large number of patients, 
and resources, which are beyond the scope of the present study. In addition, Tideman et al 
and Richens et al have shown, in randomised controlled trials, that Computer Assisted Self 
Interview (CASI) is a suitable substitute for face-to-face interviews in sexual health(40;152), 
and CASI has already successfully been incorporated into clinical practice on the basis of this 
evidence(142;144).  
7. SAFETY-RELATED OUTCOMES AND DETECTION OF ADVERSE EFFECTS  
 
Pre-exploratory study commencing 
As part of the development of the Chlamydia-OCCP (see Chapter 5), a senior researcher and I 
tested a demonstration version of the online clinical consultation to ensure that: 1. All the data 
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was collected and coded accurately in the export data sheet; 2.The logic was correct; 3. 
Patients came off the pathway when it was clinically not suitable for them to continue. 
Post-exploratory study commencing 
As well as the outcomes discussed in assessment of the completion rate, I felt that, where 
possible, it was also important to measure the proportion of patients that received 
appropriate management given the symptoms and drug/allergy history reported. This was 
captured using the following tools (already described): export data sheet, data collected from 
clinic notes for patients who dropped off the pathway, and health adviser follow-up. I will 
analyse each patient record, looking at symptoms reported in initial clinic consultation (for 
GUM patients), symptoms reported online, symptoms and management reported in clinic 
review (for patients who dropped off the pathway and came back into a study clinic), and 
health adviser follow-up,  and diagnosis made/treatment given. From this, I will assess, with a 
Consultant GUM physician, whether: 1.The criteria for patients dropping off the pathway was 
correct; 2. Patients received appropriate management. 
As this is a novel remote online clinical care pathway, where patients are potentially able to 
access treatment without being reviewed by a health care professional, it was imperative that 
we captured any adverse effects or clinical incidents.  
Shcherbatykh note that, in their experience, questionnaires combined with qualitative 
interviews are a good way of picking up adverse effects(367). Therefore, as well as the clinical 
helpline, notes of which were captured on the export data sheet, I included questions in the 
health adviser follow-up, to capture clinical adverse events, and service evaluation, to capture 
non-clinical adverse events. The qualitative researcher included questions in her topic guide to 
ensure that potential issues were explored.  
As part of the data monitoring and review process, review meetings where interim data was 
provided were conducted at one, three and six months following the start of the start of the 
study.  
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Table 72 below summarises these methods. 
Table 72: Summary of methods of evaluation and evaluation tools 
Element to 
evaluate 
Method of evaluation Evaluation tool 
Feasibility 
Assessment of length of time it takes 
users to complete the online clinical 
consultation 
User-centred interface testing 
Data captured in export data sheet 
from online clinical consultation 
Assessment of the completion rate Data captured in export data sheet 
from online clinical consultation and 
health adviser follow-up 
Assessment of usability 
Qualitative interviews 
Human computer interaction 
quantitative short online survey 
Service evaluation (quantitative 
survey) 
Quantitative survey for negative users 
Assessment of the content and 
structure of the online clinical 
consultation 
Expert review  
Cognitive testing 
User-centred interface testing  
Comparison of data collected online 
with data collected in clinic 
Assessment of users ability to 
comprehend the online clinical 
consultation and the integrity of 
their responses 
Cognitive testing 
Comparison of data collected online 
with data collected in clinic 
Acceptability 
Assessment of acceptability to users 
Qualitative interviews 
Human computer interface  
quantitative short online survey 
Service evaluation (quantitative 
survey) 
Quantitative survey for negative users 
Assessment of the content and 
structure of the online clinical 
consultation 
Expert review  
Cognitive testing 
User-centred interface testing  
Safety 
Clinical outcomes and detection of 
adverse effects 
Data captured in export data sheet 
from online clinical consultation, 
clinical helpline and health adviser 
follow-up 
Service evaluation (quantitative 
survey) 
Qualitative interviews 
Comparison of data collected online 
with data collected in clinic 
 
Highlighted cells are work conducted by other eSTI2 researchers 
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I will now discuss the quantitative evaluation tools that I developed to address the different 
evaluation approaches.  
4. QUANTITATIVE EVALUATION TOOLS 
The export data sheet, which captures all the data collected from the online clinical 
consultation, is described in Chapter 5.   
4.1 SERVICE EVALUATION FOR PATIENTS TESTING POSITIVE FOR CHLAMYDIA 
 
It is standard practice when designing a questionnaire to include techniques that test the 
integrity and consistency of the participant’s answers, along with providing internal validity. As 
these patients had been diagnosed with an infection, had been through an online consultation 
and clinical health adviser follow-up, would be offered the opportunity to participate in 
qualitative interviews, and may have opted to complete the human computer interface 
usability survey, I felt that it was imperative that this survey was short and only asked 
questions that were absolutely necessary to evaluate the system. This therefore restricted my 
ability to introduce questions that would flag if a patient was ‘yes-saying’. It was possible, 
however, to include questions that helped target appropriate questions to the patient, and 
allowed verification of their answers against other questions asked in the online clinical 
consultation. One example of this is whether the patient had tested for chlamydia prior to this 
episode; this question was included in the online clinical consultation and in the service 
evaluation. It will also be possible to check for incongruous answers with the questions that I 
have employed. An example of this is checking the response patients gave to acceptability of 
the clinical care pathway against whether they were happy with their overall experience.  
As previously described, this survey was designed to be asked during the health adviser two 
week follow-up, after the clinical follow-up section. It therefore needed to be pithy and 
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relevant to the patient. In order to achieve this, I employed a skip pattern of questioning (190), 
as with the online clinical consultation, which meant that the patients were only asked 
questions that were relevant to their experience.  
I based the content of the questions on: our needs in order to evaluate and validate the online 
clinical care pathway; questions employed by other researchers when evaluating a sexual 
health computer assisted self- interview(CASI) (152), an express sexual health clinic(144), an 
online sexual health promotion website(190;351), the BASHH Patient Survey 
Questionnaire(409), and previous surveys of preferences for receiving test 
results(315;317;318). Nicholas et al, in their qualitative evaluation of the Sexunzipped website, 
found that young people would have preferred to have a “middle of the road” option (351). 
Although it was not possible to employ this during the online clinical consultation, I did ensure 
that this option was available for the service evaluation questions.   
Weston et al, in their development of a patient satisfaction survey for use in Sexual Health 
Clinics, undertook qualitative research to identify which key themes were of greatest 
importance to patients when attending a Sexual Health Clinic. The five major areas they 
identified were: clinic location; availability of appointments; staff attitude to patients; effective 
delivery of information; confidentiality within clinic. Our needs, in surveying a patient group 
that had accessed an eSexual Health Clinic were different, with the first two areas being 
redundant. The areas I identified as being important were: patient satisfaction with the eSTI2 
results service(363); patient satisfaction with the online clinical consultation (including content 
of questions and information provided)(363); patient satisfaction with the clinical helpline; 
how this experience compared to previous experiences of testing for chlamydia (for patients 
with previous testing experience); patient experience of collection of antibiotics from their 
nominated pharmacy.  The only staff contact that users of the eSexual Health Clinic would 
have was with the health adviser, which was why I chose to ask questions relating to whether 
they used the clinical helpline and, if so how helpful they found this service.  
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I initially planned to cognitively test the questionnaire and then trial it with patients diagnosed 
with chlamydia in clinic. However, due to time constraints this was not possible. Instead, I 
sought advice from members of the expert group (mentioned in Chapter 5).  
I then arranged to discuss the health advisers’ impressions of the questionnaire two months 
after commencing the study. This coincided with the training of two new Health Advisers who 
were joining the team. Points raised included: confusion over wording/interpretation of the 
questions; questions over potential duplication of questions; concerns over how the questions 
were to be asked. I then went back to the questionnaire, re-established the information we 
were trying to gather and used this to rationalise the questions. I explored using the Likert 
Scale(410) however all Health Advisers felt this would be more confusing in terms of trying to 
explain it over the phone, was likely to take longer and was more likely to lead to 
misinterpretation. Following this meeting, I then engaged with two researchers with 
experience of quantitative surveys, one of whom was the eSTI2 PhD student conducting the 
qualitative follow-ups. I then revised the questionnaire and re-evaluated it after a month. At 
which stage, all three health advisers agreed that there were no further changes required.  
To ensure that all health advisers were asking the questions in the same way, and were 
adhering to the standard operating procedure, I went through the questionnaire with them all 
individually and then together, and we decided together the optimal approach to asking the 
questions.  
Once the service evaluation had been placed on the demonstration system, I used white box 
testing (407) to ensure that the question flow and logic were correct, depending on the 
responses given. I then checked that this was coding correctly on the export data sheet.  
The final quantitative service evaluation is shown in Table 73 below. 
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Table 73: Final quantitative service evaluation 
Data 
item 
Description Field Name Response Categories 
and Coding Structure 
6 Were you happy with the text message that 
you were sent with the link to access your 
result? [index patients only] 
 
Tick all that apply 
 
TEXTOK 
1. Yes, I was happy 
2. No I would rather 
have received the 
link in an email 
3. No I would rather it 
had the result of 
the test in the text 
message 
4. No it wasn’t clear 
5. Other (free text) 
 
 
7 Were you happy with the message that you 
received informing you that you could 
access treatment online? [sexual partners 
only] 
 
Tick all that apply 
SPTEXTOK 
1. Yes I was happy 
2. No it wasn’t clear 
3. No it was too blunt 
4. Other (free text) 
5. Not applicable 
8 When you accessed your results [index 
patient]/the online clinic [sexual partners], 
did you think the amount of information you 
were given about chlamydia was: 
 
RESINFOAMT 
1. Not enough 
2. About right 
3. Too much 
4. Not applicable 
 
9 Do you think this information on chlamydia 
and management options was 
 
RESINFOOK 
1. Very easy to 
understand 
2. Easy to understand 
3. Neither easy nor 
difficult to 
understand 
4. Difficult to 
understand 
5. Very difficult to 
understand  
6. Not applicable 
 
10 How easy did you find the questions in the 
online clinic to complete? 
EASYOCC 
1. Very easy 
2. Easy 
3. Neither easy nor 
difficult 
4. Difficult 
5. Very difficult 
6. Not applicable 
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11 How comfortable did you feel 
answering these questions? 
 
COMFORTOCC 
1. Very comfortable 
2. Comfortable 
3. Neither comfortable 
nor uncomfortable 
4. Uncomfortable 
5. Very uncomfortable 
6. Not applicable 
 
12 How comfortable were you 
answering these questions online 
compared to if you answered these 
questions face-to-face with a doctor 
or nurse? 
 
COMFOCCFTF 
1. Much more 
comfortable online 
compared to face-to-
face 
2. More comfortable 
online compared to 
face-to-face 
3. About the same 
4. Less comfortable 
online compared to 
face-to-face 
5. Much less comfortable 
online compared to 
face-to-face 
6. Not applicable 
 
13 Whilst going through the online 
clinic, did you think the amount of 
information you were given was 
 
INFOOCCAMT 
1. Not enough 
2. About right 
3. Too much 
4. Not applicable 
 
14 Did you think this information was  
 
INFOOCCOK 
1. Very easy to 
understand 
2. Easy to understand 
3. Neither easy nor 
difficult to understand 
4. Difficult to understand 
5. Very difficult to 
understand 
6. Not applicable 
 
15 Any other comments spontaneously 
made by index patient on results 
service or online consultation [No 
question asked] 
FREETXTOK Free text 
16 Did you use the telephone clinical 
helpline 
 
CLINHELP 
1. Yes (go to 16a) 
2. No (go to 17) 
 
16a Did you find it helpful? HELPFUL 
1. Yes 
2. No (go to 16b) 
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3. Unable to remember 
 
16b Why not? NOTHELPFUL 
1. Opening hours too 
restrictive 
2. Unable to answer 
question/query 
3. Other reason – free 
text 
17 Have you had chlamydia before? PREVCHLAM 
1. Yes (go to 17a) 
2. No  (go to 18) 
 
17a How did the online results system 
compare to the last experience of 
getting your results? [Do not ask 
sexual partners] 
 
OCCOMPARERES 
1. Much better 
2. Better 
3. About the same 
4. Worse  
5. Much worse 
 
17b Would you use this method of 
accessing your results again? [Do not 
ask sexual partners] 
 
 
METHAGAIN 
1. Yes 
2. No  
3. Unsure 
 
17c How did you using the online clinic 
to get antibiotic treatment compare 
to your last experience of getting 
antibiotics? 
 
OCCOMPARETREAT 
1. Much better 
2. Better 
3. About the same 
4. Worse  
5. Much worse 
6. Not applicable 
 
17d Would you use this method of 
accessing your antibiotic treatment 
again? 
 
ACCESSAGAIN 
1. Yes 
2. No  
3. Unsure 
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18 How did you access the online 
clinic? 
 
Tick all that apply 
HOWACCOCC 
1. Mobile phone 
2. Desktop computer 
3. Lap top 
4. Tablet/iPad 
5. Combination (i.e. swapped 
from one to the other)  
Free text  
 
19 Would you rather have had a face-
to-face consultation with a doctor 
or nurse? 
 
PREFACE 
1. Yes (if yes, drop down box 
with free text) 
2. No  
3. Unsure 
 
 
20 Did you have any problems getting 
your treatment from the pharmacy? 
 
PROBPHARM 
1. Yes (if yes, drop down box 
with free text) 
2. No 
3. Not applicable 
 
21 Would you recommend this online 
clinic to your friends? 
RECOMMEND 
1. Yes 
2. No 
3. Unsure 
 
22 Overall, how would you rate the 
care you received via the online 
clinic? 
RATECARE 
1. Excellent 
2. Very good 
3. Good 
4. Fair 
5. Poor 
6. Very Poor 
23 Suitable for qualitative interview? QUALINT 
1. Yes (automatically feeds to 
24) 
2. No  
24 Permission to follow-up by 
researcher? 
PERFURESEA 
1. Yes 
2. No 
If yes, drop down text box : 
best time to call for interview 
 
4.2 QUANTITATIVE SURVEY FOR PATIENTS TESTING NEGATIVE FOR CHLAMYDIA 
 
I decided to add a short survey for people who tested negative for chlamydia in order to get 
feedback on how they found using the eSTI2 results service. As this was an online evaluation of 
an online intervention, with no intermediary, it optimised external validity(411). In order to 
maximise the usefulness of this information, the initial question asked whether the users had 
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experience of testing for chlamydia prior to this episode. I did this as prior testing experience 
could influence their impression of the eSTI2 results service.   
Sources used to inform the content of the survey included  Brown et al(315), Labacher and 
Mitchell(318), and Martin et al(317). As with the service evaluation for patients testing positive 
for chlamydia, I used a skip pattern of questioning, white box testing and checked the coding 
of the survey on the export data sheet prior to the survey being put on to the live system.  
Table 74 below contains the questions asked in the negative survey.  
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Data 
item 
Description Field name Response categories and coding structure 
2d  
 
2e 
 
 
2e(i) 
 
 
 
2e(ii) 
 
 
 
 
2e(iii) 
 
Negative survey 
 
Neg results Survey, ever tested 
 
 
Neg results Survey, previously 
tested 
 
 
 
Neg results Survey, results 
method comparison 
 
 
 
Neg results Survey, future 
 
TICKNEGSURVEY 
 
NEGSRTEST 
 
 
NEGSRPVRES 
 
 
 
 
NEGSRCOMPARE 
 
 
 
NEGSRFUT 
 
 As this is a new way of getting results, we would be grateful if you could answer  
a short survey : click here(If clicked filters to 2e) 
 
Is this the first time you have been tested for chlamydia?   
No  ( dropdown to   2e (v)) 
Yes  ( dropdown  to 2e (i)) 
 
How have you got your test results in the past?  (tick all that apply)? 
1. Text message 
2. Phone call 
3. Letter 
4. Email 
5. Other 
 
Do  you think the way you got your result this time was: 
1. Much better 
2. Better 
3. About the same 
4. Worse  
5. Much worse 
 
Would you be happy to get your results this way in the future?  
       1. Yes 
       2. No 
Table 74: Negative quantitative survey 
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2e(iv) 
 
2e(v) 
 
 
 
2e(vi) 
 
 
2e(vii) 
 
 
 
 
2e(viii) 
 
 
Neg results Survey comments 
 
Neg results Survey given results 
today 
 
 
Neg results Survey happy to  
receive results online if had 
chlamydia in future 
 
Neg results Survey method 
preference of getting results 
 
 
 
 
Neg results Survey other 
comments 
 
  
NEGSRCOMM 
 
NEGSRRSTXT 
 
 
 
NEGSRFUTRST 
 
 
NEGSRPREF 
 
 
 
 
 
NEGSRCOMENT 
    
If you have any other comments please write them in the box below: ..TEXT BOX 
 
 
Were you happy with the way you were given your results (a text to say that you 
could access your results online) 
1.Yes 
2.No 
 
 
If your test showed you had chlamydia in the future, would you be happy to get 
your results this way if your test was positive 
1. Yes 
2. No  
 
Rather than logging in to get your results, would you have rather have received 
your result by: 
1.  An email with a link to access your results instead of a text  Yes/No 
2.  A text saying ‘The result of your chlamydia test is negative/positive. You do 
not/do have chlamydia’ Yes/No 
3. An email saying ‘The result of your chlamydia test is negative/positive. You do 
not/do have chlamydia’ Yes/No 
 4. Other way:  FREE TEXT 
 
Text box 
If you have any other comments please write them in the box below:  
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4.3 COMPARISON OF PATIENT INPUTTED DATA WITH DATA COLLECTED IN 
CLINIC 
 
For those patients recruited from the Barts Health Sexual Health Centre and St George’s Sexual 
Health Clinic, and for patients who dropped off the pathway and came into these clinics, data 
entered online by patients will be compared with data collected from the same patients in 
clinic. The data will be anonymised. The data items that will be compared are illustrated in 
Table 75 below. 
Table 75: Data items to be compared between patient inputted data and data collected in 
clinic 
 All participants Gender specific 
Demographics 
· Age 
· Ethnicity 
· Postcode 
· Email address 
· Gender 
· Asymptomatic screen 
 
Symptoms 
· Rash, sores or blisters 
· Skin lumps 
 
Female: presence of 
· Abdominal/pelvic pain 
· Inter-menstrual bleeding 
· Post-coital bleeding 
· Dyspareunia 
Male: presence of 
· Testicular or scrotal pain 
· Anal pain 
Medication 
and 
allergyhistory 
· Regular medications 
· Cardiac history or drugs 
· Drug allergies 
· Myasthenia gravis, liver or kidney 
problems 
· Nut/soya allergy 
Female 
· Pregnancy 
· Breast feeding 
· Need for emergency 
contraception  
History of 
previous STIs 
· Previous chlamydia 
· When  
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 All participants Gender specific 
Previous HIV 
testing 
· Previously tested for HIV 
· When 
· Result 
 
Sexual History 
· Number of sexual partners  
· Sexual preference 
· Type of sex 
· Condom use 
 
Risk 
assessment 
· History of Injecting drug use 
· History of paying or receiving 
money for sex 
· Sexual partner outside UK 
· Hepatitis B vaccination  
Female: 
· Male partner ever had sex with 
a man 
Male: 
· Ever had sex with a man 
Diagnosis and 
management 
· Patient examined 
· Diagnoses made 
· Treatment given 
Female: 
· PV examination performed 
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6. SUMMARY OF PATIENT INVOLVEMENT IN EVALUATION 
OF THE PATHWAY 
 
Patients have been involved with evaluating the pathway prior to study commencing in the 
following ways:  
1. Preliminary acceptability and interface design qualitative work conducted by 
other eSTI2 researchers 
2. Cognitive interviews  
3. Usability lab-based testing and further cognitive testing with the 
demonstration version of the eSexual Health Clinic 
 
Patients have been involved with evaluating the pathway once the study commenced in the 
following ways: 
1. Short acceptability quantitative survey for people testing negative for 
chlamydia (see page 310) 
2. Usability quantitative online survey at the end of the online clinical 
consultation (designed by another eSTI2 researcher) 
3. Quantitative service evaluation conducted at health adviser follow-up (see 
page 305) 
4. Qualitative interviews, by another eSTI2 researcher, conducted with patients 
who consented to the online pathway and consented to be contacted at 
health adviser follow-up  
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6.  DISCUSSION 
4.1 MAIN FINDINGS 
 
eSexual Health is progressively being incorporated into everyday clinical practice, with a 
variable evidence base to support it. In terms of both diagnostic and digital technological 
development, we are close to patients being able to self-sample, self-test, to be diagnosed, 
managed and able to access treatment remote from direct health care professional care and 
traditional sexual health services. However, there are several barriers to this, some of which I, 
and other members of the eSTI2 consortium, have addressed and proposed solutions for.  
At present there is little directly applicable guidance and evidence available when developing a 
novel online clinical care pathway, taking a patient from diagnosis through management 
remotely. There is, however, an existing evidence base that can be adapted and utilised to 
inform this development. One of my key findings was that, depending on the context, the 
sequence of a consultation needs to be adapted to meet the needs of the online situation. In 
the case of the Chlamydia Online Clinical Care Pathway, this has had a major impact on the 
structure and content of the online clinical consultation. In order to facilitate this, and to help 
overcome the current lack in guidance and structure, I have developed the eClinical Care 
Pathway Framework.  
I have shown that the eClinical Care Pathway Framework can be used to develop a robust, 
evidence based, online clinical care pathway. This framework has the potential to be applied to 
the management of other STIs and other medical conditions.  
Any clinical care pathway must be feasible, acceptable and safe for users. This is of paramount 
importance when an automated online clinical decision system is used, with potentially no 
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contact with a healthcare professional between receiving a diagnosis and accessing treatment. 
In this chapter I have described the current evidence base and guidance for evaluation of such 
an online clinical care pathway, and the methods that I have employed to assess whether the 
Chlamydia-OCCP is feasible, acceptable and safe.  
We have used a comprehensive mixed-method, multi-disciplinary, multi-institutional approach 
to assess these three major aspects, employing evaluation methods at all stages of the 
pathway lifecycle in a positive feedback loop that has allowed us to address barriers to 
implementation in a timely manner.  As with Dansky et al(385), we have had to adopt a 
flexible/dynamic approach to protocol, procedures and evaluation method content in order to 
be able to do this.  Although we applied a robust methodological approach to developing and 
implementing the Chlamydia-OCCP, as described in Chapters 4 and 5, it was not possible to 
predict the issues that would arise during the exploratory study. This reinforces the 
importance of piloting and rigorously evaluating all aspects of novel eHealth interventions.  
Traditional methods of research design, implementation and evaluation are not fit for purpose 
for eHealth interventions(379). Although there is an established literature on evaluating 
eHealth, this needs to be adapted and made specific for individual interventions. For example, 
although there were aspects of the Khoja-Durrani-Scott Evaluation tools (242;412)that were 
helpful in developing this evaluation, the majority of the content was not relevant for the 
evaluation of the Chlamydia-OCCP. They discuss validating the evaluation tools but do not 
describe how they went about doing this(242). 
At present in the UK, there is no mode of accrediting this type of pathway as it does not fall 
under the auspices of NHS pathways or NICE pathways.   
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4.2 STRENGTHS/WEAKNESSES/LIMITATIONS 
Methodology 
The employment of a novel framework (eCCPF) and a continuous evaluation process, with the 
feeding back of findings from operational implementation into the system, highlighted as an 
important part of the evaluation process of eHealth interventions by both Lilford et al(390) and 
Turner et al(388), enhanced the robustness of our methods(388). For example, from 
conversations that the health adviser had with patients, data collected as part of the health 
adviser follow-up and in qualitative interviews, it became apparent within a couple of months 
of the pilot study commencing that: 1. Many patients did not understand how the online 
partner notification process worked; 2. There were issues with patients collecting their 
medication from pharmacies. This is discussed further in Chapter 5, however, we were able to 
adapt the online clinical consultation, text message that the patient was sent with the 
pharmacy information on it, and service evaluation in order to resolve these issues in a timely 
manner.    
As Dansky et al(385) suggest, communication between the eSTI2 research group and the other 
stakeholders involved in the study, and within the eSTI2 research group, has been key to the 
development, implementation and evaluation of the Chlamydia-OCCP. 
As advised by May(386), we have begun to examine how this eHealth intervention could be 
embedded within existing clinical services. 
Weaknesses of the methods that I have developed and used include only using internal 
assessment(390), and not validating the service evaluation questionnaire and negative 
quantitative survey prior to use in the exploratory study. In addition, ideally I would have 
cognitively tested the questionnaires. Assessment of intra-observability and sensitivity to 
change are not covered using these methods of evaluation. Test-retest reliability would be 
difficult to apply to the methodology described above. In addition, Turner et al found only 
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limited benefit of repeating sensitive questions in their sexual health study(413). As this tool is 
being used at one point in time, there is no need for it to be capable of measuring change in an 
individual over time. 
 Furthermore, the data comparison between data collected in clinic and that collected online 
is, for the most part, not going to be directly comparable and therefore it will be difficult to 
draw any statistical robust conclusions from this comparison. A more scientifically robust 
method of evaluation would have been to have conducted a study whereby patients 
completed both an online consultation and a traditional consultation with the same questions 
being asked in both consultations. In this situation it would be necessary for half of the 
patients to have the online consultation first and then the traditional consultation, and half to 
have the traditional consultation first, followed by the online consultation.  
 
C-OCCP Pathway 
A considerable amount of work has gone into the development of the C-OCCP, which is a 
complex eHealth intervention. The concern therefore needs to be raised as to how easy it will 
be to maintain and to keep updated, particularly with the lack of regulatory and professional 
guidelines. However, I believe that, having got the fundamental structure in place, it will be 
relatively easy to update and maintain this pathway as long as, in the absence of national 
guidelines, internal/local guidelines are put in place.  
4.3 MEANING AND IMPLICATIONS 
  
The volume, diversity and rapidly evolving nature of eHealth literature, including grey 
literature, is a barrier when trying to implement a novel online clinical care pathway within the 
NHS. In addition, the Chlamydia Online Clinical Care Pathway transcends multiple different 
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regulatory and professional bodies, none of which have the capacity at present to provide 
specific guidance and accreditation for this type of complex intervention. By adopting a robust 
methodological approach, with the development and application of a novel framework, I have 
been able to adapt and apply the existing evidence base to inform the development of and 
create the Chlamydia Online Clinical Care Pathway 
Although there is literature available on evaluating eHealth interventions, much of this is 
focussed on behavioural interventions and needs to be adapted to the intervention. I have 
demonstrated that it is possible to develop the methods to establish that an online clinical care 
pathway is feasible, acceptable and safe. By adopting a multifaceted continuous evaluation 
approach, it is possible to identify issues with the pathway at an early stage and to adapt the 
pathway and evaluation, as necessary, in a timely manner.  
4.4 RECOMMENDATIONS  
 
My recommendations include: 1. Allocating at least as much time to the development of the 
evaluation of an online clinical care pathway as you do to the creation of the pathway; 2. 
Mapping the evaluation methods against your objectives and against the feasibility, 
acceptability and safety of the pathway to ensure that all aspects are covered; 3. Using a mixed 
methods approach using a multidisciplinary, multi-institutional team; 4. Continually evaluating 
all stages of development and piloting of the pathway. 
4.5 UNANSWERED QUESTIONS AND FUTURE RESEARCH 
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Although I believe that the eClinical Care Pathway Framework can be adapted for use with 
other STIs/sexual health conditions and potentially for use in other specialities, this has not as 
yet been tested.  
It is important to validate both the online clinical care pathway and the quantitative methods 
of evaluation. I intend to explore this as part of my post-doctoral research. Once a full analysis 
and evaluation of the Chlamydia-OCCP exploratory study has been conducted, it is needs to be 
implemented as a full scale trial.. In order to be feasible and sustainable in the current NHS, it 
is important that the pathway can be integrated with existing services and into existing 
systems (408). Whether this is feasible within the current NHS IT infrastructure remains to be 
seen.  
 
 
 
 
 
 
 
 
 
 
 
 
321 
 
 
 
 
Chapter 7: Conclusions 
 
The prevalence and incidence of STIs remain unacceptably high within England. Sexual health 
services are under increasing pressure to provide leaner, more cost-effective services and 
ensure barriers to access are reduced against a backdrop of financial austerity within the NHS 
as a whole and significant change in commissioning structures. More broadly across the NHS, 
policy promotes self-managed and remote care.  eHealth potentially offers an opportunity to 
address these pressures, as well as providing patients with the easily accessible knowledge 
that they require to make informed decisions, whilst facilitating data collection for both clinical 
and public health needs. However, much of the infrastructure and legislation/regulation and 
best practice guidance required to support such a shift in provision of care has been designed 
for traditional, non-eHealth, service provision and is not fit for purpose for innovative eHealth 
interventions. However, there is always likely to be a lag between innovation and 
regulations/guidance and this needs to be borne in mind when legislation and regulations are 
being introduced or updated to ensure that they are not so prescriptive that they restrict 
advancement.  
This body of work has focussed on online health, specifically related to sexual health and STIs. 
Although there are very specific attributes of care which are specific to STI management, much 
of the content is applicable or can be adapted to other fields of medicine.   
Apps to help people address their sexual health/STI concerns offer huge potential with respect 
to reach and information delivery. However, I have shown that the numerous apps currently 
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available are of highly variable quality, and poorly reflective of burden of disease. A concerning 
proportion of the apps reviewed provided potentially harmful information and few apps met 
accepted quality criteria. At present there is no way for the public to easily discern which apps 
contain trustworthy, accurate information and which ones they should interpret with care.  
Due to the large expanding volume and diverse nature of contemporary mobile medical apps, 
regulation would be challenging and potentially detrimental in terms of slowing innovation. 
Instead, I concur with Boulos et al(205) in that education of consumers is a more feasible 
option. In England we have an established NHS Choices health apps library(210) but the public 
needs to be signposted to this . Publicising through general practice, community pharmacy and 
social media could all help to achieve “brand awareness”. In addition, accreditation by the NHS 
Choices health apps library needs to become a more transparent process, with information 
provided as to what criteria the app needs to meet, who is reviewing the app, when the app 
was entered on to the library and how frequently this is reviewed. However, this would incur 
costs and this would have to be borne in mind at policy level. 
Electronic prescribing provided one of the major challenges that I have needed to overcome 
with the development of the Chlamydia Online Clinical Care Pathway. As I have described, 
electronic prescribing in the UK has developed as completely separate entities, both 
organisationally and legally, in primary and secondary care. Current regulations and legislation 
are not fit for purpose, lagging behind the rapid development within eHealth, and are 
potentially impinging innovation within the NHS. At present it is not possible to send an 
electronic prescription to a community pharmacy unless it is sent via the Electronic 
Prescription Service which is used within primary care.  Although I have reached a solution for 
the exploratory study, an alternative method will need to be found if a large scale trial is to 
take place. True patient-centred eSexual Health delivery, and potentially other specialities who 
work in both a hospital and community setting, would benefit from the ability to prescribe 
electronically across the primary/secondary care interface.  We are currently exploring options 
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that would enable this to happen. For example there would need to be a statute change in law 
so that sending an electronic prescription to a community pharmacy is possible outside of the 
Electronic Prescription Service. Alternatively, a service could be ‘bolted on’ to the Electronic 
Prescription Service which would allow eSexual Health Services to use the infrastructure 
without needing to share a patient’s NHS identification number or other identifiable data with 
the patient demographic service.  Another option would be to assess the acceptability to 
sexual health service patients and people in the community of having their details shared with 
a national IT system. If it was acceptable to a significant proportion of people, then using the 
Electronic Prescription Service would be a viable option, although consent would need to be 
gained from individual patients as part of the service.  
ONLINE ESEXUAL HEALTH  
 
eHealth is a nascent field and the lack of evidence-based methodologies for developing online 
clinical care pathways within the medical literature was striking. Delivering care, which 
includes a results service, automated online clinical consultation, and an electronic 
prescription service, meant that this was of paramount importance as this mode of delivery of 
care is novel and must be delivered robustly. Using a wide remit, informed by guidance for 
online care where it exists and traditional care where relevant, I have contributed a new 
framework to assist others in the development of online clinical care pathways. We will take 
this framework forward to apply to other conditions which are not restricted to eSexual 
Health. In order for eHealth to reach its full potential, we will increasingly need such 
frameworks to base the development and delivery of interventions on. I have suggested one 
set of methods but other approaches need to be developed by other groups.  
As part of the eSTI2 consortium, I have used robust methodology to create an automated 
online clinical care pathway for the management of patients diagnosed with genital Chlamydia 
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trachomatis. The development has been centred on the eClinical Care Pathway Framework 
which has been applied using the existing evidence base in eSexual Health. This pathway 
meets current national standards of care and is able to collect the data required for public 
health surveillance purposes.  
There is the potential for this pathway to be expanded to include management of other STIs 
and genital infections. However, this will be limited in some cases, for example the 
management of gonorrhoea, by the need for intramuscular treatment. Despite this, patients 
could still access their results and initial triage via this route, with the eSexual Health Clinic 
being embedded within a traditional sexual health clinic. This would allow patients the 
freedom to choose between online management and face-to-face management with the 
ability to switch between the two as required. In order for this to happen, the eSexual Health 
Clinic software would need to be interoperable with the traditional clinics IT infrastructure.  
Although there is a substantial amount of literature on the evaluation of eHealth interventions, 
none of these were directly applicable to the evaluation of an online clinical care pathway. I 
have needed to adopt a continuous iterative evaluation process, with flexibility in terms of 
methods employed, in forming and implementing the pathway. I have only been able to do 
this as part of a multi-disciplinary, multi-institutional team with good communication at all 
stages.  
Of concern is whether eSexual Health has the potential to reach hard to reach populations or 
whether it will actually increase the digital divide.  This needs further research and evaluation. 
Another unanswered question is whether we need an accreditation body for online clinical 
care pathways. The answer is probably yes, however it needs to be reviewed and implemented 
rapidly enough so as not to impede innovation and delay patient care.  
In summary, eSexual Health offers great potential but it is likely that this will only come to 
fruition if it has a strong evidence base and is seen as part of the larger service development. I 
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believe that the Chlamydia Online Clinical Care Pathway is a method that could potentially 
integrate existing service providers of chlamydia testing. It could provide a single point of 
access for the results service, triage and management system described, whereby patients 
who are asymptomatic or minimally symptomatic can access treatment online, and those 
patients that need to be seen by tertiary services are seen. In addition, it could ensure that all 
patients are provided with information about chlamydia, the need and a method to initiate 
partner notification, and health promotion.  
  
326 
 
 
 
Reference List 
 
 (1)  GOV.UK. NHS choices: About us.  30-8-2013. 4-1-2015.  
Ref Type: Online Source 
http://www.nhs.uk/aboutNHSChoices/aboutnhschoices/Aboutus/Pages/Introduction.aspx 
 (2)  British Association for Sexual Health and HIV.  2015. 4-1-2015.  
Ref Type: Online Source 
http://www.bashh.org/ 
 (3)  Family planning association. FPA talking sense about sex: what we do.  2015. 9-4-2015.  
Ref Type: Online Source 
http://www.fpa.org.uk/what-we-do 
 (4)  eSTI2 Consortium. eSTI2 UKCRC Consortium Application.  2010.  
 (5)  Car J, Black A, Anandan C, Cresswell K, Pagliari C. The Impact of eHealth on the Quality 
and Safety of Healthcare.  2008.  
 (6)  Ofcom. The Communication Market 2014.  2014.  
 (7)  Boulos MN, Wheeler S, Tavares C, Jones R. How smartphones are changing the face of 
mobile and participatory healthcare: an overview, with example from eCAALYX. 
Biomed Eng Online 2011;10:24. 
 (8)  Ipsos MediaCT. Social Grade. A Classification Tool.  2009. 4-6-2015.  
Ref Type: Online Source 
https://www.ipsos-
mori.com/DownloadPublication/1285_MediaCT_thoughtpiece_Social_Grade_July09_V
3_WEB.pdf 
 (9)  NHS England. Putting Patients First:The NHS England business plan for 2013/4 - 
2015/6.  2013.  
 (10)  NHS Commissioning Board. Everyone Counts: Planning For Patients 2013/14.  2013 
Dec.  
 (11)  Eng T. The e-Health Landscape - a terrain map of emerging information and 
communication technologies in health and health care.  2004. 23-2-2013.  
Ref Type: Online Source 
http://www.rwjf.org/global/404errorpage.jhtml?requestedDocument=/publications/publicatio
nsPdfs/eHealth.pdf 
 (12)  Eysenbach G. What is eHealth? J Med Internet Res 2001;3(2):e20. 
 (13)  Finch TL, Mair FS, May CR. Teledermatology in the UK: lessons in service innovation. Br 
J Dermatol 2007 Mar;156(3):521-7. 
327 
 
 
 (14)  Schmidt M, Rizvi N, Lee DM, Wood V, Amisano S, Fairley CK. An audit of completeness 
of clinical histories: before and after introduction of a pro forma. Int J STD AIDS 2005 
Dec;16(12):822-4. 
 (15)  Holkar S, Rogstad KE. Introduction of a proforma in the management of under age 
attendees at a genitourinary clinic. Int J STD AIDS 2005 Apr;16(4):278-80. 
 (16)  Nanthakumaran H, Sullivan AK, Boag FC. An audit of emergency contraception: a look 
at patient characteristics and the effects of a consultation proforma. Int J STD AIDS 
1998 Jan;9(1):48-50. 
 (17)  Abu-Rajab K, Butt A. Introduction of a proforma in the management of under-age 
attendees at a genitourinary clinic. Int J STD AIDS 2006 Jan;17(1):71. 
 (18)  Hayrinen K, Saranto K, Nykanen P. Definition, structure, content, use and impacts of 
electronic health records: a review of the research literature. Int J Med Inform 2008 
May;77(5):291-304. 
 (19)  Berlin A, Sorani M, Sim I. A taxonomic description of computer-based clinical decision 
support systems. J Biomed Inform 2006 Dec;39(6):656-67. 
 (20)  Bright TJ, Wong A, Dhurjati R, Bristow E, Bastian L, Coeytaux RR, et al. Effect of clinical 
decision-support systems: a systematic review. Ann Intern Med 2012 Jul 3;157(1):29-
43. 
 (21)  Chi CL, Street WN, Ward MM. Building a hospital referral expert system with a 
Prediction and Optimization-Based Decision Support System algorithm. J Biomed 
Inform 2008 Apr;41(2):371-86. 
 (22)  Ali MK, Shah S, Tandon N. Review of electronic decision-support tools for diabetes 
care: a viable option for low- and middle-income countries? J Diabetes Sci Technol 
2011 May;5(3):553-70. 
 (23)  Ebrahiminia V, Riou C, Seroussi B, Bouaud J, Dubois S, Falcoff H, et al. Design of a 
decision support system for chronic diseases coupling generic therapeutic algorithms 
with guideline-based specific rules. Stud Health Technol Inform 2006;124:483-8. 
 (24)  Eibling D. Making us smart: why the design of clinical decision support systems is so 
critical. Laryngoscope 2008 Dec;118(12):2121-4. 
 (25)  Fairley CK. Using information technology to control STIs. Sex Transm Infect 2011 
Dec;87 Suppl 2:ii25-ii27. 
 (26)  Forsstrom J, Nuutila P, Irjala K. Using the ID3 algorithm to find discrepant diagnoses 
from laboratory databases of thyroid patients. Med Decis Making 1991 Jul;11(3):171-5. 
 (27)  Friedlin J, Dexter PR, Overhage JM. Details of a successful clinical decision support 
system. AMIA Annu Symp Proc 2007;254-8. 
 (28)  Garg AX, Adhikari NK, McDonald H, Rosas-Arellano MP, Devereaux PJ, Beyene J, et al. 
Effects of computerized clinical decision support systems on practitioner performance 
and patient outcomes: a systematic review. JAMA 2005 Mar 9;293(10):1223-38. 
328 
 
 
 (29)  Haynes RB, Wilczynski NL. Effects of computerized clinical decision support systems on 
practitioner performance and patient outcomes: methods of a decision-maker-
researcher partnership systematic review. Implement Sci 2010;5:12. 
 (30)  Hemens BJ, Holbrook A, Tonkin M, Mackay JA, Weise-Kelly L, Navarro T, et al. 
Computerized clinical decision support systems for drug prescribing and management: 
a decision-maker-researcher partnership systematic review. Implement Sci 2011;6:89. 
 (31)  Hunt DL, Haynes RB, Hanna SE, Smith K. Effects of computer-based clinical decision 
support systems on physician performance and patient outcomes: a systematic review. 
JAMA 1998 Oct 21;280(15):1339-46. 
 (32)  Jacob J. The electronic medical record: decision support and the effective use of 
clinical guidelines. Alaska Med 2003 Apr;45(2):41-6. 
 (33)  Jeffery R, Iserman E, Haynes RB. Can computerized clinical decision support systems 
improve diabetes management? A systematic review and meta-analysis. Diabet Med 
2012 Dec 1. 
 (34)  Lamy JB, Ellini A, Ebrahiminia V, Zucker JD, Falcoff H, Venot A. Use of the C4.5 machine 
learning algorithm to test a clinical guideline-based decision support system. Stud 
Health Technol Inform 2008;136:223-8. 
 (35)  Pearson SA, Moxey A, Robertson J, Hains I, Williamson M, Reeve J, et al. Do 
computerised clinical decision support systems for prescribing change practice? A 
systematic review of the literature (1990-2007). BMC Health Serv Res 2009;9:154. 
 (36)  Randell R, Mitchell N, Dowding D, Cullum N, Thompson C. Effects of computerized 
decision support systems on nursing performance and patient outcomes: a systematic 
review. J Health Serv Res Policy 2007 Oct;12(4):242-9. 
 (37)  Robertson J, Walkom E, Pearson SA, Hains I, Williamsone M, Newby D. The impact of 
pharmacy computerised clinical decision support on prescribing, clinical and patient 
outcomes: a systematic review of the literature. Int J Pharm Pract 2010 Apr;18(2):69-
87. 
 (38)  Souza NM, Sebaldt RJ, Mackay JA, Prorok JC, Weise-Kelly L, Navarro T, et al. 
Computerized clinical decision support systems for primary preventive care: a 
decision-maker-researcher partnership systematic review of effects on process of care 
and patient outcomes. Implement Sci 2011;6:87. 
 (39)  Black AD, Car J, Pagliari C, Anandan C, Cresswell K, Bokun T, et al. The impact of 
eHealth on the quality and safety of health care: a systematic overview. PLoS Med 
2011;8(1):e1000387. 
 (40)  Richens J, Copas A, Sadiq ST, Kingori P, McCarthy O, Jones V, et al. A randomised 
controlled trial of computer-assisted interviewing in sexual health clinics. Sex Transm 
Infect 2010 Aug;86(4):310-4. 
 (41)  Munger MA, Stoddard GJ, Wenner AR, Bachman JW, Jurige JH, Poe L, et al. Safety of 
prescribing PDE-5 inhibitors via e-medicine vs traditional medicine. Mayo Clin Proc 
2008 Aug;83(8):890-6. 
329 
 
 
 (42)  Gurol-Urganci I, de JT, Vodopivec-Jamsek V, Car J, Atun R. Mobile phone messaging for 
communicating results of medical investigations. Cochrane Database Syst Rev 
2012;6:CD007456. 
 (43)  Meyer B, Atherton H, Sawmynaden P, Car J. Email for communicating results of 
diagnostic medical investigations to patients. Cochrane Database Syst Rev 
2012;8:CD007980. 
 (44)  Pinnock H, Slack R, Sheikh A. Misconnecting for health: (lack of) advice for 
professionals on the safe use of mobile phone technology. Qual Saf Health Care 2007 
Jun;16(3):162-3. 
 (45)  Department of Health Informatics Directorate. NHS Connecting for Health.  2013. 4-3-
2013.  
Ref Type: Online Source 
http://www.connectingforhealth.nhs.uk/ 
 (46)  Estcourt CS.  20-3-2013.  
Ref Type: Personal Communication 
 (47)  Blake H. Innovation in practice: mobile phone technology in patient care. Br J 
Community Nurs 2008 Apr;13(4):160, 162-0, 165. 
 (48)  Klasnja P, Pratt W. Healthcare in the pocket: mapping the space of mobile-phone 
health interventions. J Biomed Inform 2012 Feb;45(1):184-98. 
 (49)  van dM, V, van den Hout WB, Bakker MJ, Rabe KF, Sterk PJ, Assendelft WJ, et al. Cost-
effectiveness of Internet-based self-management compared with usual care in asthma. 
PLoS One 2011;6(11):e27108. 
 (50)  Ryan D, Price D, Musgrave SD, Malhotra S, Lee AJ, Ayansina D, et al. Clinical and cost 
effectiveness of mobile phone supported self monitoring of asthma: multicentre 
randomised controlled trial. BMJ 2012;344:e1756. 
 (51)  Pinnock H, Slack R, Pagliari C, Price D, Sheikh A. Understanding the potential role of 
mobile phone-based monitoring on asthma self-management: qualitative study. Clin 
Exp Allergy 2007 May;37(5):794-802. 
 (52)  Martinez-Perez B, de lT-D, I, Lopez-Coronado M. Mobile health applications for the 
most prevalent conditions by the world health organization: review and analysis. J 
Med Internet Res 2013;15(6):e120. 
 (53)  Krishna S, Boren SA, Balas EA. Healthcare via cell phones: a systematic review. 
Telemed J E Health 2009 Apr;15(3):231-40. 
 (54)  de JT, Gurol-Urganci I, Vodopivec-Jamsek V, Car J, Atun R. Mobile phone messaging for 
facilitating self-management of long-term illnesses. Cochrane Database Syst Rev 
2012;12:CD007459. 
 (55)  Blake H. Mobile phone technology in chronic disease management. Nurs Stand 2008 
Nov 26;23(12):43-6. 
330 
 
 
 (56)  Baptist AP, Thompson M, Grossman KS, Mohammed L, Sy A, Sanders GM. Social media, 
text messaging, and email-preferences of asthma patients between 12 and 40 years 
old. J Asthma 2011 Oct;48(8):824-30. 
 (57)  Smith M, Dang D, Lee J. E-prescribing: clinical implications for patients with diabetes. J 
Diabetes Sci Technol 2009 Sep;3(5):1215-8. 
 (58)  Nirantharakumar K, Marshall T, Hemming K, Narendran P, Coleman JJ. Electronic 
prescription data is useful in validating discharge diagnostic codes for patients with 
diabetes. Diabetic Medicine 2012;29. 
 (59)  Nirantharakumar K, Marshall T, Hemming K, Narendran P, Coleman JJ. Inpatient 
electronic prescribing data can be used to identify 'lost' discharge codes for diabetes. 
Diabetic Medicine 2012;29(12):e430-e435. 
 (60)  Mark DA, Fitzmaurice GJ, Haughey KA, O'Donnell ME, Harty JC. Assessment of the 
quality of care and financial impact of a virtual renal clinic compared with the 
traditional outpatient service model. Int J Clin Pract 2011 Oct;65(10):1100-7. 
 (61)  Austin BS, Gunlock TL, Krishna S, Kramer TC. Computer-aided diabetes education: a 
synthesis of randomized controlled trials. AMIA Annu Symp Proc 2006;51-5. 
 (62)  Adaji A, Schattner P, Jones K. The use of information technology to enhance diabetes 
management in primary care: a literature review. Inform Prim Care 2008;16(3):229-37. 
 (63)  Boyce N. The Lancet Technology: June, 2012. Maps, apps--and evidence? Lancet 2012 
Jun 16;379(9833):2231. 
 (64)  Muessig KE, Pike EC, Legrand S, Hightow-Weidman LB. Mobile Phone Applications for 
the Care and Prevention of HIV and Other Sexually Transmitted Diseases: A Review. J 
Med Internet Res 2013;15(1):e1. 
 (65)  Harris K, Michie K, Barber J, Winter A. Mobile applications for patients living with HIV. 
HIV Medicine 15[28-29], 1464-2662. 2014.  
Ref Type: Abstract 
 (66)  Huckvale K, Car M, Morrison C, Car J. Apps for asthma self-management: a systematic 
assessment of content and tools. BMC Med 2012;10:144. 
 (67)  Marcano Belisario JS, Huckvale K, Greenfield G, Car J, Gunn LH. Smartphone and tablet 
self management apps for asthma. Cochrane Database Syst Rev 2013;11:CD010013. 
 (68)  Neithercott T. Health apps. 12 on-the-go diabetes tools for your smartphone. Diabetes 
Forecast 2013 Jan;66(1):34-7. 
 (69)  Eng DS, Lee JM. The promise and peril of mobile health applications for diabetes and 
endocrinology. Pediatr Diabetes 2013 Jun;14(4):231-8. 
 (70)  Abroms LC, Padmanabhan N, Thaweethai L, Phillips T. iPhone apps for smoking 
cessation: a content analysis. Am J Prev Med 2011 Mar;40(3):279-85. 
 (71)  Choi J, Noh GY, Park DJ. Smoking cessation apps for smartphones: content analysis 
with the self-determination theory. J Med Internet Res 2014;16(2):e44. 
331 
 
 
 (72)  Visser BJ, Korevaar DA, Nolan T. Mobile medical apps: dangers and potential solutions. 
J Telemed Telecare 2013 Mar 21. 
 (73)  O'Neill S, Brady RR. Colorectal smartphone apps: opportunities and risks. Colorectal Dis 
2012 Sep;14(9):e530-e534. 
 (74)  O'Neill S, Brady RR. Clinical involvement and transparency in medical apps; not all apps 
are equal. Colorectal Dis 2013 Jan;15(1):122. 
 (75)  McCartney M. How do we know whether medical apps work? BMJ 2013;346:f1811. 
 (76)  Buijink AW, Visser BJ, Marshall L. Medical apps for smartphones: lack of evidence 
undermines quality and safety. Evid Based Med 2013 Jun;18(3):90-2. 
 (77)  Health apps and safety: views from recent sources. Health Devices 2012 
Oct;41(10):330-1. 
 (78)  Zanni GR. Medical apps worth having. Consult Pharm 2013 May;28(5):322-4. 
 (79)  Widmeier K. Technology for the field. Mobile apps prove vital to EMS providers. JEMS 
2012 Nov;37(11):58, 60, 62. 
 (80)  Walsworth DT. Medical apps: making your mobile device a medical device. Fam Pract 
Manag 2012 May;19(3):10-3. 
 (81)  Terry M. Medical Apps for Smartphones. Telemed J E Health 2010 Jan;16(1):17-22. 
 (82)  Franko OI. Smartphone apps for orthopaedic surgeons. Clin Orthop Relat Res 2011 
Jul;469(7):2042-8. 
 (83)  Burns E. Information for Health. Leeds: NHS Executive; 1998.  
 (84)  Department of Health. The Power of Information: Putting us all in control of the health 
and care information we need.  2012 May 21.  
 (85)  Department of Health. Liberating the NHS: An Information Revolution.  2010.  
Ref Type: Online Source 
 (86)  Department of Health. NHS Patient Experience Framework.  2012 Feb 22.  
 (87)  Department of Health. Delivering 21st Century IT Support for the NHS - A National 
Strategic Programme. London: Department of Health; 2002.  
 (88)  Department of Health. Better information, better choices, better health: Putting 
information at the centre of health. London: Department of Health; 2004.  
 (89)  NHS England. Safer hospitals, safer wards: achieving an integrated digital care record.  
2013 Jul 1.  
 (90)  NHS England. NHS Commissioning Board launches library of NHS-reviewed phone apps 
to keep people healthy.  12-3-2013. 24-6-2013.  
Ref Type: Online Source 
http://www.england.nhs.uk/2013/03/12/nhs-apps/ 
332 
 
 
 (91)  EUnetHTA. EUnetHTA guidelines.  2015. 2-12-0015.  
Ref Type: Online Source 
http://www.eunethta.eu/#tab-1-tab 
 (92)  Fanta GB, Pretorius L, Erasmus L. An evaluation of eHealth systems implementation 
frameworks for sustainability in resource constrained environments: at literature 
review. 2015. 
 (93)  Holmes KK, Sparling FP, Stamm WE, Piot P, Wasserheit JN, Corey L, et al. Sexually 
Transmitted Diseases. Fourth Edition ed. McGraw Hill; 2008. 
 (94)  World Health Organization. Sexually Transmitted Infections (STIs). Fact sheet No 110.  
2013 Nov.  
 (95)  Public Health England. Genitourinary medicine clinic activity dataset (GUMCADv2).  19-
12-2013. 19-1-2015.  
Ref Type: Online Source 
https://www.gov.uk/genitourinary-medicine-clinic-activity-dataset-gumcadv2 
 (96)  Public Health England. CTAD: Chlamydia Testing Activity Dataset.  4-6-2013. 31-12-
2013.  
Ref Type: Online Source 
http://www.hpa.org.uk/sexualhealth/ctad 
 (97)  Public Health England. Health Protection Report: Sexually transmitted infections and 
chlamydia screening in England, 2013.  14 A.D. Jun 20. Report No.: Vol 8 No. 24. 
 (98)  Public Health England. Sexually transmitted infections and chlamydia screening in 
England,2012.  2013 Jun 7.  
 (99)  Fairley CK, Williams H, Lee DM, Cummings R. A plea for more research on access to 
sexual health services. Int J STD AIDS 2007 Feb;18(2):75-6. 
 (100)  Public Health England. STI diagnoses & rates in England by gender, 2004-2013.  2015. 
9-1-2015.  
Ref Type: Online Source 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/340430/Tabl
e_1_STI_diagnoses_and_rates_in_England_by_gender.pdf 
 (101)  Public Health England. What is the NCSP?  2013. 16-12-2013.  
Ref Type: Online Source 
http://www.chlamydiascreening.nhs.uk/ys/about.html 
 (102)  World Health Organization. Defining sexual health. Report of a technical consultation 
on sexual health 28-31 January 2002, Geneva. Geneva; 2006.  
 (103)  Wellings K, Johnson AM. Framing sexual health research: adopting a broader 
perspective. Lancet 2013 Nov 30;382(9907):1759-62. 
 (104)  Sonnenberg P, Clifton S, Beddows S, Field N, Soldan K, Tanton C, et al. Prevalence, risk 
factors, and uptake of interventions for sexually transmitted infections in Britain: 
findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet 
2013 Nov 25. 
333 
 
 
 (105)  Macdowall W, Gibson LJ, Tanton C, Mercer CH, Lewis R, Clifton S, et al. Lifetime 
prevalence, associated factors, and circumstances of non-volitional sex in women and 
men in Britain: findings from the third National Survey of Sexual Attitudes and 
Lifestyles (Natsal-3). Lancet 2013 Nov 25. 
 (106)  Field N, Mercer CH, Sonnenberg P, Tanton C, Clifton S, Mitchell KR, et al. Associations 
between health and sexual lifestyles in Britain: findings from the third National Survey 
of Sexual Attitudes and Lifestyles (Natsal-3). Lancet 2013 Nov 25. 
 (107)  Mitchell KR, Mercer CH, Ploubidis GB, Jones KG, Datta J, Field N, et al. Sexual function 
in Britain: findings from the third National Survey of Sexual Attitudes and Lifestyles 
(Natsal-3). Lancet 2013 Nov 25. 
 (108)  Mercer CH, Tanton C, Prah P, Erens B, Sonnenberg P, Clifton S, et al. Changes in sexual 
attitudes and lifestyles in Britain through the life course and over time: findings from 
the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet 2013 Nov 25. 
 (109)  Department of Health. The national strategy for sexual health and HIV. London; 2001.  
 (110)  Increased transmission of syphilis in men who have sex with men reported from 
Brighton and Hove. Commun Dis Rep CDR Wkly 2000 May 19;10(20):177, 180. 
 (111)  Increased transmission of syphilis in Brighton and Greater Manchester among men 
who have sex with men. Commun Dis Rep CDR Wkly 2000 Oct 27;10(43):383, 386. 
 (112)  Doherty L, Fenton KA, Jones J, Paine TC, Higgins SP, Williams D, et al. Syphilis: old 
problem, new strategy. BMJ 2002 Jul 20;325(7356):153-6. 
 (113)  Kinghorn GR. Patient access to GUM clinics. Sex Transm Infect 2001 Feb;77(1):1-2. 
 (114)  Foley E, Patel R, Green N, Rowen D. Access to genitourinary medicine clinics in the 
United Kingdom. Sex Transm Infect 2001 Feb;77(1):12-4. 
 (115)  Djuretic T, Catchpole M, Bingham JS, Robinson A, Hughes G, Kinghorn G. Genitourinary 
medicine services in the United Kingdom are failing to meet current demand. Int J STD 
AIDS 2001 Sep;12(9):571-2. 
 (116)  Kinghorn G. A sexual health and HIV strategy for England. BMJ 2001 Aug 
4;323(7307):243-4. 
 (117)  Department of Health. The national strategy for sexual health and HIV - 
Implementation action plan.  2002 Jun 26.  
 (118)  House of Commons Health Select Committee. Third Report of the Session 2003-2003: 
Sexual Health 2003.  2003.  
 (119)  Laverty S, Pugh RN, Joseph AT. The crisis in sexual health and developing genitourinary 
medicine services: lessons from a primary care trust. Int J STD AIDS 2006 Jan;17(1):37-
43. 
 (120)  Sir Liam Donaldson CMO. Improving the Prevention and Treatment of Sexually 
Transmitted Infections (STIs), including HIV.  Department of Health; 2006 Apr 6. Report 
No.: 6352. 
334 
 
 
 (121)  Medical Foundation for AIDS and Sexual Health. Recommended Sexual Health 
Standards.  2005 Mar 16.  
 (122)  Medical Foundation for AIDS and Sexual Health. Recommended Standards for NHS HIV 
Standards.  2003.  
 (123)  Department of Health. The NHS in England: The operating framework for 2006/7.  
2006 Jan 26.  
 (124)  Mercer CH, Aicken CR, Estcourt CS, Keane F, Brook G, Rait G, et al. Building the bypass-
-implications of improved access to sexual healthcare: evidence from surveys of 
patients attending contrasting genitourinary medicine clinics across England in 
2004/2005 and 2009. Sex Transm Infect 2012 Feb;88(1):9-15. 
 (125)  Department of Health. A Framework for Sexual Health Improvement in England.  2013 
Mar.  
 (126)  Waugh MA. 'Through a glass darkly': reflections on genitourinary medicine. Int J STD 
AIDS 1991 Sep;2(5):325-32. 
 (127)  Sadler KE, Low N, Mercer CH, Sutcliffe LJ, Islam MA, Shafi S, et al. Testing for sexually 
transmitted infections in general practice: cross-sectional study. BMC Public Health 
2010;10:667. 
 (128)  Sutcliffe LJ, Sadler KE, Low N, Cassell JA. Comparing expectations and experiences of 
care for sexually transmitted infections in general practice: a qualitative study. Sex 
Transm Infect 2011 Mar;87(2):131-5. 
 (129)  Yung M, Denholm R, Peake J, Hughes G. Distribution and characteristics of sexual 
health service provision in primary and community care in England. Int J STD AIDS 2010 
Sep;21(9):650-2. 
 (130)  French RS, Coope CM, Graham A, Gerressu M, Salisbury C, Stephenson JM. One stop 
shop versus collaborative integration: what is the best way of delivering sexual health 
services? Sex Transm Infect 2006 Jun;82(3):202-6. 
 (131)  Department of Health. Summary and conclusions of CMO's Expert Advisory Group on 
Chlamydia trachomatis.  1998.  
 (132)  Gleave T. Implementing a Chlamydia pilot screening programme. Nurs Times 2002 Dec 
10;98(50):34-7. 
 (133)  Adams EJ, Turner KM, Edmunds WJ. The cost effectiveness of opportunistic chlamydia 
screening in England. Sex Transm Infect 2007 Jul;83(4):267-74. 
 (134)  Low N, Ward H. Focus on Chlamydia. Sex Transm Infect 2007 Jul;83(4):251-2. 
 (135)  Department of Health. Dr Ruth Hussey's Report.  2009.  
 (136)  House of Commons Committee of Public Accounts. Seventh Report of Session 2009-10. 
Young people's sexual health: the National Chlamydia Screening Programme.  2010 Jan 
18.  
335 
 
 
 (137)  National Chlamydia Screening Programme. NCSP scorecard Q1-4.  2012.  
 (138)  The Public Health (Venereal Diseases) Regulations July 12th 1916,  Her Majesty's 
Stationary Office (London), (1916). 
 (139)  Department of Health. The NHS Trusts and Primary Care Trusts (Sexually Transmitted 
Diseases) Directions 2000.  2000 Sep 8.  
 (140)  British Association of Sexual Health & HIV. BASHH Groups: National Audit Group.  28-1-
2013. 31-12-2013.  
Ref Type: Online Source 
http://www.bashh.org/BASHH/BASHH_Groups/National_Audit_Group/BASHH/BASHH_Groups
/National_Audit_Group.aspx?hkey=c17918b8-5c72-40bd-981f-632f89e45708 
 (141)  Public Health England. Sexually Transmitted Infections Annual Data.  17-12-2013. 31-
12-2013.  
Ref Type: Online Source 
http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/STIs/STIsAnnualDataTables/ 
 (142)  Shamos SJ, Mettenbrink CJ, Subiadur JA, Mitchell BL, Rietmeijer CA. Evaluation of a 
testing-only "express" visit option to enhance efficiency in a busy STI clinic. Sex Transm 
Dis 2008 Apr;35(4):336-40. 
 (143)  Knight V, Ryder N, Guy R, Lu H, Wand H, McNulty A. New xpress sexually transmissible 
infection screening clinic improves patient journey and clinic capacity at a large sexual 
health clinic. Sex Transm Dis 2013 Jan;40(1):75-80. 
 (144)  Martin L, Knight V, Ryder N, Lu H, Read PJ, McNulty A. Client feedback and satisfaction 
with an express sexually transmissible infection screening service at an inner-city 
sexual health center. Sex Transm Dis 2013 Jan;40(1):70-4. 
 (145)  Curry SJ. eHealth research and healthcare delivery beyond intervention effectiveness. 
Am J Prev Med 2007 May;32(5 Suppl):S127-S130. 
 (146)  Levine D, Woodruff AJ, Mocello AR, Lebrija J, Klausner JD. inSPOT: the first online STD 
partner notification system using electronic postcards. PLoS Med 2008 Oct 
21;5(10):e213. 
 (147)  Kerani RP, Fleming M, DeYoung B, Golden MR. A randomized, controlled trial of inSPOT 
and patient-delivered partner therapy for gonorrhea and chlamydial infection among 
men who have sex with men. Sex Transm Dis 2011 Oct;38(10):941-6. 
 (148)  Bilardi JE, Fairley CK, Hopkins CA, Hocking JS, Sze JK, Chen MY. Let Them Know: 
evaluation of an online partner notification service for chlamydia that offers E-mail and 
SMS messaging. Sex Transm Dis 2010 Sep;37(9):563-5. 
 (149)  Hewett PC, Mensch BS, Ribeiro MC, Jones HE, Lippman SA, Montgomery MR, et al. 
Using sexually transmitted infection biomarkers to validate reporting of sexual 
behavior within a randomized, experimental evaluation of interviewing methods. Am J 
Epidemiol 2008 Jul 15;168(2):202-11. 
336 
 
 
 (150)  Johnson AM, Copas AJ, Erens B, Mandalia S, Fenton K, Korovessis C, et al. Effect of 
computer-assisted self-interviews on reporting of sexual HIV risk behaviours in a 
general population sample: a methodological experiment. AIDS 2001;(15):111-5. 
 (151)  Kurth AE, Martin DP, Golden MR, Weiss NS, Heagerty PJ, Spielberg F, et al. A 
comparison between audio computer-assisted self-interviews and clinician interviews 
for obtaining the sexual history. Sex Transm Dis 2004 Dec;31(12):719-26. 
 (152)  Tideman RL, Chen MY, Pitts MK, Ginige S, Slaney M, Fairley CK. A randomised 
controlled trial comparing computer-assisted with face-to-face sexual history taking in 
a clinical setting. Sex Transm Infect 2007 Feb;83(1):52-6. 
 (153)  Ghanem KG, Hutton HE, Zenilman JM, Zimba R, Erbelding EJ. Audio computer assisted 
self interview and face to face interview modes in assessing response bias among STD 
clinic patients. Sex Transm Infect 2005 Oct;81(5):421-5. 
 (154)  Copas AJ, Wellings K, Erens B, Mercer CH, McManus S, Fenton KA, et al. The accuracy 
of reported sensitive sexual behaviour in Britain: exploring the extent of change 1990-
2000. Sex Transm Infect 2002;(78):26-30. 
 (155)  Kissinger P, Rice J, Farley T, Trim S, Jewitt K, Margavio V, et al. Application of 
computer-assisted interviews to sexual behavior research. Am J Epidemiol 1999 May 
15;149(10):950-4. 
 (156)  Fairley CK, Sze JK, Vodstrcil LA, Chen MY. Computer-assisted self interviewing in sexual 
health clinics. Sex Transm Dis 2010 Nov;37(11):665-8. 
 (157)  Rogers SM, Willis G, Al-Tayyib A, Villarroel MA, Turner CF, Ganapathi L, et al. Audio 
computer assisted interviewing to measure HIV risk behaviours in a clinic population. 
Sex Transm Infect 2005 Dec;81(6):501-7. 
 (158)  Langhaug LF, Sherr L, Cowan FM. How to improve the validity of sexual behaviour 
reporting: systematic review of questionnaire delivery modes in developing countries. 
Trop Med Int Health 2010 Mar;15(3):362-81. 
 (159)  Tideman RL, Pitts MK, Fairley CK. Client acceptability of the use of computers in a 
sexual health clinic. Int J STD AIDS 2006 Feb;17(2):121-3. 
 (160)  Shoveller J, Knight R, Davis W, Gilbert M, Ogilvie G. Online sexual health services: 
examining youth's perspectives. Can J Public Health 2012 Jan;103(1):14-8. 
 (161)  Superdrug Online Doctor. Sexual Health.  2015.  
Ref Type: Online Source 
https://onlinedoctor.superdrug.com/sexual-health-clinic.html 
 (162)  BBC News. Concern over online gonorrhoea treatment.  1-3-2015. 5-4-2015.  
Ref Type: Online Source 
http://www.bbc.co.uk/news/health-31649099 
 (163)  Sullivan V. Online treatment for sex infections threatens publics health.  2015. 9-4-
2015.  
Ref Type: Online Source 
337 
 
 
http://www.theguardian.com/healthcare-network/2015/apr/09/online-treatment-for-sex-
infections-threatens-publics-health 
 (164)  Woodhall SC, Sile B, Talebi A, Nardone A, Baraitser P. Internet testing for Chlamydia 
trachomatis in England, 2006 to 2010. BMC Public Health 2012;12:1095. 
 (165)  Estcourt CS. Testing and treating STIs in hard to reach populations. 15 A.D. Jun 3; 2015. 
 (166)  Schackman BR, Dastur Z, Ni Q, Callahan MA, Berger J, Rubin DS. Sexually active HIV-
positive patients frequently report never using condoms in audio computer-assisted 
self-interviews conducted at routine clinical visits. AIDS Patient Care STDS 2008 
Feb;22(2):123-9. 
 (167)  Williams ML, Freeman RC, Bowen AM, Zhao Z, Elwood WN, Gordon C, et al. A 
comparison of the reliability of self-reported drug use and sexual behaviors using 
computer-assisted versus face-to-face interviewing. AIDS Educ Prev 2000 
Jun;12(3):199-213. 
 (168)  Erens B, Phelps A, Clifton S, Mercer CH, Tanton C, Hussey D, et al. Methodology of the 
third British National Survey of Sexual Attitudes and Lifestyles (Natsal-3). Sex Transm 
Infect 2013 Nov 25. 
 (169)  Aicken CR, Gray M, Clifton S, Tanton C, Field N, Sonnenberg P, et al. Improving 
Questions on Sexual Partnerships: Lessons Learned from Cognitive Interviews for 
Britain's Third National Survey of Sexual Attitudes and Lifestyles ("Natsal-3"). Arch Sex 
Behav 2012 Jun 14. 
 (170)  Woodward CL, Roedling S, Edwards SG, Armstrong A, Richens J. Computer-assisted 
survey of attitudes to HIV and sexually transmissible infection partner notification in 
HIV-positive men who have sex with men. Sex Health 2010 Dec;7(4):460-2. 
 (171)  van der Elst EM, Okuku HS, Nakamya P, Muhaari A, Davies A, McClelland RS, et al. Is 
audio computer-assisted self-interview (ACASI) useful in risk behaviour assessment of 
female and male sex workers, Mombasa, Kenya? PLoS One 2009;4(5):e5340. 
 (172)  Morrison-Beedy D, Carey MP, Tu X. Accuracy of audio computer-assisted self-
interviewing (ACASI) and self-administered questionnaires for the assessment of 
sexual behavior. AIDS Behav 2006 Sep;10(5):541-52. 
 (173)  Dolezal C, Marhefka SL, Santamaria EK, Leu CS, Brackis-Cott E, Mellins CA. A 
comparison of audio computer-assisted self-interviews to face-to-face interviews of 
sexual behavior among perinatally HIV-exposed youth. Arch Sex Behav 2012 
Apr;41(2):401-10. 
 (174)  Scoular A, Duncan B, Hart G. "That sort of place...where filthy men go...": a qualitative 
study of women's perceptions of genitourinary medicine services. Sex Transm Infect 
2001 Oct;77(5):340-3. 
 (175)  Thomas N, Murray E, Rogstad KE. Confidentiality is essential if young people are to 
access sexual health services. Int J STD AIDS 2006 Aug;17(8):525-9. 
338 
 
 
 (176)  Fuller S, Aicken C, Sutcliffe L, stcourt CS, Gk, zidou V, et al. What are young people's 
perceptions of using electronic self-tests for STIs linked to mobile technology for 
diagnosis and care (eSTI2)? STI & AIDS World Congress, Vienna . 2013.  
Ref Type: Abstract 
 (177)  Ryder N, McNulty AM. Confidentiality and access to sexual health services. Sex Health 
2009 Jun;6(2):153-5. 
 (178)  Poulton M. Patient confidentiality in sexual health services and electronic patient 
records. Sex Transm Infect 2013 Mar;89(2):90. 
 (179)  Jaya, Hindin MJ, Ahmed S. Differences in young people's reports of sexual behaviors 
according to interview methodology: a randomized trial in India. Am J Public Health 
2008 Jan;98(1):169-74. 
 (180)  Weston R, Dabis R, Ross JD. Measuring patient satisfaction in sexually transmitted 
infection clinics: a systematic review. Sex Transm Infect 2009 Oct;85(6):459-67. 
 (181)  Gkatzidou V, Hone K, Sutcliffe LJ, Gibbs J, Sadiq ST, Sczcepura A, et al. User interface 
design for mobile-based sexual health interventions for young people: Design 
recommendations from a qualitative study on an online Chlamydia clinical care 
pathway.   2015.  
Ref Type: Unpublished Work 
 (182)  Lim EJ, Haar J, Morgan J. Can text messaging results reduce time to treatment of 
Chlamydia trachomatis? Sex Transm Infect 2008 Dec;84(7):563-4. 
 (183)  Lorimer K, McDaid L. Young Men's Views Toward the Barriers and Facilitators of 
Internet-Based Chlamydia Trachomatis Screening: Qualitative Study. J Med Internet 
Res 2013;15(12):e265. 
 (184)  Gaydos CA, Barnes M, Aumakhan B, Quinn N, Wright C, Agreda P, et al. Chlamydia 
trachomatis age-specific prevalence in women who used an internet-based self-
screening program compared to women who were screened in family planning clinics. 
Sex Transm Dis 2011 Feb;38(2):74-8. 
 (185)  Gaydos CA, Rizzo-Price PA, Barnes M, Dwyer K, Wood BJ, Hogan MT. The use of focus 
groups to design an internet-based program for chlamydia screening with self-
administered vaginal swabs: what women want. Sex Health 2006 Dec;3(4):209-15. 
 (186)  Gaydos CA, Dwyer K, Barnes M, Rizzo-Price PA, Wood BJ, Flemming T, et al. Internet-
based screening for Chlamydia trachomatis to reach non-clinic populations with mailed 
self-administered vaginal swabs. Sex Transm Dis 2006 Jul;33(7):451-7. 
 (187)  Gaydos CA, Barnes M, Aumakhan B, Quinn N, Agreda P, Whittle P, et al. Can e-
technology through the Internet be used as a new tool to address the Chlamydia 
trachomatis epidemic by home sampling and vaginal swabs? Sex Transm Dis 2009 
Sep;36(9):577-80. 
 (188)  Spielberg F, Levy V, Lensing S, Chattopadhyay I, Venkatasubramanian L, Acevedo N, et 
al. Fully integrated e-services for prevention, diagnosis, and treatment of sexually 
transmitted infections: results of a 4-county study in California. Am J Public Health 
2014 Dec;104(12):2313-20. 
339 
 
 
 (189)  eSTI2 Consortium. eSTI2 Project Plan_v2.  2011.  
 (190)  Bailey JV, Pavlou M, Copas A, McCarthy O, Carswell K, Rait G, et al. The Sexunzipped 
trial: optimizing the design of online randomized controlled trials. J Med Internet Res 
2013;15(12):e278. 
 (191)  Family planning association. FPA talking sense about sex: what we do.  2015.  
Ref Type: Online Source 
http://www.fpa.org.uk/what-we-do 
 (192)  Expert Health Limited. Dr Thom.  2015. 5-4-2015.  
Ref Type: Online Source 
https://www.drthom.com/ 
 (193)  Department of Health. GPs to 'prescribe' apps for patients.  22-2-2012. 19-11-2014.  
Ref Type: Online Source 
https://www.gov.uk/government/news/gps-to-prescribe-apps-for-patients 
 (194)  Wolf JA, Moreau JF, Akilov O, Patton T, English JC, III, Ho J, et al. Diagnostic inaccuracy 
of smartphone applications for melanoma detection. JAMA Dermatol 2013 
Apr;149(4):422-6. 
 (195)  Weaver ER, Horyniak DR, Jenkinson R, Dietze P, Lim MS. "Let's get Wasted!" and Other 
Apps: Characteristics, Acceptability, and Use of Alcohol-Related Smartphone 
Applications. JMIR Mhealth Uhealth 2013;1(1):e9. 
 (196)  West JH, Hall PC, Hanson CL, Barnes MD, Giraud-Carrier C, Barrett J. There's an app for 
that: content analysis of paid health and fitness apps. J Med Internet Res 
2012;14(3):e72. 
 (197)  Thompson MA, Misra S. Oncology Smartphone applications: perspectives from a 
researcher/community-based hematologist/oncologist and a physician reviewer of 
medical apps. Oncology (Williston Park) 2012 Mar;26(3):231, 236, 238-1, 236, 239. 
 (198)  Ritchie A. 10 apps physicians recommend to their patients. Med Econ 2013 Aug 
10;90(15):42. 
 (199)  Harrison AM, Goozee R. Psych-related iPhone apps. J Ment Health 2014 Feb;23(1):48-
50. 
 (200)  Pandey A, Hasan S, Dubey D, Sarangi S. Smartphone apps as a source of cancer 
information: changing trends in health information-seeking behavior. J Cancer Educ 
2013 Mar;28(1):138-42. 
 (201)  Arnhold M, Quade M, Kirch W. Mobile applications for diabetics: a systematic review 
and expert-based usability evaluation considering the special requirements of diabetes 
patients age 50 years or older. J Med Internet Res 2014;16(4):e104. 
 (202)  NHS Choices. Health Apps Library.  2013. 24-6-2013.  
Ref Type: Online Source 
http://apps.nhs.uk/ 
 (203)  NHS Choices health apps library.  2014. 20-11-2014.  
340 
 
 
Ref Type: Online Source 
http://apps.nhs.uk/ 
 (204)  Gkatzidou V, Hone K, Gibbs J, Sutcliffe L, Sadiq ST, Sonnenberg P, et al. A user-centered 
approach to inform the design of a mobile application for STI diagnosis and 
management. 2013. 
 (205)  Boulos MN, Brewer AC, Karimkhani C, Buller DB, Dellavalle RP. Mobile medical and 
health apps: state of the art, concerns, regulatory control and certification. Online J 
Public Health Inform 2014;5(3):229. 
 (206)  Medicines and Healthcare Products Regulatory Agency. Medicines & Medical Devices 
Regulation: what you need to know.  2008. 8-1-2015.  
Ref Type: Online Source 
http://www.mhra.gov.uk/home/groups/comms-
ic/documents/websiteresources/con2031677.pdf 
 (207)  Abroms LC, Lee WJ, Bontemps-Jones J, Ramani R, Mellerson J. A content analysis of 
popular smartphone apps for smoking cessation. Am J Prev Med 2013 Dec;45(6):732-6. 
 (208)  Estcourt C, Evans DE. Core learning outcomes in sexual and reproductive health and 
HIV for medical undergraduates: improving skills of future providers. Sex Transm Infect 
2005;81(440). 
 (209)  Lewis TL. A systematic self-certification model for mobile medical apps. J Med Internet 
Res 2013;15(4):e89. 
 (210)  NHS Choices. Health apps library: Sexual health.  2014. 22-11-2014.  
Ref Type: Online Source 
http://apps.nhs.uk/tags/sexual-health/ 
 (211)  Pimenta JM, Catchpole M, Rogers PA, Hopwood J, Randall S, Mallinson H, et al. 
Opportunistic screening for genital chlamydial infection. II: prevalence among 
healthcare attenders, outcome, and evaluation of positive cases. Sex Transm Infect 
2003 Feb;79(1):22-7. 
 (212)  Dominiak-Felden G, Cohet C, Atrux-Tallau S, Gilet H, Tristram A, Fiander A. Impact of 
human papillomavirus-related genital diseases on quality of life and psychosocial 
wellbeing: results of an observational, health-related quality of life study in the UK. 
BMC Public Health 2013;13:1065. 
 (213)  Merin A, Pachankis JE. The psychological impact of genital herpes stigma. J Health 
Psychol 2011 Jan;16(1):80-90. 
 (214)  Mark H, Gilbert L, Nanda J. Psychosocial well-being and quality of life among women 
newly diagnosed with genital herpes. J Obstet Gynecol Neonatal Nurs 2009 
May;38(3):320-6. 
 (215)  Green J. Psychosocial issues in genital herpes management. Herpes 2004 Dec;11(3):60-
2. 
 (216)  Brentjens MH, Yeung-Yue KA, Lee PC, Tyring SK. Recurrent genital herpes treatments 
and their impact on quality of life. Pharmacoeconomics 2003;21(12):853-63. 
341 
 
 
 (217)  Health on the Net. The Heath on the Net Foundation Code of Conduct for medical and 
health Web sites (HONcode).  25-8-2014. 8-12-2014.  
Ref Type: Online Source 
http://www.hon.ch/HONcode/ 
 (218)  Bender JL, Yue RY, To MJ, Deacken L, Jadad AR. A lot of action, but not in the right 
direction: systematic review and content analysis of smartphone applications for the 
prevention, detection, and management of cancer. J Med Internet Res 
2013;15(12):e287. 
 (219)  Sunyaev A, Dehling T, Taylor PL, Mandl KD. Availability and quality of mobile health 
app privacy policies. J Am Med Inform Assoc 2014 Aug 21. 
 (220)  Powell AC, Landman AB, Bates DW. In search of a few good apps. JAMA 2014 May 
14;311(18):1851-2. 
 (221)  Medicines and Healthcare Products Regulatory Agency. Medical Devices Classification.  
16-8-2013. 8-1-2015.  
Ref Type: Online Source 
http://www.mhra.gov.uk/Howweregulate/Devices/Classification/index.htm 
 (222)  Shuren J. The FDA's role in the development of medical mobile applications. Clin 
Pharmacol Ther 2014 May;95(5):485-8. 
 (223)  US Food and Drug Administration. Mobile medical apps.  6-4-2014. 16-12-2014.  
Ref Type: Online Source 
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ConnectedHealth/Mobil
eMedicalApplications/ucm255978.htm 
 (224)  Misra S. Happitque's recent setback shows that health app certification is a flawed 
proposition.  2014. 14-12-2014.  
Ref Type: Online Source 
http://www.imedicalapps.com/2014/01/happtiques-setback-future-app-certification/ 
 (225)  Chan SR, Misra S. Certification of mobile apps for health care. JAMA 2014 Sep 
17;312(11):1155-6. 
 (226)  Thompson BM, Brodsky I. Should the FDA regulate mobile medical apps? BMJ 
2013;347:f5211. 
 (227)  Charani E, Castro-Sanchez E, Moore LS, Holmes A. Do smartphone applications in 
healthcare require a governance and legal framework? It depends on the application! 
BMC Med 2014;12:29. 
 (228)  Fuller SS, Sutcliffe LJ, Estcourt CS, Gkatzidou V, Hone K, Sonnenberg P, et al. What are 
young people's perceptions of using electronic self-tests for STIs linked to mobile 
technology for diagnosis and care (eSTI2)? Sex Transm.Infect. 89[(Suppl 1)], A69. 2013.  
Ref Type: Abstract 
 (229)  Helsper E. Digital Natives and ostrich tactics? The possible implications of labelling 
young people as digital experts.  2008.  
Ref Type: Online Source 
342 
 
 
http://www.beyondcurrenthorizons.org.uk/wp-
content/uploads/final_helsper_digitalnativesostrichtactics_20081201_jb.pdf 
 (230)  Swendeman D, Rotheram-Borus MJ. Innovation in sexually transmitted disease and 
HIV prevention: internet and mobile phone delivery vehicles for global diffusion. Curr 
Opin Psychiatry 2010 Mar;23(2):139-44. 
 (231)  Nolan T. A smarter way to practise. BMJ 2011;342:d1124. 
 (232)  Chomutare T, Fernandez-Luque L, Arsand E, Hartvigsen G. Features of mobile diabetes 
applications: review of the literature and analysis of current applications compared 
against evidence-based guidelines. J Med Internet Res 2011;13(3):e65. 
 (233)  Derbyshire E, Dancey D. Smartphone Medical Applications for Women's Health: What 
Is the Evidence-Base and Feedback? Int J Telemed Appl 2013;2013:782074. 
 (234)  A reality checkpoint for mobile health: three challenges to overcome. PLoS Med 
2013;10(2):e1001395. 
 (235)  Tomlinson M, Rotheram-Borus MJ, Swartz L, Tsai AC. Scaling up mHealth: where is the 
evidence? PLoS Med 2013;10(2):e1001382. 
 (236)  Kaushal R, Shojania KG, Bates DW. Effects of computerized physician order entry and 
clinical decision support systems on medication safety: a systematic review. Arch 
Intern Med 2003 Jun 23;163(12):1409-16. 
 (237)  Kawamoto K, Houlihan CA, Balas EA, Lobach DF. Improving clinical practice using 
clinical decision support systems: a systematic review of trials to identify features 
critical to success. BMJ 2005 Apr 2;330(7494):765. 
 (238)  Health and Social Care Information Centre. Spine transition update - posted Friday 
29th August.  2015. 20-4-2015.  
Ref Type: Online Source 
http://systems.hscic.gov.uk/spine/transition 
 (239)  Health and Social Care Information Centre. Electronic Prescription Service.  2013. 29-5-
2013.  
Ref Type: Online Source 
http://systems.hscic.gov.uk/eps 
 (240)  Health and Social Care Information Centre. Spine 2 Programme. Information Pack for 
Suppliers of Systems using Spine Services.  2013 Apr 11.  
 (241)  Health and Social Care Information Centre. Electronic Prescription Service - News.  
2015. 3-5-2015.  
Ref Type: Online Source 
http://systems.hscic.gov.uk/eps/news/index_html 
 (242)  Khoja S, Durrani H, Scott RE, Sajwani A, Piryani U. Conceptual framework for 
development of comprehensive e-health evaluation tool. Telemed J E Health 2013 
Jan;19(1):48-53. 
343 
 
 
 (243)  Department of Health. Building the Information Core: Implementing the NHS Plan. 
London: Department of Health; 2001.  
 (244)  Chartered Institute for IT, Department of Health. Keeping your online health and social 
care records safe and secure.  2012.  
 (245)  Cross M. Problems with computerising patients' records are "as serious as ever," says 
MP. BMJ 2009;(338):b337. 
 (246)  Greenhalgh T, Keen J. England's national programme for IT. BMJ 2013;346:f4130. 
 (247)  Pagliari C, Singleton P, Detmer DE. NHS national programme for IT. Time for a reality 
check of NPfIT's problems. BMJ 2009;338:b643. 
 (248)  Cross M. There IT goes again. BMJ (Online) 2011;343(7824). 
 (249)  Cornford T, Savage I, Jani Y, Franklin BD, Barber N, Slee A, et al. Learning lessons from 
electronic prescribing implementations in secondary care. Studies in Health 
Technology and Informatics 2010;160(PART 1):233-7. 
 (250)  Department of Health. Reconfiguring the Department of Health's Arm's Length Bodies.  
2004.  
 (251)  legislation.gov.uk. Health and Social Care Act 2012.  2012.  
Ref Type: Statute 
 (252)  Shortliffe EH. Strategic action in health information technology: why the obvious has 
taken so long. Health Aff (Millwood ) 2005 Sep;24(5):1222-33. 
 (253)  Dornan T, Ashcroft D, Heathfield H, Lewis P, Miles J, Taylor D, et al. An in depth 
investigation into causes of prescribing errors by foundation trainees in relation to 
their medical education. EQUIP study.  2009.  
 (254)  Bignardi GE, Hamson C, Chalmers A. Can we use electronic prescribing to reduce 
prescription errors for antibiotics? J Infect 2010 Nov;61(5):427-8. 
 (255)  Bignardi GE. Reducing prescription errors. Lancet 2010;375(9713). 
 (256)  Weetman T, Aronson J, Maxwell S. Reducing prescription errors. Lancet 2010 Feb 
6;375(9713):461-2. 
 (257)  Coombes I, Reid C, Stowasser D, Duigiud M, Bedford G, Mitchell C. Reducing 
prescription errors. Lancet 2010 Feb 6;375(9713):462. 
 (258)  Motulsky A, Lamothe L, Sicotte C. Impacts of second-generation electronic 
prescriptions on the medication management process in primary care: A systematic 
review. Int J Med Inform 2013 Feb 18. 
 (259)  Greenhalgh T, Peacock R. Effectiveness and efficiency of search methods in systematic 
reviews of complex evidence: audit of primary sources. BMJ 2005 Nov 
5;331(7524):1064-5. 
344 
 
 
 (260)  British National Formulary. BNF November 2013.  BMJ Group & Pharmaceutical Press; 
2013.  
 (261)  General Medical Council. Good practice in prescribing and managing medicines and 
devices.  2013.  
 (262)  Her Majesty's Stationary Office (London). The Prescription Only Medicines (Human 
Use) (Electronic Communications) Order 2001.  2001.  
 (263)  Her Majesty's Stationary Office (London). The Prescription Only Medicines (Human 
Use) Order 1997.  1997.  
 (264)  Her Majesty's Stationary Office (London). NHS (Pharmaceuticals and Local 
Pharmaceutical Services) Regulations 2013.  2013.  
Ref Type: Statute 
 (265)  NHS Prescription Services. Current and Out of Date Prescription Form Versions.  2013. 
30-12-2013.  
Ref Type: Online Source 
http://www.nhsbsa.nhs.uk/PrescriptionServices/Documents/PrescriptionServices/Current_and
_Out_of_Date_Rx_Form_V4_Revised_June_2013.pdf 
 (266)  NHS Information Governance. Guidelines on use of encryption to protect person 
identifiable and sensitive information.  2008.  NHS Connecting for Health. 4-3-2013.  
Ref Type: Online Source 
http://www.connectingforhealth.nhs.uk/systemsandservices/infogov/security/encryptionguid
e.pdf 
 (267)  Pharmaceutical Services Negotiating Committee. Valid Prescription Forms.  2013. 29-5-
2013.  
Ref Type: Online Source 
http://www.psnc.org.uk/pages/valid_prescription_forms.html 
 (268)  Department of Health. EL (91) 127. Responsibility for prescribing between hospitals 
and GPs.  1991.  
 (269)  NHS Prescription Services. Overprint Specification for Hospital Unit FP10SS Forms.  1-4-
2013. 30-12-2013.  
Ref Type: Online Source 
http://www.nhsbsa.nhs.uk/PrescriptionServices/Documents/PrescriptionServices/Overprint_S
pecification_for_Hospital_Unit_FP10SS_April_13.pdf 
 (270)  NHS Connecting for health. EPS Release 2. Business Process Guidance for Initial 
Implementers.  2009 Apr.  
 (271)  NHS Connecting for Health. Electronic prescribing in hospitals; Challenges and lessons 
learned.  2009.  
 (272)  Cresswell K, Coleman J, Slee A, Williams R, Sheikh A. Investigating and learning lessons 
from early experiences of implementing ePrescribing systems into NHS hospitals: a 
questionnaire study. PLoS One 2013;8(1):e53369. 
345 
 
 
 (273)  Ahmed Z, McLeod MC, Barber N, Jacklin A, Franklin BD. The use and functionality of 
electronic prescribing systems in english acute NHS trusts: a cross-sectional survey. 
PLoS One 2013;8(11):e80378. 
 (274)  Health and Social Care Information Centre. Electronic Prescription Service.  2015. 21-5-
2015.  
Ref Type: Online Source 
http://systems.hscic.gov.uk/eps 
 (275)  Health and Social Care Information Centre. Release 1: What is EPS Release 1.  2013. 3-
10-2013.  
Ref Type: Online Source 
http://systems.hscic.gov.uk/eps/library/faqs/release1 
 (276)  Fernando TJ, Nguyen DD, Baraff LJ. Effect of electronically delivered prescriptions on 
compliance and pharmacy wait time among emergency department patients. 
Academic Emergency Medicine 2012;19(1):102-5. 
 (277)  Ax F, Ekedahl A. Electronically transmitted prescriptions not picked up at pharmacies in 
Sweden. Research in Social and Administrative Pharmacy 2010;6(1):70-7. 
 (278)  Fischer MA, Stedman MR, Lii J, Vogeli C, Shrank WH, Brookhart MA, et al. Primary 
medication non-adherence: Analysis of 195,930 electronic prescriptions. Journal of 
General Internal Medicine 2010;25(4):284-90. 
 (279)  Ma A, Chen DM, Chau FM, Saberi P. Improving adherence and clinical outcomes 
through an HIV pharmacist's interventions. AIDS Care - Psychological and Socio-
Medical Aspects of AIDS/HIV 2010;22(10):1189-94. 
 (280)  Harbig P, Barat I, Lund P, Damsgaard EM. Instantaneous detection of nonadherence: 
Quality, strength, and weakness of an electronic prescription database. 
Pharmacoepidemiology and Drug Safety 2012;21(3):323-8. 
 (281)  Sue Eaton. PCT lead commissioner for primary care who oversaw the implementation 
of the new community pharmacy contract and subsequent roll out of EPS.  21-10-2013.  
Ref Type: Personal Communication 
 (282)  Wikipedia. Smartphone.  30-12-2013. 31-12-2013.  
Ref Type: Online Source 
http://en.wikipedia.org/wiki/Smartphone 
 (283)  Health and Social Care Information Centre. Statistics and progress.  2015.  
Ref Type: Online Source 
http://systems.hscic.gov.uk/eps/stats 
 (284)  Health and Social Care Information Centre. Registration Authorities and Smartcards. 
Information for Patients and Public.  2015. 4-6-2015.  
Ref Type: Online Source 
http://systems.hscic.gov.uk/rasmartcards/patients 
 (285)  Health and Social Care Information Centre. Generating and signing electronic 
prescriptions.  2015. 20-4-2015.  
Ref Type: Online Source 
346 
 
 
http://systems.hscic.gov.uk/eps/library/0112.pdf 
 (286)  Health and Social Care Information Centre. Spine transition update  - posted Friday 
29th August.  2014. 20-4-2015.  
Ref Type: Online Source 
http://systems.hscic.gov.uk/spine/transition 
 (287)  NHS Connecting for health. Prescribing Systems Compliance Specification.  2012. 13-
10-2013.  
Ref Type: Online Source 
http://systems.hscic.gov.uk/eps/library/compliance/presc_22.pdf 
 (288)  National Information Governance Board for Health and Social Care. The Care Record 
Guarantee; Our Guarantee for NHS Care Records in England.  2011. 10-10-2013.  
Ref Type: Online Source 
http://systems.hscic.gov.uk/rasmartcards/documents/crg.pdf 
 (289)  Abramson EL, Malhotra S, Fischer K, Edwards A, Pfoh ER, Osorio SN, et al. Transitioning 
between electronic health records: Effects on ambulatory prescribing safety. Journal of 
General Internal Medicine 2011;26(8):868-74. 
 (290)  Abdel-Qader D, Harper L, Cantrill J, Tully M. Characterising pharmacists' interventions 
in an electronic prescribing system at hospital discharge. International Journal of 
Pharmacy Practice 2009;17(S2):B16-B17. 
 (291)  Health and Social Care Information Centre. A new way to get your medicines and 
appliances.  2014. 20-4-2015.  
Ref Type: Online Source 
http://systems.hscic.gov.uk/eps/library/patientfact.pdf 
 (292)  Her Majesty's Stationary Office (London). Medicines Act 1968.  1968.  
Ref Type: Statute 
http://www.legislation.gov.uk/ukpga/1968/67/contents 
 (293)  NHS Commissioning Board. Commissioning Policy: Defining the Boundaries between 
NHS and Private Healthcare.  2013 Apr.  
 (294)  Medicines and Healthcare products Regulatory Agency. Frequently asked questions: 
Patient Specific Directions.  29-4-2013. 30-12-2013.  
Ref Type: Online Source 
http://www.mhra.gov.uk/PrintPreview/DefaultSplashPP/CON263943?ResultCount=10&Dynam
icListQuery=&DynamicListSortBy=xCreationDate&DynamicListSortOrder=Desc&Dynam
icListTitle=&PageNumber=1&Title=Frequently%20asked%20questions%3a%20Patient
%20Specific%20Directions 
 (295)  British Medical Association. Patient Group Directions and Patient Specific Directions in 
general practice.  2010. 30-12-2013.  
Ref Type: Online Source 
http://bma.org.uk/practical-support-at-work/gp-practices/prescribing 
 (296)  Estcourt C, Sutcliffe L, Cassell J, Mercer CH, Copas A, James L, et al. Can we improve 
partner notification rates through expedited partner therapy in the UK? Findings from 
347 
 
 
an exploratory trial of Accelerated Partner Therapy (APT). Sex Transm Infect 2012 
Feb;88(1):21-6. 
 (297)  NHS England. Strategic Systems and Technology.  2015.  
Ref Type: Online Source 
http://www.england.nhs.uk/ourwork/tsd/sst/ 
 (298)  BASHH Clinical Effectiveness Group. 2013 UK national guideline for consultations 
requiring sexual history taking.  2013.  
 (299)  British Association of Sexual Health & HIV. BASHH National Audit Group.  10-7-2014. 
14-1-2015.  
Ref Type: Online Source 
http://www.bashh.org/BASHH/BASHH_Groups/National_Audit_Group/BASHH/BASHH_Groups
/National_Audit_Group.aspx 
 (300)  Horner P, Boag F, the Clinical Effectiveness Group. 2006 UK National Guideline for the 
Management of Genital Tract Infection with Chlamydia trachomatis.  British 
Association for Sexual Health and HIV; 2006.  
 (301)  Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Potential benefits, limitations, 
and harms of clinical guidelines. BMJ 1999 Feb 20;318:527-30. 
 (302)  OPEN CLINICAL knowledge management for medical care. Clinical Pathways: 
multidisciplinary plans of best clinical practice.  8-7-2013. 16-8-2013.  
Ref Type: Online Source 
http://www.openclinical.org/clinicalpathways.html 
 (303)  Cowan FM, French R, Johnson AM. The role and effectiveness of partner notification in 
STD control: a review. Genitourin Med 1996 Aug;72(4):247-52. 
 (304)  Health and Social Care Information Centre. NHS Pathways.  2015. 6-4-2015.  
Ref Type: Online Source 
http://systems.hscic.gov.uk/pathways 
 (305)  British Association of Sexual Health & HIV. BASHH Guidelines.  2015. 12-1-2015.  
Ref Type: Online Source 
http://www.bashh.org/BASHH/Guidelines/Guidelines/BASHH/Guidelines/Guidelines.aspx 
 (306)  International Union against Sexually Transmitted Infections. IUSTI Current European 
Guidelines.  31-10-2014. 12-1-2015.  
Ref Type: Online Source 
http://www.iusti.org/regions/Europe/euroguidelines.htm 
 (307)  General Medical Council. Standards and ethics guidance for doctors.  2015. 12-1-2015.  
Ref Type: Online Source 
http://www.gmc-uk.org/publications/standards_guidance_for_doctors.asp 
 (308)  BASHH & MEDFASH. Standards for the managment of sexually transmitted infections 
(STIs).  2014 Jan.  
 (309)  Faculty of Sexual and Reproductive Healthcare. Clinical Guidance.  2014. 12-1-2015.  
Ref Type: Online Source 
348 
 
 
http://www.fsrh.org/pages/clinical_guidance.asp 
 (310)  Lim MS, Hocking JS, Hellard ME, Aitken CK. SMS STI: a review of the uses of mobile 
phone text messaging in sexual health. Int J STD AIDS 2008 May;19(5):287-90. 
 (311)  Preventx Limited. test.me.  2015.  
Ref Type: Online Source 
https://www.test.me/ 
 (312)  Lloyds Pharmacy Online Doctor. Sexual Health Information.  2015. 26-5-2015.  
Ref Type: Online Source 
https://onlinedoctor.lloydspharmacy.com/uk/info/sexual-health-information 
 (313)  Singh RH, Erbelding EJ, Zenilman JM, Ghanem KG. The role of speculum and bimanual 
examinations when evaluating attendees at a sexually transmitted diseases clinic. Sex 
Transm Infect 2007 Jun;83(3):206-10. 
 (314)  Ling SB, Richardson DB, Mettenbrink CJ, Westergaard BC, Sapp-Jones TD, Crane LA, et 
al. Evaluating a Web-Based Test Results System at an Urban STI Clinic. Sex Transm Dis 
2010. 
 (315)  Brown L, Copas A, Stephenson J, Gilleran G, Ross JD. Preferred options for receiving 
sexual health screening results: a population and patient survey. Int J STD AIDS 2008 
Mar;19(3):184-7. 
 (316)  Llewellyn C, Pollard A, Miners A, Richardson D, Fisher M, Cairns J, et al. Understanding 
patient choices for attending sexually transmitted infection testing services: a 
qualitative study. Sex Transm Infect 2012 Nov;88(7):504-9. 
 (317)  Martin L, Knight V, Read PJ, McNulty A. Clients' preferred methods of obtaining 
sexually transmissable infection or HIV results from Sydney Sexual Health Centre. 
Sexual Health 2013;10(1):91-2. 
 (318)  Labacher L, Mitchell C. Talk or text to tell? How young adults in Canada and South 
Africa prefer to receive STI results, counseling, and treatment updates in a wireless 
world. J Health Commun 2013;18(12):1465-76. 
 (319)  Steedman NM, Thompson C. Telephonetics RESULTS computer-facilitated telephone 
system: a novel method for patient results retrieval. Int J STD AIDS 2007 Jun;18(6):422-
3. 
 (320)  Evans-Jones J, Steedman N, Newman M, Jones R, Milburn A, O'Mahony C. Use of 
Telephonetics RESULTS computer-facilitated telephone system with automatic results 
upload. Int J STD AIDS 2011 Sep;22(9):525-6. 
 (321)  National Chlamydia Screening Programme. Text messaging for test results 
communication within the National Chlamydia Screening Programme.  2013. 12-5-
2015.  
Ref Type: Online Source 
http://www.chlamydiascreening.nhs.uk/ps/resources/guidelines/Chlamydia_Test_Result_Noti
fication_Text%20Messaging_NCSP_Recommendations_Jan_2013.pdf 
349 
 
 
 (322)  Kohn R, Williams D, Klausner JD. Getting STD Test Results Over the Internet: San 
Francisco, 2005. 2006 National STD Prevention Conference . 9-5-2006. 21-12-2013.  
Ref Type: Abstract 
http://cdc.confex.com/cdc/std2006/techprogram/P11122.HTM 
 (323)  E-health insider. Amsterdam to launch STD clinic online.  22-10-2007. 21-12-2013.  
Ref Type: Online Source 
http://ehi.co.uk/news/EHI/3114/amsterdam-to-launch-std-clinic-online 
 (324)  Duncan B, Hart G, Scoular A, Bigrigg A. Qualitative analysis of psychosocial impact of 
diagnosis of Chlamydia trachomatis: implications for screening. BMJ 2001 Jan 
27;322(7280):195-9. 
 (325)  Department of Health, NHS. Information Governance Toolkit.  2013. 1-12-2014.  
Ref Type: Online Source 
https://www.igt.connectingforhealth.nhs.uk/Home.aspx?tk=413226979206263&cb=b4449775
-5a6f-441c-806c-b637de245051&lnv=7&clnav=YES 
 (326)  Gammell K. Mobile phone insurance: don't lose money if you lose your smartphone.  
2012.  
Ref Type: Online Source 
http://www.telegraph.co.uk/finance/personalfinance/insurance/9573224/Dont-lose-money-if-
you-lose-your-smartphone.html 
 (327)  Consumer Reports. Smart phone thefts rose to 3.1 million last year, Consumer Reports 
finds.  28-5-2014.  
Ref Type: Online Source 
http://www.consumerreports.org/cro/news/2014/04/smart-phone-thefts-rose-to-3-1-million-
last-year/index.htm 
 (328)  Bracebridge S, Bachmann MO, Ramkhelawon K, Woolnough A. Evaluation of a 
systematic postal screening and treatment service for genital Chlamydia trachomatis, 
with remote clinic access via the internet: a cross-sectional study, East of England. Sex 
Transm Infect 2012 Aug;88(5):375-81. 
 (329)  Public Health England. Commissioning, reporting and using chlamydia activity data.  
2013. 19-1-2015.  
Ref Type: Online Source 
http://www.chlamydiascreening.nhs.uk/ps/info-management.asp 
 (330)  National Chlamydia Screening Programme. Patient Group Direction for the 
administration of azithromycin for Chlamydia trachomatis.  2012. 20-4-2015.  
Ref Type: Online Source 
http://www.chlamydiascreening.nhs.uk/ps/resources/guidelines/NCSP_AZITHROMYCIN%20AD
MINSTRATION%20PGD_Sept%202012_final.pdf 
 (331)  eMC. Azithromycin 500mg tablets SPC.  17-9-2013. 22-11-2013.  
Ref Type: Online Source 
http://www.medicines.org.uk/EMC/medicine/21720/SPC/Azithromycin+500mg+Tablets/ 
 (332)  Electronic Medicines Compendium. Mizollen 10mg modified-release tablets summary 
of product characteristics.  18-5-2012. 12-12-0013.  
Ref Type: Online Source 
350 
 
 
http://www.medicines.org.uk/emc/medicine/19970/SPC 
 (333)  Nahata M. Drug interactions with azithromycin and the macrolides: an overview. 
Journal of Antimicrobial Chemotherapy 1996;37 Suppl C:133-42. 
 (334)  Owens RC, Jr., Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of 
interest. Clin Infect Dis 2006 Dec 15;43(12):1603-11. 
 (335)  Mosholder AD, Mathew J, Alexander JJ, Smith H, Nambiar S. Cardiovascular risks with 
azithromycin and other antibacterial drugs. N Engl J Med 2013 May 2;368(18):1665-8. 
 (336)  Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of 
cardiovascular death. N Engl J Med 2012 May 17;366(20):1881-90. 
 (337)  Svanstrom H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular 
causes. N Engl J Med 2013 May 2;368(18):1704-12. 
 (338)  eMC. Erythromycin 250mg Capsules SPC.  28-10-2014. 20-1-2015.  
Ref Type: Online Source 
http://www.medicines.org.uk/emc/medicine/26315/SPC/Erythromycin+250mg+Capsules/#UN
DESIRABLE_EFFECTS 
 (339)  The National Survey of Sexual Attitudes and Lifestyles. Natsal-3.  2014. 17-1-2015.  
Ref Type: Online Source 
http://www.natsal.ac.uk/natsal-3 
 (340)  Radcliffe KW, Flew S, Poder A, Cusini M. European guideline for the organization of a 
consultation for sexually transmitted infections, 2012. Int J STD AIDS 2012 
Sep;23(9):609-12. 
 (341)  Fernando I, Thompson C. Testing time: testing patient acceptance and ability to self-
screen for a No-Talk Testing service. Int J STD AIDS 2013. 
 (342)  Bowling A. Research Methods in Health; Investigating Health and Health Services. 
Third ed. McGraw Hill; 2009. 
 (343)  Macleod J, Salisbury C, Low N, McCarthy A, Sterne JA, Holloway A, et al. Coverage and 
uptake of systematic postal screening for genital Chlamydia trachomatis and 
prevalence of infection in the United Kingdom general population: cross sectional 
study. BMJ 2005 Apr 23;330(7497):940. 
 (344)  Ferreira A, Young T, Mathews C, Zunza M, Low N. Strategies for partner notification for 
sexually transmitted infections, including HIV. Cochrane Database Syst Rev 
2013;10:CD002843. 
 (345)  Low N, Welch J, Radcliffe K. Developing national outcome standards for the 
management of gonorrhoea and genital chlamydia in genitourinary medicine clinics. 
Sex Transm Infect 2004 Jun;80(3):223-9. 
 (346)  Sutcliffe L, Brook MG, Chapman JL, Cassell JM, Estcourt CS. Is accelerated partner 
therapy a feasible and acceptable strategy for rapid partner notification in the UK?: a 
qualitative study of genitourinary medicine clinic attenders. Int J STD AIDS 2009 
Sep;20(9):603-6. 
351 
 
 
 (347)  Hopkins CA, Temple-Smith MJ, Fairley CK, Pavlin NL, Tomnay JE, Parker RM, et al. 
Telling partners about chlamydia: how acceptable are the new technologies? BMC 
Infect Dis 2010;10:58. 
 (348)  Trelle S, Shang A, Nartey L, Cassell JA, Low N. Improved effectiveness of partner 
notification for patients with sexually transmitted infections: systematic review. BMJ 
2007 Feb 17;334(7589):354. 
 (349)  Althaus CL, Turner KM, Mercer CH, Auguste P, Roberts TE, Bell G, et al. Effectiveness 
and cost-effectiveness of traditional and new partner notification technologies for 
curable sexually transmitted infections: observational study, systematic reviews and 
mathematical modelling. Health Technol Assess 2014 Jan;18(2):1-viii. 
 (350)  Lim MS, Bowring AL, Gold J, Aitken CK, Hellard ME. Trends in sexual behavior, testing, 
and knowledge in young people; 2006-2011. Sex Transm Dis 2012 Nov;39(11):831-4. 
 (351)  Nicholas A, Bailey JV, Stevenson F, Murray E. The Sexunzipped trial: young people's 
views of participating in an online randomized controlled trial. J Med Internet Res 
2013;15(12):e276. 
 (352)  Allison S, Bauermeister JA, Bull S, Lightfoot M, Mustanski B, Shegog R, et al. The 
intersection of youth, technology, and new media with sexual health: moving the 
research agenda forward. J Adolesc Health 2012 Sep;51(3):207-12. 
 (353)  Bailey JV, Murray E, Rait G, Mercer CH, Morris RW, Peacock R, et al. Interactive 
computer-based interventions for sexual health promotion. Cochrane Database Syst 
Rev 2010;(9):CD006483. 
 (354)  McCarthy O, Carswell K, Murray E, Free C, Stevenson F, Bailey JV. What young people 
want from a sexual health website: design and development of Sexunzipped. J Med 
Internet Res 2012;14(5):e127. 
 (355)  Jones K, Eathington P, Baldwin K, Sipsma H. The impact of health education 
transmitted via social media or text messaging on adolescent and young adult risky 
sexual behavior: a systematic review of the literature. Sex Transm Dis 2014 
Jul;41(7):413-9. 
 (356)  Bull SS, Levine DK, Black SR, Schmiege SJ, Santelli J. Social media-delivered sexual 
health intervention: a cluster randomized controlled trial. Am J Prev Med 2012 
Nov;43(5):467-74. 
 (357)  McClean H, Chair BASHH National Audit Group, Radcliffe KCBCEG, Sullivan 
ABNAGRCEG, Ahmed-Jushuf ICBCSU. BASHH Statement on Partner Notification for 
Sexually Transmissible Infections.  3-7-2012. 28-8-2013.  
Ref Type: Online Source 
www.bashh.org/documents/4445.pdf 
 (358)  Lanjouw E, Ossewaarde JM, Stary A, Boag F, van der Meijden WI. 2010 European 
guideline for the management of Chlamydia trachomatis infections. Int J STD AIDS 
2010 Nov;21(11):729-37. 
 (359)  Society of Sexual Health Advisers. The Manual for Sexual Health Advisers.  2004. 1-12-
2014.  
352 
 
 
Ref Type: Online Source 
http://www.ssha.info/wp-content/uploads/ha_manual_2004_complete.pdf 
 (360)  Beatty PC, Willis GB. Research Synthesis: The Practice of Cognitive Interviewing. Public 
Opinion Quarterly 2007;71(2):287-311. 
 (361)  Horner P, Boag F, the Clinical Effectiveness Group. 2006 UK National Guideline for the 
Management of Genital Tract Infection with Chlamydia trachomatis.  British 
Association for Sexual Health and HIV; 2006.  
 (362)  Gkatzidou V, Hone K, Sutcliffe L, Gibbs J, Sadiq ST, Szczepura A, et al. User interface 
design for mobile-based sexual health interventions for young people: design 
recommendations from a qualitative study on an online Chlamydia clinical care 
pathway. BMC Med Inform Decis Mak 2015;15:72. 
 (363)  Ammenwerth E, Graber S, Herrmann G, Burkle T, Konig J. Evaluation of health 
information systems-problems and challenges. Int J Med Inform 2003 Sep;71(2-3):125-
35. 
 (364)  Nykanen P, Brender J, Talmon J, de KN, Rigby M, Beuscart-Zephir MC, et al. Guideline 
for good evaluation practice in health informatics (GEP-HI). Int J Med Inform 2011 
Dec;80(12):815-27. 
 (365)  Brender J, Talmon J, de KN, Nykanen P, Rigby M, Ammenwerth E. STARE-HI - 
Statement on Reporting of Evaluation Studies in Health Informatics: explanation and 
elaboration. Appl Clin Inform 2013;4(3):331-58. 
 (366)  Eysenbach G. CONSORT-EHEALTH: improving and standardizing evaluation reports of 
Web-based and mobile health interventions. J Med Internet Res 2011;13(4):e126. 
 (367)  Shcherbatykh I, Holbrook A, Thabane L, Dolovich L. Methodologic issues in health 
informatics trials: the complexities of complex interventions. J Am Med Inform Assoc 
2008 Sep;15(5):575-80. 
 (368)  Rothrock N, Kaiser K, Cella D. Developing a Valid Patient-Reported Outcome Measure. 
Clinical Pharmacology & Therapeutics 2011;90(5):737-42. 
 (369)  Hasin DS, Aharonovich E, Greenstein E. HealthCall for the smartphone: technology 
enhancement of brief intervention in HIV alcohol dependent patients. Addict Sci Clin 
Pract 2014;9:5. 
 (370)  Simoes AA, Bastos FI, Moreira RI, Lynch KG, Metzger DS. A randomized trial of audio 
computer and in-person interview to assess HIV risk among drug and alcohol users in 
Rio De Janeiro, Brazil. J Subst Abuse Treat 2006 Apr;30(3):237-43. 
 (371)  Cohall AT, Senathirajah Y, Dini S, Nye A, Powell D, Powell B. An online audio computer-
assisted self-interview for pre-screening prior to rapid HIV testing in a vulnerable 
population. AMIA Annu Symp Proc 2007;915. 
 (372)  Mevissen FE, Eiling E, Bos AE, Tempert B, Mientjes M, Schaalma HP. Evaluation of the 
Dutch AIDS STI information helpline: differential outcomes of telephone versus online 
counseling. Patient Education & Counseling 2012;88(2):218-23. 
353 
 
 
 (373)  Postel MG, De Haan HA, De Jong CA. Evaluation of an e-therapy program for problem 
drinkers: a pilot study. Subst Use Misuse 2010 Oct;45(12):2059-75. 
 (374)  Gajecki M, Berman AH, Sinadinovic K, Rosendahl I, Andersson C. Mobile phone brief 
intervention applications for risky alcohol use among university students: a 
randomized controlled study. Addict Sci Clin Pract 2014;9:11. 
 (375)  Bauermeister JA, Zimmerman MA, Johns MM, Glowacki P, Stoddard S, Volz E. 
Innovative recruitment using online networks: lessons learned from an online study of 
alcohol and other drug use utilizing a web-based, respondent-driven sampling 
(webRDS) strategy. J Stud Alcohol Drugs 2012 Sep;73(5):834-8. 
 (376)  Evans R, Joseph-Williams N, Edwards A, Newcombe RG, Wright P, Kinnersley P, et al. 
Supporting informed decision making for prostate specific antigen (PSA) testing on the 
web: an online randomized controlled trial. Journal of Medical Internet Research 
2010;12(3). 
 (377)  Moessner M, Bauer S. Online counselling for eating disorders: reaching an 
underserved population? J Ment Health 2012 Aug;21(4):336-45. 
 (378)  Christensen H, Griffiths KM, Mackinnon AJ, Kalia K, Batterham PJ, Kenardy J, et al. 
Protocol for a randomised controlled trial investigating the effectiveness of an online e 
health application for the prevention of Generalised Anxiety Disorder. BMC Psychiatry 
2010;10. 
 (379)  Atienza AA, Hesse BW, Baker TB, Abrams DB, Rimer BK, Croyle RT, et al. Critical Issues 
in eHealth Research. Am J Prev Med 2007;32(5S):S71-S74. 
 (380)  Brown W, III, Yen PY, Rojas M, Schnall R. Assessment of the Health IT Usability 
Evaluation Model (Health-ITUEM) for evaluating mobile health (mHealth) technology. J 
Biomed Inform 2013 Dec;46(6):1080-7. 
 (381)  Medical Research Council. Developing and evaluating complex interventions: new 
guidance.  2010. 1-5-2015.  
Ref Type: Online Source 
www.mrc.ac.uk/complexinterventionsguidance 
 (382)  Talmon J, Enning J, Castaneda G, Eurlings F, Hoyer D, Nykanen P, et al. The VATAM 
guidelines. Int J Med Inform 1999 Dec;56(1-3):107-15. 
 (383)  Ammenwerth E, Brender J, Nykanen P, Prokosch HU, Rigby M, Talmon J. Visions and 
strategies to improve evaluation of health information systems. Reflections and 
lessons based on the HIS-EVAL workshop in Innsbruck. Int J Med Inform 2004 Jun 
30;73(6):479-91. 
 (384)  Gustafson DH, Wyatt JC. Evaluation of ehealth systems and services. BMJ 2004 May 
15;328(7449):1150. 
 (385)  Dansky KH, Thompson D, Sanner T. A framework for evaluating eHealth research. Eval 
Program Plann 2006 Nov;29(4):397-404. 
 (386)  May C. A rational model for assessing and evaluating complex interventions in health 
care. BMC Health Serv Res 2006;6:86. 
354 
 
 
 (387)  Yusof MM, Papazafeiropoulou A, Paul RJ, Stergioulas LK. Investigating evaluation 
frameworks for health information systems. Int J Med Inform 2008 Jun;77(6):377-85. 
 (388)  Turner J, Latimer V, Snooks H. An evaluation of the accuracy and safety of NHS 
Pathways.  2008. 8-5-2015.  
Ref Type: Online Source 
http://systems.hscic.gov.uk/pathways/about/eval.pdf 
 (389)  Catwell L, Sheikh A. Evaluating eHealth interventions: the need for continuous 
systemic evaluation. PLoS Med 2009 Aug;6(8):e1000126. 
 (390)  Lilford RJ, Foster J, Pringle M. Evaluating eHealth: how to make evaluation more 
methodologically robust. PLoS Med 2009 Nov;6(11):e1000186. 
 (391)  Cummings E, Turner P. Patients at the centre: methodological considerations for 
evaluating evidence from health interventions involving patients use of web-based 
information systems. Open Med Inform J 2010;4:188-94. 
 (392)  Kumar S, Nilsen WJ, Abernethy A, Atienza A, Patrick K, Pavel M, et al. Mobile health 
technology evaluation: the mHealth evidence workshop. Am J Prev Med 2013 
Aug;45(2):228-36. 
 (393)  Ammenwerth E, Mansmann U, Iller C, Eichstadter R. Factors affecting and affected by 
user acceptance of computer-based nursing documentation: results of a two-year 
study. J Am Med Inform Assoc 2003 Jan;10(1):69-84. 
 (394)  Lobach DF, Detmer DE. Research challenges for electronic health records. Am J Prev 
Med 2007 May;32(5 Suppl):S104-S111. 
 (395)  Berg M. Implementing information systems in health care organizations: myths and 
challenges. Int J Med Inform 2001 Dec;64(2-3):143-56. 
 (396)  Murray E, Khadjesari Z, White IR, Kalaitzaki E, Godfrey C, McCambridge J, et al. 
Methodological challenges in online trials. J Med Internet Res 2009;11(2):e9. 
 (397)  http://www-vatam.unimaas.nl/.  1998. 19-5-0015.  
Ref Type: Online Source 
http://www-vatam.unimaas.nl/ 
 (398)  Talmon J, Ammenwerth E, Brender J, de KN, Nykanen P, Rigby M. STARE-HI--Statement 
on reporting of evaluation studies in Health Informatics. Int J Med Inform 2009 
Jan;78(1):1-9. 
 (399)  de Keizer NF, Ammenwerth E. The quality of evidence in health informatics: how did 
the quality of healthcare IT evaluation publications develop from 1982 to 2005? Int J 
Med Inform 2008 Jan;77(1):41-9. 
 (400)  Ammenwerth E, Schnell-Inderst P, Siebert U. Vision and challenges of Evidence-Based 
Health Informatics: a case study of a CPOE meta-analysis. Int J Med Inform 2010 
Apr;79(4):e83-e88. 
355 
 
 
 (401)  Weir CR, Staggers N, Phansalkar S. The state of the evidence for computerized provider 
order entry: a systematic review and analysis of the quality of the literature. Int J Med 
Inform 2009 Jun;78(6):365-74. 
 (402)  Michael BJ, Rimer BK, Lyons EJ, Golin CE, Frydman G, Ribisl KM. Methodologic 
challenges of e-health research. Eval Program Plann 2006 Nov;29(4):390-6. 
 (403)  Heathfield H, Pitty D, Hanka R. Evaluating information technology in health care: 
barriers and challenges. BMJ 1998 Jun 27;316(7149):1959-61. 
 (404)  Garcia de Yebenes Prous MA, Rodriguez SF, Carmona OL. [Validation of 
questionnaires]. Reumatol Clin 2009 Jul;5(4):171-7. 
 (405)  Weston RL, Hopwood B, Harding J, Sizmur S, Ross JD. Development of a validated 
patient satisfaction survey for sexual health clinic attendees. Int J STD AIDS 2010 
Aug;21(8):584-90. 
 (406)  National Institute for Health and Care Excellence. Prevention of sexually transmitted 
infections and under 18 conceptions.  2007. 14-11-2013.  
Ref Type: Online Source 
https://www.nice.org.uk/guidance/ph3 
 (407)  Pequegnat W, Rosser BR, Bowen AM, Bull SS, DiClemente RJ, Bockting WO, et al. 
Conducting Internet-based HIV/STD prevention survey research: considerations in 
design and evaluation. AIDS Behav 2007 Jul;11(4):505-21. 
 (408)  Karras BT, Tufano JT. Multidisciplinary eHealth survey evaluation methods. Eval 
Program Plann 2006 Nov;29(4):413-8. 
 (409)  University Hospitals Birmingham NHS Trust. Patient Satisfaction Survey for STI Clinics.  
2013. 3-12-2015.  
Ref Type: Online Source 
http://www.bashh.org/BASHH/Education/Patient_Satisfaction_Survey_for_STI_Clinics/BASHH/
Education/Patient_Satisfaction_Survey_for_STI_Clinics.aspx?hkey=16d8ba26-9d7b-
4bca-a40b-75563a2d76f9 
 (410)  Likert R. A technique for the measurement of attitudes. Archives of Psychology 
1932;22:1-55. 
 (411)  Rothwell PM. External validity of randomised controlled trials: "to whom do the results 
of this trial apply?". Lancet 2005 Jan 1;365(9453):82-93. 
 (412)  Khoja S, Durrani H, Scott RE, Sajwani A, Piryani U. PANACeA eHealth Evaluation.  2013. 
3-2-2015.  
Ref Type: Online Source 
http://panacea-evaluation.yolasite.com/evaluation-tools.php 
 (413)  Norris TA, Paul P, Norris AH. Limited benefit of repeating a sensitive question in a 
cross-sectional sexual health study. BMC Med Res Methodol 2013;13:34. 
 
 
 
356 
 
 
Appendix I – mobile app review exclusions 
 
Platform Title of App Author Country Region
Number of 
download
s
Rating
Number of 
ratings
Age 
restriction
Theme 
(e.g. 
health & 
fitness)
Price (£)
Last date 
updated
Author's 
description of 
app
Our 
descriptio
n of app
Target 
audience
Reason for 
exclusion
iOS
Myths of 
Sexually 
Transmitted 
Diseases
Jorge 
Gregorio 
Martin 
Bello
- - - No rating 0 17+
Health& 
Fitness
0.69 18/05/2013
Enjoy and learn at 
the same time. 
Make the quiz to 
know the myths 
andfacts of 
sexually 
transmitted 
diseases (STIs).
Questions 
and 
answers 
about STIs
General 
public
Sex Trivia
iOS
STD Dating 
Tips
Successful
Match.co
m
- - - No rating 0 17+ Books 0 26/04/2013
For people with 
STDs to find help 
and support
App for 
people with 
STIs 
providing 
info on how 
to date and 
support 
from other 
users
People 
with STI
No information 
on STD. Dating 
tips and support 
from other users
iOS
HSCC 
HIV/STD 
Application
Bohung 
Wang
USA - - No rating 0 4+
Health& 
Fitness
0 19/03/2013
This application 
allows quick and 
intuitive access 
to a variety of 
resources for 
preventing, 
detecting and 
treating STDs and 
AIDS.
Majority of 
info on 
HIV/AIDS
General 
public
Focussed on 
HIV/AIDS. Any 
reference to STDs 
are to links to 
external 
websites for 
information
iOS Chec-Mate STFree Inc. USA - - No rating 0 4+ Lifestyle 0 18/02/2012
Allows users to 
instantly locate a 
local screening 
facility to 
schedule an STI/ 
HIV screening 
then securely 
store the results 
for confidential 
sharing or 
verification with 
current or 
potential 
partner.
Allows users 
to locate 
local 
screening 
facilities, 
securely 
store the 
results for 
confidential 
sharing or 
verification 
with current 
or potential 
partner.
People 
with STI
Requires 
subscription
iOS BeForeplay
Near 
Death LLC
- - - No rating 0 12+ Lifestyle 0 05/03/2014
BeForeplay is the 
STD 
communication 
app. For many 
people it is 
awkward and 
uncomfortable to 
ask a partner 
about their 
sexual history 
and health. 
BeForeplay's goal 
is to promote this 
crucial dialogue 
and to document 
that the 
conversation 
occurred.
Provides 
documentat
ion that 
both parties 
disclosed 
whether 
they have or 
do not have 
STDs before 
engaging in 
sex
General 
public
Initially assessed 
by 1 researcher 
and excluded by 
another 
researcher. 
When I tried to 
review it on 
5/12/14 I was 
unable to find it
iOS Herpes
Personal 
Remedies, 
LLC
- - - No rating 0 12+ Medical 2.49 07/08/2014
This app 
represents the 
most 
comprehensive 
and actionable 
nutrition 
guidelines for 
how to combat 
herpes and its 
symptoms.
Suggestions 
on food may 
help combat 
herpes 
symptoms
People 
with STI
Require 
username and 
password
iOS
STDs - 
Sexually 
Transmissa
ble Diseases
Christian 
Schneider
Germany - - No rating 0 12+
Health & 
fitness
1.99 05/09/2012
This app gives you 
the possibility to 
determine 
potential 
diseases, simply 
by selecting 
symptoms.
Determine 
disease by 
selecting 
symptoms
People 
with STI
No original 
content. Links to 
secondary source
iOS
Wart 
Removal+
Daniel 
Burford
- - - No rating 0 12+ Medical 1.49 01/11/2011
Contact us to find 
out more at 
wellhappyapp@g
mail.com
General 
public
Unable to find
iOS
The Curse of 
the Tree-
Man HD
University 
of 
Nebraska - 
Lincoln
- - - No rating 0 9+ Education 0 09/02/2012
Narrated 
interactive comic 
that tells the 
story of how HPV 
attacks the body.
General 
public
Unable to find
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App 
Author Country Region
Number of 
download
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Rating
Number of 
ratings
Age 
restriction
Theme 
(e.g. 
health & 
fi tness )
Price (£)
Last date 
updated
Author's  description of app
Target 
audience
Target 
audience_
4
Include/Ex
clude
Reason for exclus ion
Android
How to 
Cure Yeast 
Infection!
bigo - - 5000 4.2 13
low 
maturi ty
health 
and 
fi tness
free 12/02/2012
"Curing Yeast Infections  the Natura l  Way" E-
Book:
The genera l  yeast infection facts  that you 
must know...
1 - 2 Second researcher unable to find app
Android
How2use 
Condom
Easytime 
Studio
- - 50 5 1
medium 
maturi ty
education £0.99 14/09/2011
Dou you know how to use condom 
correctly?This  app shows you 16 kinds  of 
usages  of condom.
1 - 2
Solely focussed on condom use, but no use 
related to sex i .e. to use the condom as  a  
ha irband
Android
Kelaha 
Projects
Bizmarkag
ency
- - 10 n/a 0
medium 
maturi ty
medica l free 11/04/2014
To be an unrelenting advocate in the fight 
aga inst cervica l  cancer. Kelaha Projects  i s  
creating greater awareness  national ly about 
the disease, whi le promoting ways  of 
prevention and early detection and serving 
as  a  rel iable center for support and access  
to counsel l ing for persons  and their fami l ies  
battl ing or otherwise affected by cervica l  
cancer, a l l  through enl is ting the involvement 
and support of the community in various  
activi ties  and programs.
1 - 2
No information about sexual  health or 
cervica l  cancer. Just information about the 
organisation Kelaha Projects  that peti tion to 
ra isse awareness . 
Android Konjy Konjy - - 50 4.5 6
medium 
maturi ty
health 
and 
fi tness
free 04/09/2014
Reproductive health mobi le app. Conta ins  
info about sex pos i tions  and sexual ly 
transmitted infections . 
1 -
2 Requires  login / s ign up by providing phone 
no and emai l  address
Android
Learn 
about 
STDs
AndreW 
BurnettY
- - ? n/a 0 everyone
health 
and 
fi tness
free 15/09/2014
 Learn about sexual ly transmitted diseases  
in the privacy of your own home with this  
video series  on STDs . Health education 
expert Jane Bogart expla ins  how to treat and 
prevent crabs , AIDS, herpes , HPV, chlamydia , 
gonorrhea, syphi l i s , Hepati ti s  C, and other 
venereal  diseases . Don't miss  the video on 
the top sex myths .
1 - 2 unable to find
Android
Love H 
Style
iGraphic 
Des igns
- - 500 2 4
medium 
maturi ty
socia l free 22/10/2013
Love H Style i s  an onl ine socia l  netowrking 
community where you can find plenty of 
helpful  information about Herpes  (HSV-1, 
HSV-2), HIV & HPV. We a lso a l low you to 
meet s ingles  throughout the world tha  come 
here to gather in search of information, 
support, friendships , and romance. 
1 - 2 Crashed on more than 2 occas ions
Android M4Mobi le
Southern 
Tier AIDS 
Program 
Inc
- - 500 4.3 6
low 
maturi ty
socia l free 04/08/2014
Beyond the socia l  aspects  of M4, we 
encourage guys  to participate in regularly 
scheduled groups  during which they can ta lk 
openly about dating, relationships , and 
safer sex practices . We a lso provide safer 
sex materia ls  and information. Free, 
confidentia l  HIV testing i s  a lso ava i lable on 
s i te at regularly scheduled times  and by 
appointment.
4 MSM 2
No sexual  health info. Condom finder for 
USA
Android
Mole and 
Wart 
Remover
bigo - - 10,000 3.3 18 everyone
health 
and 
fi tness
free 12/02/2012
Info on natura l  remedies  for warts  and 
moles . HPV can cause outbreaks  of warts  in 
various  parts  of the body and at di fferent 
times . It i s  a lso the underlying cause of 
genita l  warts , which i s  a  sexual ly 
transmitted disease (STD)
1 - 2 Doesn't discuss  genita l  warts
Android Play Safe CareXO - - 100 5 1
low 
maturi ty
health 
and 
fi tness
free 07/07/2013
A CareXO.com membership and the 
PlaySafe™ app provide you with an 
innovative way to s tay aware of your sexual  
health AND share your 3rd party veri fied STD 
s tatus  with anyone you choose in the most 
private and sens i tive methods  poss ible.
1 - 2
Requires  membership, username and 
password. You have to s ign up and then vis i t 
your loca l  test centre. Second author unable 
to find app.
Android
Random 
Sex Facts
Sociometri
cs  
Corporatio
n
- - 5,000 2.8 19
high 
maturi ty
education free 20/11/2012
Learn something new every day! Check out 
the Fact of the Day and put your sexual  
health-IQ to the test. (ages  13-18)Learn 
about common STI symptoms, contraceptive 
facts  and the latest HIV and teen pregnancy 
s tatis tics .
1 - 2
Comes  up as  1 fact as  a  time so unable to 
assess  overa l l  content. Fi rs t 10 questions  
related to pregnancy. Sex trivia
Android
S.U.P.E.R. 
Condomiz
er
refraction - - 100 4.4 10
low 
maturi ty
casual free 0/12/13
S.U.P.E.R. Condomizer i s  a  game born from 
the col laboration between S.U.P.E.R. ( a  
bulgarian Y-PEER organization) and 
Refraction, for the 10 Days  of Activism 
Campaign 2013.
This  project a ims  at ra is ing awareness  
about sexual ly transmitted diseases  and 
encourage people to use protection.
In the game you are lonely spermatozoon 
which has  to avoid diseases  as  i t gets  
harder and harder through the neverending 
journey.
1 - 2
No way of getting information to display 
apart from getting hi t by the sperm during 
the game. Information extremely brief. 
Primari ly a  game, with sex trivia , not an 
information app. 
Android
Sex 
Education 
for 
Chi ldren 
Fas  F - - 100 2 1
high 
maturi ty
education free 01/08/2014
App for providing sex education for chi ldren 
on topics  such as  puberty, STDs , pregnancy. 
1 - 2
App is  unoperational . Each topic has  a  l ink 
to a  video, the videos  can not be played.
Android Sex Facts Text Maids - - 100 4.3 17
high 
maturi ty
l i festyle free 23/08/2014
best col lection of Sex Facts  for your mobi le 
device? This  app is  fi l led with fun facts  
about sex, random, funny and interesting. 
Learn weird sex facts  about women and men 
that you might find odd, crazy or awesome! 
Discover how to improve your safe sex l i fe 
and learn sex education facts  that can help 
dispel  common myths  associated with 
orgasms and other sex related behavior. 
This  i s  an educational  app with fun sex facts  
and tips  that are for mature adult male and 
females  only
1 - 2 unable to find app
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Android
Sex Facts  
for You
Android 
Appmaker
- - 500 n/a 0
high 
maturi ty
health 
and 
fi tness
free 06/01/2014
Enjoy this  appl ication with some interesting 
facts  .
1 - 2 Sex trivia . No sexual  health info. 
Android
Sexual  
Health
Droid App 
Team
- - 10,000 4.1 63 everyone
health 
and 
fi tness
free 05/03/2011
Do you know what should you pay your 
attention to whi le have a  baby?
Do you know what should cause Uterine 
Cancer?
Do you know how pelvic pa in would occur?
You can find a l l  these answers  in the Sexual  
health appl ication, i t a lso conta in more 
useful  information about health, with i t in 
hand you could l i fe more healthy!
1 - 2
Crashed on multiple occas ions  when trying 
to access  i tems on the ini tia l  menu. unable 
to find app
Android
Sexual  
Health 
Medicine 
Help
- - 10 n/a 0
high 
maturi ty
health 
and 
fi tness
free 09/09/2014
Sexual  Health i s  an app that provides  you 
with important tips  to mainta in happy and 
healthy sex l i fe. We a l l  seem to know 
enough about such natura l  thing as  sex, but 
do we rea l ly? With Sexual  Health you wi l l  
have no doubts  you are wel l  informed about 
key factors  of wholesomeness  and harmony 
in your bedroom.
1 - 2 Unable to find
Android
Sexual  
Health 
and You
Medisurge 
Technolog
ies  P Ltd
- - 5,000 4.2 21
high 
maturi ty
health 
and 
fi tness
free 18/12/2012
The appl ication a lso provides  user a  
col lection of most asked questions  on the 
topic and their answers  by provided by 
renowned sexologis ts . Sexual  Health i s  one 
of the highest consumed health content on 
digi ta l  media . Health seekers  are reluctant 
in meeting sexologis ts  in person; hence rely 
on fami ly and friends  for solutions  to their 
sexual  problems.
1 - 2
Series  of questions  answered in a  forum 
format. Crashed on severa l  occas ions . 
Second researcher found that the app could 
not be operated
Android Smart AIDS ANLAIDS - - 1000 4.4 29
high 
maturi ty
socia l free 23/07/2014
This  i s  the fi rs t Appl ication about HIV/AIDS 
prevention and education.
Learn more about a l l  sexual  transmitted 
diseases  (STD). Test your knowledge about 
STDs  with a  quiz. 
1 - 2
text not in Engl ish even though app 
description was . 
Android
STD 
checker 
l i te
Luke 
Pammant
- - 1000 3 4
medium 
maturi ty
enterta in
ment
free 05/01/2013
Scan your friends  and yoursel f for STD's !
Li te vers ion includes :
30% chance to come up clean
8 non-fata l  STD's  and STI's
Statis tics/information and symptoms of each 
disease
Funny comments  for each disease
Raises  the awareness  of STD's  and STI's
Ad supported
Please note that this  app is  s trictly for fun. 
Any correlation to disease that the user may 
rea l ly have is  s trictly coincidence
1 - 2
In game format with trivia  re STIs . You press  
a  button to fi l l  a  syringe ful l  of blood and 
then i t ei ther announces  that you have an 
STI and gives  you a  bi t of information on that 
STI or i t tel l s  you that you are 'clean'.
Android
STD risk 
ca lculator 
l i te
Universa l  
Web 
solutions  
CA
- - 5,000 4.5 87
high 
maturi ty
health 
and 
fi tness
free 0/4/12
Works  for a l l  major STIs : Herpes  (HSV1, 
HSV2), HIV, Chlamydia , Gonorrhea, Syphi l i s , 
HPV (genita l  warts ).
STD Risk Ca lculator i s  a  ri sk assessment tool  
for your sexual  health that helps  you to 
determine the chance that you picked up a  
sexual ly-transmitted infection (STI)
1 - 2
There i s  no info on how their a lgori thm 
works  and no info about the infections . On 
the free app i t wi l l  only tel l  you your ri sk of 
having one infection. If you pay to upgrade i t 
apparently gives  you colour graphs  of a l l  the 
probabi l i ties . No information to eva luate 
rea l ly. Unable to find app.  
Android
STD 
Testing 
Ta l i sman 
Capita l  inc
- - 5,000 4.1 11
medium 
maturi ty
medica l free 15/08/2012
The tests  we offer are the same tests  that 
brick+mortar hospita ls  and doctors  use. We 
work with LabCorp and Quest, the nation's  
largest and most respected diagnostic 
laboratories . Al l  tests  offered are FDA-
approved or CLIA-certi fied, and are the most 
sophis ticated tests  ava i lable for sexual ly-
transmitted infection screening.
1 - 2
Links  s tra ight to external  webs i te. No 
information on STIs  - just a  way of getting 
tested with prices  of tests
Android
STDcommu
nity.com
STD 
Communit
y
- - 1000 2.1 10
medium 
maturi ty
enterta in
ment
free 18/02/2013
STD Community i s  a  dating and socia l  
networking s i te for people with Herpes , HPV, 
HIV, Hep C & other STD's  and STI's . Come join 
our community today and chat with others  
from around the globe. Must be 18 years  or 
older to join.
2 - 2 Requires  log in 
Android
Symptoms 
of STDs  
and 
Treatment
Cool  Help 
Guide
- - 0 n/a 0
high 
maturi ty
health 
and 
fi tness
free 19/04/2014
Symptoms Of STDs  And Treatment
Sexual ly active women under the age of 25 
and those over 25 with ri sk should be 
screened for chlamydia  and gonorrhea 
yearly. After being treated for gonorrhea a l l  
people should be re tested for the disease 
after three months .
1 - 2 unable to find app
Android
Symptoms 
of STDs  
Helpful  
Guide
WE HELP 
YOU
- - 500 2.2 4
high 
maturi ty
health 
and 
fi tness
free 02/09/2014
Deal ing With STDs:
Symptoms, Signs , Cures  and Prevention
1 - 2 Unable to find
Android
The Party's  
Over
Master 
and Bul l  
Digi ta l  
Arts  Pvt Ltd
- - 100 n/a 0
low 
maturi ty
education free 22/10/2013
The Party's  Over: Sex, Alcohol  & Pregnancy i s  
a  l ive-action program that tel l s  the s tory of 
three teenage couples  deal ing with a  variety 
of contemporary sexual  health and 
relationship i ssues , presented in the 
context of a  party. The couples  and their 
peers  explore their experiences  and feel ings  
about committed relationships , sexual  
involvement, sexual ly transmitted infections  
(STIs ) and pregnancy in both serious  and 
comedic interactions . The role of a lcohol  in 
unplanned sexual  activi ty i s  a  key focus , as  
are male respons ibi l i ties  and safer sex.
1 - 2
The app conta ins  l inks  to di fferent videos , 
and a l l  wont play when they are cl ick on. 
Unable to use the app.
Android
Vira l -
Dating - 
Meet 
Herpes/HS
V
Vira l -
Dating
- - 10 1 1
medium 
maturi ty
l i festyle £0.99 11/11/2013
Estimates  put the number of us  affected by 
herpes/HSV at between 15-20% of the 
population.
What does  that mean?
You're not a lone!
Download the Vira l -Dating.com app to 
connect with other herpes/HSV s ingles  near 
you for dating, friendship, camaraderie and 
support.
2 - 2 Requires  log in 
Android
What i s  
Herpes?
Ashley 
Cotter-
Cairns
- - 500 n/a 0
medium 
maturi ty
health 
and 
fi tness
free 11/08/2012
Herpes  can be a  very upsetting vi rus  to 
contract. It can be passed innocently from 
one person to another, yet cold sores , and 
especia l ly genita l  herpes , can cause 
embarrassment, anger, and mental  
suffering.
What i s  Herpes? teaches  you everything you 
need to know about this  vi rus .
1 - 2
Links  only to external  webs i tes  e.g. WebMD 
information/ herpes  guide/NHS choices
Android Wud U? Barnado's - - 500 4.8 12
medium 
maturi ty
l i festyle free 12/05/2014
Wud U? lets  you find out how some young 
people end up being sexual ly exploi ted. You 
can think about the decis ions  you would 
make i f you were in the same s i tuation, and 
get advice about your decis ions .
Through Wud U?, you can:
-find out how to make safe decis ions  to help 
prevent yoursel f from being sexual ly 
exploi ted
-understand more about sexual  exploi tation
-get support i f you or a  friend are at ri sk of 
sexual  exploi tation 
1 - 2
Second author unable to download despite 
sufficient  space
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Both Herpes
Personal  
Remedies , 
LLC
USA Boston 1 to 5 0 No rating 0 0 Everyone 12+ Medica l Medica l 2.49 23/07/2014 07/10/2014
This  app represents  the 
most comprehens ive and 
actionable nutri tion 
guidel ines  for how to 
combat herpes  and i ts  
symptoms.
2 - 2
Require username and 
password
Both HPV.edu
Cris tyn 
Davies
- - 100 3 1 2 1 Everyone 4+ Medica l Medica l 0 10/03/2014 03/03/2014
HPV.edu is  an app for 
young people, their 
fami ly, and educators . Be 
informed about Human 
Papi l lomavirus  (HPV) and 
HPV vaccination! HPV is  a  
vi rus  which infects  body 
surfaces . There are many 
types  of HPV. Most are 
harmless , but some can 
have more serious  
effects  on the body. The 
most serious  kinds  can 
cause severa l  types  of 
cancer. Some other types  
can cause genita l  warts .
4
Young 
people
2
Requires  username and 
password to login
Both RU Sure ICE UK
Chester, 
Cheshire
10 to 50 2 No rating 1 0
Low 
Maturi ty
12+
Health& 
Fi tness
Health& 
Fi tness
0 25/12/2012
This  app provides  help 
and advice on sexual  
health, contraception, 
and STIs  and lets  you 
know your options  i f you 
think you may be 
pregnany. It shows  you 
the locations  of these 
servies  in the Chester 
and Cheshire areas .
1 - 2
Crashed on multiple 
occas ions  
Both SeXFactor ICE UK Wirra l
10,000 - 
50,000
3.5 No rating 64 0
Medium 
Maturi ty
12+ Li festyle Li festyle 0 17/07/2013
How much do you know 
about chlamydia  and 
safer sex? Can you sort 
out the myths  from the 
facts? Play our game to 
find out.
4
People 
l iving in 
wirra l
2
Good information but 
unable to assess  as  i t 
only comes  in the format 
of questions  and 
answers  
Both Sexxie
Borderless
healthlab 
Pte.Ltd
- - 100 - 500 1 No rating 2 0
Low 
Maturi ty
12+ Medica l
Health & 
fi tness
0 17/06/2014 12/06/2014
Sex Xpert Interactive 
Education (S.E.X.X.I.E.) 
app is  an interactive 
onl ine/ mobi le learning 
appl ication on sexual  
health. With a  module 
ti tles  Sexual ly 
Transmitted Infections  
(STI), i t wi l l  give users  
education and 
knowledge on di fferent 
types  of STIs , how to 
prevent and practice safe 
sex.
1 - 2
Requires  pa id 
subscription
Both
Wel l  
Happy
NHS 
London
UK London 500-1000 4.6 8 8 2
Medium 
Maturi ty
17
Health & 
Fi tness
Health & 
fi tness
0 26/03/2013 03/04/2013
Wel l  Happy is  a  free 
health app for young 
people aged 12-25 in 
London. It a l lows  you to 
search thousands  of 
loca l  support services  in 
and around London 
including mental  health, 
sexual  health, drugs , 
a lcohol  and smoking 
services .
4
People 
l iving in 
London
2
App not functioning, so 
unable to view the 
comprehens iveness  and 
accuracy of sexual  health 
terms
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Appendix II – search strategy 
 
 
The following search strategies are described here: 
1. Electronic prescribing 
2. Development of online clinical consultation: data gathering 
3. Development of online clinical consultation: decision support 
4. Development of online clinical consultation: results service 
5. Development of online clinical consultation: partner notification 
6. Validation and evaluation of an online clinical care pathway 
7. Validation and evaluation of a results service 
8. Validation and evaluation of an online clinical consultation 
9. Validation and evaluation of a partner notification service 
10. Validation and evaluation of an electronic prescribing service 
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Electronic prescribing 
1. MEDLINE; ELECTRONIC PRESCRIBING/; 556 results. 
2. MEDLINE; exp ELECTRONIC PRESCRIBING/; 556 results. 
3. MEDLINE; PHARMACEUTICAL SERVICES, ONLINE/; 28 results. 
4. MEDLINE; exp PHARMACEUTICAL SERVICES, ONLINE/; 28 results. 
5. MEDLINE; MEDICAL ORDER ENTRY SYSTEMS/; 1613 results. 
6. MEDLINE; exp MEDICAL ORDER ENTRY SYSTEMS/; 1613 results. 
7. MEDLINE; DRUG THERAPY, COMPUTER-ASSISTED/; 1560 results. 
8. MEDLINE; exp DRUG THERAPY, COMPUTER-ASSISTED/; 1560 results. 
9. MEDLINE; 1 OR 2; 556 results. 
10. MEDLINE; 3 OR 4; 28 results. 
11. MEDLINE; 5 OR 6; 1613 results. 
12. MEDLINE; 7 OR 8; 1560 results. 
13. MEDLINE; ORGANIZATION AND ADMINISTRATION/; 14335 results. 
14. MEDLINE; exp ORGANIZATION AND ADMINISTRATION/; 1084680 results. 
15. MEDLINE; REFERENCE STANDARDS/; 34644 results. 
16. MEDLINE; exp REFERENCE STANDARDS/; 35524 results. 
17. MEDLINE; JURISPRUDENCE/ OR LEGISLATION AS TOPIC/ OR LEGISLATION, MEDICAL/; 57675 
results. 
18. MEDLINE; exp JURISPRUDENCE/ OR exp LEGISLATION AS TOPIC/ OR exp LEGISLATION, MEDICAL/; 
297441 results. 
19. MEDLINE; UTILIZATION REVIEW/; 7189 results. 
20. MEDLINE; exp UTILIZATION REVIEW/; 10563 results. 
21. MEDLINE; 13 OR 14; 1084680 results. 
22. MEDLINE; 15 OR 16; 35524 results. 
23. MEDLINE; 17 OR 18; 297441 results. 
24. MEDLINE; 19 OR 20; 10563 results. 
25. MEDLINE; exp INAPPROPRIATE PRESCRIBING/ OR exp MEDICATION ERRORS/; 11313 results. 
26. MEDLINE; INAPPROPRIATE PRESCRIBING/ OR MEDICATION ERRORS/; 11137 results. 
27. MEDLINE; 25 OR 26; 11313 results. 
28. MEDLINE; GREAT BRITAIN/; 187012 results. 
29. MEDLINE; exp GREAT BRITAIN/; 301726 results. 
30. MEDLINE; ENGLAND/; 74468 results. 
31. MEDLINE; exp ENGLAND/; 89575 results. 
32. MEDLINE; 28 OR 29; 301726 results. 
33. MEDLINE; 30 OR 31; 89575 results. 
34. MEDLINE; 9 OR 10 OR 11 OR 12; 3436 results. 
35. MEDLINE; 21 OR 22 OR 23 OR 24; 1321926 results. 
36. MEDLINE; 32 OR 33; 301726 results. 
37. MEDLINE; 34 AND 35; 2307 results. 
38. MEDLINE; 34 AND 35 AND 36; 55 results. 
39. MEDLINE; 27 AND 34; 854 results. 
40. MEDLINE; 27 AND 34 AND 36; 28 results. 
41. MEDLINE; 37 [Limit to: English Language and Humans and Publication Year 1993-Current and 
(Age Groups All 
Adult 19 plus years or Adolescent 13 to 18 years)]; 389 results. 
42. MEDLINE; 41 [Limit to: English Language and Review Articles and Humans and Publication Year 
1993-Current 
and (Age Groups All Adult 19 plus years or Adolescent 13 to 18 years)]; 18 results. 
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43. MEDLINE; 39 [Limit to: English Language and Humans and Publication Year 1993-Current and 
(Age Groups All 
Adult 19 plus years or Adolescent 13 to 18 years)]; 151 results. 
44. MEDLINE; 43 [Limit to: English Language and Review Articles and Humans and Publication Year 
1993-Current and (Age Groups All Adult 19 plus years or Adolescent 13 to 18 years)]; 12 results. 
 
 
DEVELOPMENT OF ONLINE CLINICAL CONSULTATION – DATA 
GATHERING 
1. MEDLINE; DATA COLLECTION/; 78262 results. 
2. MEDLINE; exp DATA COLLECTION/; 1520880 results. 
3. MEDLINE; HEALTH SURVEYS/; 49994 results. 
4. MEDLINE; exp HEALTH SURVEYS/; 426202 results. 
5. MEDLINE; QUESTIONNAIRES/; 310265 results. 
6. MEDLINE; exp QUESTIONNAIRES/; 318342 results. 
7. MEDLINE; MEDICAL HISTORY TAKING/; 17115 results. 
8. MEDLINE; exp MEDICAL HISTORY TAKING/; 18623 results. 
9. MEDLINE; INTERVIEWS AS TOPIC/; 44148 results. 
10. MEDLINE; exp INTERVIEWS AS TOPIC/; 59269 results. 
11. MEDLINE; 1 OR 2; 1520880 results. 
12. MEDLINE; 3 OR 4; 426202 results. 
13. MEDLINE; 5 OR 6; 318342 results. 
14. MEDLINE; 7 OR 8; 18623 results. 
15. MEDLINE; 9 OR 10; 59269 results. 
16. MEDLINE; 11 OR 12 OR 13 OR 14 OR 15; 1533468 results. 
17. MEDLINE; METHODS/; 235293 results. 
18. MEDLINE; exp METHODS/; 590192 results. 
19. MEDLINE; REFERENCE STANDARDS/; 34649 results. 
20. MEDLINE; exp REFERENCE STANDARDS/; 35530 results. 
21. MEDLINE; ORGANIZATION AND ADMINISTRATION/; 14335 results. 
22. MEDLINE; exp ORGANIZATION AND ADMINISTRATION/; 1084907 results. 
23. MEDLINE; 17 OR 18; 590192 results. 
24. MEDLINE; 19 OR 20; 35530 results. 
25. MEDLINE; 21 OR 22; 1084907 results. 
26. MEDLINE; 23 OR 24 OR 25; 1672599 results. 
27. MEDLINE; SELF DISCLOSURE/; 6855 results. 
28. MEDLINE; exp SELF DISCLOSURE/; 6855 results. 
29. MEDLINE; SOCIAL DESIRABILITY/; 4024 results. 
30. MEDLINE; exp SOCIAL DESIRABILITY/; 4024 results. 
31. MEDLINE; ATTITUDE TO COMPUTERS/; 3997 results. 
32. MEDLINE; exp ATTITUDE TO COMPUTERS/; 3997 results. 
33. MEDLINE; 27 OR 28; 6855 results. 
34. MEDLINE; 29 OR 30; 4024 results. 
35. MEDLINE; 31 OR 32; 3997 results. 
36. MEDLINE; 33 OR 34 OR 35; 14773 results. 
37. MEDLINE; ONLINE SYSTEMS/; 7361 results. 
38. MEDLINE; exp ONLINE SYSTEMS/; 13636 results. 
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39. MEDLINE; 37 OR 38; 13636 results. 
40. MEDLINE; REMOTE CONSULTATION/; 3659 results. 
41. MEDLINE; exp REMOTE CONSULTATION/; 3659 results. 
42. MEDLINE; 40 OR 41; 3659 results. 
43. MEDLINE; 39 OR 42; 17257 results. 
44. MEDLINE; 16 AND 26 AND 43; 1511 results. 
45. MEDLINE; 16 AND 36 AND 43; 114 results. 
46. MEDLINE; 44 [Limit to: English Language and Humans and Publication Year 1993-2013 and (Age 
Groups All Adult 19 plus years or Adolescent 13 to 18 years)]; 431 results. 
 
DEVELOPMENT OF ONLINE CLINICAL CONSULTATION – DECISION 
SUPPORT 
 
1. MEDLINE; DECISION MAKING/; 69986 results. 
2. MEDLINE; exp DECISION MAKING/; 123969 results. 
3. MEDLINE; DECISION SUPPORT SYSTEMS, CLINICAL/; 5235 results. 
4. MEDLINE; exp DECISION SUPPORT SYSTEMS, CLINICAL/; 5235 results. 
5. MEDLINE; 1 OR 2; 123969 results. 
6. MEDLINE; 3 OR 4; 5235 results. 
7. MEDLINE; 5 OR 6; 128957 results. 
8. MEDLINE; METHODS/; 235293 results. 
9. MEDLINE; exp METHODS/; 590192 results. 
10. MEDLINE; REFERENCE STANDARDS/; 34649 results. 
11. MEDLINE; exp REFERENCE STANDARDS/; 35530 results. 
12. MEDLINE; ORGANIZATION AND ADMINISTRATION/; 14335 results. 
13. MEDLINE; exp ORGANIZATION AND ADMINISTRATION/; 1084907 results. 
14. MEDLINE; JURISPRUDENCE/ OR LEGISLATION AS TOPIC/ OR LEGISLATION, MEDICAL/; 57677 
results. 
15. MEDLINE; exp JURISPRUDENCE/ OR exp LEGISLATION AS TOPIC/ OR exp LEGISLATION, MEDICAL/; 
297490 results. 
16. MEDLINE; 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15; 1869253 results. 
17. MEDLINE; ONLINE SYSTEMS/; 7361 results. 
18. MEDLINE; exp ONLINE SYSTEMS/; 13636 results. 
19. MEDLINE; REMOTE CONSULTATION/; 3659 results. 
20. MEDLINE; exp REMOTE CONSULTATION/; 3659 results. 
21. MEDLINE; 17 OR 18 OR 19 OR 20; 17257 results. 
22. MEDLINE; 7 AND 16 AND 21; 187 results. 
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DEVELOPMENT OF ONLINE CLINICAL CONSULTATION – RESULTS 
SERVICE 
1. MEDLINE; COMMUNICATION/; 63000 results. 
2. MEDLINE; exp COMMUNICATION/; 372562 results. 
3. MEDLINE; 1 OR 2; 372562 results. 
4. MEDLINE; (test AND result*).ti,ab; 588479 results. 
5. MEDLINE; "investigation result*".ti,ab; 669 results. 
6. MEDLINE; SEXUALLY TRANSMITTED DISEASES/di [di=Diagnosis]; 2854 results. 
7. MEDLINE; 4 OR 5 OR 6; 591670 results. 
8. MEDLINE; CELLULAR PHONE/; 4394 results. 
9. MEDLINE; exp CELLULAR PHONE/; 4734 results. 
10. MEDLINE; ELECTRONIC MAIL/ OR TEXT MESSAGING/; 2410 results. 
11. MEDLINE; exp ELECTRONIC MAIL/ OR exp TEXT MESSAGING/; 2410 results. 
12. MEDLINE; 8 OR 9 OR 10 OR 11; 6558 results. 
13. MEDLINE; PATIENT SATISFACTION/; 60360 results. 
14. MEDLINE; exp PATIENT SATISFACTION/; 62992 results. 
15. MEDLINE; 13 OR 14; 62992 results. 
16. MEDLINE; AMBULATORY CARE FACILITIES/; 12255 results. 
17. MEDLINE; exp AMBULATORY CARE FACILITIES/; 44830 results. 
18. MEDLINE; 16 OR 17; 44830 results. 
19. MEDLINE; 3 AND 7 AND 12 AND 18; 2 results. 
20. MEDLINE; 3 AND 7 AND 12 AND 15; 28 results. 
21. MEDLINE; 3 AND 12 AND 18; 46 results. 
22. MEDLINE; 3 AND 7 AND 12; 181 results. 
23. MEDLINE; 3 AND 12 AND 15; 176 results. 
DEVELOPMENT OF ONLINE CLINICAL CONSULTATION – PARTNER 
NOTIFICATION 
1. MEDLINE; CONTACT TRACING/; 3426 results. 
2. MEDLINE; exp CONTACT TRACING/; 3426 results. 
3. MEDLINE; "Partner notif*".ti,ab; 762 results. 
4. MEDLINE; 1 OR 2 OR 3; 3708 results. 
5. MEDLINE; CHLAMYDIA TRACHOMATIS/; 11029 results. 
6. MEDLINE; exp CHLAMYDIA TRACHOMATIS/; 11029 results. 
7. MEDLINE; exp SEXUALLY TRANSMITTED DISEASES/; 291769 results. 
8. MEDLINE; 5 OR 6 OR 7; 294501 results. 
9. MEDLINE; exp METHODS/ OR exp COMMUNICATION METHODS, TOTAL/; 590469 results. 
10. MEDLINE; exp PATIENT SATISFACTION/; 62992 results. 
11. MEDLINE; 4 AND 8 AND 9; 24 results. 
12. MEDLINE; 4 AND 8 AND 10; 27 results. 
13. MEDLINE; exp ONLINE SYSTEMS/; 13636 results. 
14. MEDLINE; 4 AND 8 AND 13; 1 results. 
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VALIDATION AND EVALUATION OF AN ONLINE CLINICAL CARE 
PATHWAY 
1. MEDLINE; exp CRITICAL PATHWAYS/; 4613 results. 
2. MEDLINE; exp CLINICAL PROTOCOLS/; 137360 results. 
3. MEDLINE; 1 OR 2; 141839 results. 
4. MEDLINE; exp EVALUATION STUDIES/; 206624 results. 
5. MEDLINE; exp VALIDATION STUDIES/ OR exp VALIDATION STUDIES AS TOPIC/; 73376 results. 
6. MEDLINE; 4 OR 5; 268111 results. 
7. MEDLINE; exp ONLINE SYSTEMS/; 13636 results. 
8. MEDLINE; exp REMOTE CONSULTATION/; 3659 results. 
9. MEDLINE; 7 OR 8; 17257 results. 
10. MEDLINE; 3 AND 6 AND 9; 1 results. 
11. MEDLINE; 3 AND 6; 2270 results. 
12. MEDLINE; exp INTERNET/; 54606 results. 
13. MEDLINE; exp AMBULATORY CARE FACILITIES/; 44830 results. 
14. MEDLINE; 11 AND 12; 10 results. 
15. MEDLINE; 3 AND 9; 62 results. 
16. MEDLINE; 3 AND 9 AND 13; 0 results. 
17. MEDLINE; 3 AND 12 AND 13; 0 results. 
18. MEDLINE; 3 AND 12; 206 results. 
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VALIDATION AND EVALUATION OF A RESULTS SERVICE 
1. MEDLINE; ("Test result*" OR "Investigation result*").ti,ab; 35133 results. 
2. MEDLINE; SEXUALLY TRANSMITTED DISEASES/di [di=Diagnosis]; 2854 results. 
3. MEDLINE; 1 OR 2; 37912 results. 
4. MEDLINE; exp EVALUATION STUDIES/ OR exp VALIDATION STUDIES/; 266686 results. 
5. MEDLINE; exp VALIDATION STUDIES AS TOPIC/ OR exp EVALUATION STUDIES AS TOPIC/; 1070667 
results. 
6. MEDLINE; 4 OR 5; 1262586 results. 
7. MEDLINE; exp ONLINE SYSTEMS/; 13636 results. 
8. MEDLINE; exp REMOTE CONSULTATION/; 3659 results. 
9. MEDLINE; exp INTERNET/; 54606 results. 
10. MEDLINE; 7 OR 8 OR 9; 69309 results. 
11. MEDLINE; exp TEXT MESSAGING/ OR exp CELLULAR PHONE/; 4734 results. 
12. MEDLINE; exp ELECTRONIC MAIL/; 1957 results. 
13. MEDLINE; 10 OR 11 OR 12; 74428 results. 
14. MEDLINE; 3 AND 6 AND 13; 84 results. 
 
 
VALIDATION AND EVALUATION OF ONLINE CLINICAL 
CONSULTATION 
1. MEDLINE; exp DATA COLLECTION/; 1520880 results. 
2. MEDLINE; exp HEALTH SURVEYS/; 426202 results. 
3. MEDLINE; exp QUESTIONNAIRES/; 318342 results. 
4. MEDLINE; exp MEDICAL HISTORY TAKING/; 18623 results. 
5. MEDLINE; exp INTERVIEWS AS TOPIC/; 59269 results. 
6. MEDLINE; exp DECISION MAKING/; 123969 results. 
7. MEDLINE; exp DECISION SUPPORT SYSTEMS, CLINICAL/; 5235 results. 
8. MEDLINE; exp EVALUATION STUDIES/; 206624 results. 
9. MEDLINE; exp VALIDATION STUDIES/; 71818 results. 
10. MEDLINE; exp EVALUATION STUDIES AS TOPIC/; 1070667 results. 
11. MEDLINE; exp VALIDATION STUDIES AS TOPIC/; 1592 results. 
12. MEDLINE; 8 OR 9 OR 10 OR 11; 1262586 results. 
13. MEDLINE; exp ONLINE SYSTEMS/; 13636 results. 
14. MEDLINE; exp REMOTE CONSULTATION/; 3659 results. 
17. MEDLINE; 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7; 1636466 results. 
18. MEDLINE; 12 AND 16 AND 17; 3099 results. 
19. MEDLINE; 13 OR 14; 17257 results. 
20. MEDLINE; 12 AND 17 AND 19; 697 results. 
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21. MEDLINE; 20 [Limit to: English Language and Humans and Publication Year 1993-Current and 
(Age Groups All Adult 19 plus years or Adolescent 13 to 18 years)]; 243 results. 
 VALIDATION AND EVALUATION OF A PARTNER NOTIFICATION 
SERVICE 
1. MEDLINE; exp EVALUATION STUDIES/; 206624 results. 
2. MEDLINE; exp VALIDATION STUDIES/; 71818 results. 
3. MEDLINE; exp EVALUATION STUDIES AS TOPIC/; 1070667 results. 
4. MEDLINE; exp VALIDATION STUDIES AS TOPIC/; 1592 results. 
5. MEDLINE; 1 OR 2 OR 3 OR 4; 1262586 results. 
6. MEDLINE; exp ONLINE SYSTEMS/; 13636 results. 
7. MEDLINE; exp REMOTE CONSULTATION/; 3659 results. 
8. MEDLINE; 6 OR 7; 17257 results. 
9. MEDLINE; exp CONTACT TRACING/; 3426 results. 
10. MEDLINE; "Partner notif*".ti,ab; 762 results. 
11. MEDLINE; 9 OR 10; 3708 results. 
12. MEDLINE; 5 AND 8 AND 11; 1 results. 
13. MEDLINE; exp INTERNET/; 54606 results. 
14. MEDLINE; 5 AND 11 AND 13; 17 results. 
 
 VALIDATION AND EVALUATION OF AN ELECTRONIC PRESCRIBING 
SERVICE 
1. MEDLINE; exp EVALUATION STUDIES/; 206624 results. 
2. MEDLINE; exp VALIDATION STUDIES/; 71818 results. 
3. MEDLINE; exp EVALUATION STUDIES AS TOPIC/; 1070667 results. 
4. MEDLINE; exp VALIDATION STUDIES AS TOPIC/; 1592 results. 
5. MEDLINE; 1 OR 2 OR 3 OR 4; 1262586 results. 
6. MEDLINE; exp ONLINE SYSTEMS/; 13636 results. 
7. MEDLINE; exp REMOTE CONSULTATION/; 3659 results. 
13. MEDLINE; exp INTERNET/; 54606 results. 
14. MEDLINE; 6 OR 7 OR 13; 69309 results. 
15. MEDLINE; exp ELECTRONIC PRESCRIBING/; 557 results. 
16. MEDLINE; exp MEDICAL ORDER ENTRY SYSTEMS/; 1613 results. 
17. MEDLINE; exp DRUG THERAPY, COMPUTER-ASSISTED/; 1560 results. 
18. MEDLINE; 15 OR 16 OR 17; 3411 results. 
19. MEDLINE; 5 AND 14 AND 18; 22 results. 
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APPENDIX III – STUDY PROTOCOL 
 
 Full Title Can internet-based (eSTI2) clinical care pathways for people with genital chlamydial 
infection provide an acceptable and feasible alternative to routine care?  
Short Title/Acronym eSTI2 chlamydia clinical care pathway pilot study  
Sponsor Barts Health NHS Trust  
Mr Gerry Leonard  
Head of Research Resources  
Joint Research Management Office  
5 Walden Street  
London  
E1 2EF  
Phone: 020 7882 7260  
Email: sponsorsrep@bartshealth.nhs.uk  
REC Reference XXXX  
Chief Investigator Dr. Claudia Estcourt  
Reader in Sexual Health and HIV, Honorary Consultant  
Blizard Institute  
Barts and the London School of Medicine and Dentistry  
Barts Sexual Health Centre  
St Bartholomew's Hospital  
West Smithfields  
London EC1A 7BE  
Tel: 020 7882 2316  
c.s.estcourt@qmul.ac.uk  
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1 GLOSSARY of Terms and Abbreviations  
AE Adverse Event  
AR Adverse Reaction  
ASR Annual Safety Report  
BASHH British Association for Sexual Health and HIV  
CA Competent Authority  
Checkurself National Chlamydia Screening Programme website through which people may order a 
home sampling kit for Chlamydia  
Chlamydia Chlamydia trachomatis (C.trachomatis), the commonest bacterial STI in the UK  
CI Chief Investigator  
CRF Case Report Form  
CRO Contract Research Organisation  
DMC Data Monitoring Committee  
EC European Commission  
eHealth ‘The use of emerging information and communications technology, especially the internet, 
to improve or enable health and healthcare’ [1].  
eSexual Health Clinic Online clinical management system for people with chlamydia  
eSTI2 Electronic Self-Testing Instruments for Sexually Transmitted Infections  
GAfREC Governance Arrangements for NHS Research Ethics Committees  
GCP Good Clinical Practice  
GMC General Medical Council  
GUM Genitourinary Medicine  
ICF Informed Consent Form  
Index patient individual with chlamydial infection JRMO Joint Research Management Office  
NCSP National Chlamydia Screening Programme: Public Health England’s screening program for 
people under 25 years  
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NHS REC National Health Service Research Ethics Committee  
NHS RandD National Health Service Research and Development  
NICE National Institute for Health and Care Excellence  
Participant An individual who takes part in clinical research eSTI2 Chlamydia Clinical Care Pathway 
Pilot Protocol V1. 07 06 13 P 4/25  
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Partner Notification The process by which those exposed to an STI are contacted and offered testing 
and treatment  
PI Principal Investigator  
PIL Participant Information Leaflet  
QA Quality Assurance  
QC Quality Control  
RCT Randomised Controlled Trial  
REC Research Ethics Committee  
SAE Serious Adverse Event  
Sex partner Sexual partner of index patient  
SDV Source Document Verification  
Sexual Health Adviser Health care professional responsible for partner notification  
SOP Standard Operating Procedure  
SMS Short messaging service (text message)  
SSA Site Specific Assessment  
STI Sexually Transmitted Infection  
TDL The Doctors’ Laboratory  
TMG Trial Management Group  
TSC Trial Steering Committee eSTI2 Chlamydia Clinical Care Pathway Pilot Protocol V1. 07 06 13 P 
5/25  
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2 SIGNATURE PAGE  
Chief Investigator Agreement  
The clinical study as detailed within this research protocol (Version 1, Dated 07 Jun 13), or any 
subsequent amendments will be conducted in accordance with the Research Governance 
Framework for Health and Social Care (2005), the World Medical Association Declaration of Helsinki 
(1996) and the current applicable regulatory requirements and any subsequent amendments of the 
appropriate regulations.  
Chief Investigator Name: Dr. Claudia Estcourt  
Chief Investigator Site: Barts Health NHS Trust  
Signature and Date:  
Principal Investigator Agreement (if different from Chief investigator)  
The clinical study as detailed within this research protocol (Version 1, Dated 07 Jun 13), or any 
subsequent amendments will be conducted in accordance with the Research Governance 
Framework for Health and Social Care (2005), the World Medical Association Declaration of Helsinki 
(1996) and the current applicable regulatory requirements and any subsequent amendments of the 
appropriate regulations.  
Principal Investigator Name: as above  
Principal Investigator Site:  
Signature and Date: eSTI2 Chlamydia Clinical Care Pathway Pilot Protocol V1. 07 06 13 P 6/25  
 
3 SUMMARY Short Title  eSTI2 chlamydia clinical care pathway pilot 
study  
Methodology  Prospective, mixed-method (quantitative 
and qualitative), non-randomised, 
exploratory pilot study to develop and 
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evaluate a novel clinical care pathway.  
Research Sites  Barts Health NHS Trust, St George's 
Healthcare NHS Trust  
Objectives/Aims  To develop, implement and evaluate an 
electronic clinical care pathway “eSTI2 
chlamydia clinical care pathway” for 
management of people with genital 
chlamydia infection and to explore whether 
it can provide an acceptable, and feasible 
alternative to routine care.  
This study forms part of the UKCRC funded 
eSTI2consortium (www.esti2.org.uk) which 
aims to develop and evaluate a rapid 
diagnostic self-testing device for Sexually 
Transmitted Infections (STIs) integrated 
with an electronic clinical care pathway.  
This study focusses on the clinical care 
pathway, from test result to treatment, 
ahead of development of a new eSTI2 
diagnostic device, and will inform 
development of a protocol for a future 
substantive trial which will include both 
diagnostic device and care pathway.  
Total Number of Participants/Patients  420  
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Main Inclusion Criteria  The eSTI2 chlamydia clinical care pathway 
will be explored with people from two 
different patient groups:  
1. People from participating Genitourinary 
Medicine (GUM) clinics, aged 16 or over, 
who have tested positive for genital 
chlamydia and who have not yet received 
treatment.  
2. People from participating National 
Chlamydia Screening Programme internet-
based testing areas,  
aged 16 or over, who have tested positive 
for genital chlamydia using a postal 
chlamydia test and who have not yet 
received treatment.  
Statistical Methodology and Analysis (if 
applicable)  
Quantitative analysis to quantify the 
primary outcome: proportion of chlamydia 
positive participants who receive 
appropriate treatment in each patient 
group and calculate a 95% confidence 
interval so that non-inferiority  
with respective to current pathways can be 
assessed. Qualitative methods used will 
include semi-structured interviews with a 
sub-section of participants. Thematic 
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analysis will be conducted.  
Proposed Start Date  1st August 2013  
Proposed End Date  31st July 2016  
 
INTRODUCTION AND RATIONALE FOR STUDY  
Can internet-based (eSTI2) clinical care pathways for people with genital chlamydial infection 
provide an acceptable and feasible alternative to routine care?  
Background  
Effective control of sexually transmitted infections (STIs) is challenged by inadequate access to 
prompt diagnosis and treatment for patients and their sex partners and relatively poor community 
STI surveillance to inform targeting of public health interventions. Many perceived barriers to testing 
in current traditional and outreach settings have been described [2-3]. These include stigma 
associated with attending sexual health services, geographical distance and poor transport links to 
clinical services. A fresh approach to service provision, removing some of these real and perceived 
barriers may provide an important strategy to widen access to testing and treatment, ultimately 
improving STI control within a population.  
Point of care (PoC) rapid testing for STI diagnosis may address some of these challenges by enabling 
diagnosis of infection, treatment and partner notification, the process in which a person exposed to 
an STI is informed and offered testing and treatment, within a very short time frame. Rapid test and 
PoC technologies have also the potential to be used in novel settings such as people’s homes (home 
or self-sampling/self-testing) and enhance targeted STI screening programmes aimed at reducing 
long term morbidity such as the National Chlamydia Screening Programme (NCSP) [4]. However, 
currently available licensed PoC tests for STIs are either inaccurate or potentially too expensive for 
health care providers and none are currently licenced for home testing in the UK. In some areas, 
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internet-requested STI sampling is available however, this entails a person providing a urine or swab 
sample and mailing it back for conventional laboratory based testing, followed by referral to 
traditional health care services for treatment.  
 
 
eSTI2 Consortium  
The eSTI2 chlamydia clinical care pathway pilot study sits within the eSTI2 Consortium [5], which is a 
multidisciplinary collaboration of six major UK institutions funded by the UKCRC, (Medical Research 
Council [MRC] G0901608) to deliver a five year program of research which aims to reduce the impact 
of STIs by developing, evaluating and deploying simple to use, rapid, accurate, polymicrobial and 
affordable micro-diagnostics that can be networked through mobile phones. These diagnostics may 
be deployed as self-tests (home tests), or within more traditional clinical settings.  
Clinical management and follow up of individuals who test using these technologies will be possible 
using remote management pathways (eSTI2 clinical care pathway) within “eSexual Health clinics”, 
embedded within NHS sexual health services. This could increase the treatment rate in people who 
test postive for STIs and reduce delays in accessing effective treatment.  
The innovative nature of the remote management pathway means that extensive evaluation is 
necessary before trials of a putative eSTI2 diagnostic device are implemented. Therefore, we will 
undertake this exploratory study to further develop, implement and evaluate the eSTI2 clinical care 
pathway (see below) with a view to detailed process evaluation and outcome estimation sufficient 
to allow power calculations for a future definitive trial in which the eSTI2 device and eSTI2 clinical 
care pathway are integrated within a complex intervention.  
Preclinical Data: work in preparation for the study  
The eSTI2 research team has undertaken extensive preparatory research to inform initial 
development of the eSTI2 chlamydia clinical care pathway as part of the funded research program, 
in line with the MRC’s guidance on development of complex interventions [6].  
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This includes:  
1, Qualitative study of young people’s views on the acceptability of remote home testing for STIs 
and the proposed eSTI2 clinical care pathways, using semi-structured interviews with young people 
aged 16-24 (potential users). Findings strongly supported eSTI2 approaches to STI testing and clinical 
management and informed early development of the internet and web-app based program (UCL 
ethics ref: 3490/001).  
2. Qualitative study of young people’s views of content and format of our proposed “eSexual 
Health Clinic” which will house the clinical management pathway for people diagnosed with 
C.trachomatis. This study used focus group methodology in different settings to explore the optimal 
human technology interface (Brunel Research Ethics Committee, 13.9.12).  
3. Review of the regulatory, data protection, and professional guidance relevant to developing and 
implementing ehealth clinical pathways within an NHS context. This extensive review of legal, 
regulatory, data protection, ethical, and perceptual barriers to implementation of eSTI2 chlamydia 
clinical care pathways included a comprehensive literature and policy review and consultation with 
legal experts (Professor R Ashcroft, Professor of Biomedical ethics and Law, Queen Mary University 
of London), and the trial Sponsor Trust’s data protection lead. Refinement of the pathway will be 
undertaken in this study to ensure it complies with these wide ranging regulations.  
4. Development of the public health surveillance system. Work from our eSTI2 Public Health 
England based researchers has created a robust method of ensuring that appropriate data [7] is 
available for routine surveillance purposes from the eSTI2 chlamydia clinical care pathways, and is 
collected in a way which complies with appropriate data protection guidance.  
5. Previous work from several eSTI2 researchers on novel forms of partner notification has enabled 
us to adopt the validated technologies used in the MRC funded APT trial [8] for use in the eSTI2 sex 
partner care pathway.  
We have integrated findings from the above elements of the “pre-clinical” phase to develop a 
prototype eSTI2 chlamydia clinical care pathway, which is described in detail in section 6.3.  
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Briefly, chlamydia-positive participants, in addition to the standard ways of accessing treatment, will 
be offered the online eSTI2 chlamydia clinical care pathway, within our eSexual health clinic, which 
can facilitate rapid treatment and partner notification using an online clinical consultation. Providing 
it is safe to do so, participants will be able to choose a convenient participating community 
pharmacy from which to collect their treatment. An authorisation will be emailed, using NHS.net, 
from the eSexual Health Clinic to the chosen pharmacy and pre packed antibiotics, supplied to the 
pharmacy as part of the research trial, will be dispensed by the pharmacist. In line with the General 
Medical Council (GMC) [9] prescribing guidelines and the BASHH (British Association for Sexual 
Health and HIV) guidelines [10], the participant will receive information on the common side effects 
of the medication, what to do if they have an adverse reaction and advice on further management, 
including health promotion.  
The eSTI2 chlamydia clinical care pathway is supported by a clinical telephone helpline, staffed by 
research clinical sexual health advisers from the study GUM clinics, who can provide advice and / or 
facilitate access to traditional care at any stage of the process.  
Potential benefits  
At the individual level, the potential benefits of the eSTI2 chlamydia clinical care pathways centre on 
making it easier for people with genital chlamydia to receive appropriate management in a way that 
they find easy, acceptable and feasible. At a public health level, the major advantage would be to 
increase the proportion of people with genital chlamydia who receive appropriate treatment. This 
could lead to a reduction in complications of untreated C.trachomatis and improve health outcomes 
and reduce onward transmission, leading to a reduction in community chlamydial disease, and a 
reduction in the associated economic burden. From an economics perspective, the eSTI2 chlamydia 
clinical care pathways have potential to offer a more cost-effective option than existing NHS 
treatment and partner notification service delivery models  
In short, eSTI2 chlamydia clinical care pathways could: increase access to treatment; reduce time to 
achieve treatment; increase acceptability of treatment; widen patient choice; reduce community 
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burden of chlamydial disease; provide a cost-effective service delivery model and reduce the 
economic burden associated with chlamydial disease.  
Risks from participating in this study  
After careful consideration of a wide range of clinical, ethical and data protection issues, we do not 
believe that there are any significant risks to participants in the eSTI2 chlamydia clinical care 
pathways study. Please also see Section 10. Safety Considerations.  
5 STUDY OBJECTIVES  
Primary Objective:  
To determine the acceptability and feasibility of the eSTI2 chlamydia clinical care pathway to people 
who undergo a genital chlamydia test in different settings, which reflect the potential future use of a 
new eSTI2 point of care/ home testing STI diagnostic device, fully integrated within NHS services  
Secondary Objectives:  
· To obtain preliminary evidence of effectiveness of the eSTI2 chlamydia clinical care pathway 
compared with standard care to inform a future substantive trial.  
· To determine the acceptability and feasibility of the eSTI2 chlamydia clinical care pathway to sex 
partners of people diagnosed with genital chlamydial infection.  
· To assess the effectiveness of the eSTI2 chlamydia clinical care pathway compared to costs and 
outcomes of current NHS practice in GUM clinics and the NCSP postal testing services in England.  
· To provide data to be fed into an economic simulation model to be developed for the eSTI2 
chlamydia clinical care pathway.  
 
 
 
 
Primary Outcome Measure  
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The proportion of people who test positive for genital C.trachomatis infection (index patients) and 
the proportion of those who are managed through the eSTI2 clinical care pathway who receive 
appropriate clinical management*.  
*as defined by BASHH National Standards for management of genital C.trachomatis [10].  
Secondary Outcome Measures  
Quantitative:  
• Proportion of index patients who receive antibiotic treatment solely through the electronic 
element of the eSTI2 chlamydia clinical care pathway.  
• Time from index patient receiving diagnosis to receiving appropriate treatment.  
• Proportion of sex partners treated.  
• Time from index patient receiving diagnosis to sex partner receiving appropriate treatment.  
• Indicative eSTI2 chlamydia clinical care pathway costs  
• Cost-consequence analysis of eSTI2 chlamydia clinical care pathway  
 
Qualitative:  
• Acceptability and feasibility of eSTI2 chlamydia clinical care pathways to index patients  
• Acceptability and feasibility of eSTI2 chlamydia clinical care pathways to sex partners eSTI2 
Chlamydia Clinical Care Pathway Pilot Protocol V1. 07 06 13 P 11/25  
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6 METHODOLOGY  
This study forms part of the UKCRC funded eSTI2 consortium (www.esti2.org.uk) [5] which aims to 
develop and evaluate a rapid diagnostic self-testing device for STIs integrated with an electronic 
clinical care pathway. This study focusses on the chlamydia clinical care pathway, from test result to 
treatment, ahead of development of a new eSTI2 diagnostic device, and will inform development of a 
protocol for a future substantive trial which will include both diagnostic device and care pathway.  
There is no currently available suitable alternative testing device, which we could use in this 
exploratory study of the eSTI2 chlamydia clinical care pathway, to simulate the novel eSTI2 point of 
care diagnostic test being developed in the consortium. For this reason we will include standard 
diagnostic tests in routine NHS use but explore the clinical pathway with participants from two 
contrasting service user groups:  
a. Genitourinary Medicine (GUM) clinic attenders, to explore the eSTI2 chlamydia clinical care 
pathway with a group of people with high rates of chlamydia.  
b. National Chlamydia Screening Program (NCSP) Checkurself website [11] to explore the eSTI2 
chlamydia clinical care pathway in a group of people who have already shown acceptability of using 
the internet to request a postal chlamydia test.  
 
6.1 Inclusion Criteria  
a. GUM clinics: Barts Health NHS Trust (Ambrose King Centre and Barts Sexual Health Centre), St 
George’s Healthcare NHS Trust (Courtyard Clinic)  
· Patients who have tested positive for genital C.trachomatis  
· Patients 16 years of age and over  
· Patients who consent to the study  
 
Patients who are able to read and understand English  
386 
 
 
b. NCSP Checkurself website based testing areas: Bexley, Bromley, Croydon, Greenwich, Lambeth 
and Southwark, Lewisham, Sutton and Merton, Wandsworth.  
· Patients who have tested positive for genital C.trachomatis using a test accessed through the 
NCSP Checkurself internet based postal testing website  
· Patients 16 years of age and over  
· Patients who consent to the study  
· Patients who are able to read and understand English  
 
6.2 Exclusion Criteria  
a. GUM clinics  
· Patients who are simultaneously diagnosed with another STI (as they will require more complex 
management and a face-to-face consultation)  
· Patients who have already received treatment for C.trachomatis  
· Patients diagnosed with rectal C.trachomatis  
· Patients who have not provided a mobile telephone number  
· Patients who do not meet the inclusion criteria.  
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b. NCSP Checkurself website  
· Patients who are simultaneously diagnosed with another STI (as they will require more complex 
management and a face-to-face consultation)  
· Patients who have already received treatment for C.trachomatis  
· Patients who have not provided a mobile telephone number  
· Patients who do not meet the inclusion criteria.  
 
6.3. Intervention Design  
The central components of the prototype eSTI2 chlamydia clinical care pathway we are developing 
and evaluating are the same for participants from both recruitment settings. Therefore, we will first 
describe the prototype eSTI2 chlamydia clinical care pathway and all subsequent participant 
evaluation, as this is common to all settings, then we will describe how participants from each 
setting enter the care pathway.  
6.3.1 Prototype eSTI2 chlamydia clinical care pathway  
The eSTI2 chlamydia clinical care pathway offers people with a positive C.trachomatis test the 
opportunity to undergo an online clinical consultation with the aim of obtaining appropriate 
antibiotic treatment. Providing it is safe to do so, participants will be able to choose a convenient 
participating community pharmacy from which to collect their treatment. Treatment will be 
authorised by the eSexual Health Clinic and the antibiotics will be dispensed by the pharmacist at a 
participating pharmacy. Participants will access the eSTI2 chlamydia clinical care pathway using a 
web-application specifically designed as part of the study.  
The eSTI2 chlamydia clinical care pathway also has a partner notification function (see note below) 
such that sex partners will be able to access the online clinical consultation, and obtain treatment, 
via the eSTI2 chlamydia clinical care pathway in the same way described above.  
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Note: partner notification is the process by which a person with an STI notifies their relevant sex 
partners that they have been exposed to an STI and that they need treatment. Current UK guidance 
recommends “empirical treatment” of sex partners ie that sex partners should receive treatment 
whether or not they choose to be tested for the STI in question and irrespective of the test result [8].  
The following diagram shows how the prototype eSTI2 chlamydia clinical care pathway fits within 
the eSexual Health Clinic.  
 
6.3.2 eSTI2 Chlamydia Clinical Management within the eSexual Health Clinic  
Footnotes:  
i. The eSTI2 chlamydia clinical care pathway is supported at all stages by a research clinical sexual 
health adviser-led telephone clinical helpline based in the Barts Health NHS Trust study GUM clinic.  
ii. At any stage, a participant may decide not to proceed with the eSTI2 chlamydia clinical care 
pathway, in which case his/her care will continue according to routine care pathways.  
iii. eSTI2 chlamydia clinical care pathway online clinical consultation.  
The content of the online clinical consultation will be based on questions used in routine practice, a 
previous MRC-funded exploratory trial of remote patient assessment [6] and national guidelines for 
sexual history taking [10]. All data items routinely collected in traditional consultations for public 
health surveillance purposes [7] will be included. Participants for whom the online clinical care 
pathway is unsuitable will be directed immediately away from the online pathway to the clinical 
helpline so that their care can be individually facilitated by the research clinical sexual health adviser 
by arranging a “fast track” clinical appointment for face to face assessment in one of our study GUM 
services. Evidence from previous studies [8] suggests that this is a robust method of ensuring that 
patients with more complex clinical presentations achieve appropriate care quickly and with high 
levels of satisfaction.  
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If a patient completes the online clinical consultation and it is safe to do so, an authorisation will be 
generated from the eSexual Health Clinic to a participating pharmacy and pre-packed antibiotics, 
supplied to the pharmacy as part of the research study, will be dispensed by the pharmacist.  
v. Partner notification eSTI2chlamydia clinical care pathway: National guidance from both specialist 
organisations [8] and National Institute for Health and Care Excellence (NICE) [12] states that partner 
notification is an integral part of STI treatment and should be included in all treatment discussions 
with people with acute bacterial STIs, such as chlamydia. To comply with this guidance we need to 
provide a method of partner notification within the eSTI2 chlamydia clinical care pathway. We will 
adapt the APT partner notification web tool, developed as part of a previous MRC-funded study [8] 
(Research Ethics ref:06/Q0101/3), to enable relevant sex partners of people with chlamydia on the 
eSTI2 chlamydia clinical care pathway to access their clinical assessment and treatment in the same 
way.  
As for the index patient, sex partners accessing the eSTI2 chlamydia clinical care pathway will be 
supported at all stages by the health adviser-led clinical helpline. At any stage, a sex partner may 
decide not to proceed with the clinical pathway. In which case his/her care will continue according 
to routine standards of care  
6.3.3 Piloting of the Intervention  
Prior to commencement of the recruitment phase, we will pilot the eSTI2 chlamydia clinical care 
pathway to test its safety and efficacy. We will use the medical histories from clinical records from 
previously attending Barts Health Sexual Health Services patients who would have met the study 
inclusion criteria, to develop simulated patient scenarios.  
The clinic sexual health advisers will identify the clinical notes of appropriate patients, and remove 
all patient identifiable information leaving only the clinical information. Two eSTI2 researchers and a 
research clinical sexual health adviser will then use the clinical information provided in the case 
notes to answer the health questions on the online clinical pathway to ensure the outcome, i.e. 
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whether or not it is safe to prescribe Azithromycin matches the clinical decision made during the 
face-face consultation in clinic.  
6.4 Recruitment and seeking consent  
There will be 3 steps to this process, which are explained below:  
6.4.1. Patient information  
a.GUM Clinic patients:  
During the patient registration process at the GUM clinic, receptionists routinely provide information 
explaining how patients will receive their C.trachomatis result. For many patients this will be by text 
message, as is common practice in NHS GUM services. At this time patients will be informed by the 
receptionists that the clinic is taking part in a research study looking at how patients can get 
antibiotic treatment without coming back to the GUM clinic if their C.trachomatis result is positive, 
and for further explanation they will be asked to read the Patient information leaflet (PIL) given to 
them (please see Appendix I). There will also be posters within the GUM clinic explaining the 
research study (please see Appendix II).  
b. NCSP Patients:  
People from participating local authorities (see section 6.1.b), who request a C.trachomatis test kit 
via the NHS commissioned postal chlamydia test requesting service “Checkurself “ website 
https://www.checkurself.org.uk/ [11] will receive a PIL inside the test pack sent out to them (please 
see Appendix III).  
 
6.4.2. Identification of eligible patients  
a.GUM Clinic patients:  
On a daily basis, for the duration of the study, sexual health advisers from the GUM clinics will 
identify all eligible patients and will send them individually a text message saying that their results 
are ready and giving them a link through which they can access their results on the web tool, using a 
unique identifying number given to them at registration and their date of birth.  
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b.NCSP patients:  
Collaborating NCSP areas have a contract with a diagnostic laboratory, The Doctors Laboratory (TDL), 
London, W1T 4EU, to process and send out the results of patient’s chlamydia tests. For the duration 
of the study, on a daily basis, TDL will identify all eligible patients and will send them individually a 
text message saying that their results are ready and giving them a link through which they can access 
their results on the web tool, using a unique identifying number provided on the test form, and their 
date of birth.  
6.4.3. Consent  
GUM clinic patients and NCSP patients:  
When people have accessed their result by logging on to the web-app (please see section 6.6.1 
below), which may be accessed on a smartphone or computer, they will see that they have a positive 
C. trachomatis result. They will then be given information about chlamydia and then provided with 
options for accessing treatment. This will include the opportunity to get treatment using the eSTI2 
chlamydia clinical care pathway. If they choose the eSTI2 chlamydia clinical care pathway, they will 
first be directed to the consent page which includes a second opportunity to read the PIL via a link 
on the web page. Once they have consented, they will be directed onto the online clinical 
consultation and will become patients of Barts Health NHS Trust Sexual Health Services.  
Qualitative interviews:  
There is information on the PIL explaining that participants may be asked to participate in an online 
telephone discussion about their views and opinions of the eSTI2 chlamydia clinical care pathway. 
Participants in the research study will be followed up by telephone by clinical sexual health advisers, 
as per routine care, two weeks following their online clinical consultation to ascertain adherence to 
treatment and partner notification outcomes. At this time the clinical sexual health adviser will ask a 
sub section of patients, based on the researchers’ sampling criteria, if they would like to take part in 
a telephone discussion with a researcher who is interested in getting their views and opinions of the 
eSTI2 chlamydia clinical care pathway, whether or not they received all of their care this way. This 
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will include people who attend clinic for reasons of preference or because the eSTI2 chlamydia 
online clinical consultation indicated that it was inappropriate to provide treatment remotely. If 
patients agree, the clinical sexual health adviser will agree a time that is convenient to the 
participant for the researcher to telephone. The researcher will obtain verbal consent at that point.  
We will conduct two sets of interviews with different participants. One set will focus on the process 
and content of the eSTI2 chlamydia clinical care pathway (please see Appendix IV) and the second 
set will focus on the human technology interface aspects of the eSexual Health Clinic (please see 
Appendix V). 
 
6.5 Follow-up of participants  
All C.trachomatis positive participants will receive clinical follow up in line with national 
recommendations [10]. The clinical follow up and the additional research follow up activities are 
detailed below:  
Two weeks after the patient is sent his/her results by text, in line with national recommendations, 
the research clinical sexual health adviser will telephone all participants with positive C.trachomatis 
tests to ensure that treatment has occurred and partner notification has been initiated / completed 
(as described above in section 6.4.3). They will also ask a limited number of service evaluation 
questions (please see Appendix VI) about the eSTI2 chlamydia clinical care pathway, which will be 
recorded on the study database (please see section 6.6.1 below).  
6.6 Procedure for Collecting Data  
6.6.1 Web-application and study database  
A web-application linked to the study database will be created according to the needs of the eSTI2 
chlamydia clinical care pathway. A web-based front end tool (web tool) for the database will also be 
created which will enable the research team to integrate and access the data according to access 
principles described in section 8.5. The commissioned company chosen will adhere to the 
requirements of the Department of Health for all commercial third parties processing personal 
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identifiable data on behalf of NHS organisations and they will complete the Information Governance 
Toolkit. This will be achieved in the following ways:  
I. The database will be commissioned in accordance with current NHS standards for data storage and 
transfer, under the oversight of NHS information officers in relevant NHS trusts. Data will be stored 
on secure servers with access controls. Only appropriate clinicians will have access to personal 
identifiable information.  
 
II. Collecting the minimum number of data items for appropriate clinical care and justifying the 
intended use of each data item stored or transferred.  
 
III. A steering group will oversee the commissioning and specification of the web tool to be used for 
data transfer. The steering group will include at least one member with experience of successfully 
commissioning electronic health records and a good understanding of relevant legislation and web 
security issues, and will include Barts Health NHS Trust Data protection lead.  
 
IV. Confidentiality: Only essential personal information will be obtained for the purpose of the study. 
All information will be obtained with strict adherence to the Caldicott principles of confidentiality as 
outlined in the Caldicott report 1997 and referred for permission to the relevant NHS data 
protection officer and Caldicott guardian at every stage. In addition we will make sure that all staff 
will receive training on the use of the web tool, and the web tool will have appropriate security 
levels set up, including access controls so that sensitive information can be seen only by the 
clinicians.  
 
V. No information will be collected or stored on the web-app or on the users’ mobile phones or 
computers. All the data captured through the web-app will be transmitted, processed and stored on 
the server.   
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6.6.2 Qualitative interviews  
Semi–structured interviews with participants will be audio recorded. Recordings will be securely 
stored on password protected computers within a locked office within the Barts Health NHS Trust 
research team and deleted after the transcription has been checked. Transcripts will be kept in 
password protected computer files, and all potentially identifiable information (e.g. names) omitted 
from the transcripts.  
6.7 Subject withdrawal (including data collection / retention for withdrawn participants)  
All participants will be informed during the consent process that they can withdraw from the study 
at any point by contacting the Chief Investigator. Should the participant request to be withdrawn 
from the study, the information already gathered would not be used for research purposes. 
However, once consented, participants will become patients of Barts Health NHS Trust. Therefore, 
essential patient details will be retained irrespective of research study participation status as per 
standard clinical care. In addition, and as per standard practice, patients will be contacted for clinical 
care purposes (e.g. routine clinical follow ups, partner notification) irrespective of their research 
study participation status. This information will not be accessible to researchers.  
6.8 End of Study Definition  
The end of the study will be when the final analysis (statistical or qualitative, whichever is later) has 
been performed.  
7 STATISTICAL CONSIDERATIONS  
7.1 Sample size  
In total we aim to recruit the following number of participants:  
1: 121-164 index patients from GUM clinics  
2: 108-156 index patients from NCSP internet test request sites  
3: 40-60 index patients purposively sampled from across both study arms for qualitative follow up 
interviews  
4: 100 sex partners who have chosen to access care through eSTI2 chlamydia clinical care pathway  
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7.1.1 Justifications for sample size  
a. GUM clinic  setting  
In assessing the performance of the eSTI2 clinical care pathways we will examine the proportion 
who receive appropriate treatment amongst those offered the eSTI2 clinical care pathways. The 
current proportion of GUM patients who receive appropriate treatment in the absence of the eSTI2 
clinical care pathways is considered to be around 98% [13]. We aim to demonstrate non-inferiority 
of the eSTI2 clinical pathway i.e. that treatment outcomes for participants who receive treatment via 
eSTI2 clinical care pathway are better or only slightly worse than 98% [i.e. non-inferior].  
If the true proportion of patients who are offered the eSTI2 clinical care pathways and receive 
appropriate treatment is in fact 99%, then 121 patients will provide 80% power to demonstrate that 
the proportion is greater than 94%, and 164 patients will provide 80% power to show the proportion 
is greater than 95%. Assuming 50% uptake, we will aim to offer the eSTI2 clinical care pathways to 
242-328 eligible patients  
b. NCSP Checkurself website  
 
The current proportion of NCSP patients who receive appropriate treatment in the absence of eSTI2 
clinical care pathways is considered to be around 88% [14]. We aim to demonstrate non-inferiority 
of the eSTI2 clinical care pathway i.e. that treatment outcomes for participants who receive 
treatment via eSTI2 clinical care pathway are better or only slightly worse than 88% [i.e. non-
inferior]. Assuming that the eSTI2 treatment rate will be just a little higher than NCSP (at 90%), 156 
participants will provide 80% power to show it is greater than 82%, and 108 participants to show it is 
greater than 80%, i.e. to demonstrate non-inferiority to current NCSP treatment rates (88%). 
Assuming 50% uptake, we aim to offer the study to 216-312 eligible patients.  
7.2 Method of Analysis  
7.2.1 Statistical methods  
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The primary outcome (appropriate clinical management through the eSTI2 clinical care pathway) is 
binary. The proportion with the primary outcome will be reported for each setting with a 95% 
confidence interval, which will be used to establish non-inferiority or otherwise. Associations with 
the primary outcome will be tested using chi-squared tests, and odds ratios with 95% confidence 
intervals will be reported. Multiple factors can be examined using logistic regression leading to 
adjusted odds ratios with 95% confidence intervals. Statistical analyses will be performed using a 
statistical software package by members of the research team, under the supervision of the trial 
statistician (Dr Andrew Copas, UCL).  
Qualitative follow up interviews will be analysed thematically. Recurring themes and concepts will 
be identified and applied systematically to the transcripts. At least two researchers experienced in 
qualitative research will undertake analysis, and reliability will be enhanced by double coding a 
subset of transcripts and comparing inter-rater reliability. 8 ETHICS  
The study will be carried out in accordance with the ethical principles in the Research Governance 
Framework for Health and Social Care, Second Edition, 2005 and its subsequent amendments as 
applicable and applicable legal and regulatory requirements. All study researchers will have had up 
to date Good Clinical Practice (GCP) training prior to study start.  
8.1 Safe Prescribing  
Due to the novel nature of the eSTI2 chlamydia clinical care pathway we have conducted a literature 
review to identify, and thereby address, the legal, regulatory, ethical and perceptual barriers to 
implementing an eHealth STI clinical care pathway. In addition, we have drawn on the experience of 
the APT study [8], which also used a novel method of authorising antibiotic treatment. We have 
followed the GMC Good Prescribing Guidelines [9], which contain explicit guidance on remote 
prescribing and we will ensure that prescribing within the eSTI2 model satisfies all the necessary 
conditions. We will conduct extensive evaluation of the online clinical consultation prior to it being 
used in the exploratory study to ensure that we are satisfied that the web tool appropriately 
identifies patients for whom it would not be safe to manage via the online clinical care pathway. We 
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have robust processes in place to fast track such patients quickly for management in conventional 
health care settings.  
8.2 Informed consent and withdrawal of consent  
Participants will be made aware that the eSTI2 chlamydia clinical care pathway is an additional 
means of accessing treatment and that all routine alternatives are available to them should they 
prefer not to participate or withdraw at any stage after consenting to participate. Participants can 
withdraw at any stage without compromise to any aspect of their medical care.  
8.3 Patient Support  
A clinical helpline, staffed by specialist sexual health advisers from the Barts Health NHS Trust study 
clinic is available throughout the study should a participant require advice, psychological support or 
reassurance. This helpline is also the mechanism for facilitating rapid referral into traditional services 
for people for whom the eSTI2 chlamydia clinical care pathway is not medically appropriate. Work 
from members of the research team has demonstrated, in another study which used a similar clinical 
helpline, that people valued this highly and that it was extremely effective in moving people rapidly 
into appropriate care [8].  
8.4 Duty of Care  
We are approaching the issue of Duty of Care using parallels to the traditional context. Patients 
recruited through Barts Health sexual health services remain patients of Barts Health NHS Trust and 
so there is no change in duty of care. Patients who are recruited from St George’s NHS Healthcare 
Trust sexual health services become patients of Barts Health NHS Trust as soon as they consent to 
the study and thus Barts Health NHS Trust assumes duty of care from that point. Barts Health NHS 
Trust will also assume duty of care for all people who test positive for C.trachomatis via the 
Checkurself website testing as soon as they engage with the eSTI2 chlamydia clinical care pathway / 
eSexual Health Clinic.  
8.5 Data Management  
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The web tool will be commissioned in accordance with current NHS standards for data storage and 
transfer. Data will be stored on secure servers with access controls. Only appropriate clinicians will 
have access to patient identifiable information.  
· The minimum number of data items will be collected for appropriate clinical care and we will 
justify the intended use of each data item stored or transferred.  
 
· The steering group will oversee the commissioning and specification of the web tool to be used 
for data transfer. The steering group will ensure that at least one member will have experience 
of successfully commissioning electronic health records and has a good understanding of 
relevant legislation and web security issues.  
 
· Confidentiality: Only essential personal information will be obtained for the purpose of the 
study. All information will be obtained with strict adherence to the Caldicott principles of 
confidentiality as outlined in the Caldicott report 1997 and referred for permission to the 
relevant NHS data protection officer and Caldicott guardian at every stage. In addition we will 
make sure that all staff will receive training on the use of the web tool, and the web tool will 
have appropriate security levels set up, including access controls so that sensitive information 
can be seen only by the clinicians.  
 
· The web app developed for the study is just an interface for the web tool. No information will be 
collected or stored on the app.  
 
8.6 Conflict of interest  
There are no known conflicts of interest.  
9 CONFIDENTIALITY AND DISSEMINATION  
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At the end of the study, the findings will be disseminated to the health services and biomedical 
community through conference communications and publication in peer-reviewed, open access, 
scientific press. Direct quotations from participants will be altered as appropriate so that they are 
not attributable to the individual.  
10 SAFETY CONSIDERATIONS  
10.1 Participant safety  
Oral Azithromycin 1g is the nationally recommended first line treatment for uncomplicated genital 
chlamydia [10] and will be used in the study. It is well tolerated and has low allergenicity. All 
participants requiring treatment will undergo a detailed clinical assessment to determine whether 
the treatment is appropriate and treatment will only be provided if it is medically appropriate. Of 
note, Azithromycin 1g has been used in the USA in several large trials of patient delivered partner 
therapy in which people with chlamydia are given doses of Azithromycin to take to their partners 
without an interceding medical assessment of the sex partner. In over 2000 doses given, there were 
no adverse reactions or safety concerns [15,16]. In line with the GMC prescribing guidelines [9] and 
the BASHH guidelines [10], the participant will receive information on the common side effects of 
the medication, what to do if they have an adverse reaction and advice on further management, 
including health promotion.  
Clinical support will be available for the duration of the study in the form of a dedicated clinical 
helpline staffed by a study clinic-based sexual health advisor who will be able to deal with queries or 
concerns about the research and/or any clinical matters. This has been shown previously to afford 
excellent clinical outcomes and high levels of patient satisfaction [8].  
10.2 Research staff security  
The risk to staff will be minimal. Research staff will not come into face to face contact with 
participants. Qualitative interviews will be conducted by telephone.  
11 DATA HANDLING AND RECORD KEEPING  
11.1 Confidentiality  
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All information related to participants will be kept confidential and managed in accordance with the 
Data Protection Act 1998, The Caldicott Report and Caldicott Principles 1997, NHS Confidentiality 
Code of Practice 2003, The Freedom of Information Act 2000, The Research Governance Framework 
for Health and Social Care, and the conditions of Research Ethics Committee Approval. The 
Information Governance Toolkit will be applied to the pathway and the appropriate standards met. 
Any patient identifiable data, both transferred and stored, will be encrypted in line with NHS 
Information Governance ‘Guidelines on use of encryption to protect person identifiable and 
sensitive information’ 2008. SMS and email use will adhere to the 2010 NHS Information 
Governance Information Risk Management guidance with NHS.net being used for email 
communications both between the web tool and pharmacies, and the web tool and patients. A 
record of these emails will be kept as part of the patient’s electronic health record. The transfer of 
patient identifiable data via these mediums will be minimised wherever possible. Patient electronic 
health records will be stored on a server provided by xxxxxxxx. The software used will be designed to 
securely collect the data from the online survey and ethical hacking will be used to ensure the level 
of security is maintained against current threats.  
Semi–structured interviews with participants and the researcher will be audio recorded and labelled 
with a unique number. Recordings will be securely stored on password protected computers within 
a locked office and deleted after transcription. Transcripts will be kept in password protected 
computer files, and all potentially identifiable information (e.g. names) omitted from the transcripts.  
11.2 Record Retention and Archiving As is required by the Research Governance Framework and 
Trust Policy, the research participant records will be kept for a further 20 years. After the study has 
ended, research data will be stored in Barts Health archive facility in Prescot Street, London E1. 
Access will be by formal request to this office and is only available to members of the research team.  
Clinical records will be stored by Barts Sexual Health Clinic according to current NHS practice.  
12 LABORATORIES  
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Please note, as previously described, participants in the GUM and NCSP internet testing settings will 
undergo routine diagnostic tests in line with their routine clinical care and will only be recruited to 
the study once they have a positive chlamydia test result.  
13 MONITORING andAUDITING  
A data monitoring committee (DMC) will not be established for the exploratory study. However a 
steering committee which will include the Barts Health NHS Trust data information officer will be set 
up. The central responsibilities of this Steering committee will be to make recommendations to CI 
and sponsor on further conduct of this exploratory study, based on results of the monitoring 
procedures described below. Such recommendations could include modifying its protocol. Any such 
modifications should not violate the concepts behind the original study protocol. If changes in the 
study conduct are recommended by the steering committee, sufficient information should be 
provided to allow the sponsor and the CI to decide whether and how to implement them. The 
implementation of any steering recommendation is the responsibility of the CI and sponsor who are 
also free to neglect (in whole or in part) any recommendations of this Steering committee. The 
sponsor and the CI bear the final responsibility for the conduct of the exploratory study. This 
responsibility cannot be transferred to the Steering committee.  
Monitoring procedure and Audit  
The Steering committee will review accumulating data in an un-blinded fashion in order to monitor 
and audit the study conduct. Two months following the beginning of patient recruitment, the data 
manager will collate and clean all data necessary, and the study statistician will perform interim 
analysis. The study statistician will apply the statistical methods specified in the protocol to analyse 
study outcome measures and provide the Steering committee with data and analysis for checking.  
14 STUDY COMMITTEES  
Research progress will be monitored at monthly intervals by the Clinical and Public Health 
Workstream of eSTI2. This multidisciplinary working group will review research processes (and any 
402 
 
 
data produced) to ensure the exploratory studies are methodologically robust, evidence-based and 
delivered in a timely and ethical manner.  
In addition, the exploratory studies progress will also be presented and reviewed six-monthly by the 
eSTI2 Consortium Scientific Steering Committee. This committee will ensure that the exploratory 
studies stay within the vision of the larger Consortium project.  
15 FINANCE AND FUNDING  
This study is funded as part of a Consortium Grant under Phase II of the UKCRC Translational 
Infection Research Initiative (UKCRC G0901608 )  
16 INDEMNITY  
We will seek sponsorship from Barts Health NHS Trust. We will require insurance and indemnity 
cover for all participants.  
17 DISSEMINATION OF RESEARCH FINDINGS:  
Study endpoints, whether negative or positive, will be reported and disseminated through the 
following channels:  
· Research findings will be published in journals with open access within 6 months of publication 
(as per Wellcome Trust policy).  
· Research findings will be presented at UK and international meetings orally or via posters.  
· A report of the pilot findings will be freely available on the eSTI2 Consortium website after 
publication in scientific journals. A link to the report will be circulated to stakeholders, 
collaborators and piloting sites once the report is ready.  
· We will make presentations to community groups, including the study GUM clinic user groups   
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Appendix IV: Main study abstract 
submitted to ISSTDR 2015 
 
Is an automated online clinical care pathway for people with genital chlamydia (Chlamydia-OCCP) 
within an eSexual Health Clinic feasible and acceptable? Proof of concept study  
 
Authors: 
Estcourt CS1, Gibbs J1, Sutcliffe LJ1, Gkatzidou V2, Tickle L1, Hone K2, Aicken C3, Lowndes C4, Harding-
Esch E4, Eaton S5, Oakeshott P6, Szczepura A5, Ashcroft R1, Hogan G7, Nettleship A8,  Pinson D9, Sadiq 
ST6, Sonnenberg P3 
 
1Queen Mary University of London, 2Brunel University London, 3University College London, 4Public 
Health England, 5Warwick University, 6St George’s University of London, 7The Doctors Laboratory, 
8epiGenesys, 9The Royal Borough of Greenwich 
 
Introduction: 
UK health strategy supports self- and internet-based care. Within the eSTI2 consortium 
(www.esti2.org.uk) we developed UK’s first automated Online Clinical Care Pathway for 
people with genital chlamydia (Chlamydia-OCCP) within an eSexual Health Clinic (eSHC). 
Chlamydia-OCCP includes: STI results service; clinical consultation; electronic prescription 
via community pharmacy; partner notification (PN); with integral telephone helpline 
support. It complies with regulatory, professional, prescribing and surveillance 
requirements. We report on a study to assess Chlamydia-OCCP feasibility and acceptability 
as an alternative to routine care.    
 
Methods: 
Non-randomised, exploratory study to evaluate Chlamydia-OCCP: 21.07.14 -13.03.15 
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Participants: 1) chlamydia-positive untreated Genitourinary Medicine (GUM) clinic 
attenders; 2) people testing chlamydia-positive and negative through six National Chlamydia 
Screening Programme (NCSP) areas’ online postal self-sampling service 
Exclusions: under 16yrs; co-existing STIs, extra-genital chlamydia 
Intervention: eligible people were sent an SMS message with a link to access results from 
eSHC via a password protected web-app, optimised for smartphone use. Having consented 
online chlamydia-positive users followed the automated Chlamydia-OCCP.  Patients who 
declined received routine care.  
Evaluation: treatment rate; time to treatment; PN outcomes; engagement with clinical helpline and 
health promotion; safety; acceptability, costs. 
 
Results: 
GUM: of 197 eligible patients, 161 accessed results online, 112 consented, 110/112 (98%) treated 
(72 exclusively via Chlamydia-OCCP, median 1day). NCSP: of 145 eligible patients, 133 accessed 
results online, 104 consented, 92/104 (88%) treated (59 exclusively via Chlamydia-OCCP, median 
1day). 
28/515 sexual partners were managed solely online. 1176/1936, (61%) NCSP chlamydia-negative 
people accessed results online, of whom 407 accessed online health promotion. All patients who 
didn’t access results online were managed routinely. Patients moved effectively between online, 
telephone and clinic-based care.   
 
Conclusion: 
Chlamydia-OCCP is a feasible, acceptable, safe alternative to routine care for management of people 
with genital chlamydia. Preliminary evidence indicates comparable treatment outcomes. If linked to 
home testing, Chlamydia-OCCP offers potential for wholly remote care.  
 
 
